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'' One can never be too thin or too rich'' 




The past two decades have seen an upturn in interest in the psychiatric disorders 
anorexia and bulimia nervosa. Although this renewed interest has been reflected in the 
amount of research being undertaken, little is understood about the aetiology of these often 
devastating disorders. In particular, only limited work has been carried out examining the 
possible neurobiological abnormalities that may underlie, or impart vulnerability to the 
development of anorexia and bulimia nervosa. While evidence now exists to suggest that 
serotonergic dysregulation occurs during clinical episodes of both disorders, the precise 
nature of the dysregulation remains unclear. Furthermore, interpretation of eating disorder 
research is complicated by confounding factors of the illnesses themselves, including 
weight loss and the physical consequences of behaviours such as bingeing and purging, 
and by a paucity of knowledge regarding the normal control of human feeding behaviour. 
The work in this thesis uses three experimental paradigms, i.e. the neuroendocrine 
challenge test, a test meal procedure and administration of an amino acid drink free in 
tryptophan, to examine the role of serotonin in the development of the eating disorders. 
More specifically, the neuroendocrine approach was used to examine the effects of weight 
loss on d-fenfluramine and meta-chlorophenylpiperazine-induced prolactin responses in 
healthy controls and, in combination with a test meal, to examine the effects of m-
chlorophenylpiperazine on food intake and prolactin response in healthy women. In 
addition, the effect of a tryptophan-free amino acid drink on mood and food intake was 
examined in both healthy women and in women recovered from bulimia nervosa. 
Experimental findings reported in this thesis demonstrate no effect of tryptophan-free 
amino acid drink administration on mood and food intake. In contrast, evidence is 
presented in support of the hypothesis that moderate dieting is associated with alterations 
in brain serotonin function, and that such effects are confined to women, suggesting that 
women are more vulnerable than men to the effects of weight loss and altered food intake. 
The mechanism underlying dieting-induced alterations in brain serotonin function is 
discussed, with experimental evidence suggesting a possible pre-synaptic site of action. 
Studies utilising the serotonin agonist meta-chlorophenylpiperazine confirm the 
importance of serotonergic pathways in the control of food intake in humans and suggest 
involvement of 5-HT2c receptors in mediating the effects of human feeding behaviour. 
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1.1 OVERVIEW OF EATING DISORDERS AND 
DIETING BEHAVIOUR 
Although Morton published the first case reports of anorexia nervosa in the literature 
as early as 1694, little is understood about the aetiology of this often devastating disorder. 
The past two decades have seen an upturn in interest in anorexia nervosa and the more 
recently defined eating disorder syndrome, bulimia nervosa, an interest reflected in the 
increased research into many aspects of these illnesses. Although such research has led to a 
better understanding of the eating disorders in general, particularly in the area of 
epidemiology, many questions with respect to aetiology remain unanswered. 
1.1.1 CLASSIFICATION OF EATING DISORDERS AND ISSUES 
RELATING TO RESEARCH 
For the purposes of this thesis, the term "eating disorders", will refer to the two main 
psychiatric syndromes, anorexia nervosa and bulimia nervosa as defined below. 
DSM-IIIR Diagnostic criteria for Anorexia Nervosa: 
For a diagnosis of anorexia nervosa, all of the following must be met: 
A Refusal to maintain body weight over a minimal normal weight for age and height, eg., 
weight loss leading to maintenance of body weight 15% below that expected; or failure to 
make expected weight gain during period of growth leading to body weight 15% below 
that expected. 
B. Intense fear of gaining weight or becoming fat, even though underweight. 
C. Disturbance in the way in which one's body weight, size or shape is experienced, eg., 
the person claims to "feel fat" even when emaciated, believes that one area of the body is 
"too fat" even when obviously underweight. 
'.)· 
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D. In females, the absence of at least three consecutive menstrual cycles when otherwise 
expected to occur (primary or secondary amenorrhoea). (A woman is considered to have 
amenorrhoea if her periods occur only following hormone administration, eg. the oral 
contraceptive pill). 
DSM-IIIR Diagnostic Criteria for Bulimia Nervosa: 
For a diagnosis of bulimia nervosa, all of the following must be met: 
A Recurrent episodes of binge-eating (rapid consumption of a large amount of food in a 
discrete period of time). 
B. A feeling of lack of control over eating behaviour during the eating binges. 
C. The person regularly engages in either self-induced vomiting, use of laxatives or 
diuretics, strict dieting or fasting, or vigorous exercise in order to prevent weight gain. 
D. A minimum average (sic) of two binge-eating episodes a week for at least three 
months. 
E. Persistent overconcern with body shape and weight. 
These clinically defined disorders are closely related but the exact nature of their 
relationship remains unclear. Not only do they share many demographic, clinical and 
psychometric features but considerable movement occurs from one disorder to the other, 
especially in the direction from anorexia to bulimia nervosa (Fairburn, 1983; Garner et al, 
1985). Indeed definitions of the two syndromes remain in flux and considerable literature 
exists to suggest that subgroups of the disorders ( other than the two main categories 
defined above) can be distinguished on certain factors such as history, weight loss and 
psychopathological characteristics (Kaye and Weltzin, 1991b). It may also be possible that 
underlying psychobiological correlates further separate and/or distinguish such subgroups. 
In anorexia nervosa two main eating patterns can be distinguished: a restrictor subtype 
where weight loss is obtained purely through food restriction and bulimic anorectics who 
may qualify for the diagnosis of both DSM-IIIR anorexia nervosa and DSM-IIIR bulimia 
nervosa (Kaye and Weltzin, 1991b). The third main subgroup of the eating disorders is 
composed of normal weight patients meeting the diagnostic criteria for bulimia nervosa. 
The confounding factors of starvation along with the biological consequences of 
bingeing and purging have further encouraged researchers in the area of 
psychopharmacology to study the eating disorders in terms of the above subgroups rather 
than as the two clinically defined entities. Equally important is the increasing trend to look 
at different stages of the disorder, such as when the patient is acutely ill and upon 
"recovery", usually defined as abstinence from bingeing and purging behaviour in the 
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presence of weight restoration. This is especially significant in helping distinguish possible 
biological "state" (ie. those abnormalities present only during the acute illness) from "trait" 
(ie. those abnormalities present upon recovery) markers. Research looking at biological 
aspects of the eating disorders, which will be discussed below, can be divided into two 
categories. In earlier work patient definition was limited to allocating subjects to either of 
the broad clinical entities of anorexia or bulimia nervosa, while more recent studies have 
been heavily influenced by the factors outlined above. Where ever possible, research 
findings in this thesis will be reported and discussed within eating disorder subgroups (ie. 
restrictor anorectics, bulimic anorectics and normal weight bulimics) with the stage of the 
illness identified. 
1.1.2 ANOREXIA NERVOSA 
1.1.2.1 Epidemiology 
The first study looking at the incidence of anorexia nervosa within a defined 
population was carried out by Theander (1970) who examined ninety-four female cases in 
southern Sweden and reported an annual incidence rate in women of 0.24 per 100,000 
inhabitants. Kendell et al (1973) studied the incidence of anorexia nervosa in three 
different regions: North-east Scotland (the Aberdeen case register, between 1966-9), 
Monroe county, New York State (1960-9), and Camberwell, London (1965-71). Using a 
case register approach, he found the incidence of anorexia nervosa varied between 0.37 per 
100,000 per year in Monroe County to 1.6 per 100,000 per year in North-east Scotland. 
These earlier studies share methodological problems, such as diagnostic criteria variability, 
making it difficult to draw firm conclusions, but all demonstrated a trend suggesting an 
increase in case numbers over time. The trend was also seen in follow-up studies carried 
out in New York State, Zurich and Aberdeen looking at case registers up until the late 
1970s (Jones and Fox, 1980; Szmukler et al, 1986; Willi et al, 1990), although an 
increase over time was not a universal finding (Williams and King, 1987). While improved 
recognition of the disorder may have played a part, these figures are thought to reflect a 
true increase in the disorder. 
More recent studies have suggested that the incidence of anorexia nervosa may be 
levelling out with Willi et al (1990) and Hall and Hay (1991) reporting stable incidence 
and referral rates over the periods 1983-1985 and 1977-86 respectively. While Willi et al 
(1990) found a significant increase from 0.38 cases per 100,000 females (12-25 years) for 
1956-1958 to 0.55 per 100,000 for 1963-1965 to 1.12 per 100,000 for 1973-1975, in 
contrast, they found no further increase between 1983-1985. Similarly, Hall and Hay 
(1991) reported a constant referral rate of 5 per 100,000 population (34 per 100,000 for 
females aged 15-34 years) for the period 1977-1986. These findings are in keeping with 
those of Hoek (1991)who found 6.3 cases (both hospital and general practitioner) per 
100,000 population over the years 1985 and 1986. 
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1.1.2.2 Clinical Features 
The essential features of anorexia nervosa centre around a refusal to maintain body 
weight, over a minimal normal weight for height, consequent upon an intense fear of 
gaining weight or becoming fat. This is usually accompanied by a distorted body image 
manifested by patients stating that they "feel fat" although underweight or even severely 
emaciated. In women, amenorrhoea is also present (American Psychiatric Association, 
1987). A preoccupation with body shape and dissatisfaction with some aspect of their 
physical appearance is usual. The condition usually begins in adolescence and is seen 
predominantly in females (Fairburn, 1983). 
Low body weight is usually accomplished by severe food restriction despite normal 
feelings of hunger and a preoccupation with food. Excessive exercise and laxative abuse 
are common as is the use of self-induced vomiting, with some studies reporting a 
prevalence rate of concomitant problems with bulimia amongst 40-50% of diagnosed 
anorectic patients (Mitchell et al, 1990b ). Chronic starvation results in a number of body 
changes such as gastric constriction, the appearance of lanugo hair on the face, back and 
limbs and cardiovascular compensation reflected in bradycardia, postural hypotension and 
poor peripheral perfusion. A low basal metabolic rate and low circulating sex steroid 
hormone levels indicate the presence of endocrine abnormalities (Sharp and Freeman, 
1993). Affective symptoms, especially depression and mood !ability are common features 
and are often accompanied by social withdrawal and a lack of sexual interest (Fairburn, 
1983). 
1.1.2.3 Aetiological Theories 
While the fundamental cause underlying anorexia nervosa is not understood, it is now 
usually viewed as arising from a complex interaction of biological, psychological and 
social factors. Fairburn (1983) has suggested that these factors may function by imparting 
vulnerability, or by acting as precipitants to, or perpetuators of the illness. 
Early studies were heavily influenced by traditional psycho-analytical teaching, 
viewing the disorder as a defence against fantasies of impregnation. This idea was later 
replaced by that of Bruch (1962), who saw the disorder as arising from a disturbance of 
body image, seen alongside the anorectic's inability to interpret her own bodily sensations 
and paralysed by an overwhelming sense of ineffectiveness and lack of autonomy. Slade 
and Russell (1973) described an objective technique for determining bodily perception and 
used it to demonstrate that anorectic patients markedly overestimated their own body 
width. 
For Crisp (1976), the core pathology was the development of a weight phobia 
"hingeing on and pivoting round puberty". The central phobia was not seen as being 
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directed towards an excess of weight but towards a "normal (functioning) adolescent 
weight". Crisp felt that for some individuals, fearful of adolescence, an association 
developed between the normal weight gain of puberty and the psychosexual and other 
maturational tasks expected by these changes. Carbohydrate starvation acted to halt the 
onset of adolescence and provided a means of returning to the safe and familiar state of 
childhood. 
The personalities of patients who develop anorexia nervosa have also been the subject 
of considerable research. Based mainly upon the analysis of detailed clinical information, 
the results have at best been conflicting and must be interpreted in the light of their serious 
methodological limitations (Smart et al, 1976). Some authors have failed to find a uniform 
personality structure while others have emphasised traits such as obsessionality, 
conformity and goodness (Bruch, 1962; Crisp, 1976). Even those studies that have used 
objective personality assessments require careful interpretation because of methodological 
problems such as the use of nonvalidated scales and single assessments carried out at the 
time of illness. Overall, the results have continued to provide inconclusive evidence, 
although individual studies have reported personality profiles suggesting high neuroticism 
and introversion ( Smart et al, 1976). 
It was the work of Minuchin et al (1975) that first drew attention to the possibility that 
factors existing outside the individual may influence the onset of the disorder. In his 
development of an open systems family model, Minuchin outlined three conditions he 
believed to be necessary for the development and maintenance of severe psychosomatic 
disorders (including anorexia nervosa) in children. In addition to a child's physiological 
vulnerability, he described a type of family organisation that "encourages somatization". In 
particular, four characteristics ie. enmeshment, overprotectiveness, rigidity and a lack of 
conflict resolution were said to characterise the way in which families of anorectics 
operated. The final condition proposed in this family model was the tendency by the 
family to use the ill child to avoid family conflict. 
In a study of fifty-six families of anorectic patients, Kalucy et al (1977) identified 
another set of factors, which he called "weight pathology". "Weight pathology" described 
"deviations in weight, shape, eating behaviour and activity" which he reported to be 
present in 40% of anorectic families. In later research, designed to test Kalucy's 
hypothesis, Hall et al (1986) was unable to demonstrate any significant differences in 
either weight history or attitudes towards weight-related matters between fifty-eight 
mothers of anorectic patients and a matched control group of 204 mothers of New Zealand 
schoolgirls. Garfinkel et al (1983) also failed to find differences between the parents of 
patient and control groups with respect to weight, Eating Attitudes Test scores (EAT) 
(Garner and Garfinkel, 1979) and on measures of body satisfaction or idealization of 
thinness. 
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While many of these earlier hypotheses, developed from case studies and heavily 
influenced by psycho-analytical and more recently, psychological theories, have their 
attractions from an intuitive viewpoint, none have been satisfactorily tested and no firm 
evidence exists to support them. 
In the cognitive-behavioural model of anorexia nervosa, dysfunctional thoughts and 
attitudes are seen as central to the maintenance of the disorder. Most of these attitudes 
revolve around a core belief that thinness is not only highly desirable but comes to 
represent the sole measure of success. Weight loss, often positively remarked upon by 
others in the early stages of dieting, is said to become a positive self-reinforcer in itself as 
patients experience the pleasure of successful weight loss and a develop a sense of control 
over their lives through the discipline dieting represents (Garner and Bemis, 1982 ). As 
anxiety about eating increases, a phobia towards food and weight gain develops, which is 
further reinforced in a negative way by the avoidance of feared situations (Garner and 
Bemis, 1982). The importance of cognitive factors in the maintenance of these avoidant 
behaviours has been emphasised by Bandura (1978), who stated that "behaviour is so 
powerfully controlled by bizarre internal contingencies that neither the beliefs nor the 
accompanying actions are much affected even by extremely punishing environmental 
consequences". 
Evidence for a genetic contribution in the aetiology of anorexia nervosa comes from 
family and twin studies. Family studies have consistently demonstrated an increased 
prevalence rate of anorexia nervosa amongst first degree relatives of anorectic patients. 
Theander (1970) reported a 6.6% sibling risk for the disorder in his study of ninety-four 
anorectic probands while Crisp et al (1980) found that 7% of siblings had either had or 
were still suffering from anorexia nervosa. Fourteen percent of the mothers and 9% of the 
fathers were also reported to have histories consistent with the disorder, although some of 
these diagnoses were described as "marginal". Holland et al (1988), reporting only on 
female first-degree relatives found a rate of nearly 5%. Other studies have reported an 
increased risk of both eating and affective disorders amongst first degree relatives (Hudson 
et al, 1983a; Gershon et al, 1984). 
The finding that a disorder occurs with increased prevalence within families of 
probands compared to the general population is consistent with either a genetic or 
environmental mode of transmission. Twin studies, however, provide confirmation of a 
genetic contribution to aetiology. Some of the first twin studies published were criticised 
on the basis of inadequate diagnostic clarification and inaccurate determination of 
zygosity. More recently Holland et al (1984) reported that of thirty female twin pairs, 55% 
of the monozygotic twins were concordant for anorexia nervosa compared to only 7% of 
the dizygotic pairs, although the question of selection bias with this particular group of 
patients was raised. A follow-up study, designed to minimise this problem was later 
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completed and reported a 56% concordance rate for anorexia nervosa in twenty-five 
monozygotic female twins compared to 5% of dizygotic pairs (Holland et al, 1988). 
Interest in the possibility that a neuroendocrine abnormality may contribute to the 
aetiology of anorexia nervosa arose from the observation of amenorrhoea as a central 
feature and consistent findings that abnormalities of hypothalamic-pituitary and 
neurotransmitter function exist in patients suffering from the disorder (Garfinkel et al, 
1975; Gerner and Gwirtsman, 1981; Halmi et al, 1987; Gwirtsman et al, 1989a; Kaye et 
al, 1990b ). While earlier theories such as anterior pituitary insufficiency have now been 
largely discarded, debate continues over the significance of other neuroendocrine 
abnormalities, in particular, whether they represent abnormalities intrinsic to the disorder, 
or are best explained as consequences of the illness (Halmi et al, 1987; Gwirtsman et al, 
1989a). To date almost all research in this area has been carried out on acutely ill patients, 
where the picture is complicated by the epiphenomena of starvation and weight loss, with 
or without purging effects, or on recently "recovered" anorectics who have just undergone 
refeeding. Research results must therefore be interpreted in this light. 
Most endocrine abnormalities seen in anorexia nervosa are now thought to reflect 
starvation as indices frequently return to normal upon weight restoration (Halmi et al, 
1987). Abnormalities include hypercortisolaemia, reduced gonadotrophin levels 
(luteinising hormone and follicle stimulating hormone), low serum tri-iodothyronine and 
delayed thyroid stimulating hormone responses to thyroid releasing hormone (TRH), 
elevated basal growth hormone (GH) levels, as well as incomplete suppression of 
adrenocorticotropic hormone (ACTH) and cortisol by dexamethasone (Garfinkel et al, 
1975; GernerandGwirtsman, 1981; Halmi eta!, 1987; Gwirtsmanetal, 1989a). 
Studies on neurotransmitter systems raise the possibility that abnormalities specific to 
anorexia nervosa may underlie the disorder as some changes persist with recovery. 
Evidence that the noradrenergic system may be involved comes partly from studies 
looking either directly at cerebral spinal fluid (CSF) concentrations of noradrenaline and 
its metabolite 3-methoxy-4-hydroxyphenylglycol or by studying peripheral 3-methoxy-4-
hydroxyphenylglycol concentrations in the plasma or urine. In the acutely ill emaciated 
anorectic, consistently lower concentrations of plasma and urine 3-methoxy-4-
hydroxyphenylglycol and CSF noradrenaline and 3-methoxy-4-hydroxyphenylglycol have 
been found compared to healthy controls suggesting reduced noradrenaline turnover 
(Halmi et al, 1978; Gerner and Gwirtsman, 1981; Halmi et al, 1987). While these 
findings may be secondary to starvation, as plasma noradrenaline and urinary 3-methoxy-
4-hydroxyphenylglycol increase to near normal upon weight recovery (Halmi et al, 1978 ), 
one study found 50% lower CSF noradrenaline concentrations in their long-term weight 
recovered (twenty +/- seven months) anorectics (Kaye et al, 1984b). This raises the 
possibility that a "pervasive defect in noradrenaline metabolism may be a trait marker of 
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anorexia nervosa" (Fava et al, 1989). Other studies have examined noradrenergic function 
using neuroendocrine challenges or looked at lymphoctye ,8-adrenergic receptor binding. 
Again, while many of the abnormalities noted during the acutely ill phase normalise upon 
weight restoration, some do not. The clonidine-induced GH response, as a measure of 
postsynaptic sensitivity, was found to be normal in low-weight anorectics, but blunted 
following weight restoration (Kaye et al, 1985). 
Abnormalities of other neurotransmitter systems have also been postulated. Findings 
on dopamine metabolism have been, at best, inconsistent (Fava et al, 1989) while some 
evidence for alterations in CSP opioid activity in underweight anorectics has been 
demonstrated compared to controls (Kaye et al, 1982). However, it is the serotonergic 
system that has been most implicated in the pathogenesis of the eating disorders and will 
be discussed in full later. 
The influence of socio-cultural factors in the aetiology of anorexia nervosa was been 
suggested by several lines of research. From very early studies an over-representation in 
upper social classes has been noted (Kendell et al, 1973; Crisp et al, 1976; Szmukler et 
al, 1986) and to some extent the disorder appears to be confined to areas where a 
"Western" style culture predominates. It has been suggested that the relatively recent shift 
in the idealized female shape from a curved figure to a thin, lean look has placed 
increasing pressure upon Western women to conform and may have contributed to the 
rising incidence of anorexia nervosa (Kendell et al, 1973; Garner et al, 1980; Willi and 
Grossmann, 1983; Szmukler et al, 1986). In support of this theory, Garner et al (1980) 
point to data from magazine centerfold and Miss American Pageant contestants which 
demonstrate a significant trend towards a thinner ideal. The average weight of the Miss 
America Pageant contestant has fallen over twenty pounds in the past thirty years. They 
further point out that these changes have occurred against a trend towards increasing 
standard body weight and size for North American women. The impact of this pressure to 
conform is said to be reflected in the high levels of reported body weight and shape 
dissatisfaction, and the fact that dieting behaviour is endemic amongst young females in 
our culture today (Johnson-Sabine et al, 1988; Whitaker et al, 1989). 
To examine further the question that socio-cultural factors may influence the 
development of anorexia nervosa, Garner and Garfinkel (1980) examined a population of 
183 professional dance students and fifty-six fashion models who, it could be argued by 
their career choice, would face intense pressure to maintain body weight and shape close to 
the currently accepted ideal. Seven percent of the modelling and 6.5% of the dance group 
met strict criteria for anorexia nervosa with all but one case in the dance group developing 
the disorder while studying dance. Furthermore, within the dance group, the risk for 
anorexia was higher amongst those students in programmes in which there was greater 
pressure to succeed as professionals. The authors argue that "these data suggest that both 
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pressures to be slim and achievement expectations are risk factors in the development of 
anorexia nervosa", although it would be difficult to separate out these two factors as for 
these students, achievement would depend upon slimness. 
1.1.2.4 Treatment and Outcome 
It was Sir William Gull (Gull, 1874) who provided the classic description of anorexia 
nervosa, highlighting the patient's denial of her illness and reluctance to cooperate in 
treatment as specific challenges. Since then, although many different treatments have been 
advocated, it remains true that no specific treatment for the disorder exists (Hsu, 1986). 
Most clinicians would agree, however, that improving patient functioning in certain key 
areas is central to a successful outcome (Hsu, 1986; Hall, 1987). Hall (1987) has 
emphasised the need "to facilitate the patient's recovery to normal physical functioning, 
including the loss of symptoms of starvation, maintenance of normal weight and endocrine 
functioning, loss of pathological attitudes to food and body fat and, at the same time, to 
facilitate the patient's emotional growth". 
Few studies have rigorously compared the different treatments currently in use 
(Russell et al, 1987 ), despite claims by some authors for the superiority of their particular 
approach (Rosman et al, 1977). In particular, little comparison of the different 
psychotherapeutic approaches that dominate treatment has been done. More recently by 
employing a randomised, controlled trial design to compare family therapy with individual 
supportive therapy, Russell et al (1987) have demonstrated some evidence that family 
therapy may be more effective for those patients whose illness has begun early (before the 
age of nineteen years) and has not yet become chronic. There was "a more tentative 
finding" that individual supportive therapy was of greater value in the older patient. 
In their study, Hall and Crisp (1987) studied thirty out-patients with severe anorexia 
nervosa who were randomly allocated to either treatment regimes consisting of dietary 
advice or combined individual and family therapy. At twelve months follow-up, both 
groups showed significant overall improvement, with the dietary advice group making 
significant weight gain. Although the weight gain in the psychotherapy group did not quite 
reach significance, improvements in sexual and social functioning were also noted. 
The use of drugs in the treatment of anorexia nervosa has remained limited and is 
usually seen as most effective when it forms part of a comprehensive management 
approach (Kennedy and Goldbloom, 1991). These authors state that the rationale for 
prescribing usually falls into three categories: a) drugs to promote food intake and weight 
gain, b) drugs to treat associated psychiatric disturbance and c) those that are used to treat 
any medical complications resulting from starvation. Controlled trials to date have shown 
little benefit in terms of weight gain following the use of cyproheptadine ( Goldberg et al, 
1979), amitriptyline (Halmi et al, 1986), clonidine (Casper et al, 1987), or the selective 
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dopamine antagonists pimozide (Vandereycken and Pierloot, 1982) or sulpiride 
(Vandereycken, 1984 ). Similarly, the use of chlorpromazine, a drug popular in the 1960s, 
is not backed by controlled trials in support of its efficacy (Vandereycken, 1984) 
As depression is a common symptom in anorexia nervosa, the use of antidepressant 
drugs has been advocated for the promotion of both improved mood and food intake. 
While several uncontrolled case studies, such as that by White and Schnaultz (1977), using 
tricyclic antidepressants, have reported improvements in mood paralleling weight gain, 
only a few controlled trials have been reported. Both clomipramine (Lacey and Crisp, 
1980) and amitriptyline (Biederman et al, 1985) were found ineffective for either weight 
gain or behavioural changes. 
Overall, the treatment for anorexia nervosa remains eclectic in its approach. While the 
lack of a specific treatment may appear a disadvantage, many clinicians feel that the 
diversity of needs demonstrated by their patients and the patients' families seeking help, is 
best served by a flexible management plan (Hsu, 1986; Hall, 1987). 
Most outcome studies into anorexia nervosa have shared multiple methodological 
problems. These include short periods of follow-up in highly selected patient populations, 
a failure to use standardised criteria for both diagnosis of the disorder and in evaluating 
outcome, along with high failure-to-trace rates. The differences in approach have resulted 
in findings that vary considerably, making it difficult to make comparisons between 
studies and to draw firm conclusions (Herzog et al, 1988). Two recent publications 
(Morgan et al, 1983; Hall et al, 1984 ), however, used essentially the same methodology 
as earlier research by Morgan and Russell (1975) and Hsu et al (1979) allowing 
comparisons to be made and identifying similar trends (Hsu, 1988). All four studies 
followed their patients for at least four years and used Morgan and Russell's outcome 
criteria, based upon body weight and restoration of menstruation. At follow-up, between 
50% and 60% of patients were normal in weight and 47%-58% were menstruating 
regularly, findings in keeping with those of Theander (1970). The mortality rates varied 
between 1 % (Morgan et al, 1983; Hall et al, 1984 ) and 5% (Morgan and Russell, 1975 .). 
Varying degrees of food and weight preoccupation remained common even in those given 
a "good" or "intermediate" outcome (Hall et al, 1984). 
Several factors have been identified as poor prognostic indicators for recovery from 
anorexia nervosa: longer duration of illness, lower minimum weight, pre-morbid 
personality and social difficulties, disturbed relationships within the family and failed 
previous treatment (Morgan and Russell, 1975; Hsu et al, 1979; Morgan et al, 1983 ). Hall 
et al ( 1984) failed to demonstrate similar results, identifying only marriage at presentation 
as the one prognostic factor of a worse outcome. The latter authors warned in assessing the 
relevance of this finding that compared to the other three studies their married group was 
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older (27.9 years vs 18.3 years) and had a significantly longer duration of time at weight 
below 15% of average body weight (70 months vs 21.3 months). 
Mental state examination has also been utilised at follow-up to assess outcome. 
Although studies report high levels of symptomatology, especially affective symptoms, 
few studies have used standardized interviews enabling diagnostic criteria to be applied 
(Hsu, 1988). In a study by Morgan and Russell (1975), 45% of patients with anorexia 
nervosa reported the presence of affective symptoms (mainly depression) while 23% were 
troubled by symptoms of obsessive-compulsive disorder. The findings for Hsu et al (1979) 
were 38% and 22% respectively. Hall et al (1984) found that DSM-III criteria for a 
psychiatric disorder other than an eating disorder were fulfilled by 50% of her patients at 
follow-up. Dysthymic disorder proved the most common diagnosis, occurring in 34% 
(although exclusively in patients with continuing eating difficulties) while a further 6% 
were found to have major depression, 4% alcohol abuse and 2% each to have 
schizophrenia, bipolar disorder and personality disorder. Only 20% of the sample were free 
of any physical or mental abnormality at the time of interview. 
A recent publication by Ratnasuriya et al ( 1991) looked at the twenty year outcome in 
a cohort of anorectic patients, reporting extended follow-up of the patients studied by 
Morgan and Russell (1975). The authors were interested in determining whether or not 
long-term findings confirmed those of the earlier study and if factors prognostically 
significant at five years were still predictors at twenty years. While predictors of outcome 
at five years remained fairly consistent, a later age of onset was also identified as being 
particularly predictive of a worse outcome at twenty years. The overall outcome of the 
cohort, however, was not as good as that expected from the intermediate term findings. In 
particular, the authors found a mortality rate (attributable to anorexia) of 15%, a finding in 
keeping with the 18% earlier reported by Theander (1985), but higher than the shorter term 
studies. The study by Ratnasuriya et al (1991) also demonstrated a high degree of ongoing 
morbidity, with one third of those alive at follow-up still leading a "socially isolated and 
restricted life" and reporting a high level of dependence on their families of origin. 
Concerns over sexuality, marriage and child-bearing were also present in 50% of patients. 
Taken together, these studies point to the very serious nature of anorexia nervosa, 
especially if it takes a chronic course. While the findings of two studies (Theander, 1985; 
Ratnasuriya et al, 1991) suggest that full recovery is still possible after fifteen years or 
more of illness, it also appears that the hope of recovery gradually decreases with time, 
dropping off steeply after twelve to fifteen years. 
c\ 
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1.1.3 BULIMIA NERVOSA 
1.1.3.1 Epidemiology 
Since bulimia nervosa (Russell, 1979) and bulimia (American Psychiatric Association, 
1980), were first defined in the literature, numerous epidemiological surveys have been 
carried out in an attempt to estimate their true prevalence. To date, most of these studies 
have used only simple self-report questionnaire measures, often on selected populations, 
thus raising important methodological problems in the interpretation of the data, but some 
preliminary impressions have been gained. 
Two American studies yielded high prevalence rates for bulimic behaviour with up to 
60% of female college students reporting binge-eating, while 5% and 13% met DSM-III 
criteria for bulimia nervosa (Halmi et al, 1981; Hart and Ollendick, 1985). Other 
American authors have reported a three-fold increase in the prevalence of DSM-III bulimia 
nervosa in recent years (Pyle et al, 1986), a finding in keeping with those of Hall and Hay 
(1991), who report a six-fold increase in the annual referral rate amongst New Zealand 
women for the period 1977-1986 (from 6 to 44 per 100,000 females aged 15-29 years). 
In contrast, two British studies, also using self-report questionnaires in a female 
population (attending a family planning clinic), revealed less alarming results in terms of 
binge-eating. Cooper and Fairburn (1983) found a prevalence of binge-eating (defined as 
excessive and uncontrollable eating) of 20.9% with 2.9% currently using induced vomiting 
as a means of weight control. Applying conservative criteria however, based upon 
Russell's definition, only 1.9% appeared to fulfil diagnostic criteria for bulimia nervosa per 
se. This study was replicated in 1986 with similar results ie. 27 .1 % women reporting 
binge-eating and 1.8% meeting criteria for bulimia nervosa (Cooper et al, 1987). In a New 
Zealand population based survey utilising a self-report questionnaire followed up by 
interview, Bushnell et al (1990) found a life time prevalence for females of 1.9% with 
1.0% of women between the ages of eighteen and forty-four years currently meeting DSM-
III criteria for bulimia, findings in keeping with those rates seen in the British studies. 
At present it is unclear why the epidemiological research into bulimia nervosa 
continues to produce such different prevalence and incidence rates between the U.S.A. and 
Britain. One explanation is that it reflects genuine differences in disturbed eating 
behaviour in the two countries. Other authors suggest diagnostic variability, differing 
methods of assessment and the use of selected populations (such as college students) hold 
the key (Cooper et al, 1987). In the area of bulimia nervosa, more population based 
surveys using direct interviews are required. 
"\ 
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1.1.3.2 Clinical Features 
Central to the disorder of bulimia nervosa are recurrent episodes of binge-eating, 
defined as the rapid consumption of large amounts of food within a discrete period of time, 
with an associated feeling of loss of control over eating during the episodes (American 
Psychiatric Association, 1987). Weight gain is avoided either by the use of self-induced 
vomiting, laxative or diuretic abuse, strict dieting or fasting between binges or by the use 
of vigorous exercise. The frequency of binge-eating and vomiting varies, but can occur ten 
times or more each day (Fairburn, 1983). A persistent overconcern with body shape and 
weight is also present (American Psychiatric Association, 1987). 
Patients with bulimia are usually of normal weight although a subgroup tend to be 
slightly overweight (Russell, 1979). The syndrome is seen predominantly in females with 
only 10-15% of cases affecting males (Carlat and Camargo, 1991). The age of onset is 
usually in late adolescence or early adulthood. Unlike anorexia nervosa, persistent 
amenorrhoea is not present although menstrual irregularities have been reported in up to 
50% of cases (Fairburn, 1983) and patients are more likely to be sexually active. 
Depressive features including low self esteem and feelings of worthlessness are common, 
as are symptoms of anxiety which can be severe and disabling (Cooper and Fairburn, 
1986). In some patients, impulsive behaviours such as stealing, alcohol or drug abuse and 
sexual promiscuity are also seen (Fairburn, 1983 ). 
Physical complications may result from bulimia, usually from self-induced vomiting or 
purging behaviours and may become life-threatening. These include electrolyte imbalances 
which may induce cardiac arrhythmias, urinary infections and renal failure, epileptic 
seizures, tetany, swollen salivary glands, dental decay and widely fluctuating weight levels 
(Russell, 1979). 
1.1.3.3 Aetiological Theories 
In common with anorexia nervosa, the aetiology of bulimia nervosa remains unknown 
although again a complex interaction of biological, psychological and social factors has 
been proposed. Methodological limitations of studies on bulimic patients include the 
confounding effects of ongoing bingeing and purging, possible underlying malnutrition 
effects despite patients remaining within the normal weight range, the presence of affective 
illness or other co-morbidity such as substance abuse and an almost complete lack of 
studies on long-term recovered patients. 
Perhaps the most important predisposing factor so far identified is a past history of 
anorexia nervosa (Fairburn, 1983). While more than half of Russell's (1979) original group 
of bulimics had past histories of unequivocal anorexia nervosa (a rate now thought to 
reflect a unique referral population), a community study has suggested the true incidence 
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to be much less than 50%, including highly doubtful cases (Pyle et al, 1981). Indeed, 
Mitchell et al (1985) found that only 4.3% of his 275 bulimic patients had been treated in 
the past for anorexia nervosa or low body weight. Nevertheless, these rates are much 
higher than those seen in the general population. 
The importance of the patient's beliefs and attitudes to weight and shape are 
emphasised in the cognitive-behavioural model of bulimia nervosa. It is these attitudes that 
are seen as central to the maintenance of the disorder (Fairburn et al, 1986) and must 
therefore be altered before lasting recovery can occur. Typical belief systems include a 
tendency to evaluate self-worth and success only in terms of slimness and personal 
attractiveness, a vehement dislike of fatness and a positive attitude to the maintenance of 
self-control (Fairburn et al, 1986 ). While Fairburn points out that such attitudes are widely 
held in Western societies, it is the rigidity and extremity of the bulimic patient's beliefs 
(which are also seen as having great personal significance) that lead to dysfunctional styles 
of reasoning. Such thinking styles include "dichotomous thinking, overgeneralisation and 
errors of attribution" and through their emphasis on the extreme importance of weight and 
shape are thought to explain the maintenance of much of the patient's behaviour (Fairburn 
et al, 1986). The value of a cognitive-behavioural model can to some extent be evaluated 
by its treatment success. While short-term outcome appears as good as other treatment 
approaches, studies on long-term follow-up, allowing a better evaluation of lasting change 
to be made, are still not available. 
Some evidence now exists from family and twin studies for a genetic vulnerability in 
the development of the disorder, although similar methodological limitations outlined for 
the anorexia nervosa studies equally apply. Nevertheless, in an uncontrolled family study 
by Hudson et al (1983b) the prevalence of bulimia amongst relatives of bulimic probands 
was found to be 3.4%, while a controlled study by Kassett et al (1989), which included 
collecting information by direct interview, reported an increased risk of all eating disorders 
amongst relatives of bulimic probands compared to relatives of normal controls. Not all 
research groups, however, have demonstrated this increased risk for family members 
(Hudson et al, 1987; Logue et al, 1989). To date, only a few twin studies have been 
published but these also support the possibility of a genetic predisposition, with reported 
concordance rates for bulimia in monozygotic and dizygotic twins ranging between 
22.9%-83% and 0%-26.7% respectively (Logue et al, 1989; Fichter and Noegel, 1990; 
Hsu et al, 1990; Kendler et al, 1991 ). Fichter and Noegel's (1990) study also reported a 
higher concordance rate for any eating disorder between his monozygotic and dizygotic 
twins. 
A highly significant association has been found between bulimia nervosa and the 
affective disorders, especially depression, although the exact nature of the relationship 
remains uncertain (Russell, 1979; Hatsukami et al, 1984; Walters et al, 1992). While 
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depressive symptoms are commonly seen in patients suffering from bulimia nervosa and 
many patients meet diagnostic criteria for affective disorder at some stage in their lives 
(Pope et al, 1983; Mitchell et al, 1986; Fichter and Noegel, 1990), several studies have 
also reported higher rates of affective disorders amongst first-degree relatives of bulimic 
probands than amongst relatives of both psychiatric and normal controls (Hudson et al, 
1983a; Hudson et al, 1987; Kassett et al, 1989; Logue et al, 1989). One study by Wilson 
and Lindholm (1987), looking at fifty-seven bulimic patients, suggested a correlation 
between the severity of the eating disorder and the degree of depression. These authors 
reported that the more severe the bulimia, "the more likely the bulimic was to be suffering 
from depression to a very high degree". Other studies have reported higher than expected 
rates of substance abuse, both alcohol and drugs (Kassett et al, 1989) and obesity (Fairburn 
and Hay, In press) amongst relatives of bulimic probands and have suggested that these 
may also represent risk factors in the development of the disorder. 
Episodes of amenorrhoea or oligomenorrhoea are common features of bulimia nervosa 
(Fairburn and Cooper, 1984) in conjunction with other hormonal abnormalities 
(Gwirtsman et al, 1983; Levy et al, 1988; Coiro et al, 1992). Consequently, interest has 
developed in the concept of disturbances of the hypothalamic-pituitary-adrenal axis 
underlying bulimia nervosa or playing a role in its maintenance (Morley and Blundell, 
1988; Leibowitz, 1990; Kaye and Weltzin, 1991a). A consistent finding is a failure to 
suppress cortisol following a dexamethasone suppression test in normal weight bulimic 
women (Gwirtsman et al, 1983; Mitchell and Bantle, 1983 ). Failure of suppression may 
be a feature of concurrent depression, malnutrition and/or low weight (Gwirtsman et al, 
1983), a failure of bulimic patients to absorb or metabolise dexamethasone (Walsh et al, 
1987a) or intrinsic neurobiological abnormalities distinct from the above epiphenomena. 
Other abnormalities of the hypothalamic-pituitary-adrenal axis reported in normal 
weight bulimic women (although acutely ill) include delayed (Levy et al, 1988) or blunted 
thyroid stimulating hormone responses to TRH (Gwirtsman et al, 1983) and abnormal GH 
and cortisol responses to an intravenous glucose tolerance test (Coiro et al, 1992). Findings 
on hormone levels have been inconsistent, with twenty-four hour cortisol secretion 
reported as either normal (Walsh et al, 1987b; Weltzin et al, 1991) or elevated (Mortola et 
al, 1989); basal GH levels either normal (Kaye et al, 1989) or elevated ( Kiriike et al, 1987) 
while twenty-four hour secretion of GH was found to be normal by Weltzin et al, (1991). 
Similar inconsistencies have been seen with prolactin (PRL) and ACTH (Mitchell and 
Bantle, 1983; Levy et al, 1988; Kaye et al, 1989; Mortola et al, 1989; Weltzin et al, 
1991). In a more recent paper by Gwirtsman et al (1989a) some attempt to look at 
pituitary-adrenal function following abstinence of bingeing and vomiting was made by 
examining peripheral and central cortisol and ACTH levels. While indices of pituitary-
adrenal function were found to be normal in acutely ill bulimics who were still bingeing 
and vomiting, CSF ACTH levels were significantly reduced following one month of 
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abstinence. As the declines in CSF ACTH levels were found to be negatively correlated to 
individual patient's energy intake during abstinence, the authors raised the possibility that 
their results reflected the relative caloric restriction observed during abstinence in all their 
patients, compared to the same patients' intake while actively ill (and still bingeing and 
purging). 
Studies on neurotransmitter systems have consistently found abnormalities present in 
actively ill bulimics. Noradrenergic alterations have included reduced plasma and CSF 
noradrenaline levels (Kaye et al, 1990a; Kaye et al, 1990), while both lymphocyte and 
mononuclear leukocyte /3-adrenoceptor activity have also been reported to be increased, 
but this finding has not been consistent (Lonati-Galligani and Pirke, 1986; Buckholtz et 
al, 1988). Interestingly, in the study by Buckholtz et al (1988)' evidence for lymphocyte /3-
adrenergic hypersensitivity was also seen during the "controlled" phase of their patients' 
illnesses, defined as abstinence from bingeing and purging for three weeks, maintenance of 
a stable diet and weight stabilised within 15 % of that expected. Other researchers have 
found increased platelet a2-adrenoceptor activity (Heufelder et al, 1985) but this finding is 
not consistent with that of Kaplan et al (1989) who reported no differences in either 
MHPG levels or GH responses to the a2-agonist clonidine (when used as a neuroendocrine 
challenge), in both bulimics and controls. 
Few investigations have been reported on other neurotransmitter systems in bulimia, 
with the exception of the serotonergic system which will be discussed in detail later. CSF 
concentration of homovanillic acid, the major metabolite of dopamine has been reported as 
normal (Kaye et al, 1990a) or reduced (Jimerson et al, 1992) in acutely ill patients. 
Some evidence exists for peptide neuromodulator disturbance in bulimia nervosa. The 
peptide cholecystokinin and neuropeptides such as neuropeptide Y have been shown to be 
important in mediating satiety and in stimulating carbohydrate feeding respectively ( Gibbs 
et al, 1973; Smith and Gibbs, 1985; Stanley et al, 1986). Peripheral cholecystokinin is 
synthesised in the intestinal mucosa and is thought unlikely to cross the blood-brain-barrier 
so that its satiety promoting effects are mediated by vagal afferent fibres. Abundant 
cholecystokinin is also found in the brain and some evidence exists of a role for central 
nervous system cholecystokinin in the promotion of satiety (Baile and Della-Fera, 1985). 
Geracioti and Liddle (1988) found an impaired cholecystokinin response to food intake, 
along with impaired post-prandial satiety, in a group of fourteen bulimic women. In this 
study, not only were plasma cholecystokinin responses to a meal found to be reduced in 
bulimic patients when compared to controls, but a statistical correlation was found 
between the cholecystokinin levels and measures of satiety. The plasma cholecystokinin 
concentration in the bulimic patients, however, may also have been influenced by 
abnormalities of gastrointestinal physiology, such as delayed gastric emptying which has 
been recognised in bulimic patients (Robinson et al, 1988). Elevation of the CSF 
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concentration of another neuropeptide, peptide YY, has been reported in normal-weight 
bulimics following one month's abstinence from bingeing and purging, compared to 
themselves when acutely ill (Kaye et al, 1990b). The authors suggested that increased 
peptide YY activity may contribute to the drive to over-eat in these patients. 
In keeping with the studies on anorexia nervosa, no consistent personality type 
predisposes to the development of bulimia nervosa. Patients suffering from bulimia 
nervosa share the anorectic's discontent with their body shape and weight, tend to have low 
self esteem and a significant subgroup are reported as having impulse-control difficulties 
(Fairburn, 1983). A high rate of childhood sexual experiences has been reported by women 
with eating disorders (Palmer et al, 1990). Methodological problems existed with the early 
studies on sexual abuse and later, better designed research has not always confirmed the 
initial findings, raising the question of whether sexual abuse is indeed a specific risk factor 
(Fairburn and Hay, in press). 
Socio-cultural factors thought to be important for the large increase in cases of 
anorexia nervosa probably apply equally to bulimia nervosa and have been previously 
outlined. 
1.1.3.4 Treatment and Outcome 
Evaluation of the different treatment approaches to bulimia nervosa has been made 
difficult by an almost complete lack of controlled trials. In a recent review of the 
controlled studies looking at psychological treatments, Fairburn (1988) concluded that for 
most patients, an outpatient approach utilising some form of cognitive behavioural therapy 
provided the best results. He also stated that many questions are still to be answered; in 
particular, the role of drug treatment remains uncertain, as does that of some of the other 
psychotherapies, such as family therapy. 
Some attempts to determine the important components of psychotherapy that lead to a 
successful outcome have been made. In a study designed to evaluate the different 
components of cognitive behavioural therapy, Freeman et al (1988) found a purely 
behavioural approach to be as effective as one incorporating cognitive restructuring. 
Fairburn and colleagues however, conducted a similar comparison and found the 
behavioural approach inferior on most outcome measures including drop out from 
treatment, with drop out rates of 32% and 12% respectively for the behavioural and 
cognitive behavioural groups (Fairburn, 1988). Final evaluation of these contradictory 
results is still awaited as follow-up data are not yet available, but central to the discussion 
is the cognitive view that lasting recovery from bulimia nervosa depends not only on 
behavioural change but also upon changes in attitudes to body weight and shape (Fairburn, 
1988). 
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Preliminary evidence exists to suggest that psychotherapeutic treatments not 
incorporating a cognitive behavioural approach may be equally effective for bulimia 
nervosa. Kirkley et al (1985) compared group cognitive behavioural treatment with a form 
of non-directive group therapy and while at the end of the treatment phase the cognitive 
behavioural group were doing better, at three month follow-up, there were no longer 
differences between the groups. Seventy seven percent of the cognitive behavioural group 
and 78% of the non-directive group had achieved a 60% reduction in their vomiting 
frequency. Fairburn (1988) and colleagues have presented some preliminary results on a 
study looking at a three way comparison of behavioural therapy, cognitive behavioural 
therapy and modified interpersonal psychotherapy. This latter treatment "does not address 
the specific psychopathology of these patients: instead it concentrates exclusively on their 
mood and their relationships". To date, while the purely behavioural group has fared less 
well, the other two treatment groups have made equal progress, with decreases in both 
eating behaviour and in overall levels of general psychopathology. 
One controlled trial has compared family therapy with non-specific individual 
supportive psychotherapy. Russell et al (1987) randomly allocated twenty-three patients 
who met his criteria for bulimia nervosa (Russell, 1979) to either of the above groups for 
one year's treatment. The outcome was poor for both groups with the majority of patients 
showing little improvement and no difference was seen between treatment approaches but 
the results must be interpreted in the knowledge that the patients were largely composed of 
treatment resistant cases at a tertiary referral centre. Nor was treatment designed 
specifically for bulimia nervosa, rather the study was part of a major family therapy 
treatment trial for anorexia nervosa. 
Pharmacological treatment has been advocated because of its potential simplicity and 
cost effectiveness. Numerous controlled trials have now demonstrated antidepressant 
treatment to be superior to placebo in reducing abnormal eating behaviour, including 
binge-eating and vomiting, as well as improving the depressed mood that commonly 
accompanies bulimia nervosa. Amitriptyline (Mitchell and Groat, 1984), imipramine (Pope 
et al, 1983 ) and fluoxetine (Fluoxetine Bulimia Nervosa Collaborative Study Group, 
1992) have all been found significantly effective in this way. Interestingly, the effects on 
eating do not appear to depend upon mood change per se. In other words, an anti-bulimic 
effect has been proposed although the best antidepressant effects appear to be seen in those 
patients who also meet criteria for major depression at the start of treatment (Mitchell and 
Groat, 1984 ). The value of antidepressant treatment will not be determined until adequate 
follow-up studies are carried out. Only one such trial has done this and results suggested 
that often complicated drug regimes were required and discontinuation of medication often 
led to a return of symptoms (Fairburn, 1988). 
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There is a need to directly compare drug treatment with psychotherapeutic approaches. 
Mitchell et al (1990a) recently reported a controlled trial comparing imipramine treatment, 
placebo treatment, imipramine treatment plus intensive group psychotherapy and the same 
group psychotherapy plus placebo. All three active treatments resulted in significant 
improvements in eating behaviour and mood when compared to placebo. The results also 
suggested that the improvements seen with intensive group psychotherapy were superior to 
drug treatment and the addition of drug treatment to group psychotherapy did not add to 
those gains made by therapy alone when looking at eating behaviour. Symptoms of anxiety 
and depression were further improved by the combined treatment approach. 
It is clear from the published research that no single treatment for bulimia nervosa 
works for all patients. As is the case with anorexia nervosa, most clinicians adopt a flexible 
approach but usually incorporate some form of psychotherapy with or without 
antidepressant treatment. Subgroups of patients, such as those with histories of major 
weight fluctuations (either overweight or underweight), personality difficulties or multiple 
addictive behaviours will continue to have special needs (Fairburn, 1988). The results of 
long-term follow-up studies are needed to enable optimisation of treatment in terms of the 
maintenance of initial symptom improvement. 
When Russell first drew attention to a subgroup of eating disordered patients with 
bulimic and purging behaviour in the presence of normal weight, he proposed that bulimia 
nervosa may represent an "ominous variant of anorexia nervosa" (Russell, 1979). In the 
absence of longer term follow-up data, he proposed that the prognosis was likely to be 
similar to the poor outcome seen in anorectics who were also habitual bingers and purgers. 
Theander (1970) and Hsu et al (1979) had also reported an association between severe 
self-induced vomiting and a more serious outcome in anorexia nervosa. Russell ( 1979) 
further based his pessimism upon the increased resistance to treatment, the more frequent 
and serious nature of physical complications and the "considerable" risk of suicide he had 
observed in his original group of patients. 
Although long-term outcome studies are still awaited on bulimia nervosa, more recent 
literature has suggested that the prognosis for this disorder, at least in the intermediate 
term, is somewhat better than Russell first suggested. A dozen or so studies have been 
published with follow-up periods of one to five years, including those of Fairburn et al 
(1986), Swift et al (1987), Hsu and Sobkiewicz (1989), Herzog et al (1991) and Lacey 
(1983). While most have methodological short comings such as retrospective data 
collection, selected patient populations and differing diagnostic criteria and outcome 
measures, overall they lend support to the view that bulimia nervosa can follow a chronic, 
fluctuating course and that outcome has a somewhat heterogeneous pattern. 
As might be expected, rates of recovery appear to vary depending upon patient 
selection criteria. The best rates have been reported for outpatient groups who have 
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completed treatment programs (Lacey, 1983; Fairburn et al, 1986) and the least promising 
results are seen with inpatient populations (Swift et al, 1987). Recovery rates of 30% to 
70% and 13-40% (for at least twelve months follow-up), for outpatient and inpatient 
groups respectively have been reported, with significant improvements in symptoms such 
as vomiting and bingeing, along with enhanced social functioning, improved depressive 
features and menstruation ( Swift et al, 1987). 
Hsu and Sobkiewicz (1989) reported on a consecutive series of forty-five bulimic 
patients who had been followed for four to six years after termination of treatment. Of the 
thirty-five patients successfully followed, 16% still met criteria for bulimia nervosa while a 
further 16% had occasionally binged or purged in the previous six months and were 
therefore diagnosed as subclinical cases. These authors also compared patients' current 
status to that found at an earlier assessment taken at one to three years post treatment. Most 
patients who had received "good" outcomes at the earlier assessment maintained their 
improvement with sixteen of the twenty-three "good outcome" subjects having no bulimic 
features. In contrast, of the seventeen patients with bulimic features at the first follow-up, 
only five had recovered by the second assessment. 
A recent study looking at mortality rates in bulimia nervosa has suggested lower 
figures than those originally thought probable by Russell (1979) in his initial report. Patton 
(1988) looked at a series of 460 consecutive patients with eating disorders seen between 
1971 and 1981 and found a crude mortality rate of 3 .1 % for those with bulimia nervosa, 
although it should be noted that the minimum follow-up period was only four years. 
1.1.4. DIETING BEHAVIOUR IN THE NORMAL POPULATION 
1.1.4.1 Epidemiology 
Most surveys looking at dieting behaviour amongst the normal population have studied 
those groups at high risk from developing the eating disorders, such as adolescent and 
school-age populations. Consequently, few data define the rates of dieting in the 
population at large. While caution must be applied in generalising findings from 
adolescent groups to the entire community, such studies are of particular interest as they 
reflect eating behaviours and attitudes occurring at the age of onset for the development of 
anorexia and bulimia nervosa. 
The experience of feeling "too fat" is reported by most girls at some stage during their 
adolescence (Nylander, 1971; Leichner et al, 1986), an experience that increases with age 
(Nylander, 1971) and is more prevalent amongst those of higher body weight (Dwyer et al, 
1967). Similarly, concerns about overweight and overeating are reported more often 
amongst girls than boys (Whitaker et al, 1989) with between 63-70% of high school girls 
reporting dissatisfaction with and wanting to reduce their weight (Huenemann et al, 1966). 
In contrast, most adolescent males report a wish to gain weight. 
,, 
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Although many methods of weight control are common amongst young women 
(Whitaker et al, 1989), dieting is said to be the most common behavioural response to the 
experience of feeling fat (Huenemann et al, 1966). It is not surprising, therefore, that 
dieting behaviour is also highly prevalent amongst adolescents. In an unselected English 
state-schoolgirl population, Johnson-Sabine et al (1988) found that 20% of fourteen to 
sixteen year olds were currently dieting and a follow-up study twelve months later (Patton 
et al, 1990) continued to demonstrate a dieting point prevalence rate of 21.3%. The 
prevalence of dieting amongst girls appears to increase with age, at least until mid-
adolescence, and to be most common amongst those who are heavier (Dwyer et al, 1967; 
Nylander, 1971; Whitaker et al, 1989). Whitaker et al, (1989) surveyed 91 % of an 
American county high school population and found the rate of dieting amongst girls 
increased from 13% per year for thirteen year-olds to 42% per year at aged sixteen. In 
contrast, dieting rates amongst boys remained steady at 8 % per year between the ages of 
twelve and sixteen. Indeed, 50% of the entire female school population had initiated 
dieting by the age of 14.8 years while 50% of the males had still not dieted by the age of 
nineteen. 
In his prospective follow-up study, Patton et al (1990) attempted to identify amongst 
schoolgirls those factors associated with attempts at weight control. He found that a 
childhood history of obesity, currently being heavier than average, having a family history 
of obesity or a mother perceived as thin, along with a personal history of amenorrhoea and 
current high levels of stress (either social, home life or financial in origin) were all factors 
predictive of attempts at weight control. The discrepancy between a girl's perceived weight 
and her ideal weight also seems to be an important determinant of dieting, regardless of her 
actual body weight (Dwyer et al, 1967). 
Weight concerns and dieting behaviour are not just confined to adolescence. Several 
recent community studies have clearly demonstrated that abnormal eating attitudes and 
dieting behaviours are common place in the general population, especially amongst young 
adults (Cooper and Fairburn, 1983; Cooper et al, 1987; Bushnell et al, 1990). A 
preoccupation with the desire to be thin and dissatisfaction with one's own body weight 
and shape persist into adulthood, particularly amongst women (Bushnell et al, 1990). Both 
young adult males and females report binge-eating on a regular basis with a smaller 
percentage using behaviours such as self-induced vomiting, strenuous exercise, diet pills or 
laxatives as weight control measures (Halmi et al, 1981; Bushnell et al, 1990). 
J akobovits et al ( 1977) reported that 11 % of the female college population he studied 
were on a diet, while a further 75% were consciously trying to limit their food intake. 
Other authors have linked dieting behaviour and the pursuit of thinness, at least in the 
North American population, to higher social class (Goldblatt et al, 1965) while Garner et 
al (1980) have reported on the more widespread sociocultural expectations placed upon 
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Western women to conform to the currently idealised thin female shape. Evidence is now 
emerging to suggest that such strong expectations are beginning to having effects across 
cultural boundaries, amongst women of immigrant groups living in Western societies 
(Dolan et al, 1990). 
1.1.4.2 Psychological Effects of Dieting 
Food restriction has clear implications for an organism in terms of survival and its 
ability to function well. Despite the importance of adequate nutrition, relatively little 
research has been carried out on the effects of dieting and food restriction in humans. 
Much of the existing literature on dieting in normal populations has developed from the 
eating disorders literature, and has therefore often been a series of analogue studies seeking 
to understand clinical eating disorders using populations of healthy volunteers. More 
recently, there has been a move towards examining the psychological consequences of 
dieting and food restriction, coupled with attempts to delineate eating behaviour patterns in 
healthy subjects. 
Effects of Dieting on Psychological Functioning 
Little work has been carried out in the area of how dieting may effect psychological 
functioning. The first direct evidence came from a Minnesota study (Keys et al, 1950) 
which identified a large number of psychological and physiological changes associated 
with weight loss over twenty-four weeks. The main findings were of subjective increases 
in lethargy, depression and irritability along with decreased ratings of energy. 
More recently, it has been shown that female dieters perform less well on demanding 
cognitive tasks compared to non-dieters of both high and low restraint (Rogers and Green, 
1993). This finding has since been replicated (Green et al, in press), demonstrating that the 
performance deficits encompass a range of behaviours including reaction times and 
memory (impaired recall). 
Cognitive functioning in the eating disorders themselves have similarly been poorly 
studied. One group of researchers have reported impaired performance in a group of 
patients with bulimia nervosa compared to healthy controls (Laessle et al, 1990), with a 
correlation seen between metabolic signs of starvation and the size of impaired 
performance on tasks. General cognitive impairment has been demonstrated in restricting 
anorectics (Fox, 1981 ), while Hamsher et al l (981) have shown that deficits in attention 
also occur in this same subgroup. 
What is not clear is whether cognitive defects are the result of food deprivation or form 
an intrinsic part of the eating disorder itself but they are thought to play a role in the 
maintenance of abnormal eating behaviours (Fairburn et al, 1986). 
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Effects of Dieting on Mood 
Evidence for an association between dieting and mood changes remains equivocal. 
Few studies have examined the effects of dieting on mood in healthy populations but those 
that have have yielded contradictory results. Keys et al (Keys et al, 1950) reported a 
decrease in mood following a twenty-four week semi-starvation diet and this finding was 
later replicated by Fichter et al (Fichter et al, 1985) studying five healthy volunteers placed 
on a three week starvation regime. In contrast, however, Pirke et al (Pirke et al, 1985b) 
found no change in mood across a six week diet and reported no change following a two 
week dieting period. 
1.1.4.3 Dieting, Eating Disturbance and Eating Disorders 
In recent years, interest has grown in the concept that dieting behaviour may act as a 
risk factor in the development of the eating disorders, thus moving away from the 
traditional clinical stance which viewed dieting simply as a symptom of the established 
illness. The concern that dieting behaviour plays a role in the establishment of disturbed 
eating and eating disorders comes from research encompassing mainstream psychology 
and more directly, clinical studies of eating disordered populations. 
Much of our understanding of the link between dieting and disordered eating comes from 
the area of psychology. Wardle and Beinart (1981) and Polivy and Herman (1985) have 
proposed that an association, perhaps even causal, may exist between excessive dietary 
restraint (ie. the conscious control of food intake in order to prevent weight gain or 
promote weight loss) and binge-eating. Although it is increasingly recognised that 
episodes of bingeing, food cravings and difficulties with stopping eating once started are 
behaviours that occur in unrestrained eaters and are in themselves probably not abnormal, 
the frequency of these activities is much greater in restrained eaters (Wardle and Beinart, 
1981). Bingeing may represent a physiological response to short periods of starvation or to 
trying to maintain one's weight below a natural "set-point" for body weight which has been 
proposed by Nisbett (1972) to exist for us all. 
Recent laboratory research in the area of "counter-regulation" has suggested that 
cognitive factors may also be important in the mechanism leading to bingeing. Counter-
regulation refers to the phenomena whereby highly restrained eaters will eat more 
following a large energy preload compared to a no preload condition, a response in direct 
contrast to that seen in unrestrained eaters and to what might be expected in purely 
physiological terms (Hibscher and Herman, 1977). Counter-regulation has also been 
shown to occur in dieters, where Herman and Mack (1975) demonstrated that dieters ate 
more following a milkshake (preload condition) than after no milkshake (no preload 
condition). The importance of the belief regarding the amount of calories consumed, rather 
than the actual energy load ingested, was further demonstrated by Wooley (1972) and it 
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has been suggested that once the dieter thinks she has overeaten or exceeded her dietary 
allowance, she abandons all dietary restraint. A similar mechanism has been proposed to 
underlie binge-eating. No direct evidence exists that this cognitive process is necessary to 
the process of counter-regulation which occurs in dieters, or that it is indeed present 
(Jansen et al, 1988; Jansen, 1990). 
Animal studies have provided further evidence of the link between food restriction and 
the subsequent development of abnormal eating. Young female rats will normally gain 
weight on an ad libitum diet of palatable food. An experiment by Coscina and Dixon 
(1983), however, demonstrated that a group of previously food deprived rats gained 
significantly more weight than controls, and that the weight gain was in direct proportion 
to the length of previous food deprivation. The differential weight gain was shown to be a 
result of difference in food consumption rather than metabolic alterations. This animal 
model suggests that prior deprivation influences the tendency to overeat even after weight 
loss has been restored. 
For the substantial proportion of eating disordered patients who develop binge-eating, 
even where a past history of frank anorexia nervosa does not exist, it is usual for a period 
of food restriction or dieting to have preceded the onset of binge-eating. Additionally, the 
clinical picture frequently consists of alternate severe food restriction and compensatory 
bingeing (Fairburn, 1983 ). Clinical case reports suggest that bulimic anorectic patients 
often have marked periods of weight loss in the year preceding the onset of bulimia 
(Russell, 1979). Garfinkel et al (1980) demonstrated that in a group of sixty-eight bulimic 
anorectic patients, their bulimia developed a mean of 19.2 +/- 8 months after the onset of 
dieting. A similar pattern is also seen in normal weight bulimics and in obese subjects 
where Telch and Agras (1993) demonstrated that 62% of obese non-binge eaters reported 
an onset of binge-eating episodes in the three month period immediately after concluding a 
twelve week very low calorie diet. 
Few data exist on dieting in normal populations. Most dramatic is the evidence from 
Keys et al (1950) who studied the effects of starvation on World War II conscientious 
objectors. These men were placed on a twenty-four week semi-starvation diet resulting in a 
weight loss equal to 26% of their body mass. Upon refeeding and a return to their normal 
body weight, they continued to exhibit a persistent tendency to binge, often to the limit of 
their physical capacity, a behaviour that had not been present premorbidly. More recently, 
Warren and Cooper (1988) found increased ratings of food preoccupation, increased urges 
to eat more frequently and feelings of lack of control over eating in fourteen people placed 
on a three week calorie controlled diet. 
Evidence from several epidemiological studies has suggested that disordered eating 
patterns and the eating disorders themselves may arise out of "normal" dieting or follow 
periods of unintentional weight loss (Theander, 1970; Johnson-Sabine et al, 1988). Two 
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studies, following a prospective design in an "at risk" group (London schoolgirls), 
illustrate this first point (Johnson-Sabine et al, 1988; Patton et al, 1990). The point 
prevalence of dieting over the two years encompassed by the study remained steady at 
about 20%, with considerable movement occurring in and out of the dieting group over 
time. While Patton et al (1990) found that the majority of dieters either did not progress 
from "simple" dieting or had ceased dieting altogether within twelve months, 21 % of the 
original dieters had in fact developed eating disorders during this interval and constituted 
50% of the new cases found at second interview. In contrast, less than 1 % of girls 
classified as non-dieters in the original survey were diagnosed as cases at follow-up. The 
authors concluded that "the relative risk in the total study population for a dieter of being 
diagnosed a case at follow-up was nearly eight times that of non-dieters". 
As outlined above, evidence exists from a wide range of studies to suggest that dieting 
behaviour may predispose to the development of the eating disorders. What remains poorly 
understood is the mechanism underlying the transition from normal dieting to abnormal 
eating. In particular, little research has been carried out on the neurobiological 
consequences of food restriction which, it could be argued, mediate the behavioural 
changes accompanying dieting. 
1.2 5-HYDROXYTRYPTAMINE 
1.2.1 5-HYDROXYTRYPTAMINE BIOCHEMISTRY 
1.2.1.1 Tryptophan and Transportation to the Brain 
The mammalian brain utilises a number of monoamines as neurotransmitters. One of 
these, the indoleamine serotonin, is synthesised in the brain from the amino acid 
tryptophan (TRP) via the 5-hydroxyindole pathway. TRP cannot be synthesised by 
mammalian cells and is therefore an essential amino acid which must be obtained either 
from dietary sources, breakdown of tissues protein, or from lysis of neuronal proteins 
(Wurtman, 1978; Wurtman et al, 1981). 
TRP is transported into the brain via the blood-brain-barrier. Here, as a large neutral 
amino acid (LNAA), it is in direct competition with other LNAAs (ie. the aromatic amines 
such as tyrosine and threonine and the branch chain amino acids including isoleucine, 
leucine and valine) for the transportation carrier (Wurtman et al, 1981 ). Thus, it is the ratio 
of TRP to other LNAAs that determines the amount of TRP being transported and 
consequently, it is argued that the entry of circulating TRP into the brain can be 
accelerated by either raising plasma TRP or by lowering plasma levels of other LNAAs 
(Fernstrom and Wurtman, 1972). That this regulatory system is important in controlling 
levels of brain TRP is supported by animal studies in the rat that have shown that the major 
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metabolic consequence of TRP administration is to stimulate 5-hydroxytryptamine (5-HT) 
synthesis (Fernstrom, 1983). 
In plasma, TRP in the L-isomer form binds to serum albumin and under normal 
physiological conditions, only ,.,10% remains unbound (free TRP). TRP is loosely bound, 
however, to its albumin carrier and is rapidly stripped off its binding site once inside the 
brain (Yuwiler et al, 1977). In plasma, non-esterified fatty acids will directly compete with 
TRP for albumin binding sites, displacing TRP, and thus increasing the availability of free 
TRP (Curzon et al, 1973). 
Considerable debate exists in the literature as to whether it is the ratio of free or total 
TRP to other LNAAs that is important in determining the rate at which TRP will enter the 
brain. Wurtman (1978) has argued that it is the ratio of total TRP to competing LNAAs 
that is the determining factor, while Bloxam and Curzon (1978) suggest free TRP levels 
are more important. In a series of experiments in the rat, Fernstrom et al (1976) compared 
brain TRP levels with plasma free TRP, plasma total TRP and the ratio of both free and 
total TRP to other LNAAs. They concluded from this work that the best correlations of 
brain function were with measures of total rather than free plasma TRP. The findings of 
Curzon (1988), however, are in direct conflict. His refeeding experiments in the rat have 
shown that the ratio of total plasma TRP to LNAAs remains constant while an overall fall 
in brain TRP, plasma free TRP and consequently, in the ratio of free plasma TRP to other 
LNAAs occurred. No alteration in the ratio of total plasma TRP to LNAAs was found, 
indeed, an increase in plasma total TRP was noted (Sarna et al, 1984 ). How the animal 
studies relate to changes that may occur in humans is unclear. 
Methodological difficulties ensure that human studies directly measuring brain TRP 
levels are almost impossible to carry out, but one such study by Gillman et al (1981) 
reported good correlations between serum free TRP and brain TRP levels in depressed 
human subjects undergoing psychosurgery. Poor correlations were seen between serum 
total TRP or the ratio of plasma TRP to LNAA and brain TRP. This study was complicated 
by the fact that its subjects were depressed. Another human study, utilising CSF TRP as an 
indirect index of brain TRP levels concluded that the relationship between plasma free 
TRP and brain TRP was not clear cut (Perez-Cruet et al, 1974), illustrating the complexity 
of the situation in vivo and the potential interaction between nutrient status and 
neurotransmitter regulation. 
1.2.1.2 5-HT Synthesis and Metabolism 
Monoamine neurotransmitter synthesis is controlled by the hydroxylase enzymes. In 
the formation of 5-HT, the essential amino acid TRP initially undergoes hydroxylation to 
form 5-hydroxytryptophan. The reaction is catalysed by the enzyme tryptophan 
hydroxylase, which is exclusively localised within 5-HT-producing neurones (Lovenberg 
't 
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et al, 1968). Under normal physiological conditions, tryptophan hyroxylase is only 50% 
saturated with substrate and acts as the rate limiting step in the synthesis of serotonin. 
Early animal research established that alterations in levels of brain TRP directly affect the 
degree of enzyme saturation, in turn driving TRP hydroxylation and determining the rate 
of 5-hydroxytryptophan, and ultimately, 5-HT production (Ashcroft et al, 1965; 
Fernstrom and Wurtman, 1971 b; Grahame-Smith, 1971 ). Therefore, the hypothesis is that 
substrate availability rather than end-product inhibition controls 5-HT synthesis in the 
brain, although some debate exists (Fernstrom, 1983 ). The final step in synthesis is 
conversion of 5-hydroxytryptophan to 5-HT by the enzyme aromatic L-amino acid 
decarboxylase (Lovenberg et al, 1962). Activity of the latter enzyme is much greater than 
that of tryptophan hydroxylase (Ichiyama et al, 1968) and normally, little 5-
hydroxytryptophan is found within the mammalian brain (Fernstrom, 1983 ). Once formed, 
5-HT is stored in granules at the presynaptic nerve terminals ready for release. 
The main 5-HT metabolite in the brain is 5-hydroxyindoloacetic acid (5-HIAA) which 
is formed by a two step process. 5-HT is first oxidised to 5-hydroxyindoleacetaldehyde by 
monoamine oxidase (MAO) and then dehydrogenated to 5-HIAA by aldehyde 
dehydrogenase. A small amount of 5-hydroxyindoleacetaldehyde also appears to be 
reduced to 5-hydroxytryptophol by aldehyde reductase (Cheifetz and Warsh, 1980). Other 
minor metabolic pathways exist including a conjugation pathway to a sulphate derivative, 
and action by N-methyl transferase to produce methylated compounds such as bufotenin. 
1.2.2 5-HT NEUROANATOMY AND CLASSIFICATION 
1.2.2.15-HT Pathways 
Serotonin is one of the most phylogenetically ancient neurotransmitters. 5-HT 
neurones mature early in fetal life and have widespread projections throughout the central 
nervous system. Serotonergic cell bodies are largely confined to the brain stem and in 
1964, Dahlstrom and Fuxe ( 1964) described nine groups in the rat brain ( designated B 1-
B 9) corresponding largely to the raphe nuclei (figure 1.1; see over). Of these, groups B6 
and B7 (the largest group of serotonergic neurones) are usually grouped together as 
comprising the dorsal raphe nucleus, while the BS cell group comprises the median raphe 
nucleus (Molliver, 1987). A third cluster, known as B9, is located in the rostral brainstem 
and corresponds in part to the tegmental reticular nucleus of the pons (Sipe et al, 1978 ). It 
is these three raphe groups, ie. the dorsal raphe nucleus, median raphe nucleus and B9, that 
are thought to be of particular significance in that they give rise to most of the ascending 
serotonergic projections to the forebrain (Molliver, 1987). 
Most serotonergic projections ascend to the forebrain via the medial forebrain bundle, 
which is situated in the lateral hypothalamus (Anden et al, 1966). They then fan out to 
reach the neocortex, septum, hippocampus, amygdala, cingulum, olfactory bulb and 
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ventrolateral cortical regions (Parent et al, 1981). These projections appear to be organised 
into two distinct systems with studies demonstrating that the dorsal and median raphe 
nuclei have different patterns of innervation within the forebrain, along with distinct 
morphology of their axon terminals (Kohler, 1982; Kohler and Steinbusch, 1982; 
O'Hearn and Molliver, 1984 ). Serotonergic projections from the median raphe nucleus are 
found preferentially in the hippocampus and septum. These axons are relatively coarse and 
beaded, with large spherical varicosities. Those from the dorsal raphe nucleus on the other ... 
hand, project primarily to the cortex and striatum, are very fine in structure and particularly 
sensitive to the neurotoxic effects of amphetamine derivatives (O'Hearn et al, 1988). 
Moreover, the two axon types have different pharmacological properties and are therefore 
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Figure 1.1 Serotonergic pathways in the rat brain. 
Recently, it was discovered that the fine 5-HT axon terminals (from the dorsal raphe 
nucleus) were most closely associated with 5-HT 2 receptors (Kosofsky and Molliver, 
1987). This finding has further suggested that separate serotonergic projections arising 
from different raphe nuclei may terminate in relation to specific 5-HT receptor subtypes, 
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raising the possibility that separate projections may subserve different functions (Molliver, 
1987). 
Thus it would appear that 5-HT innervation of the cortex and limbic system does not 
function in a homogeneous way, but consists of distinct neuronal projections with high 
degrees of anatomical, morphological and pharmacological specialisation (Molliver, 1987; 
Cowen, 1991). Such an organisational pattern may well have major implications for our 
understanding of psychiatric illness. In particular, Cowen (1991) has suggested that, as 
evidence from animal studies supports the hypothesis that 5-HT pathways regulate many 
behavioural and affective states that are disturbed in psychiatric illness, the presence of 
distinct pathways provides us with an opportunity to investigate specific behaviours using 
selective pharmacological agents. 
1.2.2.2 Receptor Subtypes 
In 1957, it was first reported by Gaddum and Picarelli that 5-HT interacted with at 
least two distinct receptors in the guinea pig. Since then, our knowledge about this diverse 
system of neurotransmitter receptors has expanded rapidly, with the seminal delineation of 
5-HT I from 5-HT2 receptors by Peroutka et al (1979) and the subsequent classification of 
5-HT receptors into three main families (5-HT I, 5-HT 2 and 5-HT 3 ) based upon binding 
affinities and ligand studies by Bradley et al (1986). It was also shown that these three 
families could be separated largely by nature of their secondary messenger systems, ie. the 
mechanisms that mediate the intracellular responses to receptor activation (Cowen, 1991). 
More recent work, especially in the area of molecular biology, has served to confirm and 
extend the view of the distinct identity of these three groups (Humphrey et al, 1993 ), but 
has also led to the identification of an additional class of 5-HT receptors (designated 5-
HT 4), as well as highlighting areas of dissatisfaction within the existing classification 
system. Through the cloning and sequencing of receptors, it has been realised that no 
single criterion, such as the action of specific ligands, should be used alone to classify 
receptors. Pertinent to this issue has been the debate surrounding the correct nomenclature 
of the 5-HT IC receptor, thought for many years to be more closely linked to the 5-HT 2 
family. The result has been the introduction of a new classification by the Serotonin Club 
Receptor Nomenclature Committee (Humphrey et al, 1993) that has included the newly 
identified 5-HT 4 receptor family (Bockaert et al, 1990). 
This thesis adopts the new classification system outlined in Table 1.1 (see over) 
alongside the traditional system. 
5-HT1 Receptor Family 
Under the new classification, the 5-HTI family is subdivided into 5-HTIA, 5-HT rn, 5-
HT m, 5-HT IE and 5-HT IF (Heuring and Peroutka, 1987; Humphrey et al, 1993), with the 
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5-HT IC receptor now transferred to the 5-HT 2 family, and renamed 5-HT 2c (see Tablel.). 
The 5-HT I family shares nanomolar affinity for 5-HT and carboxyamidotryptamine, and 
micromolar affinity for 5-HT antagonists such as ketanserin and mesulergine. The 5-HT I 
receptors also share the property of linkage to a G-protein as their secondary messenger 
system, the activation of which leads to the inhibition of adenylate cyclase (Peroutka, 
1988). 
T bl 11 5 HT a e - receptor f ·1 1 "f am1 y c ass1 1cat10n 
SUPERFAMIL Y GROUP RECEPTOR PREVIOUS NAME 
SUBTYPE 
G-Protein 5-HTI 5-HT IA G21 
5-HT 1B 5-HT IDB 
5-HT ID a 5-HT ID 
5-HT IDB 5-HT 1B 
5-HT IE 
5-HT IF 5-HT 6, 5-HT IBB 
G-Protein 5-HT2 5-HT2A "classical" 5-HT2 
5-HT 28 5-HT 2F 
5-HT2c 5-HT IC 
Ligand-gated 5-HT 3 M 
G-Protein 5-HT4 
From Humphrey et al (1993) 
5-HT 1A receptors are regarded as being the phylogenetically oldest members of this 
family. Recently, specific radioligands have been developed for the 5-HT 1A receptor, the 
prototype of which is the aminotetralin, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-0H-
DP AT) (Hoyer et al, 1985). 5-HT I A receptors also display high affinity for some 
pyrimidinylpiperazines (eg. ipsapirone and buspirone) (Traber and Glaser, 1987), and 
benzodioxanes (eg. spiroxatrine, MDL 72832). These receptors have a heterogeneous 
distribution in the brain with high concentrations found on the cell bodies of 5-HT 
neurones in the raphe nuclei and at post synaptic locations in the hippocampus, amygdala 
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and certain hypothalamic nuclei (Pazos et al, 1988). The 5-HT lA receptors on the cell 
bodies act as autoreceptors having an inhibitory effect upon 5-HT neuronal firing. Thus the 
administration of a selective 5-HT 1A agonist such as 8-0H-DPAT leads to decreased raphe 
cell firing and a subsequent diminished release of 5-HT (Sharp et al, 1989). Activation of 
post-synaptic 5-HT lA receptors on the other hand, mediates the effects of 5-HT released 
from the nerve terminals of which a typical response is post-synaptic cell hyperpolarisation 
due to entry of potassium ions (Bobker and Williams, 1990; Cowen, 1991 ). 
5-HT 1B receptors are species specific and so far have been found only in the rat, 
mouse, and hamster brain (Hoyer and Middlemiss, 1989). In the rodent they are present in 
high densities in the basal ganglia (Pazos et al, 1988) and have high affinity for 5-HT, (-) 
pindolol and relatively low affinity for 8-0H-DPAT or buspirone. The human equivalent is 
the 5-HT m~ receptor (see Table 1.1), although this differs from the rat 5-HT 1B receptor in 
displaying typical 5-HT m characteristics (eg. ,B-adrenergic antagonists have low affinity). 
5-HT m receptors are found in the striatum, substantia nigra, neocortex and 
hypothalamus (Pazos et al, 1988), where in species lacking 5-HT18 receptors, (eg. 
primates), they function as nerve terminal autoreceptors, regulating the release of 5-HT 
(Schlicker et al, 1989). To date, few selective ligands for the 5-HT 10 receptor exist, but 
recently sumatriptan (GR 43175) has been described as a selective 5-HT 10 agonist 
(Schoeffter and Hoyer, 1989). 
5-HT2 Receptor Family 
The 5-HT 2 family consists of 5-HT2A, 5-HT 2B and 5-HT2c (previously 5-HT 1c). These 
receptor subtypes share a common secondary messenger system linked to G-proteins 
which involves hydrolysis of phosphoinositides and mobilisation of intracellular calcium 
(Hoyer, 1988b; Hartig, 1989) and are located post-synaptically. 5-HT2A receptors are 
found in high concentrations in the cerebral cortex, certain regions of the amygdala, 
cingulate and hippocampus, while 5-HT2c receptors are concentrated in the choroid 
plexus, basal ganglia, cerebral cortex, hippocampus and hypothalamus (Pazos et al, 1988). 
5-HT3 Receptor Family 
First identified in the peripheral nervous system, 5-HT 3 receptor binding sites have 
only recently been located in the central nervous system (Kilpatrick et al, 1987). This 
family of receptors differs from that of the 5-HT 1 and 5-HT 2 classes in that they are 
directly coupled to ion channels without intervening G-proteins or secondary messenger 
systems (Peroutka, 1988 ). On the basis of binding studies with selective antagonists, it has 
been suggested that receptor subtypes exist, but further studies are required to confirm this 
(Peroutka, 1988). Within the central nervous system, 5-HT3 receptors are found in highest 
concentration in the brain stem in the region of the nucleus tractus solitarius (Pratt et al, 
"f 
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1990) and in lesser numbers in the limbic system, including the hippocampus and 
amygdala, as well as regions of the entorrhinal cortex (Kilpatrick et al, 1987). 
5-HT4 Receptor Family 
Little has yet been published on the 5-HT 4 family of receptors. It appears that the 
receptors are G-protein linked (Humphrey et al, 1993) and positively coupled to adenylate 
cyclase (Dumuis et al, 1988). 
1.2.3 THE ROLE OF 5-HT IN THE BRAIN 
Evidence now exists to suggest that serotonin plays a significant role in the control of 
many aspects of human emotions and behaviour, including mood (Meltzer and Nash, 
1988; Deakin and Graeff, 1991; Power and Cowen, 1992), appetite and food intake 
(Blundell, 1984; Leibowitz and Shor-Posner, 1986; Silverstone and Goodall, 1986) and 
aggressive and impulsive behaviour (Shaw et al, 1967; Linnoila et al, 1992). While 
abnormalities are seen within all these areas during episodes of clinical eating disorders, a 
full review is beyond the scope of this thesis. Emphasis will, therefore, be given to two 
areas most directly implicated in the pathogenesis of eating disorders, that is the role of 
serotonin in feeding behaviour and mood. 
1.2.3.15-HT and Feeding Behaviour 
It is now firmly established that brain serotonin plays a central role in the control of 
feeding behaviour in both animals and humans (Samanin, 1983; Blundell, 1984; 
Leibowitz and Shor-Posner, 1986; Curzon, 1990). One of the most striking and consistent 
findings in this area of research has been the suppression of food intake by experimental 
conditions that either directly, or indirectly, enhance brain 5-HT neurotransmission. The 
converse of this effect, ie. an increase in food consumption accompanying reduced brain 5-
HT has also been demonstrated but appears to be a less robust phenomenon more sensitive 
to experimental design. More recent experiments have further suggested that 5-HT may 
also be important in controlling circadian patterns of feeding and in determining 
macronutrient choice through satiety mechanisms involving the termination of feeding 
behaviour (Leibowitz, 1990). 
Animal Studies 
The earliest studies to provide evidence that brain 5-HT mechanisms were important in 
the control of food intake came from research in rats. Peripheral administration of TRP 
(Fletcher and Burton, 1984) and 5-hydroxytryptophan (Joyce and Mrosovsky, 1964 ), 
precursors of serotonin, were both found to suppress food consumption. Similar results 
were then demonstrated utilising a wide range of peripherally administered drugs which all 
had the net effect of enhancing brain 5-HT function. 5-HT agonists such as quipazine 
... )~ 
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(Samanin et al, 1977 ), meta-chlorophenylpiperazine ( mCPP) ( Samanin et al, 1979 ), the 5-
HT releasing drug d-fenfluramine (Samanin et al, 1980), and 5-HT reuptake inhibitors 
including fluoxetine and zimelidine (Leibowitz, 1990) were all shown to produce 
hypophagia. Evidence for a major role by serotonergic receptors in mediating the action of 
these peripherally administered drugs was supplied by studies demonstrating that centrally 
acting, but not peripherally acting, 5-HT antagonists reversed the fenflurarnine-induced 
suppression of feeding (Carruba et al, 1986). In addition, fenfluramine-induced anorexia 
was found to be attenuated by neurotoxin (Clineschmidt, 1973) or electrolytic lesions 
(Samanin et al, 1972) which depleted brain 5-HT stores. 
Other experiments in the rat have looked at the effects of central nervous system 
manipulations on anorexia. Bilateral intraventricular injections of the neurotoxin p-
chlorophenylalanine, which causes marked depletion of presynaptic brain 5-HT, was found 
to produce clear hyperphagia with transient weight gain (Breisch et al, 1976). Similar 
findings followed 5-HT depletion in the septum, hippocampus and hypothalalmus by 
another neurotoxin, 5,7-dihydroxytryptamine (Saller and Stricker, 1976), although these 
findings were not universal (Hoebel et al, 1978). In a study by Waldbilling et al (1981), 
chemical depletion of hippocampal and hypothalamic serotonin led to an increase in food 
intake but this was only sustained in those rats on a high fat (highly palatable) diet, 
suggesting serotonin depletion augmented the capacity of a highly preferred diet to 
increase food consumption. It has been suggested that this interaction between central 
manipulation and diet composition may account for some of the negative findings 
following brain serotonin depletion (Blundell, 1984). Brain 5-HT depletion has also been 
achieved by surgical lesions. Lesions of the media forebrain and midbrain tegrnentum have 
been found to cause hyperphagia (Grossman et al, 1977; McDermott et al, 1977), while 
those of the B8 raphe nuclei (but not B7 or B9) led to weigh gain (Geyer et al, 1976). 
Studies using central nervous system microinjections of serotonergic agents have 
highlighted the importance of the hypothalamus as playing a critical role in the regulation 
of feeding behaviour (Leibowitz et al, 1988; Leibowitz, 1990). The hypothalamus is 
known to receive and integrate input from a wide range of sources reflecting the 
organism's nutritional status, and three nuclei (the paraventricular nucleus (PVN), 
ventromedial nucleus and the suprachiasmatic nucleus) situated in the medial 
hypothalamus, are now known to be especially sensitive to direct serotonergic stimulation 
(Rogacki et al, 1989). 
Injections of 5-HT directly into the PVN inhibit feeding without any general effects 
upon arousal (Leibowitz and Papadakos, 1978), with doses of between 1 µg and IOµg 
producing reliable dose-dependent decreases in food consumption of up to 50% in food 
deprived rats. Furthermore, 5-HT injected into the PVN immediately prior to injections of 
noradrenaline (which stimulates feeding), was found to inhibit the feeding response to 
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noradrenaline by 90% (Leibowitz and Papadakos, 1978). Similar results have been 
reported for 5-hydroxytryptophan, the precursor of 5-HT (Leibowitz and Papadakos, 
1978). Studies with the drug d-fenfluramine, which is believed to act through release of 
endogenous 5-HT, demonstrated that it too mimicked the feeding-inhibitory action of 
exogenous serotonin when injected into these medial hypothalamic regions (Leibowitz et 
al, 1988; Weiss et al, 1989). 5-HT reuptake inhibitors such as fluoxetine also suppress 
noradrenaline-induced and deprivation-induced feeding when injected into the PVN 
(Blundell, 1984). 
Examination of the way serotonin influences meal patterns led to the hypothesis that it 
has specific effects in controlling temporal aspects of feeding (Blundell, 1984). 
Administration of serotonin or d- fenfluramine directly into the PVN was found to affect 
meal patterns by significantly reducing the size and duration of individual meals in 
association with a reduced rate of food consumption (Shor-Posner et al, 1986; Leibowitz 
et al, 1988 ). In contrast, these drugs had no effect upon the latency to meal onset (ie. the 
length of time between meals) or upon meal frequency, suggesting 5-HT is acting 
primarily through satiety mechanisms, or in other_ words, serotonin influences the 
termination of feeding rather than the initiation of eating. Similar effects have been 
demonstrated in animals receiving peripheral injections of serotonergic agents (Blundell, 
1984; Leibowitz et al, 1988). 
Evidence from both hypothalamic and peripheral studies suggests a role for serotonin 
in macronutrient choice (Wurtman and Wurtman, 1979; Blundell, 1984; Leibowitz et al, 
1988). Serotonin appears to be primarily concerned with the control of carbohydrate and 
protein intake, with serotonergic stimulation leading to a reduction in the proportion of 
carbohydrate consumed in the diet. In animals tested in a two-diet self-selection paradigm, 
both peripheral injections of 5-HT agonists (Wurtman and Wurtman, 1979) and central 
injections of serotonin and norfenfluramine directly into the PVN, (Shor-Posner et al, 
1986) were found to reduce the intake of energy-rich carbohydrate while sparing protein 
ingestion. The 5-HT precursor, TRP, was also found to affect macronutrient choice with 
both acute and chronic administration to rats between meals leading to a subsequent 
reduction in carbohydrate consumption with a corresponding increase in protein intake (Li 
and Anderson, 1984; White et al, 1988). Similar findings have been observed after 
hypothalamic serotonergic stimulation in freely-feeding rats. Serotonin injected directly 
into the PVN results in a dose-dependent decrease in carbohydrate consumption with no 
effect (or a slight enhancing effect) on protein or fat intake (Leibowitz et al, 1988; Weiss 
and Leibowitz, 1988). Direct d-fenfluramine and fluoxetine injections into the PVN, 
suprachiasmatic and ventromedial nuclei are effective in suppressing carbohydrate intake, 
presumably through their 5-HT enhancing actions (Weiss and Leibowitz, 1988; Weiss et 
al, 1989). Peripheral administration of d-fenfluramine and fluoxetine suppresses food 
intake, but drug dosage and the nutritional status of the animal appear important, while the 
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effects upon macronutrient choice usually involve suppression of fat as well as 
carbohydrate (Blundell, 1986; Shor-Posner et al, 1986; Leibowitz et al, 1988). With 
peripheral administration of 5-HT antagonists such as cyproheptadine and metergoline, the 
opposite effect is found, ie. an enhanced intake of carbohydrate and fat (Shor-Posner et al, 
1986; Leibowitz et al, 1988; Dourish et al, 1989; Stallone and Nicolaidis, 1989). A 
mechanism underlying the control of carbohydrate intake has been proposed, whereby 
carbohydrate ingestion through enhancing brain uptake of TRP (see section 1.2.1), may 
directly increase 5-HT synthesis thus inhibiting further carbohydrate intake and promoting 
protein intake (Li and Anderson, 1984; Wurtman and Wurtman, 1979). 
Taken together, these experiments demonstrate the key role serotonin depletion and 
enhancement play in the development of hyperphagia (and in some situations weight gain) 
and hypophagia respectively. They further suggest that the site of 5-HT depletion is 
crucial, and highlight the hypothalamic region as an important zone of action for 5-HT in 
the mediation of feeding behaviour (Blundell, 1984; Leibowitz, 1990). Studies on meal 
patterns have demonstrated significant and specific effects of serotonin on temporal 
aspects of feeding through its action on satiety mechanisms, while also suggesting a role in 
macronutrient selection through the control of carbohydrate and protein intake. 
The introduction of specific 5-HT ligands and their subsequent availability as 
challenge drugs has led to an interest in the role of receptor subtypes in mediating feeding 
behaviour. Findings from studies with 5-HT antagonists have suggested that 5HT 1 
receptors may mediate centrally acting serotonergic-induced feeding suppression. This 
proposal is supported by the lack of effect of either the selective 5-HT2 receptor antagonist 
ritanserin or the 5-HT 3 receptor antagonists ICS205-930 and MDL 72222 upon food intake 
in freely feeding rats (Massi and Marini, 1987; Dourish et al, 1989). In contrast, however, 
the 5-HT 1 antagonists metergoline and methylsergide, were both effective in abolishing 
PVN responsiveness to serotonin stimulation (Weiss et al, 1986). More recently it has been 
demonstrated that metergoline produces a dose-dependent increase in food intake and 
carbohydrate preference in food-deprived rats (Stallone and Nicolaidis, 1989). Further 
evidence for a role by 5-HT1 receptors comes from a study by Weiss et al (1986) who 
demonstrated that intrahypothalamic injections of /3-adrenergic blockers, which also 
possess 5-HT lA/lB binding properties, significantly attenuated serotonin-induced feeding 
inhibition. 
Attempts to further delineate the receptor subtypes involved in feeding behaviour have 
highlighted the role of the 5-HT 1B receptor in the rat, which is thought to be selectively 
involved in serotonin-induced hypophagia. Direct 5-HT receptor stimulation by PVN 
injections of the 5-HT 1B agonists quipazine, RU 24969 (Weiss et al, 1986), and 1-[3-
(trifluoromethyl)-phenyl] piperazine (TFMPP) (Hutson et al, 1988), in common with other 
drugs that enhance brain 5-HT function, have been shown to suppress food intake. In 
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contrast, 8-0H-DPAT, the selective 5-HT IA agonist, while having no significant effects 
upon feeding when administered into the PVN, causes significant hyperphagia when 
injected into the midbrain raphe nuclei (Dourish et al, 1986; Hutson et al, 1988). 8-0H-
DPAT-induced hyperphagia is thought to result from 5-HT IA autoreceptor activation in the 
brainstem, reducing endogenous serotonin release, and thereby reversing the natural 
inhibitory action of serotonin on feeding (Leibowitz, 1990). Evidence also exists to 
suggest that the 5-HT ic receptor is important in the control of eating behaviour in the rat. 
Both m-chlorophenylpiperazine (mCPP) and TFMPP, which have high affinities for the 5-
HT IC receptor subtype, are known to suppress food intake following intraventricular or 
PVN administration (Hutson et al, 1988; Kennett and Curzon, 1988b), an effect blocked 
by mianserin, a potent 5-HT1c antagonist (Kennett and Curzon, 1988b). In keeping with 
these findings, binding studies in the rat have demonstrated high densities of 5-HT 18 and 
5-HT lC receptors in the hypothalamus, with the highest concentrations of 5-HT rn 
receptors situated in the medial hypothalamic nuclei, precisely where endogenous 
serotonin is believed to be acting to modulate nutrient intake (Rogacki et al, 1989; Weiss 
et al, 1989). 
Human Studies 
Human feeding behaviour is thought to be more complex than that of animals, with 
significant influences from psychological, emotional and cognitive factors as varied as past 
experiences and associations, through to the hedonic aspects of food presentation such as 
taste, colour and smell (Silverstone and Goodall, 1986). As eating in humans can be driven 
by different motivations, it is important to identify these differing influences when 
considering the neurobiological basis of feeding. One important distinction that must be 
drawn is between hunger and appetite. Silverstone and Goodall (1986) define "hunger", 
when applied to humans, as those psychological sensations that accompany significant 
food deprivation, while "appetite" is said to refer to a person's desire for a particular food 
at a given time, regardless of the reason. These distinctions complicate the picture, but 
such influences can be teased out in human studies by carefully worded questions, usually 
presented to subjects in the form of visual analogue rating scales (Silverstone and Goodall, 
1986). While such influences are acknowledged as playing an important role in human 
feeding behaviour, the following review will focus on the effects of serotonin. 
There is considerable evidence that serotonin also plays a crucial role in determining 
aspects of human feeding. Peripheral administration of drugs which stimulate serotonin 
function have been found to suppress aspects of food intake. Oral TRP causes a dose-
dependent suppression of food intake in healthy male volunteers, a finding that reaches 
significance with 2g of TRP in terms of both total calories consumed and reduced 
carbohydrate intake (with a smaller effect on protein) (Silverstone and Goodall, 1986). A 
study by Hrboticky et al (1985) similarly demonstrated that 2g and 3g of oral TRP had 
~7. 
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short term anorexigenic effects when given to lean healthy young males prior to a meal. In 
this experiment, total food intake was significantly reduced as evidenced by a 18-20% 
reduction in energy consumption. 
The effects of 5-HT antagonists on food consumption have also been studied. Early 
clinical observations that cyproheptadine, when given to asthmatic children caused weight 
gain, led to the suggestion that the drug may be acting as an appetite stimulant and 
increasing caloric intake (Lavenstein et al, 1962 ). Several controlled studies in healthy but 
underweight adult volunteers confirmed a significant increase in both appetite ratings (as 
determined by daily hunger rating scales) and weight gain secondary to an increased 
caloric intake in subjects taking cyproheptadine (Pawlowski, 1975; Silverstone and 
Goodall, 1986). These effects were thought to be mediated by the drug's 5-HT receptor 
antagonist activity. Methysergide, when used to treat migraines has similarly been reported 
__ JQ <::il,use weight gaiIL(Graham, 1967 ). The effects of the 5-HT antagonist meterg9Jine on 
fenfluramine-induced anorexia were examined in another double-blind, placebo-controlled 
trial. While no effects upon food intake or hunger were observed for the eight subjects 
overall, fenfluramine significantly lowered food intake in four out of the eight volunteers. 
Furthermore, in three of these subjects, this anorectic effect was blocked by metergoline 
pretreatment (Goodall et al, 1984). Metergoline alone has also been shown to significantly 
increased food intake when compared to placebo (Silverstone and Goodall, 1986). In a 
later study by the same group, d-fenfluramine-induced anorexia in healthy male volunteers 
was attenuated by pre-treatment with the 5-HT 2A12c antagonist ritanserin (Goodall et al, 
1993). 
Clinical experience with antidepressant drugs further supports the hypothesis that 5-
HT influences food intake in humans. The tricyclic antidepressant amitriptyline, which 
possesses potent 5-HT antagonist properties, is thought to cause weight gain through 
increasing carbohydrate cravings (Paykel et al, 1973), findings in keeping with animal 
studies showing increased carbohydrate intake with reduced 5-HT neurotransmission (see 
section 1.2.3.1). In contrast, the selective 5-HT reuptake inhibitor, zimelidine, is known to 
cause weight loss, presumably through its ability to enhance serotonergic 
neurotransmission (Gottfries, 1981), while fluvoxamine (Abell et al, 1986) and fluoxetine 
(Fuller and Wong, 1989) also decrease food intake in humans although some debate exists 
as to whether the anorectic effect in fluoxetine is 5-HT mediated. 
Serotonin effects on temporal aspects of feeding behaviour have similarly been 
elicited. As seen in the rat, administration of serotonergic drugs such as d-fenfluramine, 
lead to a reduction in both the rate of eating and the size of individual meals through their 
effects upon satiety (Hill and Blundell, 1986). Influences on macronutrient selection are 
also seen. In one study, oral administration of lg TRP to healthy volunteers as part of a 
high protein meal, led to a decrease in carbohydrate intake at a later free choice meal 
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(Blundell and Hill, 1987). Wurtman and Wurtman (1984) demonstrated that d-
fenfluramine, when given to obese subjects, suppressed carbohydrate intake while sparing 
protein consumption, a finding in keeping with that of the Goodall et al ( 1991) study 
where both d- and 1-fenfluramine were found to exert an anorectic effect (as measured by 
total energy intake) on male volunteers, with d-fenfluramine producing a significant 
reduction in carbohydrate consumption while sparing protein. Of particular interest from 
this latter study was the finding that the effect of d-fenfluramine was not seen upon 
carbohydrate per se, but only upon nonsweet carbohydrate. The specificity of these effects 
may help account for studies with d-fenfluramine that have shown inconsistent results 
(Hill and Blundell, 1986). 
The technique of indirectly lowering human brain TRP through dietary manipulation is 
being utilised increasingly and usually involves the administration of either a low TRP diet 
or a TRP-free amino acid drink. In the rat (Biggio et al, 1974) and non human primates 
(Young et al, 1989), low TRP diets have been found to significantly lower plasma and 
tissue TRP as well as brain serotonin, while in humans, the ingestion of a 50 or 100g TRP-
free amino acid drink has been shown to lower plasma TRP by 70-80%, a fall thought also 
to be accompanied by reduced brain TRP levels (for full discussion see section 2.2). In a 
study carried out by Young et al (1988), the effects of a low TRP drink on food intake was 
examined in healthy male subjects. TRP depletion was found to have no effect upon total 
calorie or carbohydrate intake but resulted in a small but significant reduction in protein 
selection at a subsequent buffet style meal. A more recent study, however, utilising a 50g 
TRP-free amino acid drink paradigm failed to elicit any effects of TRP depletion on 
appetite and food intake in terms of either calories consumed or macronutrient choice in a 
group of twelve healthy female volunteers (Van de Kar, 1991). 
To date little is known about the role different 5-HT receptor subtypes play in the 
control of human feeding behaviour. The available data outlined above suggest 5-HT 1 and 
possibly 5-HT2 receptors are involved in mediating serotonin-induced hypophagia while 
some preliminary results have suggested that 5-HT 1 A agonists such as gepirone and 
buspirone cause hyperphagia (Dourish, 1992). The lack of specific ligands available for 
use as 5-HT receptor antagonists in humans has meant that receptor subtype roles have yet 
to be determined, however, the failure to detect 5-HT 18 receptors in humans suggests that 
5-HT lC or possibly, 5-HT ID and 5-HT 2 receptors may be involved in mediating serotonin-
stimulatory feeding effects (Leibowitz, 1990). 
1.2.3.2 Effects of 5-HT on Mood 
While the literature on 5-HT and the role it plays in the control of mood is somewhat 
contradictory many researchers believe there now exists strong evidence for a direct link 
between the two (Young, 1986; Deakin and Graeff, 1991; Power and Cowen, 1992). 




antidepressant drugs, neuroendocrine challenge studies in depression and TRP depletion 
studies. These will be briefly reviewed. 
A central role for 5-HT in the control of mood was originally proposed in the serotonin 
hypothesis which postulated that a functional deficit of 5-HT was a causal factor in the 
pathogenesis of depression (Coppen, 1967). This theory was in part based upon the 
observation of the therapeutic efficacy in the treatment of depression of drugs that 
enhanced serotonergic neurotransmission (DeMontigny and Blier, 1984). Furthermore, 
several early studies found low CSF 5-HIAA levels (the major metabolite of 5-HT) in 
depressed patients. While CSF metabolite results have often been conflicting, overall the 
data suggests that for a subgroup of patients, especially those prone to impulsive, violent 
suicide, 5-HIAA levels are indeed low. Reduced levels of 5-HT and/or 5-HIAA and 
increased numbers of 5-HT 2 receptor binding sites have been reported from postmortem 
examinations of the brains of suicide victims (Meltzer and Nash, 1988; Mann et al, 1989). 
Neuroendocrine challenge studies have also provided evidence suggesting that 
dysregulation of this neurotransmitter occurs during episodes of depression. PRL and GH 
responses to TRP (Heninger et al, 1984) and d-fenfluramine (O'Keane and Dinan, 1991 ), 
and PRL responses to the 5-HT reuptake inhibitor clomipramine (Golden et al, 1990) have 
all been found to be blunted in depression, although again inconsistencies exist in the 
literature (Power and Cowen, 1992 ). 
While clinical trials suggest that precursors of 5-HT, including TRP, are not generally 
effect as antidepressants on their own, TRP will potentiate the action of antidepressant 
drugs such as monoamine oxidase inhibitors, effects thought t0 be the direct result of 
enhanced 5-HT synthesis and decreased 5-HT breakdown (Grahame-Smith, 1971 ). 
Furthermore, in some studies mildly depressed patients have been found to benefit from 
the antidepressant effects of TRP alone (Thomson et al, 1982). 
The results of TRP depletion studies in normal subjects have been somewhat 
contradictory. In an initial study by Young et al (1985), administration of a 100g TRP-free 
amino acid drink was found to have a significant mood lowering effect upon healthy 
young male subjects, a finding later replicated by the same group (Smith et al, 1987). 
More recent work has failed to replicate these finding in healthy female subjects (Van de 
Kar, 1991), although some methodological issues exist that may account for these 
differences. Patient groups have also been examined. Delgado et al (1990) administered a 
100g TRP-free amino acid drink to a group of twenty-one recently recovered depressed 
patients maintained on antidepressants. This led to a significant lowering of plasma TRP 
and was accompanied by a return of full clinical depression within five to seven hours of 
receiving the drink. Reversal of antidepressant activity secondary to TRP depletion has 
been suggested as the underlying mechanism. In contrast, drug-free depressed patients 
reported no alteration in mood during TRP depletion, achieved by a combination of a low 
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TRP diet for twenty-four hours followed by TRP-free amino acid drink, but had a bimodal 
change in mood on the day following the amino acid drink procedure (Miller et al, 1992). 
Twenty-three percent of patients reported a worsening of their depression while 37% 
showed an improvement, as reflected in a fall in the Hamilton Rating Scale for Depression 
of greater than ten points. The mood response was highly correlated with ultimate 
treatment response as patients who relapsed after TRP-depletion proved highly treatment 
resistant, and those that improved showed a good response to antidepressant medication. 
While these results suggest different pathophysiological mechanisms may be operating in 
different subgroups of depression, the reason for mood enhancement following TRP-
depletion remains uncertain. It has been suggested that acute depletion may be followed by 
a rapid return of TRP concentrations to normal, enhancing overall 5-HT neurotransmission 
and therefore improving mood (Miller et al, 1992). 
1.2.4 MEASURES OF BRAIN 5-HT FUNCTION IN HUMANS 
In animals, brain 5-HT and metabolites such as 5-HIAA can be measured directly. This 
1s usually carried out using methods of receptor binding and electrophysiological 
techniques. Direct measures for central 5-HT are not yet possible in the living human 
brain, and a variety of indirect methodologies have therefore been developed. 
1.2.4.1 CSF 5-HIAA 
CSF can be obtained from the lumbar space and the concentrations of 5-HIAA 
measured. This is an invasive technique and has been criticised as not necessarily 
reflecting events occurring in higher regions of the central nervous system (Bulat, 1984 ). 
1.2.4.2 Post Mortem 5-HT Receptor Binding Studies 
Receptor binding studies offer an index of receptor numbers in particular brain regions. 
The imipramine binding site is thought to be located on the 5-HT nerve terminals 
associated with the 5-HT uptake site or transporter (Paul et al, 1984). Studies of [3H]-
imipramine binding may therefore provide an index of 5-HT uptake site numbers and/or 
function. 
1.2.4.3 Neuroendocrine Challenge Studies 
The measurement of anterior pituitary hormone responses to 5-HT drugs provides an 
indirect measure of brain 5-HT function (see section 2.1 for full explanation). The basis for 
this approach is the finding that alterations in brain 5-HT function leads to a corresponding 
alteration in the levels of certain plasma hormones, including PRL, cortisol, ACTH and 
GH (Tuomisto and Mannisto, 1985).Thus, if a standardised pharmacological challenge of 
5-HT pathways is employed, the size of the resulting hormonal response provides an index 
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of the functional state of the 5-HT pathways mediating that endocrine response (Cowen et 
al, 1992). 
1.2.4.4 Peripheral Measures 
Platelet 5-HT 
Measures of platelet 5-HT uptake sites offer a model for the functional status of central 
5-HT neurones. The human platelet expresses a functional 5-HT receptor which resembles 
the 5-HT2 subtype (Geaney et al, 1984). It is controversial, however, whether platelet and 
5-HT neuronal function can be equated. For example, a recent study of central 5-HT 
neurone lesioning in rats demonstrated a profound change in brain 5-HT levels and 
receptor binding, but had no effect on paroxetine binding (Moret and Briley, 1991 ), 
suggesting that peripheral mechanisms, rather than central one may be responsible for 
platelet abnormalities. 
Plasma Tryptophan 
Measurement of plasma TRP is more fully discussed in sections 1.2.1 and 2.2. It is 
considered that plasma TRP levels and the ratio of TRP to other LNAAs determine uptake 
of TRP into the brain, and hence determine the synthesis of brain 5-HT. The effect has 
been well documented, and has been shown in examples of TRP depletion and 
supplementation in both rats and non-human primates (Biggio et al, 1974; Gibbons et al, 
1979b; Young et al, 1989). 
1.3 5-HT IN EATING DISORDERS AND DIETING 
The balance of pharmacological evidence to date, from both animal and human 
studies, supports the hypothesis that serotonergic dysfunction occurs in the eating 
disorders (Leibowitz, 1990). Research has escalated over the past two decades and findings 
from basic animal work have been applied to human studies in an attempt to understand 
the exact nature of the serotonergic abnormalities. In addition, research suggests that 
dieting alters brain 5-HT function, findings that may have implications for the 
development of the eating disorders. 
1.3.1 ANOREXIA NERVOSA 
1.3.1.1 Precusor and Metabolite Studies 
Early studies of serotonergic function in anorexia nervosa measured peripheral 
concentrations of the precursor amino acid TRP and the major metabolite of 5-HT, 5-
HIAA, in the urine and plasma. Inconsistent results were found in the acutely ill anorectic 
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patient. While Coppen et al (1976) reported reduced free and bound plasma TRP levels, 
Russell (1967) did not find any alterations in plasma concentrations amongst his patients. 
Kaye et al (1984b) compared the plasma TRP /LNAA ratio in anorectic patients, before 
and following short- and long-term recovery, with a group of controls and also found no 
difference. Such results argued against the hypothesis of reduced plasma TRP availability, 
secondary to reduced dietary intake, to the brain for 5-HT synthesis in the acute phase of 
anorexia nervosa. Evidence, however, from the small number of studies is by no means 
conclusive. 
The rationale behind CSF neurotransmitter and metabolite studies is that they provide 
a more direct measure of central neurotransmitter function compared to peripheral studies. 
Alterations in CSF 5-HIAA concentrations, however, may not necessarily reflect 
alterations in serotonergic neurotransmission; as Kaye et al ( 1991) points out factors such 
as alterations in the metabolism of 5-HT or metabolic clearance of the metabolites may 
also be implicated. Despite these limitations, valuable information has been gained from in 
vivo human studies. 
Studies of CSF 5-HIAA concentrations have consistently found low levels in 
malnourished and underweight anorectic patients (Gillberg, 1983; Kaye et al, 1984b; 
Kaye et al, 1988 ). Refeeding and short-term weight restoration appear to normalise CSF 5-
HIAA levels ( Gerner et al, 1984; Kaye et al, 1988 ), with weight restoration defined as up 
to two months target weight maintenance. Many patients, despite reaching target weight 
remained significantly underweight compared to the normal population and were still 
amenorrhoeic. The reduced CSF 5-HIAA concentrations seen in acutely ill patients are 
thought to reflect starvation, as even partially refed patients who have made only minimal 
weight gain have been shown to have normal levels (Gerner et al, 1984). In an attempt to 
avoid the complicating factors of malnutrition and recent refeeding, Kaye et al (1991) 
studied 5-HIAA levels in long-term weight restored patients who had maintained a stable 
weight above 85% average body weight for at least six months. These authors found 
increased 5-HIAA concentrations in the CSF of their subjects compared to controls. 
Although some methodological difficulties exist with this paper, such as studying a mixed 
restrictor/bulimic population, the inclusion of patients who were continuing to purge and 
binge on a regular basis and/or were still amenorrhoeic, it raises the possibility of 
increased brain 5-HT function as a trait marker in long-term recovered anorexia nervosa. 
Some differences between restrictor and bulimic subgroups can be demonstrated. Kaye 
et al (1984a) measured CSF 5-HIAA levels in anorectics after an intravenous probenecid 
infusion, which blocks the active transport of 5-HIAA out of the CSF and thus allows the 
metabolite to accumulate. The restrictor type anorectic patients were found to have 
consistently higher levels of 5-HIAA compared to the bulimics, regardless of short- or 
long-term recovery status. The hypothesis that restrictor type anorectics have greater 
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serotonergic activity is further supported by the treatment study of Halmi et al ( 1986) 
using the serotonergic antagonist cyproheptadine, in which restrictor type anorectics were 
found to respond significantly better than the bulimic subgroup. The exact significance of 
this difference in CSF 5-HIAA levels is not yet understood. It is possible that it reflects 
differences in weight and nutrition, membrane transport or other differences in central 
probenecid effects between restrictor and bulimic subtypes (Kaye et al, 1984a), but more 
excitingly, it may represent a trait marker for the two subgroups reflecting 5-HT turnover 
rates that are independent of starvation or other central effects (Brewerton et al, 1990). 
Indeed it has been suggested that greater serotonergic activity amongst restrictor anorectics 
may account for their more obsessional, ritualistic, perfectionistic and rigid personality 
traits which, it has been argued, persists even with long-term weight recovery and may 
contribute to the high relapse rates seen in this disorder ( Kaye and Weltzin, 1991 b ). 
1.3.1.2 Platelet Studies 
Blood platelets have been shown to take up, store and release 5-HT by mechanisms 
similar to that of central monoamine neurones (Zemishlany et al, 1987). Consequently, 
platelet 5-HT uptake and imipramine binding, a measure of 5-HT receptor site numbers, 
have been used as models of studying central serotonergic function in many psychiatric 
illnesses (Zemishlany et al, 1987). Studies in anorexia nervosa, however, have been few, 
making it impossible to draw firm conclusions at this stage. Those studies that have been 
carried out have reported decreased imipramine binding suggesting reduced 5-HT activity 
in the acute phase of the illness (Weizman et al, 1986). A difference in 5-HT uptake was 
not found between anorectic patients and control subjects (Weizman et al, 1986; 
Zemishlany et al, 1987). Neither of these studies reported on bulimic verses restrictor 
subgroups. 
Platelet MAO activity similarly has been studied as a measure of serotonergic function 
in different psychiatric populations. To date only one paper has reported on MAO activity 
in anorexia nervosa. Biederman et al (1984) found reduced MAO activity amongst a 
subgroup of anorectic patients with depression but normal activity in the non-depressed 
anorectics and controls. 
1.3.1.3 Neuroendocrine Studies 
Neuroendocrine challenge tests have become increasingly recognised as valid, if 
indirect, measures of central serotonergic function (Checkley, 1980; Cowen et al, 1990b; 
Yatham and Steiner, 1993). To date however, few studies using neuroendocrine challenges 
have been carried out in anorexia nervosa. 
Brewerton et al ( 1990) have reported blunted PRL responses (peak minus baseline) to 
both TRP and the 5-HT agonist mCPP in underweight anorectic patients when compared to 
p 
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healthy controls. Furthermore, responses to TRP and mCPP challenges carried out in 
patients four weeks after achieving their goal weights were also found to be blunted. Ten 
out of twelve in the TRP group and eight out of twelve in the mCPP group had higher PRL 
responses to the challenge drug at goal weight than when underweight. The authors could 
not account for the findings in this subgroup in terms of plasma drug concentration 
differences, baseline oestradiol levels, Hamilton Rating Scale or Beck Depression 
Inventory scores or number of years of illness. One possible explanation is that blunted 
PRL responses reflect malnutrition and low weight, and could be expected to normalise 
once weight is within normal range. This is supported by finding a trend towards higher 
PRL responses in most patients achieving their goal weights. The fact that the PRL 
responses remain somewhat blunted at goal weight could simply reflect the patients' 
ongoing low body weights which were only 85%+/- 3% of average body weight. Blunted 
responses can also occur secondary to low PRL stores or impairment of the pituitary 
lactotroph function. However, as PRL responses to TRH, which acts directly at pituitary 
level to release PRL, have been found to be largely (Beumont et al, 1976; Kiriike et al, 
1987; McBride et al, 1991) but not always (Waldhauser et al, 1984), normal in 
underweight anorectic patients this explanation also seems unlikely. 
An alternative explanation, that cannot be proven one way or the other on the current 
available literature, is that serotonergic receptor responsivity of the pathways mediating the 
PRL responses to these challenge drugs are blunted in anorexia nervosa, regardless of 
patients' weights and nutritional status at the time of testing (Brewerton et al, 1990). 
Goodwin et al (1989), however, failed to find blunted PRL responses to a TRP 
infusion in thirteen acutely ill anorectic patients compared to controls. In this paper a 
significantly blunted GH response to the same TRP infusion was reported, suggesting 
different effects for the two hormones in anorexia nervosa. The authors suggested that the 
blunted GH response may be related to reduced dopamine function ( Kaye et al, 1984b) 
secondary to dietary factors. 
1.3.2 BULIMIA NERVOSA 
1.3.2.1 Precursor and Metabolite Studies 
It has been suggested that bulimic behaviour is consistent with hyposerotonergic 
activity but evidence for this occurring in bulimia nervosa is inconsistent (Kaye and 
Weltzin, 1991b ). In one of the few peripheral studies published looking at 5-HT function 
Lydiard et al (1988) found no baseline plasma TRP/LNAA ratio differences in normal 
weight bulimic patients compared to healthy controls, suggesting normal TRP availability. 
In an uncontrolled laboratory study of nine actively bingeing bulimic patients, Kaye et al 
(1988) found an inverse relationship between the development of satiety (defined as 
cessation of bingeing and vomiting) and the plasma TRP/LNAA ratio. In other words, 
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"bulimic patients who developed an increased plasma TRP ratio during bingeing and 
vomiting had fewer cycles of bingeing and vomiting .... than did subjects who did not 
develop an increase in the plasma TRP ratio" (Kaye et al, 1988). 
The authors raise the possibility that an increase in plasma TRP/LNAA ratio may be 
associated with the termination of a binge episode through its effects upon brain 5-HT 
metabolism. This suggestion is further supported by their finding that those patients who 
exhibited increased plasma TRP/LNAA ratio, were also found to have greater increases in 
plasma PRL, suggesting enhanced brain 5-HT neurotransmission had indeed occurred. 
A number of studies have reported normal CSF 5-HIAA concentrations in normal 
weight bulimic patients (Jimerson et al, 1988; Kaye et al, 1990a) although in Jimerson's 
study patients with a binge frequency of twice daily or above were found to have lower 
CSF 5-HIAA levels than both less symptomatic patients and controls. The lower 5-HIAA 
levels did not appear to relate to differences in body weight or to a history of depression 
and suggest that higher frequencies of bingeing may be "associated with relatively 
persistently reduced central serotonin turnover" (Jimerson et al, 1990). Whether or not the 
negative correlation between binge frequency and CSF 5-HIAA concentrations represent 
serotonergic dysregulation intrinsic to the development of the disorder, or occurs as a 
consequence of persistent bingeing and purging behaviour and/or nutritional disturbances 
has still to be determined. 
1.3.2.2 Platelet Studies 
Goldbloom et al (1990) recently reported on twenty-two normal weight bulimic 
patients, who were still actively bingeing and purging, and found increased platelet 5-HT 
uptake compared to controls. No significant correlations were found between platelet 5-HT 
uptake results and depression scores, body weight, or frequency of recent bingeing and 
vomiting behaviour, nor were there significant menstrual or seasonal effects, both of which 
are known to influence platelet 5-HT uptake. Goldbloom et al (1990) suggest that 
increased platelet 5-HT uptake could reflect decreased availability of 5-HT at postsynaptic 
receptors at the hypothalamic level, thus reducing satiety signals and, possibly, altering 
macronutrient choice towards increased carbohydrate preference. In contrast, Hallman et al 
(1990) reported no difference in platelet 5-HT uptake, but lower platelet MAO activity, 
between controls and a group of sixteen women who currently met DSM-III criteria for 
bulimia nervosa. 
In a single preliminary report on platelet 3H-imipramine binding, a group of non-
depressed bulimic patients were found to have significantly reduced density of binding 
sites compared to controls (Marazziti et al, 1988). 
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1.3.2.3 Neuroendocrine Studies 
Neuroendocrine studies in bulimia nervosa are few in number, but those that have been 
reported provide evidence for serotonergic dysregulation. Peak PRL responses to m CPP 
were blunted compared to controls in bulimic patients meeting both DSM-III and DSM-
IIIR criteria, regardless of the presence or absence of major depression, while the PRL 
response to a TRP challenge in the same group of patients was also found to be blunted, 
but only in those bulimics concurrently meeting criteria for major depression (Brewerton et 
al, 1992). The blunted PRL responses to mCPP were not related to age, body weight, 
medication, plasma drug levels or baseline oestradiol levels. The possibility that the 
blunted PRL responses were due to alterations in pituitary lactotroph activity is not 
supported by other work demonstrating that bulimic patients have normal PRL responses 
to a TRH challenge (Levy et al, 1988; McBride et al, 1991 ). An inverse correlation was 
found between PRL responses following the m CPP challenge and baseline cortisol levels 
in the bulimic patients, paralleling animal work where PRL responses to mCPP were found 
to be blunted following long-term cortisol treatment (Bagdy et al, 1989a) and human 
studies in depression where a similar inverse relationship has been observed (Hsu, 1990; 
Power and Cowen, 1992 ). 
Brewerton et al (1992) suggest that the different hormonal responses to the two 
serotonergic drugs could reflect a number of factors including differential involvement of 
presynaptic (TRP) and postsynaptic (mCPP) mechanisms, different 5-HT receptor 
subtypes mediating the responses of the two drugs or different anatomical loci of action 
(Brewerton et al, 1992). While careful controls for recent dieting, bingeing and purging 
behaviour ( over the previous four weeks prior to testing) were made in the study, it is still 
not possible to conclude whether the blunted PRL responses reflect 5-HT dysregulation 
consequent on long-term bingeing and purging behaviour that had not normalised by the 
time of testing, or whether it reflects a "premorbid state that predisposes these patients to 
bulimia nervosa" (Brewerton et al, 1992). 
McBride et al (1991) have recently reported on dl-fenfluramine challenges in a group 
of eating disordered women. Unfortunately, numbers were too small to allow subgroup 
responses to be individually analysed, but they reported a trend towards reduced PRL 
responses to dl-fenfluramine in seven patients of whom four currently met criteria for 
bulimia nervosa. There was also preliminary results from three patients retested at six to 
twelve weeks after successful treatment suggesting that responses remained blunted. 
Using the 5-HT precursor 5-HTP, Goldbloom et al (1990) has examined central 5-HT 
function in bulimia nervosa. In keeping with the other 5-HT neuroendocrine challenge 
studies they found evidence suggesting reduced serotonergic activity. Both the GH and 
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PRL responses to intravenous 5-hydroxytryptophan were found to be blunted in the 
bulimic patients compared to controls. 
1.3.3 EFFECTS OF DIETING ON 5-HT 
Examining the effects of altered nutrition on brain 5-HT function has important 
implications for our understanding of psychiatric illness, especially the eating disorders. 
Such research will enable us to separate those neurobiological abnormalities that are the 
result of food deprivation from those that are intrinsic to the aetiology of the disorders 
themselves. The following review focuses on studies carried out in relation to 5-HT 
function. The effects of food intake and dietary restriction on levels of neurotransmitter 
precursors, and on the synthesis of brain neurotransmitters will be examined. With respect 
to human functioning, studies examining the neurochemical effects of dieting will also be 
covered. 
1.3.3.1 Amino Acid Precursor Supply in Relation to Dietary Restriction 
Most research looking at the effects of food deprivation on amino acid supply have 
focused upon tyrosine and TRP, the amino acid precursors for the neurotransmitters, 
dopamine and catecholamines, and serotonin respectively. However, studies of the effects 
of fasting have encompassed most amino acids. 
Short periods of fasting (24 to 120 hours) have been shown to have little effect on 
plasma concentrations of most amino acids in the rat (Enwonwu, 1987), with levels of 
plasma phenylalanine increasing but alanine, arginine, glutamine and threonine all 
showing moderate decreases. Brain concentrations of most amino acids in the rat also 
remain unaltered, although the modest plasma changes are reflected by increases in brain 
phenylalanine and decreases in alanine and arginine (Knott et al, 1973 ). For two amino 
acids, however, the impact of fasting on brain concentrations may not be reflected in 
changes in plasma concentrations. Plasma threonine falls significantly following a twenty-
four hour fast (Enwonwu, 1987), but concentrations remain unaltered in the brain. In 
contrast, it has been argued that plasma TRP levels are unaltered in response to fasting, yet 
brain levels significantly increase (Curzon et al, 1972). Fernstrom and Wurtman (1971a) 
further demonstrated that brain TRP levels increase when rats are given a large 
carbohydrate meal free of TRP. 
One possible explanation for these apparently paradoxical results has been put forward 
by Curzon (1988) who hypothesised that fasting increases plasma unesterified fatty acids 
(released from fat stores), which directly compete with TRP for binding to plasma 
albumin. This results in increased concentration of free plasma TRP available for transport 
across the blood-brain-barrier (Knott and Curzon, 1972; Curzon et al, 1973). A high 
carbohydrate meal causes insulin release, resulting in an increased uptake of LNAA into 
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muscle and a reduction in the ratio of LNAA/TRP, again enhancing transportation of TRP 
to the brain ( see section 1.2.1.1). 
A complex relationship appears to exists between TRP intake, plasma levels and brain 
concentrations in the rat following short term fasting. It is not clear how well these 
findings can be applied to the human situation, in particular to sustained food restriction as 
opposed to total fasting. One study has examined this issue in a healthy human population 
and found no alteration in the ratio of plasma TRP/LNAA over a six week diet compared 
to controls (Schweiger et al, 1986). 
1.3.3.2 Effects of Dieting on Brain 5-HT Function 
To date, only a handful of published studies have looked at the effects of dieting on 
brain 5-HT function in humans. These have utilised the indirect neuroendocrine challenge 
paradigm which will be outlined in detail in section 2.1. 
The first evidence that dieting may effect human brain 5-HT function came from a 
study by Goodwin et al (1987b) who placed a group of twelve healthy men and women on 
a calorie controlled diet for three weeks. Although no effect upon plasma TRP levels were 
found, an enhanced PRL response to a subsequent TRP challenge was demonstrated in the 
women but not the men. This same group of researchers (Anderson et al, 1990a) later 
replicated these results in another group of volunteers, with the additional finding that 
dieting led to a fall in total plasma TRP in both male and female dieters. (The significant 
reduction in total plasma TRP following dieting replicated an earlier finding Anderson et 
al, 1989). The enhanced PRL response to the TRP challenge after dieting was again 
demonstrated as occurring in women alone, despite greater absolute and percentage body 
weight loss in males (Anderson et al, 1990a). 
It was hypothesised (Goodwin et al, 1987b; Anderson et al, 1990a) in light of these 
findings that moderate dieting decreases plasma TRP sufficiently in women to reduce brain 
5-HT synthesis (see section 1.2.1 ). The reduced TRP would lead to an overall reduction in 
5-HT neurotransmission across the synapse, and in turn, produce an adaptive 
supersensitivity of the post-synaptic 5-HT receptors, as reflected in the enhanced PRL 
response to TRP. Thus, although dieting increased the PRL response to a TRP challenge, 
the underlying change was a functional decrease in brain 5-HT neurotransmission. Support 
for this theory comes from a recent study by Delgado et al (1989) who demonstrated that a 
ten day low-TRP diet in healthy volunteers significantly reduced plasma TRP levels in 
both males and females, and in females alone this change was associated with an enhanced 
PRL response to a subsequent TRP challenge. Consistent with the dieting work, the plasma 
TRP fall was greater in the women than in the men. 
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Two reasons, not necessarily mutually exclusive, were suggested for the effect being 
female specific. Firstly, plasma TRP levels fell further in the women than in the men 
(Anderson et al, 1990a) so that brain 5-HT synthesis could have been more severely 
affected. Secondly, it is well established that rates of 5-HT turnover in both human (Young 
et al, 1980) and non-human primates (Young and Ervin, 1984) are greater in females 
compared to males, again making female brain 5-HT function more likely to be 
compromised. 
In order to examine the specificity of these diet induced changes on 5-HT-mediated 
brain function, Anderson et al ( 1989) carried out a series of experiments in which they 
demonstrated that dieting had no effect upon the PRL response to the dopamine antagonist 
metaclopramide. These results suggested that the enhanced PRL response seen in women 
following dieting was not the result of changes in dopaminergic neurotransmission, a 
possible alternative explanation as PRL release is under the inhibitory control of dopamine 
(Quigley et al, 1980). Furthermore, Anderson et al (1989) showed that these changes were 
not secondary to direct stimulatory effects upon the pituitary lactotrophs as dieting had no 
effect upon the TRH-induced release of PRL. Dieting was also found to have no effect on 
the physiological release of PRL, as measured by sleep-induced changes, nor upon basal 
PRL measurements. A further study by Goodwin et al (1988) has failed to find dieting-
induced effects upon the hypothalamic-pituitary-adrenal axis as measured by alterations in 
the rate of non-suppression of cortisol by an oral dose (1mg) of dexamethasone. 
Taken together, these results suggest an effect of dieting upon brain 5-HT-mediated 
PRL release, but this suggestion rests on findings utilising TRP as the challenge probe. 
The findings further suggest that such dieting induced changes are probably restricted to 
women. In view of the central role that brain 5-HT plays in the control of mood and 
appetite (see sections 1.2.3 and 1.1.4.3) and the widespread evidence now existing to 
suggest that dieting behaviour acts as a risk factor in the development of eating disorders 
(see section 1.1.4.3), these findings are of considerable interest, particularly as it is well 
recognised that the vast majority of eating disorders occur in females. The question 
therefore arises as to whether or not women have a neurobiological vulnerability to 
developing the eating disorders. Indeed one possible mechanism would be through 
differing biological responses to alterations in food intake, compared to men, as the above 
evidence suggests may be the case for TRP and subsequent brain 5-HT synthesis. 
1.3.4 CURRENT STATUS OF 5-HT RESEARCH IN EATING 
DISORDERS AND DIETING 
1.3.4.1 Anorexia Nervosa 
Overall, research findings suggest that 5-HT dysregulation does occur in anorexia 
nervosa although the precise nature of the dysregulation remains unclear. While it is 
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reasonably clear that the low CSF 5-HIAA concentrations seen in acutely ill patients 
probably reflect starvation, it is also possible that restrictor- and bulimic-type anorectic 
subgroups can be separated on the basis of central 5-HT turnover rates, the former having 
higher rates than the latter. The finding by Kaye and Weltzin (1991b) that CSF 5-HIAA 
concentrations are elevated in long-term recovered anorectics further raises the possibility 
of increased 5-HT neurotransmission in individuals with this disorder. Increased 
serotonergic activity is theoretically consistent with many features seen in anorexia 
nervosa and raises the intriguing possibility that anorectic patients may reduce food intake 
in order to lower brain 5-HT activity. 
The blunted hormonal responses to mCPP, TRP and dl-fenfluramine may appear at 
first glance to contradict the CSF metabolite results, in that they suggest reduced 5-HT 
neurotransmission. All the neuroendocrine studies published so far, however, have been 
carried out either on acutely ill patients, or on patients who have only recently recovered 
and in whom body weight often remains low and menstrual functioning impaired. As with 
the metabolite studies, effects of starvation, low body weight and/or partial refeeding could 
still be having a significant influence at this stage. 
1.3.4.2 Bulimia Nervosa 
In bulimia nervosa there is also evidence for a disturbance in 5-HT function. Precursor 
and metabolite studies, platelet re-uptake findings and experiments with three separate 5-
HT neuroendocrine challenge probes suggest that, at least during the acute and early 
recovery phases of the disorder, 5-HT function is abnormal. Long-term recovery studies 
are still awaited. To date most of the evidence, although indirect, supports a state of 
relative hyposerotonergic activity, which is theoretically consistent with many of the 
features and behaviours typical of bulimia nervosa. 
While the initial results on 5-HT function in the eating disorders are exciting, they 
need to be interpreted in the light of several major research limitations. Perhaps the most 
important is the difficulty in determining when an individual patient's nutritional status and 
weight has been restored to a level at which normal functioning can be assumed to have 
resumed ( Goldbloom et al, 1991 ), thus removing the confounding factors of starvation and 
low body weight. Starvation is known to bring about significant cognitive, affective and 
behavioural changes (Garfinkel and Kaplan, 1985) along with metabolic alterations in its 
own right (Sharp and Freeman, 1993 ). While starvation effects have obvious application to 
anorectic patients, it is increasingly recognised that they probably play an major role in 
bulimia nervosa as well (Pirke et al, 1985a; Gwirtsman et al, 1989b). It has been proposed 
in light of the "set-point" theory, that for many bulimic patients, "normal" body weights as 
determined by standard population measures may in fact be below their "natural" weight 
(Russell, 1979; Garner et al, 1985). Thus, a weight within the standard range for such a 
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patient may in fact represent a chronic state of starvation, even after apparent clinical 
recovery. 
In addition to weight changes and nutritional effects, some behaviours seen in the 
eating disorders such as bingeing or purging through vomiting, laxative abuse or diuretics 
also have biological consequences and must therefore be carefully controlled for. 
In terms of research, the methodological issues outlined above become important when 
trying to separate out biological abnormalities that occur as a consequence of the disorder 
or are important in symptom maintenance (such as starvation effects), from those that 
might predispose an individual to the development of eating difficulties and hence are 
important in furthering our understanding of the pathogenesis of the disorders. While 
prospective research would be ideal in enabling us to tease out these different factors, 
major practical and financial problems exist with carrying out such studies. Long-term 
recovered patients offer the most fruitful alternative in that confounding factors can be 
minimised, allowing a more accurate assessment of underlying brain 5-HT activity. Such 
studies are still awaited for both anorexia and bulimia nervosa. Further benefit would be 
gained by examining the confounding factors themselves (such as the effects of weight 
loss on brain 5-HT function) thus enabling a more accurate interpretation of the currently 
available research. 
1.3.4.3 Dieting 
While strong evidence now exists for an effect of dieting upon brain 5-HT function, 
the available data suggest the effects are confined to women. Whether or not females have 
a neurobiological vulnerability to developing the eating disorders remains unclear as 
further dieting studies are required to replicate earlier work demonstrating female-specific 
brain 5-HT changes. The exact mechanism by which dieting produces changes in brain 5-
HT function is also still to be elicited. TRP is a rather non-specific challenge (Yatham and 
Steiner, 1993) and no direct evidence exists from the above studies to support the 
supersensitivity hypothesis. An enhanced PRL response to a TRP challenge would also be 
consistent with the hypothesis that dieting leads to increased brain 5-HT function, as 
proposed by Curzon (1988) although it would be difficult to explain the reduced plasma 
TRP findings in terms of his hypothesis. 
Anorexia and bulimia nervosa are associated with high morbidity and significant 
mortality. In view of the significant implications clarification of the issues outlined above 
would have, in terms of aetiology and furthering our understanding of the factors that lead 
to symptom maintenance, it would be important to pursue these issues further. The main 
body of work carried out for this thesis addresses these points. 
.j;, ..... 
Chapter 2 
EXPERIMENTAL APPROACH AND 
GENERAL METHODS 
In this thesis the effects of dieting on brain 5-HT function and the role of serotonergic 
pathways in the control of appetite have been examined. Broadly, three experimental 
approaches were utilised; neuroendocrine challenge tests, TRP depletion studies and a test 
meal procedure. In this chapter the rationale for use of the three approaches is considered 
and general experimental techniques are outlined. 
2.1 NEUROENDOCRINE TESTS OF 5-HT FUNCTION 
In a recent publication, Cowen et al (1990b) stated that "measuring brain 5-HT 
function in the living human brain presents obvious difficulties but endocrine responses to 
increased brain 5-HT function (5-HT neuroendocrine challenge tests) offer a possible 
approach". 
2.1.1 RATIONALE FOR USE OF NEUROENDOCRINE CHALLENGE 
TESTS 
Although an indirect measure, the rationale behind neuroendocrine testing is the role 
monoamine pathways play in the control of anterior pituitary hormone secretion (for a full 
review see Tuomisto and Mannisto, 1985). Neurones utilising monoamine 
neurotransmitters innervate hypothalamic nuclei which contain the cell bodies of anterior 
pituitary hormone releasing (and inhibitory) factor neurones. The anterior pituitary 
hormone releasing and inhibitory neurones project to the median eminence where their 
nerve terminals end adjacent to capillaries of the hypothalamo-hypophyseal portal system. 
Stimulation of the neurones results in secretion of either releasing or inhibitory factors 
which enter the portal system and are transported to the anterior pituitary. Here the 
hormone releasing or inhibitory factors interact with specialised anterior pituitary cells to 
either stimulate or inhibit the release of specific hormones. Neuroendocrine testing 
involves giving a drug to selectively stimulate one of the monoamine pathways and then 
measuring the resultant change in hormone release, with the change in hormone output 
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providing an index of the functional activity of the monoamine pathway with which the 
drug interacts (Checkley, 1980). Two assumptions are implicit: firstly, that the hormone 
response results from the stimulation of one type of neurotransmitter releasing system and 
secondly, that these receptors are situated within the brain and not within the pituitary or 
peripheral nervous system (Checkley, 1980). 
2.1.2 INNERVATION OF THE HYPOTHALAMUS AND PITUITARY 
AND THE RELATIONSHIP TO NEUROENDOCRINE FUNCTION 
5-HT innervation of the hypothalamus arises principally from brainstem median and 
dorsal raphe nuclei (Ungerstedt, 1971; Kellar et al, 1977; Palkovits et al, 1977). The 
hypothalamus as a whole is one of the most densely 5-HT innervated structures in the 
central nervous system with the greatest concentration of 5-HT neurones situated within 
the ventromedial and mamillary nuclei (Takeuchi, 1989). Animal work suggests that 
individual hypothalamic nuclei receive differential 5-HT innervation but species 
differences do exist and must be taken into account. 5-HT projections to the 
suprachiasmatic nucleus and the anterior hypothalamic region arise principally from the 
median raphe nucleus (Van de Kar and Lorens, 1979). In contrast, serotonergic neurones 
from the dorsal raphe nucleus do not project exclusively to specific hypothalamic 
structures. The anterolateral hypothalamic region and the arcuate nucleus receive 5-HT 
neuronal projections originating from both the dorsal and median raphe nuclei (Van de Kar 
and Lorens, 1979). 
Release of the hypothalamic releasing and inhibitory factor hormones is regulated by 
the hypothalamic nuclei. For example, the arcuate and ventromedial hypothalamic nuclei 
are involved in regulating the secretion of luteinizing hormone (Halasz and Pupp, 1965; 
Voloschin et al, 1968), while cells containing corticotropin-releasing hormone are located 
within the PVN and are known to have nerve terminals that extend to the external zone of 
the median eminence ( Olschowka et al, 1982). 
Autoradiography and immunocytochemistry techniques in the rat have demonstrated 
the presence of 5-HT axon terminals and neurones containing vasoactive intestinal 
polypeptide (thought to be a strong candidate as a physiological prolactin releasing factor) 
in the suprachiasmatic nucleus (Bosler and Beaudet, 1985), suggesting a role by this 
structure in the regulation of PRL secretion. Hokfelt et al (1982) demonstrated the 
presence of peptide histidine isoleucine amide, a vasoactive intestinal peptide homologue 
capable of releasing PRL (Werner et al, 1983), in the PVN, dorsomedial, ventromedial and 
premamillary nuclei, but again the greatest density of fibres were found concentrated in the 
suprachiasmatic nucleus. Watts et al ( 1987), however, were unable to demonstrate the 
presence of efferent fibres from the suprachiasmatic nucleus to the median eminence, 
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raising the question as to whether or not the suprachiasmatic nucleus was directly involved 
in 5-HT-mediated PRL release. It is possible that the suprachiasmatic nucleus exerts its 
effects via regulation of hormonal circadian rhythms (Watts et al, 1987 ). The PVN has also 
been implicated in 5-HT-mediated PRL release. In the rat, the PVN's parvocellular region 
is moderately innervated by 5-HT fibres originating from both dorsal and median raphe 
nuclei (Sawchenko et al, 1983). Lesions of the PVN abolish the PRL response to 5-
hydroxytryptophan and stress (Minamitani et al, 1987), and a parvocellular paraventricular 
neuronal system, extending to the external layer of the median eminence and containing 
the PRL releasing agent, peptide histidine isoleucine amide, has been demonstrated by 
Hokfelt et al (1982). The arcuate nucleus receives both 5-HT and dopaminergic 
innervation (Kiss and Halasz, 1986) while 5-HT innervation in the median eminence is 
largely confined to the external layer ( Soghomonian et al, 1988). 
2.1.3 5-HT REGULATION OF PROLACTIN RELEASE 
While PRL is secreted by cells in the anterior lobe of the pituitary gland, secretion is 
predominantly under inhibitory hypothalamic control (Tuomisto and Mannisto, 1985). 
Conditions that disconnect the anterior pituitary from the hypothalamus, such as 
hypothalamic lesions (Arimura et al, 1972) are known to increase PRL release. The control 
of PRL release is complex, regulated by a family of multiple PRL-releasing and PRL-
inhibiting factors which are in turn dependent upon physiological conditions. 
Dopamine, originating in the tuberoinfundibular system in the arcuate nucleus exerts a 
tonic inhibitory control so that any increase in dopamine secretion will result in a 
corresponding decrease in PRL release. In contrast, animal studies have suggested 
hypothalamic and PVN peptides, including vasoactive intestinal peptide, neuropeptide Y, 
histamine, TRH polypeptide histidine isoleucine-27, oxytocin and arginine vasopressin are 
important in stimulating the release of PRL (Kjaer et al, 1994; Arey and Freeman, 1992). 
For example, the neurohormone oxytocin is thought to increase PRL secretion following 5-
HT stimulation (Bagdy and Makara, 1993), while the hypothalamic neurotransmitter 
histamine appears to participate in stress-induced PRL release, an effect perhaps mediated 
via the hypothalamic factor arginine vasopressin (Kjaer et al, 1994). 
The regulatory peptides vasoactive intestinal peptide and neuropeptide Y are 
influenced by the thyroid hormones. Thyroid hormones have an inhibitory action upon 
vasoactive intestinal peptide and neuropeptide Y-producing cells of the pituitary. In 
clinical conditions of hypothyroidism there is an increase in gene expression and hence 
peptide levels, an effect abolished following anterolateral deafferentation of the 
hypothalamus, suggesting a role for some hypothalamic factor in the mediation of the 
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effects of hypothyroidism on pituitary vasoactive intestinal peptide and neuropeptide Y 
levels (Michalkiewicz and Suzuki, 1994). 
Oestrogen is similarly thought to be a stimulatory factor for PRL, acting at multiple 
sites to control the release of PRL from the anterior pituitary. Animal studies have 
suggested that oestrogen increases the number of PRL-secreting cells in the pituitary gland 
and inhibits the feedback loop on PRL by suppressing hypothalamic DA secretion 
(Leibenluft et al, 1994). 
A wide range of drugs, including antipsychotic and antidepressant medications are 
capable of inducing stimulation or suppression of PRL secretion, mainly through their 
effects upon central neurotransmitter pathways. Direct (e.g. dopamine and apomorphine) 
and indirect dopamine ( e.g. amphetamine and nomifensine) receptor agonists decrease 
PRL release, as do drugs which impair 5-HT neurotransmission (e.g. metergoline and 
methysergide), y-aminobutyric acid-mimetic drugs (e.g. sodium valproate, histamine H2 
receptor agonists and cholinergic (muscarinic and nicotinic) receptor agonists. In contrast, 
the main classes of PRL-stimulating drugs include dopamine receptor antagonists and 
drugs that indirectly impair dopamine neurotransmission (e.g. both typical and atypical 
antipsychotics, carbidopa), drugs that enhance 5-HT neurotransmission including 5-HT 
precursors (e.g. L-tryptophan and 5-hydroxytryptophan), 5-HT agonists (e.g. quipazine) 
and indirect 5-HT agonists including 5-HT reuptake inhibitors (e.g. fluoxetine) and 
releasers of 5-HT such as d-fenfluramine (Muller et al, 1983) 
While the importance of these factors in the regulation of PRL secretion must be 
acknowledged, a full overview of PRL regulation is beyond the scope of this thesis. Thus, 
the brief review below will focus on the role 5-HT plays in PRL release. 
2.1.3.1 Animal Studies 
Animal studies have demonstrated that 5-HT containing cells in the dorsal raphe 
nucleus stimulate PRL release (Van de Kar and Bethea, 1982; Barofsky et al, 1983). One 
study suggested that cells from the median raphe nucleus may be involved, but because of 
methodological limitations, the authors' conclusions remain tentative (Fessler et al, 1984 ). 
PRL release induced by 5-hydroxytryptophan, restraint, or other stress is inhibited by 
electrolytic lesions of the PVN (Minamitani et al, 1987). Physiological release of PRL 
occurs secondary to suckling. Suckling induces a significant increase in plasma vasoactive 
intestinal peptide concentration and a concomitant increase in plasma PRL concentration 
(Rolandi et al, 1987). Injections of the neurotoxin 5,7-dihydroxytryptamine into the 
anterior pituitary inhibits suckling-induced PRL release in the female rat (Parisi et al, 
1987), as do lesions of serotonergic neurones in the dorsal raphe nucleus (Barofsky et al, 
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1983) and depletion of central 5-HT stores with p-chlorophenylalanine (Kordon et al, 
1973). These studies suggest involvement of serotonergic neurones in either, or both, the 
PVN and anterior hypothalamus in the regulation of PRL secretion (Van de Kar, 1991), 
although other hypothalamic sites may also be involved (Van de Kar, 1991). 
Administration of 5-HT precursors, including TRP and 5-hydroxytryptophan increase 
plasma PRL in the rat (Lu and Meites, 1973), as do several 5-HT receptor agonists, along 
with the 5-HT releasing drug fenfluramine (Van de Kar et al, 1985; Serri and Rasio, 
1987). Administration of RU 24969, a 5-HT IAIIB agonist, and MK-212, a nonselective 5-
HT 112 agonist, increase plasma PRL in a dose dependent manner, in contrast to the 
selective 5-HTIA agonists, 8-0H-DPAT and ipsapirone, which inconsistently elevate PRL 
(Van de Kar et al, 1989). More recently, the 5-HT 2A 12c agonist 1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane (DOI) has been found to increase plasma PRL, an effect 
inhibited by ritanserin, a 5-HT2A/2c antagonist (Rittenhouse et al, 1990; Rittenhouse et al, 
1993). The non-selective 5-HT agonist mCPP similarly increases PRL in the rat (Aulakh et 
al, 1988b ). Pre-treatment with the 5-HT 2 receptor blocker L Y53857 failed to block either 
RU 24969 or fenfluramine-induced PRL release (Van de Kar et al, 1989a; Van de Kar et 
al, 1989b) and ketanserin, a selective 5-HT 2 antagonist, failed to block the PRL response 
to the 5-HT 2 agonists 5-methoxy-N,N-dimethyltryptamine and quipazine or the PRL 
response to the 5-HT precursor, 5-hydroxytryptophan. Pre-treatment with the 5-HT 2 
receptor antagonist ritanserin, however, has been reported to block quipazine and d-
fenfluramine-induced PRL release (Di Renzo et al, 1989). The role of 5-HT3 receptors in 
the control of PRL secretion has also been examined. In a study by Jorgensen et al ( 1993), 
the 5-HT3 agonist 2-methyl-5-HT was found to have little or no effect in increasing PRL 
on its own but was found to enhance the PRL releasing activity of other 5-HT1 receptor 
agonists such as RU 24969. Pre-treatment with ICS 205930, the 5-HT 3 antagonist, was 
found to have no effect on RU 24969-induced PRL release. In contrast, the 5-HT3 
antagonists ICS 205930 and GR 38032F have been reported to block the PRL response 
induced by 5-HT and combined fluoxetine and 5-hydroxytryptophan (Jorgensen et al, 
1992). In summary, no consistent receptor subtype has been found to induce PRL release 
in the rat and evidence to date suggests involvement of 5-HT 1, 5-HT2 and 5-HT 3 receptors 
in the mediation of the PRL response. 
The mechanism underlying serotonergic-induced PRL secretion is thought to be 
release of a prolactin releasing factor (Clements et al, 1978), possibly the polypeptide 
vasoactive intestinal peptide, which stimulates PRL secretion (Shimatsu et al, 1982). The 
finding that vasoactive intestinal peptide antiserum attenuates 5-hydroxytryptophan-
induced PRL release in the rat, strengthens the hypothesis that vasoactive intestinal peptide 
may act as an important mediator of serotonergic-induced PRL secretion (Ohta et al, 
56 
1985). 5-HT does not act by inhibiting dopaminergic tuberoinfundibular neurones (Pilotte 
and Porter, 1981 ). 
2.1.3.2 Human Studies 
Although hampered by a lack of 5-HT challenge drugs suitable for human studies, the 
available evidence supports a significant role for serotonergic neurones in the release of 
PRL in man. Administration of the 5-HT precursors TRP (Maclndoe and Turkington, 
1973; Charney et al, 1982; Cowen et al, 1985) and 5-hydroxytryptophan (Meltzer et al, 
1982) increases plasma PRL in humans, although the increase in PRL following 5-
hydroxytryptophan appears to be less consistent. The PRL response to TRP is enhanced by 
pretreatment with 5-HT uptake inhibitors including clomipramine ( Anderson and Cowen, 
1986) and fluvoxamine (Price et al, 1989). Clomipramine alone, when given 
intravenously, will produce a reliable increase in plasma PRL (Laakmann et al, 1984; 
Golden et al, 1989) but less consistent effects follow oral administration (Laakmann et al, 
1984). mCPP, thought originally to be a selective 5-HT 1 agonist, stimulates PRL secretion 
(Mueller et al, 1985; Kahn et al, 1990; Kahn and Wetzler, 1991) but it is now clear that 
this compound also binds to other 5-HT receptor subtypes (Hamik and Peroutka, 1989). 
The 5-HT IA partial agonist gepirone (Anderson et al, 1990) and the 5-HT releasing drug d-
fenfluramine (Quattrone et al, 1983; O'Keane et al, 1991) also increase plasma PRL 
concentrations. Furthermore, subacute and chronic pre-treatment with lithium has been 
shown to enhance the PRL response to both TRP ( Glue et al, 1986) and clomipramine 
(Mccance et al, 1989), effects probably mediated through the drugs' capacity to facilitate 
pre-synaptic 5-HT release (Treiser et al, 1981; Walsh et al, 1991). In contrast, an 
increased PRL response is not seen following administration of the 5-HT 2118 agonist 
quipazine (Parati et al, 1980). 
Studies with 5-HT antagonists have yielded more conflicting results (Tuomisto and 
Mannisto, 1985). Serotonin antagonists are known to inhibit suckling-induced PRL release 
in puerperal women (Crosignani et al, 1979), while the non-selective 5-HT antagonist 
metergoline will either block or attenuate the prolactin response to TRP (McCance et al, 
1987), mCPP (Mueller et al, 1986; Kahn et al, 1990) and fenfluramine (Quattrone et al, 
1983). Oral methysergide, another non-selective 5-HT antagonist, inhibits sleep-induced 
PRL release in man (Tuomisto and Mannisto, 1985) and ergot alkaloids with 5-HT 
blocking properties, are known to decrease PRL in a number of pathological conditions 
(Chiodini et al, 1976; D'Agata et al, 1977) as well as in normal puerperium (Delitala et al, 
1977). Pindolol, the /3-blocker with 5-HT lA/1B antagonist properties has been reported to 
attenuate the PRL response to TRP (Smith et al, 1991) and the 5-HT 212c antagonist 
ritanserin attenuated the mCPP-induced PRL response (Seibyl et al, 1991 ). In contrast, 





volunteers. The decrease in PRL response seen with 5-HT antagonists may result from the 
non-specificity of the drugs (Tuomisto and Mannisto, 1985). Many of the drugs have 
mixed dopaminergic agonist/antagonist properties which may in themselves explain PRL 
secretion (Creese etal, 1975; Cocchi etal, 1978; Ellis etal, 1991). 
Overall, data from both animal and human studies support the hypothesis that 5-HT 
acts as a stimulatory transmitter in the secretion of PRL (Tuomisto and Mannisto, 1985; 
Cowen and Anderson, 1986). Serotonergic neurones arising in the dorsal raphe nucleus 
stimulate PRL release in the rat by activation of 5-HT 1 and/or 5-HT 2 receptors located on 
the putative prolactin releasing factor neurones (Van de Kar, 1991). A similar mechanism 
involving 5-HT neurones is proposed for man, but the small number of antagonist drugs 
available for human work has meant that identification of the exact 5-HT receptor subtype 
mediating PRL secretion has yet to be determined (Van de Kar, 1991). Data outlined 
above, however, suggests a role by 5-HT 1 and possibly 5-HT 2A/2C receptors although 
unidentified 5-HT receptor subtypes cannot be ruled out (Van de Kar, 1991). 
When plasma PRL levels are measured throughout the morning a fall in concentration 
is seen across time, reflecting the circadian fall in PRL release that occurs in humans at 
this time of day (Figure 2.1). All neuroendocrine challenge tests in this thesis were carried 
out during the morning. 
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Figure 2.1. Mean ± sem PRL response in twelve healthy female volunteers 
following placebo administration at 0900 hours. PRL levels fell across time 




2.1.4 5-HT CHALLENGE DRUGS IN HUMANS 
The recent discovery of multiple biochemical forms of the 5-HT receptor (Peroutka et 
al, 1979; Peroutka, 1988) has been associated with a growing awareness of the distinct 
functional properties mediated by each receptor subtype (see section 1.2.2). In man, the 
post synaptic effects of 5-HT appear to be mediated by multiple 5-HT receptor subtypes. 
5-HT IA receptors are found presynaptically on the 5-HT cell bodies where they function as 
autoreceptors ( Cowen et al, 1990b ). A similar auto receptor function is carried out by 5-
Hf ID receptors located on the nerve terminals (Hoyer, 1988a). Outlined in Figure 2.2 is a 
schematic diagram of a typical 5-HT neurone and synapse, with receptor subtypes 
indicated. 
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Figure 2.2 Schematic diagram of 5-HT neurone and synapse 
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The delineation of 5-HT receptor subtypes has in turn led to an interest in the 
development of selective agonist and antagonist drugs that can be utilised safely in man. A 
wide range of drugs, including 5-HT precursors, releasing agents, reuptake inhibitors, 
receptor agonists and antagonists have been used as 5-HT neuroendocrine challenge 
probes (Yatham and Steiner, 1993). Some of these are outlined in Table 2.1. 
Table 2.1 
Drugs Used to Evaluate Human Serotonergic Function 
Precursors in Serotonin Synthesis TRP 
5-Hydroxytryptophan 
Serotonin Releasing Agents d-Fenfluramine 
dl-Fenfluramine 
Serotonin Reuptake Inhibitors Clomipramine 
Fluoxetine 
Fluvoxamine 
Serotonin Agonists mCPP (5-HT lA/lD/lc) 
Buspirone (5-HT IA) 
Gepirone (5-HT IA) 
Ipsapirone (5-HT IA) 
Quipazine (5-HT 1) 
Serotonin Antagonists Methysergide (5-HT 112 ) 
Metergoline (5-HT 112 ) 
(-) Pindolol (5-HT lA/lB) 
Ritanserin (5-HT zAnd 
Ketanserin (5-HT 2) 
Most drugs utilised as 5-HT challenge probes share the problem of lack of serotonergic 
specificity. For example, the 5-HT precursors, including TRP and 5-hydroxytryptophan, 
are not 5-HT specific as they affect catecholamine metabolism (van Praag et al, 1986) and 
the 5-HT releasing drug, dl-fenfluramine is also known to effect dopaminerf ' 
neurotransmission at high concentrations (Invernizzi et al, 1986). Drugs acting as 5-H1 
antagonists also lack 5-HT specificity. Methysergide and metergoline have dopaminergic 
agonist properties (Krulich et al, 1981) and a recent study by Ellis et al (1991) 
demonstrated that the PRL response to the dopamine agonist haloperidol was blocked by 
metergoline, suggesting that metergoline's PRL inhibitory action may be dopaminergic 
rather than serotonergic-mediated. Another 5-HT antagonist, cyproheptadine, has 
antagonist properties at both muscarinic and histaminic receptors sites (Leysen et al, 
1981). More selective antagonist drugs are beginning to become available such as the 
selective 5-HT 2 antagonists ritanserin and ketanserin. 
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The development and availability of specific 5-HT agonists that stereo-selectively 
interact with specific receptor subtypes has equally been slow, although the recent 
introduction of the azapirones ( 5-HT IA partial agonists including gepirone, ipsapirone and 
buspirone) and the non-selective 5-HT agonist mCPP, is said to have improved the 
situation (Yatham and Steiner, 1993). These new drugs are not without their own problems 
however. For example, at least one of the azapirones, buspirone, has recently been reported 
to affect dopaminergic transmission (Cowen et al, 1990a). A comprehensive review of all 
5-HT drugs utilised in man is beyond the scope of this thesis but a brief overview of the 
challenge drugs used in the following experimental work will be outlined below. 
2.1.4.1 Fenfluramine 
Chemistry, Pharmacokinetics, Receptor Binding and Behavioural Studies 
Fenfluramine exists in two stereo-isomer forms; the racemic isomer, dl-fenfluramine 
and the dextro-rotatory isomer, d-fenfluramine (Campbell, 1991; McTavish and Heel, 
1992). Fenfluramine's main action appears to be on the serotonergic system where it brings 
about an enhancement of 5-HT neurotransmission. Early studies demonstrated that 
enhancement of serotonergic neurotransmission took place indirectly by stimulation of pre-
synaptic 5-HT release from nerve terminals. Hence, depletion of 5-HT stores was believed 
to be necessary before the drug could exert its pharmacological effect (Fuller et al, 1988). 
More recent studies have demonstrated that fenfluramine also exerts effects on 
serotonergic neurotransmission through inhibition of 5-HT re-uptake (Campbell, 1991) 
and possible direct post-synaptic agonist activity at 5-HT 2c receptor sites by the 
metabolite, norfenfluramine (lnvernizzi et al, 1982). Specific binding studies of d-
fenfluramine in the mouse, rat and guinea pig (Mennini et al, 1988) have demonstrated 
that the highest binding is to 5-HT IA > 5-HT IC > 5-HT IB/ID but as affinity to all these 
receptor subtypes is low, it is unlikely to contribute to the pharmacological activity 
(Campbell, 1991 ). An indirect action on 5-HT through stimulation of 5-HT 1 receptors is 
further suggested by studies demonstrating attenuation of fenfluramine-induced anorexia 
in both rats (Neill and Cooper, 1989) and man (Goodall and Silverstone, 1988b) by the 5-
Hf 112 antagonist metergoline but failure to block the food inhibitory effect of fenfluramine 
by either the 5-HT 2 antagonist ketanserin or the 5-HT 3 antagonist, ICS-205-930 (Neill and 
Cooper, 1989) and only partial blockade by the 5-HT212c antagonist ritanserin (Samanin et 
al, 1989). 
Both isomers are capable of inducing 5-HT release, but d-fenfluramine is more potent 
in this respect (Campbell, 1991) and has the added advantage of being more serotonin 
specific in that it does not effect catecholamine neurotransmission (Consolo et al, 1980; 




concentrations of 5 µmol/1 leads to a 25 % stimulation of serotonin release, which is 
accompanied by increased brain 5-HT concentrations (McTavish and Heel, 1992). The 
higher specificity and potency of the dextro-isomer has led to it become the preferred drug 
for use as a 5-HT challenge probe. 
In humans d-fenfluramine remains detectable in plasma for up to forty-eight hours 
after a single oral dose, while multiple administration leads to the development of steady-
state plasma concentrations in four to eight days (McTavish and Heel, 1992). The drug is 
highly lipophilic and is, therefore, widely distributed throughout the body. However, it 
does not appear to accumulate within the tissues and is virtually entirely eliminated via the 
kidneys. d-Fenfluramine has one main active metabolite, d-norfenfluramine, which is 
detectable in plasma one to two hours after administration of the parent drug. At 31.2 
hours, the elimination half-life of d-norfenfluramine is longer than that of d-fenfluramine 
(18.2 hours) (McTavish and Heel, 1992). 
Neuroendocrine Studies 
In the rat, dl-fenfluramine (Van de Kar et al, 1985) induces a dose-dependent increase 
in plasma PRL. The dl-fenfluramine-induced PRL response is potentiated by pretreatment 
with the 5-HT precursor, TRP, and blocked by pretreatment with 5-HT re-uptake inhibitors 
including fluoxetine and indalpine (Van de Kar et al, 1985). Inhibition of fenfluramine's 
action by 5-HT re-uptake inhibitors is thought to take place by a mechanism in which the 
5-HT re-uptake inhibitors prevent entrance of fenfluramine into the serotonergic nerve 
terminals. Stimulation of 5-HT release is therefore prevented. Similar results were 
obtained by Serri and Rasio (1987) using d-fenfluramine at doses thought to ensured-
fenfluramine's relative specificity in interacting with serotonergic pathways. A dose-
dependent increase in PRL followed d-fenfluramine administration which and this 
response was partially blocked by fluoxetine pre-treatment. Human studies further support 
the hypothesis that the fenfluramine-induced PRL response is 5-HT mediated. Plasma PRL 
is significantly increased by fenfluramine in healthy volunteers (Quattrone et al, 1978; 
Quattrone et al, 1983; Lewis and Sherman, 1985), depressed patients (Siever et al, 1984; 
Maes et al, 1989; O'Keane and Dinan, 1991) and in patients with other psychiatric 
illnesses (Lerer et al, 1988; McBride et al, 1991). The effect is dose-dependent and 
attenuated by pretreatment with the 5-HT antagonists, metergoline (Quattrone et al, 1978; 
Quattrone et al, 1983) and cyproheptadine (Lewis and Sherman, 1984). In a study by 
Goodall et al (1993), PRL responses to d-fenfluramine were abolished by pretreatment 
with the 5-HT 2A/2c antagonist ritanserin. 
In summary, administration of d- or dl-fenfluramine leads to a dose-dependent increase 




at least for d-fenfluramine, the PRL response is 5-HT mediated. Furthermore, the most 
likely mechanism of action is indirect enhancement of serotonergic neurotransmission 
through 5-HT 1 receptors secondary to pre-synaptic 5-HT release and re-uptake inhibition. 
Direct post-synaptic receptor activity by the metabolite d-norfenfluramine is also possible. 
Thus, d-fenfluramine is a relatively specific 5-HT drug, well tolerated by humans 
(Campbell, 1991 ), that can be utilised to examine brain serotonergic function. 
2.1.4.2 mCPP 
Chemistry, Pharmacokinetics, Receptor Binding and Behavioural Studies 
mCPP belongs to the piperazine group of drugs and is a metabolite of the 
antidepressant trazodone (Caccia et al, 1982). Early animal work suggested that the effects 
of m CPP were most consistent with direct agonist activity at central 5-HT receptors 
(Samanin et al, 1979), findings in keeping with in vitro studies. Receptor binding in the rat 
has demonstrated a potent interaction by mCPP with 5-HT1A, 5-HTrn 5-HTm and 5-HT 2c 
receptors (Hoyer, 1988a; Hamik and Peroutka, 1989), with the most potent agonist 
activity occurring at 5-HT rni2c receptor sites. In the rodent, mCPP also binds to other 5-
HT 2 and 5-HT 3 receptors where it displays antagonist activity (Conn and Sanders-Bush, 
1987; Kilpatrick et al, 1987). Less potently, m CPP binds to a 1-adrenergic and /3-
adrenergic receptors (Invemizzi etal, 1981). 
Rat behavioural responses to mCPP include decreased food intake (Samanin et al, 
1979; Bagdy et al, 1989b) and reduced locomotion (Vetulani et al, 1982; Kennett and 
Curzon, 1988c; Bagdy et al, 1989b ), effects that are blocked by pretreatment with 5-HT 
antagonists. Kennett and Curzon (1988c) were able to block mCPP-induced hypoactivity 
with the 5-HT 112 antagonists metergoline and cyproheptadine, and with the 5-HT 2c 
antagonist, mianserin but not with either the 5-HT 2 receptor antagonists ketanserin or 
ritanserin, or the 5-HT 3 antagonist ICS 205-930. Furthermore, blockade of mCPP-induced 
hypoactivity was not achieved with the 5-HT lA/lB antagonists (-) pindolol, (-) propranolol 
and ( +/-) cyanopindolol, or following pretreatment with the 5-HT lA/2 and dopamine 
receptor antagonist spiperone. Pretreatment with metergoline, cyproheptadine, mianserin 
and the 5-HT 2c12 antagonist 1-naphthyl-piperazine, but not ketanserin, ritanserin or ICS 
205-930, were found to oppose the mCPP-induced reductions in feeding (Kennett and 
Curzon, 1988c ). Furthermore, administration of m CPP in the rat produces a dose-related 
hyperthermic response which is abolished by pretreatment with the 5-HT antagonist 
metergoline, but not the dopamine antagonist haloperidol, nor (-) pindolol, propranolol, or 
ritanserin. Taken together, the results from the above experiments strongly suggest that 
mCPP exerts its behavioural and hyperthermic effects via 5-HT receptors. More 
specifically, they suggest a role by 5-HT 2c receptors in mediating hypoactivity, 5-HT rni2c 
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receptors in feeding behaviour, while debate continues as to whether or not 5-HT 1 or 5-
Hf 2 receptors mediate the hyperthermic effects of mCPP (Pawlowski, 1984; Wozniak et 
al, 1989). 
Binding studies on human brain cortex have also demonstrated potent activity by 
mCPP at central 5-HT receptor sites. In a study by Hamik and Peroutka (1989) mCPP 
demonstrated equal and high potency at all 5-HT receptor subtypes, while displaying less 
potent activity at m-adrenergic, dopamine D 1 and D2, and ,8-adrenergic receptors. When 
administered to humans, mCPP produces marked psychological effects including increased 
ratings in anxiety and decreases in happiness and calmness (Charney et al, 1987). 5-HT 
agonist activity by m CPP to induce an anxiogenic effect in humans is consistent with 
current hypotheses about the central role of 5-HT in the aetiology of anxiety disorders 
(Kahn et al, 1988) and is in keeping with findings from animal anxiety models. Although 
findings with 5-HT antagonists are somewhat inconsistent (Kahn et al, 1988), treatments 
which decrease 5-HT neurotransmission are known to have anxiolytic effects (Geller and 
Blum, 1970; Winter, 1972). In a study by Pigott et al (1993), intravenous administration 
of mCPP (0. lmg/kg) to ten patients with Obsessive Compulsive Disorder led to a 
significant exacerbation of their symptoms, including anxiety ratings. Pretreatment by the 
5-HT antagonist metergoline however, completely blocked the exacerbation of symptoms, 
suggesting that these behavioural responses are also 5-HT 112 receptor mediated. This study 
replicated findings of an earlier one by the same group in which oral mCPP-induced 
anxiety in six Obsessive Compulsive Disorder patients was blocked by metergoline 
pretreatment ( Pigott et al, 1991). 
When administered to humans, oral mCPP (0.25mg/kg) produces peak plasma 
concentrations after 2.5 hours (Kahn et al, 1990), and at a dose of 0.5mg/kg has a half life 
of approximately three hours (Murphy et al, 1989). Gender differences in absorption 
appear to exist. mCPP plasma concentrations in both healthy volunteers and patients in one 
study were twice as high in the men as in the women (Kahn et al, 1991). Oral 
administration produces wide variability in mCPP blood levels and the response is not 
clearly dose-related (Kahn and Wetzler, 1991). Intravenous mCPP results in more 
consistent plasma concentrations, but has the disadvantage of a greater number and 
severity of side effects including nausea, sweating, light headedness, palpitations, anxiety 
and chest pressure (Murphy et al, 1989). The physical effects of mCPP, such as nausea and 
light-headedness, appear to be dose-related, while mCPP-induced anxiogenic effects and 
panic attacks have a more complex relationship with the drug's administration. The onset 
of panic attacks and of anxiety-related symptoms appears dose-dependent following oral 
administration, but is dependent upon duration of infusion time after intravenous 
administration. A shorter infusion time has been found to i1,1duce panic attacks in greater 
numbers of patients and healthy volunteers (Kahn and Wetzler, 1991). mCPP elevates 
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blood pressure and pulse rate but not consistently (Mueller et al, 1985; Murphy et al, 
1989; Kahn et al, 1990). 
Neuroendocrine Studies 
mCPP consistently enhances PRL release in both rats (Aulakh et al, 1988a; Bagdy et 
al, 1989b) and non-human primates (Aloi et al, 1984 ). In the rat the mCPP-induced PRL 
response is blocked by pretreatment with the 5-HT 112 receptor antagonist metergoline ( Aloi 
et al, 1984; Bagdy et al, 1989b), but not the 5-HT 212c receptor antagonist ritanserin or 5-
HT 3 antagonist MDL 72,222 (Bagdy et al, 1989b). Ritanserin pretreatment in the rhesus 
monkey also leads to only partial blockade of the m CPP-induced PRL response 
(Henninger et al, 1988). 
Human neuroendocrine studies in healthy volunteers have demonstrated consistent 
mCPP-induced PRL responses at oral doses of 0.5 and 0.75mg/kg, with marginal effects 
seen at 0.25mg/kg (Mueller et al, 1985; Murphy et al, 1989; Kahn et al, 1990). mCPP-
induced PRL responses have also been reported in patient populations (Zohar et al, 1987; 
Kahn et al, 1992). The dose-response relationship does not appear to be linear, with 
0.5mg/kg of mCPP releasing five times more PRL than the 0.25mg/kg dose (Kahn et al, 
1990). Peak hormone responses across the three doses were reached at approximately two 
hours after drug administration (Kahn et al, 1990). Intravenous administration within the 
dose range of 0.06-0. lmg/kg also produce reliable and consistent elevations in PRL when 
compared to placebo, with a smaller PRL response reported at 0.05mg/kg (Charney et al, 
1987; Lawlor et al, 1989; Murphy et al, 1989). Time to peak PRL response appears 
variable following intravenous mCPP and may occur as late as ninety to 120 minutes 
(Kahn et al, 1990). Gender differences have been reported for mCPP-induced PRL 
responses. Although mCPP plasma concentrations are lower in women compared to men at 
a given dose, PRL release is greater (Charney et al, 1987; Kahn et al, 1991 ). It has been 
suggested that the gender difference is be due to circulating oestrogens in women 
potentiating the mCPP-induced PRL response as has been reported with other 5-HT 
challenge drugs (O'Keane et al, 1991). Blockade of oral mCPP-induced PRL responses 
have been reported following pretreatment with both metergoline (4mg) and methysergide 
(4mg), the 5-HTI/2 antagonists (Kahn et al, 1990). In a study by Pigott et al (1991), 
pretreatment with metergoline was found to block the PRL response to mCPP in a group of 
twelve patients with Obsessive Compulsive Disorder. 
In a drug capable of inducing panic attacks and anxiety symptoms, the question must 
be raised as to whether or not the hormone responses are secondary to its behavioural and 
physical effects. The finding that hormonal responses followed the onset of physical and 
behavioural responses would support this theory. Following intravenous administration of 
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mCPP, this sequence of events has been reported with peak hormonal responses reported 
to occur fifteen to thirty minutes after peak anxiety levels ( Charney et al, 1987; Murphy et 
al, 1989). However, following oral administration, the picture is much less clear. One 
study reported peak anxiety as preceding peak PRL response by ninety minutes (Murphy et 
al, 1989), but another found the peak physical symptoms coincided with peak PRL levels 
(Kahn et al, 1990). No increases in anxiety were reported to have occurred. 
In summary, considerable evidence exists from both animal and human studies to 
support the use of mCPP as a highly selective probe of serotonergic function (Kahn and 
Wetzler, 1991). It appears most potent as a 5-HT agonist and in humans, induces reliable 
PRL responses following oral and intravenous drug administration. Animal studies suggest 
mCPP-induced PRL is probably mediated via direct agonist activity at post-synaptic 5-
Hf 1B (rat) or 5-HT 212c (rhesus monkey) receptors. The limited antagonists studies so far 
carried out in humans confirm mCPP-induced PRL release via agonist action at 5-HT 
receptors, but the subtype(s) involved remains unknown. While caution must be taken in 
the interpretation of mCPP-induced PRL responses where significant behavioural effects 
have occurred, careful study design should minimise potential confounding factors. 
2.1.5 METHODOLOGICAL CONSIDERATIONS 
The need for careful control of neuroendocrine challenge tests has been emphasised by 
Checkley (1980), who outlined specific criteria that must be satisfied before it can be 
assumed that a hormone response to a particular drug results from stimulation of a 
specified receptor. The criteria are: 
i) The same hormone response should result from the administration of all drugs which 
act as agonists for the specified receptor. 
ii) The hormone response to receptor stimulation should be inhibited by drugs which act 
as selective antagonists for the receptor. 
iii) The hormone response should not be inhibited by drugs which are antagonists at other 
receptors. 
iv) Further evidence is provided if antagonists of the receptor also inhibit hormone 
responses to physiological stimuli such as sleep or exercise. 
In order to establish that the receptor being stimulated is located within the brain, two 
further considerations are required: 
v) If the hormone response is only produced by agonist drugs that cross the blood-brain-
barrier, then it can be assumed that the drugs must be working within the brain. 
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vi) Hormone responses produced by agonist drugs that do not cross the blood-brain-
barrier may still be acting at receptors within the brain. This assumption is accepted if 
animal experiments provide evidence that the receptors lie within the median eminence, a 
structure without the usual blood-brain-barrier. 
The above criteria apply to drugs acting directly at the site of the receptor. For 
precursors of the challenge drug or indirect agonists, alterations in hormone responses may 
also result from changes in neurotransmitter release or reuptake. 
Accurate interpretation of monoamine function using a neuroendocrine challenge is 
only possible if careful controls are made of all other biological variables that may in 
themselves alter the hormone responses under examination (Checkley, 1980). Such 
controls are applicable to both healthy and patient populations and those seen as most 
important are outlined below. 
i) For patient populations, the concurrent use of psychotropic drugs is a major source of 
artefact in neuroendocrine testing as most alter monoamine function (Checkley, 1980). 
Some psychotropic drugs act directly at the level of the pituitary to alter hormone 
secretion (Meltzer et al, 1978) while others may interact with the psychoactive drugs (eg. 
amphetamine or clonidine) being employed as the neuroendocrine challenge. Other 
psychotropic medication is known to alter receptor sensitivity (Friedhoff and Alpert, 
1978). Consequently, it is usual to exclude the concurrent use of antidepressant and 
neuroleptic drugs with a washout period of at least three weeks, although debate exists as 
to whether or not this length of time is sufficient (Corn et al, 1984; Schittecatte et al, 
1989). Night sedation is often permitted but again caution is required as evidence exists 
that, at least acutely, benzodiazepines may alter hormone responses (Nutt and Cowen, 
1987). 
ii) For all subject groups, the use of recreational drugs such as alcohol, caffeine and 
nicotine must be considered. Excessive intake of alcohol leads to suppression of pituitary 
hormone responses (Chalmers et al, 1977), while excessive caffeine, which is 
pharmacologically related to amphetamines, may stimulate hormone release (Checkley, 
1980). Subjects partaking in excess of either are, therefore, best excluded. 
iii) Age and sex must be controlled for as both influence hormone secretion. 
iv) Hormone responses such as GH and PRL appear to alter at different phases of the 
menstrual cycle. Studies utilising the 5-HT lA partial agonist buspirone, have shown 
marked variations in PRL response across the menstrual cycle with a three fold increase 
67 
A. 
seen premenstrually (Yatham et al, 1989; Dinan et al, 1990). In a more recent paper, d-
fenfluramine-induced PRL responses also varied with the phase of menstrual cycle and 
were found to be greatest at mid-cycle (O'Keane et al, 1991). Such variations in hormone 
responses are thought to be primarily oestrogen effects. Careful control of the menstrual 
cycle phase during which the neuroendocrine challenge is carried out is therefore essential. 
v) The secretion of ACTH, GH and PRL are all increased by stressful situations (Mason, 
1968; Greene et al, 1970), including procedures such as venipuncture. A baseline period 
of 30-60 minutes following insertion of the venous cannula (before the challenge drug is 
given and hormone sampling begins) is usually incorporated into the neuroendocrine 
procedure. The challenge drug itself may produce unwanted side effects such as nausea 
and anxiety, which again will influence the hormone response. 
vi) Nutritional status is likely to be important. Malnutrition is known to directly affect 
hormone secretion (see sections 1.1.2.3 and 1.3.1.3), and moderate weight loss has been 
shown to influence PRL responses to TRP in women (Goodwin et al, 1987b; Anderson et 
al, 1989). 
vii) A number of other variables are thought important in influencing hormonal 
responses. These include severe physical activity (Casmore et al, 1977), the presence of 
chronic physical illness (Krieger, 1975) and pregnancy (Burns, 1976). Standardization of 
the time of day at which tests are carried out is necessary due to the pulsatile and circadian 
rhythm of secretion that governs most anterior pituitary hormones. 
Three other points not covered by Checkley ( 1980) are emphasised by Anderson 
(1992). 
viii) The hormone response depends not only upon the activity of the monoamine 
synapse with which the drug interacts, but on a series of steps beginning with the 
monoamine neurone and ending with secretion of the hormone from the anterior pituitary. 
Other variables such as the rate at which the hormone is cleared from the body will also 
influence the final response. Thus, any given challenge tests the function of the whole 
neuroendocrine system and an abnormality in any one of the steps could account for an 
abnormal finding in a given patient population. 
ix) Consideration must be given to the pharmacokinetics of the challenge drug being used. 
Oral administration of drugs such as tricyclic antidepressants are known to result in 
variable absorption rates (Preskorn, 1993) leading to inconsistent plasma levels which in 
tum may affect the hormone response. 
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x) Finally, great inter-individual variations in hormone responses to a given challenge 
drug exist, with the consequence that small changes may be obscured by the size of the 
variance, leading to false negatives (type II errors). Anderson (1992) points out that while 
no easy solution exists for this problem, study replication and the use of appropriate 
statistical analyses will lessen the possibility of small but important changes being missed. 
2.2 TRYPTOPHAN DEPLETION STUDIES OF 5-HT 
TRP depletion studies provide an alternative method of studying 5-HT function in the 
living human brain (Young et al, 1985; Delgado et al, 1990; Oldman et al, 1994). The 
rationale behind these studies is the role TRP availability plays in the control of brain 5-
HT synthesis (see section 1.2.1 for a full explanation). 
2.2 1 ANIMAL STUDIES 
Animal work has demonstrated that dietary manipulations which acutely lower plasma 
TRP produce decreases in brain 5-HT turnover in both rodents and non-human primates 
(Young et al, 1989; Gartside et al, 1992). Increases (Fernstrom and Hirsch, 1975) and 
decreases (Gal and Dreses, 1962) in dietary TRP lead to corresponding changes in brain 
TRP and 5-HT levels in rodents. In a study by Biggio etal (1974), a TRP-free diet given to 
rats produced a 90% reduction in plasma free TRP accompanied by a 85% reduction in 
brain TRP, a 58% fall in brain 5-HT and a 76% fall in brain 5-HIAA within two hours of 
depletion. Furthermore, dietary TRP depletion in rodents enhances behavioural indices 
thought to be mediated by decreased brain 5-HT function. TRP depletion in rats increases 
sensitivity to pain (Lytle et al, 1975), increases muricidal behaviour i.e. mouse killing 
(Gibbons et al, 1979a) and reduces rapid eye movement sleep (Moja et al, 1979), 
behaviours that are all reversed by TRP repletion. 5-HT depletion secondary to a low TRP 
diet has also been shown to result in enhanced PRL responses to a 5-hydroxytryptophan 
infusion, presumably through the development of post-synaptic receptor supersensitivity 
secondary to reduced brain 5-HT synthesis (Clemens et al, 1980). The administration of 
TRP-free amino acid drinks to rats also leads to a rapid reduction in plasma TRP and brain 
5-HT concentrations (Moja et al, 1989) while Gartside et al (1992) were able to show that 
administration of a similar amino acid treatment decreased the 5-HT release evoked by 
electrical stimulation of the dorsal raphe nucleus of rats in vivo. In a study by Young et al 
(1989) the effects of TRP depletion in non-human primates i.e. vervet monkeys was 
examined. Using a TRP-free amino acid drink paradigm, a smaller but highly significant 
reduction in plasma TRP was seen compared to those changes obtained in the rodent. The 
reduced plasma TRP levels were accompanied by reductions in CSF 5-HIAA 
concentrations (Young et al, 1989), suggesting corresponding reductions in central 5-HT 
function. 
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2.2.2 HUMAN STUDIES 
In humans, brain 5-HT can be reduced either by blocking synthesis or by restricting 
dietary TRP (Miller et al, 1992). Two clinical studies published in the 1970s utilised the 5-
HT synthesis inhibitor p-chlorophenylalanine, which blocks synthesis of 5-HT by 
inhibition of the rate limiting enzyme tryptophan hydroxylase. The authors used p-
chlorophenylalanine to examine the role of 5-HT in depression and found that inhibition of 
5-HT synthesis by p-chlorophenylalanine reversed the antidepressant effects of both the 
tricyclic imipramine (Shopsin et al, 1975) and the monoamine oxidase inhibitor 
tranylcypromine (Shopsin et al, 1976). However, the use of p-chlorophenylalanine is 
associated with side effects (Shopsin et al, 1976) including a high incidence of allergic 
eosinophilia, rendering its use as an investigative agent in humans highly problematic 
(Miller et al, 1992). Diets free or low in TRP have been administered to healthy volunteers 
as an alternative method of reducing brain 5-HT. In a study by Delgado et al (1989) 
subjects were given diets containing two different magnitudes of TRP restriction, i.e. 
200mg and 700mg TRP respectively for ten days. Both diets led to a reduction in total 
plasma TRP of between 15% and 20% with greater falls observed in the women compared 
to the men. No significant fall in plasma free TRP was seen but a trend towards a decrease 
was noted. Of further interest were the responses to an intravenous TRP infusion given in a 
neuroendocrine challenge paradigm, both before and following the ten day low TRP diet. 
An enhanced PRL response was seen following the low TRP diet, in keeping with the 
animal data. Several practical issues including the complexities of administering a low 
TRP diet and the modest falls in plasma TRP obtained as a result, limit dietary restriction 
as a method of 5-HT depletion (Miller et al, 1992). 
A number of studies have been published which utilise a mixture of amino acids 
deficient in TRP to achieve an acute reduction in transportation of plasma TRP to the 
brain, and hence a reduction in brain 5-HT synthesis (Young et al, 1985; Delgado et al, 
1990). This method of amino acid loading reduces brain TRP in two ways. Firstly, TRP 
transportation into the brain occurs by an active transport system, which is shared by five 
other amino acids. Competition for the carrier site can lead to a deficiency of any of these 
amino acids relative to the others (Gessa et al, 1974 ). Thus, if a large amino acid load 
deficient in TRP is given, the ratio of TRP to other large neutral amino acids will fall, 
reducing the amount of TRP transported across the blood brain barrier. As outlined in 
section 1.2.1, TRP availability to the brain acts as the rate limiting step in the synthesis of 
5-HT, hence any reduction in TRP entering the brain will be accompanied by a fall in 5-
HT synthesis. Secondly, and perhaps more importantly, an amino acid load deficient in 
TRP appears to increase protein synthesis in the liver leading to a subsequent fall in tissue 
and plasma TRP stores (Biggio et al, 1974 ). The drive for protein synthesis depletes 
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plasma TRP, thereby diminishing TRP transportation into the brain through increased 
competition with other amino acids. This method has been shown to effectively reduce 
levels of plasma total and free TRP in humans (Young et al, 1985; Delgado et al, 1990 ). 
For example, in the study of Young et al ( 1985), a 1 OOg amino acid drink deficient in TRP 
led to a 60% reduction in plasma free TRP five hours after administration. Acute TRP 
depletion has been shown to reverse the analgesic effects of morphine in the cold-pressor 
test in healthy males (Abbott et al, 1992) in keeping with the animal literature that 
suggests 5-HT mediated behaviours are also altered by the amino acid drink paradigm. 
Furthermore, as outlined above, animal data strongly supports the hypothesis that reduced 
plasma TRP leads to reduced brain TRP and a fall in 5-HT synthesis. 
In conclusion, this methodology provides an acute manipulation of brain 5-HT which 
can be safely carried out in the human population. Most studies in humans have used doses 
of 100g of amino acids (Young et al, 1985; Smith et al, 1987; Delgado et al, 1990) but 
such high doses are associated with a high incidence of nausea. A pilot study carried out 
by our group examined the effects of a 52g dose of amino acids given to nine healthy 
volunteers (Oldman et al, 1994). The 52g dose led to a fall in both total and free plasma 
TRP 4.5 hours after administration. The magnitude of the fall was comparable to that seen 
with the higher dose of 100g and the drink well tolerated by subjects in terms of unwanted 
side effects. On the basis of these findings, the 52g amino acid drink appeared to offer the 
most effective method of acutely lowering plasma TRP allowing an accurate assessment of 
the effects of acute brain 5-HT depletion on appetite and mood in the absence of 
confounding side effects. 
2.2.3 THE MENSTRUAL CYCLE: EFFECTS ON APPETITE AND 
TRYPTOPHAN METABOLISM 
2.2.3.1 Menstrual Cycle Effects on Appetite 
Any study that aims to examine appetite in women must take into account the effects 
of hormone changes across the menstrual cycle. The past few years have brought an 
increased awareness of the changes in mood and appetite that accompany the phases of the 
menstrual cycle in both normal women and in women that report pre-menstrual symptoms 
(Bancroft et al, 1988; Warner and Bancroft, 1990; Goodall and Silverstone, 1993). Most 
published studies have simply divided the menstrual cycle into follicular (defined as the 
first ten days of the cycle from the onset of menses) and luteal (defined as the last ten days 
of the cycle before the onset of menses) phases, but two studies have further differentiated 
the periovulatory phase ( Gong et al, 1989; Lyons et al, 1989). Methods of measuring food 
intake have also varied. Food diaries, recording daily intake over the two ten day periods 




out", have been the most common approach. However, some researchers have utilised a 
test meal method, again given at times to correspond with the follicular and luteal phases. 
While criticism has been levelled at the methodological limitations of both study 
approaches (Goodall and Silverstone, 1993 ), consistent findings have been reported across 
the menstrual cycle with respect to both total energy intake and macronutrient selection 
In a population survey carried out by Warner and Bancroft (1990), 5,457 women 
completed a menstrual health questionnaire that had been published in a women's 
magazine. Of the women who completed the questionnaire, 36% reported "severe" 
cravings for sweet foods around the time of menstruation, 7% reported "severe" cravings 
for salty foods and 11 % reported cravings for other types of food perimenstrually. A 
prospective study was then carried out on seventy-six women who had reported 
premenstrual cravings in the magazine survey (Bancroft et al, 1988). The study confirmed 
a premenstrual pattern of food craving in 72% of the women, with cravings confined to the 
menstrual phase in 13%. No consistent association between food cravings and mood 
change, in terms of either severity or timing of symptoms, or between food cravings and 
breast tenderness were found. The authors concluded, therefore, that perimenstrual food 
craving was a cyclical phenomena in its own right and not dependent upon mood or other 
physical changes. In support of this hypothesis, Cohen et al (1987) found no relationship 
between mood scores, reported food cravings and eating scores amongst his group of 
healthy undergraduate women. However, Both-Orthman et al (1988) reported a significant 
positive correlation, premenstrually, between mood change and increased appetite in 
women reporting severe cyclical mood swings. This finding did not extend to those 
women who did not report significant premenstrual mood changes. 
Other studies have examined total energy intake between the follicular and luteal 
phases. In two out of three studies using daily food diaries over ten days of the follicular 
and luteal phases, mean energy intake was found to be higher in the luteal phase compared 
to the early follicular phase (Dalvit-McPhillips, 1983; Giannini et al, 1985; Manocha et 
al, 1986) and appeared to be accompanied by greater food cravings (Cohen et al, 1987). A 
higher mean energy intake during the luteal phase compared to the follicular phase has 
been confirmed by three further studies using single day food measurements (Pliner and 
Fleming, 1983; Leiter et al, 1987; Bowen and Grunberg, 1990), but Wurtman et al (1989) 
were unable to replicate these findings using a test meal procedure given in the follicular 
and luteal phases. Measurements of appetite have been found to be increased in the 
premenstrual week (Both-Orthman et al, 1988), while Lyons et al (1989) reported 
decreases in energy intake in the periovulatory period compared to premenses, 
postovulatory and menses phases. 
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Macronutrient preference across the menstrual cycle has been examined. Increased 
carbohydrate (Dalvit-McPhillips, 1983; Leiter et al, 1987), sweet food (Leiter et al, 1987; 
Bowen and Grunberg, 1990) and fat (Anantharaman-Barr et al, 1988; Tarasuk and Beaton, 
1991) consumption has been reported in the luteal phase compared to the follicular, while 
a significant decreased protein intake has been found in the periovulatory phase (Lyons et 
al, 1989), and perimenstrually (Abraham et al, 1981). 
2.2.3.2 Menstrual Cycle Effects on Tryptophan Metabolism 
One study has examined the effects of the menstrual cycle on TRP loading. Hrboticky 
et al (1989) studied the metabolism of TRP during the follicular and luteal phases of the 
menstrual cycle in eight healthy women. Three grams of TRP or placebo was given during 
the follicular and luteal phases across two menstrual cycles in a cross over design. Three 
hours after TRP administration, plasma kyneurine concentrations were 40% higher, and 
urinary kyneurine excretion was 28% greater in the luteal compared to the follicular phase. 
The results strongly suggest that rate of catabolism of TRP, via the kyneurine pathway in 
the liver, is altered across the menstrual cycle and is higher in the luteal phase. 
2.2.3.3 Appetite Research Design 
As can be seen from the above brief review, consistent changes in appetite occur 
across the menstrual cycle and must, therefore, be taken into account in any study design. 
The most consistent change occurs in the late luteal phase and involves increased energy 
intake and enhanced carbohydrate consumption. Increased metabolism of TRP during the 
luteal phase is also suggested from the findings of one paper. On the basis of these results, 
it would be important to exclude the premenstrual phase from both appetite and endocrine 
studies. 
2.3 GENERAL METHODS 
2.3.1 MEASURES OF VITAL SIGNS AND SIDE EFFECTS 
Adverse reactions and side effects from challenge drugs were monitored by a 
combination of physiological readings to observe changes in the subject's vital signs, and 
visual analogue (VA) scales. 




layers, the hexane extract was transferred to a tapered 10ml tube which contained 1ml of 
0.05M sulphuric acid for back extraction. To the remaining aqueous phase, 50µ1 of butyl 
acetate and 500µ1 of 5M ammonia was added and vortexed for twenty-five seconds. The 
solution was centrifuged at 2000g for five minutes and the lower aqueous phase aspirated 
and discarded. The upper solvent phase was then ready for injection into the gas liquid 
chromatograph (Varian 3400; Varian Ltd., Wotton-on-Thames, Surrey). 
Results were interpolated from standard curves and linear calibration curves were 
obtained for both d-fenfluramine and d-norfenfluramine in plasma with high correlation 
coefficients (r=0.98). The intra-assay CV was between 3.3% and 12% for both d-
fenfluramine and d-norfenfluramine, while the inter-assay CV was 6.9% and 27.5% ford-
fenfluramine and d-norfenfluramine respectively. The limit of detection for d-fenfluramine 
was 0.5ng/ml and for d-norfenfluramine, 2ng/ml. 
2.3.2.4 mCPP Assay 
Plasma mCPP was assayed by high performance liquid chromatography as described 
by Franklin (1992). This procedure, based on solid-phase sorbent extraction of mCPP from 
the plasma followed by isocratic reversed-phase high performance liquid chromatography 
with coulometric detection, utilises gepirone was as the internal standard. 
Standard curves were prepared fresh daily and consisted of five concentration points over 
the range l-25ng/ml of mCPP in drug free plasma. Using the Vac-Elut Manifold system 
(Jones Chromatography Ltd.; Hengoed, Mid-Glamorgan), 50ng of the internal standard 
gepirone was added to each 1ml volume of sample or standard. Cyanopropyl sorbent 
columns (Bond Elut, Analytichem International, Habour City, USA) were conditioned 
with single column volumes of methanol and water, the vacuum being diverted to keep the 
columns from drying out. The sample or standard was transferred to the column and the 
vacuum applied to allow the materials to pass completely through. Each column was 
washed with two column volumes of distilled water and taken to full dryness under 
vacuum. The vacuum was again diverted and the manifold needles wiped dry and a 
collection tray containing 10x75mm glass tubes inserted into the Vac-Elut Manifold 
system. The compounds were eluted with one column volume of methanol and the 
methanolic eluates evaporated to dryness under vacuum at 40°C. Samples were 
reconstituted in mobile phase (0.04M potassium phosphate buffer adjusted to pH6.45 with 
2M KOH, acetonitrile and methanol [600:250: 150 v/v]), vortexed and injected into the 
high performance liquid chromatograph (Coulochem II, BSA, Bedford, Mass., USA). 
Results were interpolated from standard curves, determined by assaying pooled drug-
free plasma spiked with known amounts of mCPP. Peak heights rather than peak areas in 
the chromatograms were normally measured. Concentrations of mCPP were assessed by 
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using the slope of the standard curve for peak-height ratios for the analyte and the internal 
standard. The intra-assay CV was between 3-8.5% and the inter-assay CV was 5.9%. The 
detection limit was 0.07ng and plasma concentrations of mCPP are quoted in nanograms 
per millilitre (ng/ml). 
2.3.2.5 Oestradiol Assay 
Plasma oestradiol concentrations were measured usmg a highly specific 
radioimmunoassay kit from Diagnostic Products Corporation, Los Angeles, California. 
The kit contained all necessary reagents and tubes for the procedure, including oestradiol 
antibody-coated tubes, iodinated oestradiol (125J-oestradiol) and oestradiol calibrators (i.e. 
0, 20, 50, 150, 500, 1800 or 3600pg/ml of oestradiol in processed human plasma) from 
which the standard curve was constructed. 
Four plain uncoated polypropylene tubes were labelled "total" and "non specific 
binding" in duplicate. 100µ1 of each calibrator solution, the control solution and unknown 
plasma sample were pipetted into duplicate sets of antibody-coated tubes. 1ml of 125J-
oestradiol was added to all tubes, vortexed, and the resultant solution incubated for three 
hours at room temperature. The contents of each tube, except "total" tubes, were decanted 
and allowed to drain on absorbent paper for two to three minutes. The tubes were placed in 
the gamma counter to be counted for five minutes. 
Results were calculated by standard curve interpolation. Plasma oestradiol 
concentrations are quoted as pg/ml. The intra-assay and inter-assay CV s varied from 4-7% 
and 4.2-8.1 % respectively over the range of the standard curve. The limit of detection was 
8pg/ml. 
2.3.2.6 TRP Assays 
Total Tryptophan 
Plasma total TRP was assayed according to the method described by Bloxam and 
Warren (1974). 10µ1 volumes of plasma were added to 2ml of ice-cold 10% (W/V) 
trichloroacetic acid contained in 4ml polystyrene tubes. The tubes were centrifuged at 
2,500g for fifteen minutes at 4°C to remove the protein precipitate. Standards in the range 
0-20 ng/ml TRP were prepared similarly. For very high values of plasma TRP (following 
TRP infusion) the deproteinised sample was further diluted with 10% TCA to give values 
within the range of the standard curve. To each sample/standard on ice was added 0.2ml of 
2% (W/V) formaldehyde and 0.1ml of 6mM ferric chloride in 10% TCA, the tubes 




hour. The fluorescence in each tube was measured in a Hitachi model 2000 
spectrofluorimeter (excitation wavelength 300nm, emission wavelength 440nm). 
Results were interpolated from standard curves constructed of fluorescence versus 
TRP concentration. Plasma TRP concentrations are quoted as micrograms per millilitre 
(µg/ml). Intra- and inter-assay coefficients of variation were 4.4% and 9.4% respectively 
and the limit of detection was O. lng/1. 
Free Tryptophan 
Plasma free TRP was assayed according to the method described by Bloxam et al, 
(1977) 200µ1 of plasma was pipetted into the reservoir of a Millipore ultrafree 10,000 
NMWL filter (Millipore UK Ltd.; Watford, UK). The sample was gassed with a 95% 
oxygen/5% carbon dioxide mixture by inserting a 19 gauge syringe needle into the 
reservoir above the sample for thirty seconds before quickly closing the top of the 
centrifuge tube to maintain the gas atmosphere. This prevents plasma pH increasing during 
centrifugation due to loss of carbon dioxide (which would result in a change in the 
proportion of TRP bound to albumin). The tubes were then inverted for ten minutes before 
being centrifuged for thirty minutes in an Eppendorf benchtop micro-centrifuge. The 
resultant filtrate was analysed as described for total TRP. 
2.3.3 MEASURES OF APPETITE 
Two methodologies were combined to measure appetite. Total calorie intake and 
macronutrient intake (carbohydrate, protein and fat) were calculated from the test meal 
procedure, while self-rating scales were used to measure appetite related parameters and 
macronutrient preferences. 
2.3.3.1 Test Meal Procedure 
The test meal is designed to measure total calorie intake (calculated in kilojoules [kJ]) 
and the calorie intake of each macronutrient (carbohydrate, protein and fat). 
Selection of Items 
As part of the initial screening procedure, subjects completed a food item checklist 
designed to determine food preferences from which the test meals were later based (see 
Appendix Four). Each volunteer was asked to rate a list of food item on a scale from one to 
nine, where one equated with "extremely dislike" and nine with "extremely like". Seven 
different food categories were included in the list and the test meal made up to include 
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items from each category plus margarine and tomatoes, thus ensuring a good selection of 
food from each type of macronutrient. Where ever possible, the favourite foods from each 
category was chosen but where some or all of the food items in one category were rated 
equally, set rules for selection were followed. If no clear favourite food item existed, the 
first item on the list was chosen eg. Rich Tea biscuits for the biscuit category. 
For sandwich fillings the same rules were applied, with four choices provided. Two 
protein items were always included in the final selection, and if this was not achieved on 
preference alone, the least preferred non-protein item was swapped for the highest rated 
remaining protein food. The inclusion of two protein items within the sandwich fillings 
ensured a balanced selection of macronutrients and included cheddar cheese, cottage 
cheese, ham, tuna and chicken roll. 
Amounts 
In order to ensure that no constraints were placed on subjects in terms of the amount of 
a particular food, and hence macronutrient consumed, excess portions of each item was 
presented. The quantities with the approximate weights are set out in Appendix Five. 
Weights of particular items varied slightly because quantities were kept constant eg. two 
tomatoes. 
Presentation 
Test meals were presented in a standardised manner to minimise any confounding 
factors, such as visual cues that might help the volunteer determine how much of a 
particular item had been consumed. All excess packaging was removed (eg. crisp packets, 
yoghurt pots) and food presented on plates and in dishes that were kept identical for all test 
meals. Items of food were presented in a standardised layout on two trays which had been 
set by the author. Drinking water was also made available during the meal. 
Instructions to Subjects 
Volunteers were given a standard set of instructions before eating. They were asked "to 
ignore any dietary restrictions that you may have placed upon yourself with regards the 
types of foods that you would/would not eat, or the quantities of food that you would/ 
would not eat, and to eat until you have had enough". 
Calculation of Food Consumed 
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During preparation of the meals, all food items were pre-weighed to the nearest O. lg 
using electronic scales (Ohaus, model CT1200-S, sensitive to the nearest O.Olg) and the 
weights entered onto a record sheet (see Appendix Six). The prepared food was then kept 
in the refrigerator covered with clingfilm to minimise water loss, which might alter the 
weight. Immediately the volunteer had completed the meal, food items were again weighed 
to the nearest O.lg and the final weights entered onto the record sheet. 
Calculation of Calorie Consumption 
Food consumption was calculated by subtraction of the final weight for each item from 
its original weight. Data were then analysed to determine total calories consumed, total 
calories of each macronutrient i.e. fat, carbohydrate and protein, and total calories of sweet 
and savoury foods. Analysis of data was carried out on "Direct", a specifically designed 
software programme (for Goodall and Silverstone; London; UK). The programme is 
designed to analyse each meal separately and to provide a printout of the breakdown data 
for that meal. 
2.3.3.2 Visual Analogue Scales 
Visual analogue scales were used to measure parameters of appetite and satiety and 
included ratings such as "wish to eat" and "fullness". Each VA scale consisted of a ten 
centimetre line with a scale from zero to one hundred marked out in increments of ten 
across the top (see Appendices Three and Seven). Subjects were instructed to complete the 
VA scales by either placing a mark on the line or encircling the number that most closely 
reflected how they felt. For the test meal, the VA ratings were related to normal aspects of 
appetite and satiety including wish to eat, feel full, find/found the meal satisfying and 
could eat a large amount of food, and subjects were required to rate how they felt at that 
precise moment. 
2.3.3.4 Presentation of Appetite Rating Scales 
All V As were given in a standardised order ten minutes before and ten minutes after 
the test meals. 
2.3.4 MEASURES OF MOOD 
A combination of V As and the Profile of Mood States Questionnaire (POMS) were 
used to assess mood. In keeping with the appetite scales, subjects were instructed to 
complete the mood scales according to how they felt at that moment. Mood scales were 
included in the V As as outlined in Appendices One, Two, Three and Eight. 
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2.3.4.1 Profile of Mood States Questionnaire 
Mood was assessed using the sixty-five item version of the POMS (see Appendix 
Nine). Designed as a standardised adjective rating scale, this version measures six mood or 
affective states i.e. anxiety/tension, depression, anger/hostility, vigour, fatigue and 
confusion, and is recognised as a sensitive measure for use in normal, non psychiatric 
populations. Subjects are instructed to rate their current mood state by circling the number 
which best reflects to how they feel on a scale from zero ("not at all") to four 
("extremely"). The scores are then tallied to provide six subscale totals. 
2.4 SELECTION AND ASSESSMENT OF SUBJECTS 
2.4.1 SCREENING QUESTIONNAIRES 
2.4.1.1 Beck Depression Inventory 
The Beck Depression Inventory (Beck et al, 1961) was used to screen volunteers for 
the presence of depressive illness and is outlined in Appendix Ten. The inventory is a 
twenty-one item, self-rated questionnaire in which each item describes a specific 
behavioural manifestation of depression. Volunteers were asked to rate each item, made up 
of four to six self-evaluative statements, by ~electing the statement that best fitted them 
over the preceding week. Completion of the scale resulted in a total score (maximum of 
sixty) that provided a measure of the depth of depression. The Beck Depression Inventory 
has been validated for both psychiatric in- and outpatients and is provides a sensitive 
measure of change in depressed mood. It is also a useful tool in screening the normal 
population. for the presence of depressive illness. 
2.4.1.2 Eating Attitudes Test 
The forty item Eating Attitudes Test was used to screen for the presence of eating 
disorders amongst normal volunteers, and to help elicit the continuing presence of an 
eating disorder amongst recovered bulimics. The Eating Attitudes Test (Garner and 
Garfinkel, 1979) is a self-rating scale with satisfactory reliability and validity for use as a 
screening device and is outlined in Appendix Eleven. The questionnaire is designed to help 
quantify disordered attitudes towards eating and food, and to address a broad range of 
symptoms of anorexia nervosa in three subscales i.e. dieting, bulimia and food 
preoccupation. Each question is accompanied by a six point scale in columns marked 
"never, rarely, sometimes, often, very often and always". Subjects were instructed to mark 
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the column for each question that most closely applied to how they had been over the 
previous four weeks. The completed questionnaire provided a total score, out of possible 
maximum of 120, that could be used as a guide to the extent of the presence of disordered 
eating patterns. A follow-up clinical interview enabled a firm diagnosis to then be made. 
2.4.2 VOLUNTEER SELECTION 
2.4.2.1 Normal Volunteers 
Normal volunteers were recruited from hospital staff, research colleagues and by 
newspaper and poster advertisements. Potential subjects received a semi-structured clinical 
interview, physical examination, electrocardiogram (for all neuroendocrine challenge 
studies), and underwent routine blood screening (full blood count, platelets, liver function 
test, creatinine and urea and electrolytes). They also completed the Beck Depression 
Inventory, the Eating Attitudes Test and food preference forms from which acceptable test 
meals could later be prepared (see section 2.3.3.1). Subjects were excluded if they had any 
of the following: a history of cardiac or endocrine abnormality or any potentially life 
threatening illness (eg., cancer), present or past history of psychiatric illness or substance 
abuse; alcohol intake above twenty-one units for men and fourteen units for women; drug 
treatment within the preceding two months. For the dieting studies, volunteers were 
required to be of normal weight, or no more than one and one-half stone overweight, as 
determined by a body mass index (weight in kg divided by height in metres2) of between 
twenty and twenty-seven for females and twenty and thirty-two for males. All volunteers 
were required to be free of any eating disorder as determined by an abnormal Eating 
Attitudes Test score greater than twenty-five, or greater than fifteen when the presence of 
abnormal eating or an eating disorder was confirmed by clinical interview. 
2.4.2.2 Recovered Female Bulimic Patients 
Ex-patients were recruited mainly from newspaper advertisements, but a number of 
other sources were used including psychology outpatient waiting listings and medical 
records at the W arneford Hospital in Oxford and direct approaches to general practitioners 
within the area. All subjects had, at some stage in the past, met criteria for DSM-IIIR 
Bulimia Nervosa (American Psychiatric Association, 1987) but were now recovered. 
Recovery was determined by a semi-structured clinical interview administered by the 
author and the EAT and EDE-Q3 (Cooper and Fairburn, 1987) self-rating scales on eating 
behaviour. Criteria for recovery were: i) no episodes of self-induced vomiting, excessive 
exercise or laxative use within the past six months; ii) no more than one objective binge (a 
discrete episode of eating in which an abnormally large amount of food is consumed 
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accompanied by a sense of loss of control over eating) in the same period; iii) no more 
than one subjective binge per week (a discrete episode of eating in which the subject feels 
they have eaten an excessive amount for them, but the amount consumed would not be 
regarded by the average person to be excessive, accompanied by a sense of loss of control 
over eating). In addition, subjects were required to be of normal weight as determined by a 
body mass index between twenty-one and twenty-eight, to have regular eating habits and 
following a normal diet and their weight stable in the previous three months. Potential 
subjects scoring above twenty on the Beck Depression Inventory or currently undergoing 
treatment for major depression were excluded, as were those subjects who had been on 
medication in the previous three months ( other than benzodiazepines) or who were judged 
to have a significant current physical illness, or a history of alcohol or drug abuse. 
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Chapter 3 
EFFECTS OF DIETING ON BRAIN 
5-HT FUNCTION 
3.1 INTRODUCTION 
The literature reviewed in Chapter One strongly suggests that "normal" dieting is in 
itself a risk factor in the development of the eating disorders. Dieting behavio.ur now 
appears to be endemic amongst the adolescent and young adult population in Western-
style societies, and for the majority it remains predominantly a harmless pursuit. Recent 
evidence from animal and human studies, however, suggests that some physiological 
changes accompanying food restriction may contribute to the development of clinical 
eating disorders in predisposed individuals (see sections 1.1.4.3, 1.2.3 and 1.3.3). 
Previous work, outlined in section 1.3.3, demonstrates that moderate weight loss 
through dieting leads to an enhanced PRL response to a subsequent TRP challenge in 
women but not men (Goodwin et al, 1987b; Anderson et al, 1990a). Animal and human 
data suggest that the PRL response to TRP is probably 5-HT mediated (Marsden and 
Curzon, 1976; Cowen and Anderson, 1986; Price et al, 1990), and work carried out by 
Anderson et al (1989) further suggests that dieting-induced changes in the PRL response to 
TRP may also be 5-HT mediated. On the basis of these findings, it was suggested that 
moderate weight loss through dieting decreases plasma TRP sufficiently in women to 
reduce brain 5-HT synthesis. A subsequent reduction in 5-HT neurotransmission across the 
synapse results, which in turn produces an adaptive supersensitivity of post-synaptic 5-HT 
receptors, as evidenced by an enhanced PRL response to a TRP challenge after dieting 
(Goodwin et al, 1987b; Anderson et al, 1990a). As the enhanced PRL response has been 
reported only in women, it raises the possibility that females may be particularly 
vulnerable to dieting-induced changes in brain 5-HT function. This possibility is of interest 
in view of the consistent finding that clinical eating disorders such as anorexia and bulimia 
nervosa are largely confined to women. Additionally, mood and appetite become severely 
disrupted during established eating disorders (see section 1.1), behaviours in which brain 
5-HT pathways have a central role. 
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The hypothesis that dieting alters brain 5-HT function in women (but not men) is 
however, based on only a small number of studies. Furthermore, the studies published to 
date have all utilised intravenous TRP as the neuroendocrine challenge, which may in 
itself be problematic. Some researchers have raised doubts as to whether or not TRP-
induced PRL release necessarily reflects changes in brain 5-HT neurotransmission (van 
Praag et al, 1986), as TRP is known to interact with dopaminergic pathways which may in 
turn influence PRL release (Price et al, 1990). In addition, the earlier studies demonstrated 
that dieting reduces plasma total TRP, raising the possibility that alterations in TRP 
disposition may occur following infusion (if TRP is used as the 5-HT challenge drug). 
Finally, as a pre-synaptic challenge of 5-HT pathways, TRP infusion is unable to provide 
direct evidence to support the presence of post-synaptic 5-HT receptor supersensitivity. 
While the finding of an enhanced PRL response to a TRP infusion is consistent with the 
development of post-synaptic receptor supersensitivity, it is also consistent with pre-
synaptic enhancement of 5-HT neurotransmission (eg. through increased 5-HT release). 
Enhanced 5-HT neurotransmission across the synapse would in itself lead to an increased 
PRL response, even if post-synaptic receptor sensitivity was unaltered. 
As has been previously outlined, d-fenfluramine administration in humans is well 
tolerated, has minimal side effects, and leads to a dose-dependent increase in plasma PRL 
concentration (section 2.1.4.1). Substantial evidence from animal and human studies 
suggests that the d-fenfluramine-induced PRL response is 5-HT mediated, and that the 
most likely mechanism of action is indirect enhancement of serotonergic 
neurotransmission through 5-HT 2 receptors, secondary to pre-synaptic release and re-
uptake inhibition. An enhanced PRL response to d-fenfluramine would, therefore, provide 
additional evidence in support of the hypothesis that dieting-induced changes in the PRL 
response are 5-HT mediated. 
Similarly, animal and human studies suggests that mCPP is also a highly selective 
probe of serotonergic pathways. It too is well tolerated and produces a reliable and 
consistent increase in PRL secretion when administered to humans (section 2.1.4.2). In 
contrast to d-fenfluramine, mCPP appears most potent as a 5-HT agonist, acting directly at 
post-synaptic 5-HT receptors. The mechanism of action of mCPP would, therefore, allow 
the hypothesis of post-synaptic receptor supersensitivity to be directly tested and the 
finding of an enhanced PRL response to mCPP, would provide strong evidence in support 
of this theory. 
Few studies have examined whether or not order effects on PRL response occur as 
a result of repeat challenges with 5-HT test drugs. By necessity, dieting studies involve 
individual subjects undergoing two challenge tests, before and after dieting. Two d-
85 
fenfluramine challenges carried out one month apart to correspond with the dieting 
challenge tests would enable any order effects on PRL response to be elicited. 
In order to firmly establish the hypothesis that dieting alters brain 5-HT function 
and that such changes are confined to women, replication of the earlier work is required. 
Replication utilising more specific 5-HT challenge drugs, such as d-fenfluramine and 
mCPP, would also provide further evidence that the dieting-induced changes are indeed 5-
HT mediated. Using a neuroendocrine approach, the aim of the present study was 
threefold: firstly, to attempt to replicate earlier findings of sex-specific (women only) 
dieting-induced increases in the PRL-response to a 5-HT challenge drug (d-fenfluramine); 
secondly, to examine more closely the mechanism underlying diet-induced changes in 
brain 5-HT function by using the combination of a pre-synaptic (d-fenfluramine) and post-
synaptic (mCPP) challenge probe, and thirdly, to investigate the possibility of an order 
effect of repeat d-fenfluramine administration on PRL responses by carrying out two d-
fenfluramine challenge tests one month apart. 
3.2METH0DS 
3.2.1 DETERMINATION OF DRUG DOSAGE 
3.2.1.2 Intravenous mCPP (0.04mg/kg Intravenous mCPP Pilot Study) 
Introduction 
Human neuroendocrine studies have demonstrated that intravenous administration 
of mCPP enhances PRL release in healthy volunteers. Within the range of 0.06-0. lmg/kg, 
a reliable and consistent elevation in PRL is seen when compared to placebo, while smaller 
responses have been reported at 0.05mg/kg (Charney et al, 1987; Lawlor et al, 1989; 
Murphy etal, 1989). Most studies in the literature, however, have been carried out on men. 
One study that did include female subjects found a clear gender difference in terms of drug 
absorption and PRL response to mCPP. Plasma mCPP levels in the men were twice that of 
the women for a given dose, but subsequent PRL responses were greater in the women 
despite the lower drug concentrations (Kahn etal, 1991). 
Investigation of dieting-induced receptor supersensitivity requires the use of mCPP at a 
dose capable of producing reliable, but submaximal PRL responses (Kahn and Wetzler, 
1991). A submaximal response before dieting would enable an enhanced post-dieting 
response (due to the development of receptor supersensitivity) to be seen as a further 
elevation in plasma PRL. In contrast, a dose that was too high may lead to a ceiling effect, 
obscuring the effects of receptor supersensitivity, while a dose that was too low would fail 
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to produce any consistent PRL elevation. The gender differences described above suggest 
that a smaller dose than those outlined in the literature may produce a satisfactory 
submaximal PRL response in women. A pilot study was, therefore, carried out to 
determine whether or not an intravenous dose of 0.04mg/kg m CPP would prove to be 
suitable for use in women enabling the detection of supersensitivity effects. 
Subjects, Methods and Statistics 
Fifteen healthy female volunteers were recruited as described under the Selection and 
Assessment section in Chapter Two. All subjects were of normal weight as determined by 
a body mass index between twenty and twenty-eight (mean body mass index± sem=23.4 ± 
0.44; range 20.8-26.3). The women were aged between twenty-one and thirty seven years 
(mean age ± sem=25.6years ± 1.12), and all had given written, informed consent to 
participating in the study which had been approved by the local ethics committee. 
The study was of a double-blind placebo controlled design. Subjects underwent 
neuroendocrine testing on two occasions approximately one week apart during the early to 
mid-follicular phase of a single menstrual cycle (determined by plasma oestradiol levels; 
see section 3.3.1.1). On one occasion the women received intravenous placebo (20mls of 
0.9% NaCl administered by infusion pump [Sage instruments] over ninety seconds), and 
on the other occasion they received intravenous mCPP 0.04mg/kg (Mandeville Medicines 
Ltd; Aylesbury: UK) made up to 20mls with 0.9% NaCl and administered by infusion 
pump over ninety seconds. Subjects received either m CPP or placebo at time 0. Blood 
sampling for PRL estimation was carried out at fifteen minute intervals between -30 
minutes and +120 minutes, and at fifteen minute intervals between time O and +120 
minutes for drug level estimation. Other neuroendocrine procedure details were identical to 
those outlined in section 3.2.3. Similarly, assay procedure and statistical analysis was also 
carried out in the manner described in sections 3.2.2 and 3.2.4 respectively. 
Results 
Three females were determined by plasma oestradiol concentrations to have undergone 
neuroendocrine testing outside the early to mid-follicular phase of the menstrual cycle and 
were, therefore, excluded from further analysis. Following m CPP administration, 
detectable concentrations of mCPP were present in plasma from+ 15 minutes. Peak mean± 
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Figure 3.1. (a) mCPP mean± sem plasma drug levels following intravenous 
mCPP 0.04mg/kg administration to twelve female volunteers. (b) Effect of 
intravenous mCPP administration (0.04mg/kg) on PRL response in twelve 
female volunteers. The PRL response to mCPP was significantly increased 
following m CPP administration compared to placebo at the time points 
indicated. Fisher's test: ** p < 0.01. 
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Intravenous administration of mCPP was associated with rapid onset of action of the 
drug. This led to an increase in plasma PRL levels without the usual initial fall observed 
following oral drug administration, in keeping with the circadian fall in PRL release across 
the morning. Basal PRL concentrations were not significantly different at placebo and 
mCPP challenges (mean± sem PRL concentration at time 0: placebo=198.lmIU/l ± 21.6; 
mCPP=163.lmlU/l ± 16.3; p=0.12), but a significantly enhanced PRL response was seen 
following mCPP administration compared to placebo (Figure 3.lb). When analysed with 
two way repeated measures analysis of variance CANOVA), the PRL data (change from 
baseline) revealed a significant main effect of occasion [i.e. effect of m CPP versus 
placebo] (F=18.97; d.f.=1,7; p=0.001), no significant main effect of time [i.e. variation in 
PRL over time] (F=l.63; d.f.=7,77; p=0.14), but a significant occasion by time interaction 
[i.e. effect of mCPP on variation of PRL over time] (F=4.60; d.f.=7,77; p=0.0002). 
Similarly, when analysed as area under the curve (AUC-B), PRL responses were 
significantly increased following mCPP administration compared to placebo (mean ± sem 
PRL: placebo=-5362mIU/l-1.min-1 ± 1051; mCPP=2818mIU/I-1.rnin-1 ± 1770; p=0.0009). 
Conclusions 
Intravenous administration of mCPP at a dose of 0.04mg/kg led to detectable 
concentrations of the drug being present in plasma from + 15minutes. Plasma drug 
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concentrations were marginally lower than those reported in the literature with the higher 
intravenous dose of O.lmg/kg (Pigott et al, 1993), but led to a significant increase in PRL 
compared to placebo. Additionally, the PRL levels achieved in response to 0.04mg/kg 
intravenous mCPP were less than those reported in the literature (Charney et al, 1988; 
Murphy et al, 1989), suggesting the dose would be suitable in determining receptor 
supersensitivity in dieting women. 
3.2.1.1 d-Fenfluramine 
In contrast to data on mCPP, a substantial body of evidence exists in the literature 
demonstrating significant increases in PRL release following administration of d-
fenfluramine in humans (Quattrone et al, 1978; Quattrone et al, 1983; Lewis and 
Sherman, 1985; Lerer et al, 1988; O'Keane and Dinan, 1991). Furthermore, the dose 
required to produce reliable and consistent PRL responses has been well established, with 
d-fenfluramine appearing to produce a dose-dependent release of PRL (Quattrone et al, 
1978; Quattrone et al, 1983 ). In a study by Silverstone and Feeney (1989), a significant 
but submaximal increase in PRL was seen following administration of 30mg oral d-
fenfluramine to healthy volunteers. The authors concluded that this dose produced 
consistent PRL responses while causing a minimum of side effects. The dieting study 
would also require the use of d-fenfluramine at a dose that produced a reliable, but 
submaximal PRL response, enabling the detection of dieting-induced receptor 
supersensitivity through further enhancement of the PRL response (see above section on 
mCPP). Minimal side effects would ensure a stress reaction did not occur, making 
interpretation of any enhanced PRL response difficult. For these reasons, the dose of 30mg 
d- fenfluramine was chosen for use in the dieting study. 
3.2.2 SUBJECTS AND DIET INSTRUCTIONS 
3.2.2.1 Repeat d-Fenfluramine Administration Study 
Ten healthy female volunteers were recruited as described under the Selection and 
Assessment of Subjects in Chapter Two (section 2.4.2). To ensure comparability with 
female dieters, all subjects were of average weight or no more than one and one-half stone 
overweight, as determined by a body mass index between twenty and twenty eight. Mean 
body mass index was 22.9 and ranged from 21.0-24.9. Subjects had a mean age of 24.4 
years and ranged between twenty and twenty-eight. All gave written, informed consent to 
participating in the study which was been approved by the local ethics committee. 
Subjects underwent neuroendocrine testing on two occasions one month apart. Testing 
was timed to mirror those of the dieting study i.e. challenges were carried out in the early 
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to mid-follicular phase of two consecutive menstrual cycles with menstrual cycle phase 
confirmed by plasma oestradiol levels. Subjects were requested to eat normally throughout 
the study and not to diet. 
3.2.2.2 Effects of Dieting on d-Fenfluramine-induced PRL Response 
Twenty-six healthy volunteers (fourteen women and twelve men) were recruited as 
described under Selection and Assessment in Chapter Two. All subjects were of normal 
weight, or no more than one and half stone over weight as measured by a body mass index 
of between twenty-one and twenty-eight for women (mean body mass index=24.0; range 
21.6-27) and twenty-one to twenty-eight for all but one of the men (mean body mass 
index=25.2; range 20.9-32). One male had a body mass index above twenty-eight but as 
this was judged to be largely muscle bulk rather than fat he was included in the study. The 
women were aged between twenty and thirty-seven (mean age=26. l years) and the men 
between twenty and forty-two years of age (mean age=30.8 years). Subjects gave written, 
informed consent to participating in the study which was passed by the local ethics 
committee. 
Subjects underwent neuroendocrine testing before, and following a three week 
calorie controlled diet of 1000 kcal for women and 1200 kcal for men. The onset of dieting 
was delayed by one week following the initial challenge. This ensured that both challenges 
in the women were carried out at the same phase of two consecutive menstrual cycles. 
Neuroendocrine tests were timed so that they took place in the early to mid follicular phase 
of the menstrual cycle and confirmed by plasma oestradiol concentration. To ensure 
comparability with the women, men also delayed the onset o'f their diet by one week 
following the initial challenge. 
To replicate the work of Anderson et al (1990a), an identical diet was used which 
provided equal absolute carbohydrate intake in males and females, because of the potential 
effect carbohydrate intake has on plasma TRP. The diet was provided by the Oxford 
University Department of Nutrition and Dietetics and was designed to provide a set 
number of calories in specific macronutrient proportions. Women received 1000 kcal per 
day as 31 % protein, 44% carbohydrate and 25% fat. Men received 1200 kcal per day as 
30% protein, 36% carbohydrate and 34% fat. Subjects were provided with a daily eating 
plan which they were instructed to follow. The eating plan provided flexibility and variety 
through a fixed number of carbohydrate and protein "exchanges", coupled with a set 
amount of fat (as low-fat spread) and a list of unlimited "free foods" which were low in 
both calories and protein (eg. salad vegetables, low calorie soft drinks). The daily eating 
plan is outlined in Appendix Twelve. Subjects were asked to keep a food diary which was 
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checked weekly to ensure compliance. Weekly weights were also recorded to monitor 
progress and weekly fasting plasma TRP levels were measured. 
3.2.2.3 Effect of Dieting on mCPP-induced PRL Response 
Twelve healthy female volunteers were recruited as described under Selection and 
Assessment of Subjects in Chapter Two. All subjects were of normal weight, or no more 
than one and half stone over weight as measured by a body mass index of between twenty-
one and twenty-eight (mean body mass index=25.0; range 22.3-28) The women were aged 
between twenty and thirty-eight (mean age=29.2 years). Subjects gave written, informed 
consent to participating in the study which was approved by the local ethics committee. 
Subjects underwent neuroendocrine testing before, and following a three week 
calorie controlled diet of 1000 kcal (see section 3.2.1.2 for diet details). The onset of 
dieting was delayed by one week following the initial challenge. This ensured both 
challenges were carried out at the same phase of two consecutive menstrual cycles. 
Neuroendocrine tests were timed so that they took place in the early to mid follicular phase 
of two consecutive menstrual cycles and menstrual cycle phase confirmed by plasma 
oestradiol concentration. 
3.2.3 NEUROENDOCRINE CHALLENGE PROCEDURE 
Neuroendocrine testing was carried out following an overnight fast with subjects 
requested not to eat or drink from midnight. Subjects were brought to the Research Unit at 
approximately 08.30 hours and an indwelling venous cannula inserted into the arm. During 
testing, subjects rested semi-supine on a bed and were not allowed to eat, drink, smoke or 
sleep. 
3.2.3.1 d-Fenfluramine Challenges 
After insertion of the venous cannula, a blood sample for baseline plasma PRL and 
fasting TRP estimation was taken. Subjects were then left to rest quietly on the bed for 
thirty minutes before administration of the test drug between 09.00 hours and 09.30 hours 
(time 0). Dexfenfluramine hydrochloride, 30mg (Servier Laboratories Ltd; Slough; U.K.), 
was administered orally in two 15mg capsules. Blood sampling for plasma PRL estimation 
was carried out every thirty minutes from time O until + 240 minutes. At hourly intervals 
from time O until +240 minutes, blood was removed for drug (d-fenfluramine and d-
norfenfluramine) concentration analysis. 
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3.2.3.2 mCPP Challenge 
Following venous cannula insertion, blood samples for baseline plasma PRL and 
fasting TRP estimation were taken and subjects then left to rest quietly on the bed for sixty 
minutes. Administration of the test drug took place between 09.30 hours and 10.00 hours 
(time 0). mCPP (0.04mg/kg) for intravenous use (Mandeville Medicines Ltd; Aylesbury; 
UK) was made up to 20ml with 0.9% NaCl and administered by infusion pump (Sage 
instruments) over ninety seconds at time 0. Blood samples for PRL estimation and drug 
concentration were taken every fifteen minutes from -60 minutes to + 120 minutes after 
drug administration. An extra 10ml blood sample was taken at -30 minutes for fasting TRP 
levels. 
All assays were processed using the methods described in Chapter Two with analysis 
of all samples from each individual volunteer carried out in the same batch. 
3.2.4 SUBJECTIVE RA TINGS 
3.2.4.1 d-Fenfluramine Challenges 
d-Fenfluramine is generally well tolerated by humans but some side effects have been 
reported to occur, especially at higher doses. Although the dose of 30mg utilised in these 
experiments could be expected to be largely side-effect free, VA scales for drowsiness, 
depression, nausea, happiness, light-headedness, hunger and dizziness were presented to 
subjects throughout testing (Appendix One). The VA rating scales were presented in the 
standardised manner outlined in section 2.3.1 at hourly intervals from time O until +240 
minutes. Blood pressure and pulse readings were monitored automatically by machine 
every thirty minutes from -30 minutes until +240 minutes. 
3.2.4.2 mCPP Challenge 
mCPP is also well tolerated by humans, but transient side effects have been reported to 
occur, especially at higher doses. Although the intravenous dose of 0.04mg/kg utilised in 
the present experiment could be expected to produce minimal side-effects, VA scales for 
happiness, anxiety, hunger, light-headedness, nausea, mellowness, sweatiness and a sense 
of unreality were presented to subjects throughout testing (Appendix Two). The VA rating 
scales were presented in the standardised manner outlined in section 2.3.1 at -40 min, then 
at fifteen minute intervals from time O to +60 minutes, and thereafter at thirty minute 
intervals until + 120 minutes. Blood pressure and pulse readings were monitored 
automatically by machine at -40 minutes, every fifteen minutes between time O and +60 




3.2.5 STATISTICAL ANALYSIS 
Data approximated satisfactorily to a normal distribution. PRL data were plotted 
against time (as change from baseline) and then analysed with two way repeated measures 
analysis of variance (ANOV A) with Fisher's test of least significant difference as a post 
hoc range test. PRL data were also analysed as area under the curve with subtraction of 
baseline secretion (AUC-B) extrapolated from time O using the trapezoid method. Drug 
concentration data were measured as area under the curve (AUC) from time 0. VA data 
were plotted against time as change from baseline (at time 0), and then analysed with 
ANOVA. 
3.3 RESULTS 
3.3.1 REPEAT d-FENFLURAMINE ADMINISTRATION STUDY 
3.3.1.1 Oestradiol Levels and Plasma TRP 
Three females were found to have under gone neuroendocrine testing at different 
phases of the menstrual cycle (as determined by plasma oestradiol concentration 
differences of greater than 50pg/ml), and were therefore, excluded. Plasma oestradiol 
concentrations at first and second challenge tests in the excluded subjects were 46 and 
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Figure 3.2. (a): Mean ± sem plasma total and free TRP and (b): plasma d-
fenfluramine and d-norfenfluramine drug concentrations (mean AUC ± sem; 
ng/ml-1.min-1) in seven female subjects at repeat d-fenfluramine challenges one 
month apart. 
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Plasma total and free TRP concentrations were not significantly different at baseline 
sampling at repeat d-fenfluramine challenges (Figure 3.2a). Mean± sem plasma total TRP 
concentrations at first and second challenges were 13.39µg/ml ± 1.31 and 12.33µg/ml ± 
0.93 respectively (p=0.55), and mean ± sem plasma free TRP concentrations were 
0.68µg/ml ± 0.13 and 0.78µg/ml ± 0.06 (p=0.34) respectively. 
3.3.1.2 Plasma Drug Levels: d-Fenfluramine and d-Norfenfluramine 
Concentrations of d-fenfluramine and d-norfenfluramine were detected in the plasma 
following d-fenfluramine administration from +60 minutes and no differences in drug 
levels were seen between first and second challenge (Figure 3.2b). Peak d-fenfluramine 
concentrations of 34.7ng/ml and 3 l .4ng/ml were reached at + 180 minutes during the first 
and second challenges respectively. ANOVA revealed no significant main effect of 
occasion [i.e. effect of repeat challenge] (F=l.07; d.f.=1,3; p=0.34), a significant main 
effect of time [i.e. variation in plasma drug levels over time] (F=19.76; d.f.=3,18; 
p=0.0001) but no significant main occasion by time interaction [i.e. effect of repeat 
challenge on drug level variation over time] (F=0.28; d.f.=3,18; p=0.84). When analysed 
as AUC, d-fenfluramine levels were not altered between challenges (Fig 3.2b). Mean± 
sem plasma d-fenfluramine responses were 6191ng/ml-1.µiv-1 ± 1505 and 4986ng/ml-
1.min-1 ± 755 respectively (p=0.36). Peak d-norfenfluramine levels of 8.2ng/ml and 
7.2ng/ml were reached at +240 minutes during the first and second challenge test. The 
ANOVA again revealed no significant main effect of occasion (F=0.56; d.f.=1,3; p=0.48), 
a significant main effect of time (F=41.76; d.f.=3,18; p=0.0001) but no significant main 
occasion by time interaction (F=l.99; d.f.=3,18; p=0.15). Similarly, when analysed as 
AUC, mean ± sem d-norfenfluramine plasma responses were not significantly different 
between challenges at 980ng/ml-1.min-1 ± 142 and 786ng/ml-1.min-1 ± 15 (Figure 3.2b; 
p=0.50). 
3.3.1.3 PRL Response to Repeat d-Fenfluramine Administration 
Plasma PRL levels showed an initial fall, in keeping with the natural circadian fall in 
PRL release seen across the morning (see section 2.1.3), then increased in response to d-
fenfluramine administration at both challenges (Figure 3.3). Basal PRL concentrations 
were not significantly different at either challenge (mean ± sem PRL at time 0: 1st 
challenge=263mIU/l ± 59; 2nd challenge=267mIU/l ± 37; p=0.09), and PRL responses to 
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Figure 3.3. Mean ± sem plasma PRL concentration (change from baseline) 
following two d-fenfluramine challenges one month apart in seven female 
volunteers. PRL responses were not significantly different between challenges. 
The ANOV A on change from baseline data revealed no significant main effect of 
occasion [i.e. the effect of a repeat challenge] (F=0.20; d.f.=1,7; p=0.67), a significant 
main effect of time [i.e. the variation in PRL response over time] (F=5.81; d.f.=7,42; 
p=0.0001) but no significant occasion by time interaction [i.e. effect of a repeat challenge 
on the variation in PRL response over time] (F=l.42; d.f.=7,42; p=0.22). When analysed 
as AUC-B no significant effect of repeat d-fenfluramine challenge was revealed on PRL 
response. Mean ± sem plasma PRL at first and second challenge were -13194mIU/I-1.min -1 
± 5735 and -15574mIU/l-1.min-1 ± 4858 respectively (p=0.75). 
3.3.1.4 Subjective Ratings 
Some of the women reported an increase in drowsiness following d-fenfluramine 
administration at first and second challenges. Baseline drowsiness ratings at first and 
second challenges were not significantly different (p=0.41) and no significant effect of 
repeat d-fenfluramine administration on drowsiness was found. The ANOVA on change 
from baseline data revealed no significant main effect of occasion [i.e. effect of repeat 
challenge] (F=0.34; d.f.=1,3; p=0.58), no significant main effect of time [i.e. variation in 
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drowsiness over time] (F=2.74; d.f.=3,18; p=0.07) and no significant occasion by time 
interaction [i.e. effect of repeat challenge on variation in drowsiness over time] (F=0.64; 
d.f.=3,18; p=0.60). 
Two women reported increases in nausea following d-fenfluramine administration at 
the first challenge, but none reported increases in nausea at the second challenge. No 
baseline differences between challenges were seen, however (p=0.36), and no significant 
effect of repeat d-fenfluramine administration on nausea found. The ANOVA on change 
from baseline data revealed no significant main effect of occasion (F= 18; d.f.= 1,3; 
p=0.69), no significant main effect of time (F= 1.65; d.f.=3, 18; p=0.21) and no significant 
occasion by time interaction (F=l.65; d.f.=3,18; p=0.21). 
Similarly, with VA ratings of light-headedness and dizziness, four women experienced 
increases following d-fenfluramine administration at first challenge and three women 
reported increases at the second challenge test. Baseline ratings in light-headedness and 
dizziness were not significantly different between tests (p=0.30 and p=0.36 respectively). 
The ANOVAs again revealed no significant main effect of occasion (light-headedness: 
F=l.50; d.f.=1,3; p=0.27; dizziness: F=l.0; d.f.=1,3; p=0.36), no significant main effect of 
time (light-headedness: F=l.43; d.f.=3,18; p=0.27; dizziness: F=2.ll; d.f.=3,18; p=0.13) 
and no significant occasion by time interaction (light-headedness: F=l.87; d.f.=3,18; 
p=0.17; dizziness: F=l.80; d.f.=3,18;p=0.18). 
No significant effects in terms of baseline changes or effects of repeat d-fenfluramine 
administration were seen on hunger (baseline difference: p=0.96; ANOV A occasion by 
time interaction: F=2.64; d.f.=3,18; p=0.08), depression (baseline difference: p=0.20; 
ANOVA occasion by time interaction: F=l.33; d.f.=3,18; p=0.30) or happiness (baseline 
difference: p=0.92; ANOVA occasion by time interaction: F=0.56; d.f.=3,18; p=0.65). 
3.3.1.5 Correlations 
No significant correlation was found between plasma d-fenfluramine or d-
norfenfluramine concentration and PRL response at the first (d-fenfluramine: r=0.27; 
p=0.56; d-norfenfluramine: r=0.19; p=0.68) or second (d-fenfluramine: r=-0.25; p=0.59; d-
norfenfluramine: r=0.46; p=0.30) challenge. When basal PRL levels were examined, no 
significant correlation was found between basal PRL and PRL response at first (r=-0.75; 
p=0.05) or second (r=-0.57; p=0.18) challenge. Plasma total and free TRP levels did not 
correlate with PRL response. At first challenge no significant correlation was found 
between PRL response and plasma total or free TRP (total TRP: r=-0.19; p=0.69; free 
TRP: r=-0.24; p=0.61). Similarly. at second challenge, no significant correlations were 





(r=-0.37; p=0.42). Furthermore, no significant correlation was found between plasma 
oestradiol levels and PRL response at first (r=-0.23; p=0.63) or second challenge (r=-0.59; 
p=0.17). 
A significant, positive correlation was found between plasma d-fenfluramine and d-
norfenfluramine concentrations at first challenge (r=0.89; p=0.008; Figure 3.4a) but not at 
second challenge (r=0.07; p=0.89). When analysed as change in drug concentration across 
challenges, a highly significant positive correlation was found between plasma d-
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Figure 3.4. Drug level correlations m women undergoing repeat d-
fenfluramine challenges. (a): Correlation between AUC plasma d-fenfluramine 
and plasma d-norfenfluramine drug levels (ng.ml-1.min-1) at the first challenge. 
(b): Correlation between change in AUC plasma d-fenfluramine and d-
norfenfluramine drug levels (ng/ml-1.min- 1) between first and second 
challenge. 
3.3.2 EFFECTS OF DIETING ON d-FENFLURAMINE-INDUCED PRL 
RESPONSE 
3.3.2.1 Weight Loss, Oestradiol Levels and Plasma TRP 
All dieters lost weight. Male dieters lost more weight on average than female dieters 
but the difference in weight loss did not reach statistical significance (mean± sem: 3.77kg 
± 0.30 vs 3.38kg ± 0.19; p=0.29). When calculated as percentage body weight loss, weight 
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loss by the women was greater than the men but again, the difference did not reach 
statistical significant (mean± sem; 5.27% ± 0.38 vs 4.75% ± 0.37; p=0.33). 
Two female subjects were found to have under gone neuroendocrine testing at 
different phases of the menstrual cycle (50pg/ml or greater difference in plasma oestradiol 
concentration) and were, therefore, excluded from further analysis. The excluded subjects' 
plasma oestradiols at the time of neuroendocrine testing were 44 and l 15pg/ml, and 180 
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Figure 3.5. Mean± sem plasma total (a) and free (b) TRP in twelve male and 
females before and after dieting. In female dieters, plasma total and free TRP 
levels were significantly reduced after dieting. Paired t test: ** p < O.Ol 
Dieting significantly decreased total and free plasma TRP in the women but not in the 
men (Figure 3.5). Following dieting, mean± sem total plasma TRP in the women fell from 
12.05µg/ml ± 0.76 to 9.27µg/ml ± 0.40 (p=0.002), while mean± sem free plasma TRP was 
reduced from 0.90µg/ml ± 0.07 to 0.72µg/ml ± 0.05 (p=0.006). In the men, mean± sem 
total plasma TRP concentrations before and after dieting were 12.70µg/ml ± 0.60 and 
1 l.82µg/ml ± 0.74 respectively (p=0.24), and mean± sem plasma free TRP concentrations 
were 0.83µg/ml ± 0.13 and 0.84µg/ml ± 0.13 respectively (p=0.96). 
3.3.2.2 Plasma Drug Levels: d-Fenfluramine and d-Norfenfluramine 
Following d-fenfluramine administration, detectable concentrations of d- fenfluramine 
and d-norfenfluramine were present in plasma from +30 minutes. Dieting did not 
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significantly alter plasma concentrations of either d-fenfluramine or d-norfenfluramine in 

































































Figure 3.6. Plasma d-fenfluramine (a) and d-norfenfluramine (b) drug 
concentrations (shown as mean AUC ± sem; ng/mI-1.min-l) in twelve male and 
female volunteers before and after dieting. 
In the men, peak plasma concentrations of d-fenfluramine (mean ± sem: pre-
diet=l8.6ng/ml ± 1.53; post-diet=17.8 ± 1.49) were detected before and after dieting at 
+240 min and +210 minutes respectively. The ANOVA revealed no significant main effect 
of occasion [i.e. an effect of dieting] (F=0.04; d.f.=1,8; p=0.85), a significant main effect 
of time [i.e. a variation in drug level over time] (F=105.4; d.f.=8,88; p=0.0001) but no 
significant occasion by time interaction [i.e. effect of dieting on variation in drug level 
over time] (F=0.47; d.f.=8,88; p=0.88). Similarly, when analysed as AUC, dieting had no 
significant effect on d-fenfluramine (mean± sem: pre-diet=2598ng/mI-1.min·1 ± 230; post-
diet=2551ng/mI-1.min-l ± 244; p= 0.89; Figure 3.6a). Peak d-norfenfluramine plasma 
levels were seen at +240 minutes before dieting (mean± sem=8. lng/ml ± 1.02) and +210 
minutes after dieting (mean ± sem=9.0ng/ml ± 1.05). The ANOVA again revealed no 
significant main effect of occasion (F=0.23; d.f.=1,8; p=0.64), a significant main effect of 
time (F=57 .70; d.f.=8,88; p=0.0001) but no significant occasion by time interaction 
(F=0.63; d.f.=8,88; p=0.75). When analysed as AUC plasma d-norfenfluramine in the 
males were also unaltered by dieting (Fig 3.6b). Mean± sem plasma d-norfenfluramine: 
pre-diet=878ng/ml-l.min-l ± 96; post-diet=1009ng/mI-l.min-l ± 183; p=0.42. 
In women dieters, peak mean ± sem plasma d-fenfluramine concentrations of 
25.3ng/ml ± 2.64 were seen at +210 minutes before dieting, and 25.30ng/ml ± 2.62 at +240 






(F=0.70; d.f.=1,8; p=0.42), a significant main effect of time (F=43.3; d.f.=8,88; p=0.0001) 
but no significant occasion by time interaction (F=l.38; d.f.=8,88; p=0.22). When d-
fenfluramine data were analysed as AUC, no significant effect of dieting was found 
(Figure 3.6a). Mean ± sem plasma d-fenfluramine before and after dieting were 
3832ng/mI-l.rnin-1 ± 580 and 3569ng/ml-1.min-1 ± 456 (p=0.35). Mean± sem peak d-
norfenfluramine levels before and after dieting were 6.5ng/ml ± 2.32 and 8.8ng/ml ± 2.48 
respectively and were reached at +240 minutes. The ANOV A again revealed no significant 
main effect of occasion (F=4.68; d.f.=1,8; p=0.05), a significant main effect of time 
(F=8.99; d.f.=8,88; p=0.0001) but no significant occasion by time interaction (F=l.06; 
d.f.=8,88; p=0.40). Similarly, when analysed as AUC, mean± sem d-norfenfluramine was 
not significantly different following dieting (Fig 3.6b): pre-diet=758ng/ml-1.min-1 ± 327; 
post-diet=91 lng/ml-1.rnin-1 ± 343; p=0.07. 
3.3.2.3 PRL Response to d-Fenfluramine 
In women dieters, plasma PRL levels initially fell, in keeping with the circadian fall in 
PRL release seen across the morning, and then rose in response to d-fenflurarnine 
administration both before and after dieting (Fig 3.7). 
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Figure 3.7. Mean ± sem plasma PRL concentration (change from baseline) 
following d-fenfluramine administration in twelve female volunteers before and 
after dieting. The PRL response was significantly enhanced after dieting at the 
time points indicated when compared to the pre-diet challenge (ANOV A). 





Basal PRL concentrations were significantly lower following dieting (mean± sem 
PRL concentration at time 0: pre-diet=293mIU/l ± 29; post-diet=254mIU/l ± 32; p=0.03). 
However, the PRL response to d-fenfluramine was significantly enhanced in women after 
dieting when compared to the pre-diet challenge. The ANOVA on change from baseline 
data revealed a significant main effect of occasion [i.e. an effect of dieting] (F=5.76; 
d.f.=1,7; p=0.04), a significant main effect of time [i.e. a variation in PRL response over 
time] (F=17.21; d.f.=7,77; p=0.0001) and a significant occasion by time interaction [i.e. an 
effect of dieting on the variation in PRL response over time] (F=2.72; d.f.=7,77; p=0.01). 
The post hoc range testing revealed plasma PRL levels to be significantly elevated at +90, 
+120, +180, +210 and +240 minutes after dieting (p< 0.01). Similarly, when analysed as 
AUC-B, PRL levels were significantly elevated after dieting. Mean± sem PRL before and 
following dieting was -9723mIU/I-1.min-1 ± 5043 and 4716mIU/I-1.min-1 ± 6075 
respectively (p=0.03). 
Plasma PRL levels in male dieters also increased (after the initial fall seen reflecting 
circadian release patterns) following d-fenfluramine administration both before, and after 
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Figure 3.8. Mean ± sem plasma PRL concentration (change from baseline) 
following d-fenfluramine administration in twelve male volunteers before and 
after dieting. PRL responses were not significantly different after dieting. 
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Basal PRL concentrations in the men were not significantly different before and after 
dieting (mean ± sem PRL concentrations at time 0: pre-diet=199mIU/l ± 42; post-
diet=l 70mIU/l ± 34; p=0.12), and the PRL response to d-fenfluramine was unaltered by 
dieting (Figure 3.8). The ANOVA on change from baseline data revealed no significant 
main effect of occasion (F=0.37; d.f.=1,7; p=0.55), a significant main effect of time 
(F=15.0; d.f.=7,77; p=0.0001) but no significant occasion by time interaction (F=0.68; 
d.f.=7,77; p=0.70). When analysed as AUC-B, the PRL response to d-fenfluramine in men 
was unchanged by dieting. Mean± sem plasma PRL: pre-diet=-5803mIU/l-1.min-1 ± 5570; 
post-diet=-3906rnIU!l-1.min-1 ± 5200; p=0.31). 
3.3.2.4 Subjective Measures 
Data from two male subjects for drowsiness, nausea, dizziness and hunger VA ratings, 
and from one male subject for light-headedness, depression and happiness VA ratings were 
not collected. Data from one female subject on all VA were not collected. Data from ten 
males for drowsiness, nausea, dizziness and hunger and from eleven males for light-
headedness, depression and happiness is presented below, along with the VA data from 
eleven female dieters. 
An increase in drowsiness following d-fenfluramine administration was experienced 
by some males before and after dieting. Baseline drowsiness in the men was not 
significantly higher following dieting (p=0.36) and no significant effect of dieting on 
drowsiness was found. The ANOV A on change from baseline data revealed no significant 
main effect of occasion [i.e. effect of dieting] (F=0.02; d.f.=1,3; p=0.90), no significant 
main effect of time [i.e. variation in drowsiness over time] (F= 1. 82; d.f.=3,27; p=0.17) and 
no significant occasion by time interaction [ effect of dieting on variation in drowsiness 
over time] (F=0.50; d.f.=3,27; p=0.68). All but three of the women dieters experienced an 
increase in drowsiness following d- fenfluramine administration before dieting, and all but 
two after dieting. However, baseline drowsiness in the women before and after dieting was 
not significantly different (p=0.70) and no significant effect of dieting on drowsiness was 
found. The ANOVA on change from baseline data revealed no significant main effect of 
occasion (F=2.77; d.f.=1,3; p=0.13), a significant main effect of time (F=3.36; d.f.=3,30; 
p=0.03) but no significant occasion by time interaction (F=0.41; d.f.=3,30; p=0.75). 
No men reported increases in nausea in response to d-fenfluramine before dieting and 
only three reported an increase during the post-dieting challenge. Baseline nausea was not 
significantly elevated after dieting (p=0.17), and no significant effect of dieting on nausea 
was seen. The ANOV A on change from baseline data revealed no significant main effect 
of occasion (F=0.50; d.f.= 1,3; p=0.50), no significant main effect of time (F= 1,0; 
d.f.=3,27; p=0.41) and no significant occasion by time interaction (F=l.0; d.f.=3,27; 
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p=0.41). Three women reported increases in nausea following d-fenfluramine 
administration before dieting and three after dieting. Baseline nausea in the women was 
not significantly altered by dieting (p=0.34), and again no significant effect of dieting on 
nausea was seen when analysed with ANOV A on change from baseline data. 
An increase in dizziness in response to d-fenfluramine was reported by one male 
before, and by three males after dieting. Baseline dizziness was not significantly elevated 
after dieting (p=0.62) and no significant effect of dieting on dizziness was found. The 
ANOVA on change from baseline data in the male dieters revealed no significant main 
effect of occasion (F=2.25; d.f.=1,3; p=0.17), no significant main effect of time (F=0.47; 
d.f.=3,27; p=0.70) and no occasion by time interaction (F=l.14; d.f.=3,27; p=0.35). 
Amongst the female dieters, increased dizziness was reported by three subjects in response 
to d-fenfluramine administration before, and by four subjects following dieting. Basal VA 
ratings before and after dieting were not significantly different (p=0.18) and no significant 
effect of dieting on dizziness was found. The ANOV A on change from baseline data in the 
women revealed no significant main effect of occasion (F=l.95; d.f.=1,3; p=0.19), no 
significant main effect of time (F=l.65; d.f.=3,30; p=0.20) and no significant occasion by 
time interaction (F=0.24; d.f.=3,30; p=0.87). 
Similar result were seen with the VA ratings for light-headedness. Three men reported 
increases in light-headed following d-fenfluramine administration before dieting, and four 
men reported increases in light-headedness after dieting. However, basal light-headedness 
ratings were not significantly different before and after dieting (p=0.17), and again no 
significant effect of dieting was seen The ANOV A on change from baseline data revealed 
no significant main effect of occasion (F=0.73; d.f.=1,3; p=0.41), no significant main 
effect of time (F=0.24; d.f.=3,30; p=0.87) and no significant occasion by time interaction 
(F=0.23; d.f.=3,30; p=0.88). Amongst the female dieters, three reported increases in light-
headedness following administration of d-fenfluramine before dieting and five after 
dieting, although baseline light-headedness ratings were not significantly different before 
and after dieting (p=0.05). The ANOV A on change from baseline data revealed no 
significant main effect of occasion (F=l.97; d.f.=1,3; p=0.19), a significant main effect of 
time (F=3.42; d.f.=3,30; p=0.03) but no significant occasion by time interaction (F=0.82; 
d.f.=3,30; p=0.50). 
Two male dieters reported increases in feelings of depression in response to d-
fenfluramine administration before, and three after, dieting. Basal depression VA ratings 
were not significant lower following dieting (p=0.22), and no significant effect of dieting 
on depression was found. The ANOV A on change from baseline data revealed no 
significant main effect of occasion (F=0.0006; d.f.=1,3; p=0.98), no significant main effect 
of time (F= 1.45; d.f.=3 ,30; p=0.25) and no significant occasion by time interaction 
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,,/ (F=l.18; d.f.=3,30; p=0.33). None of the female dieters reported feelings of depression 
throughout testing either before or after dieting. 
All but two of the male dieters reported increases in hunger following d-fenfluramine 
administration before dieting and all but one after dieting. Baseline hunger ratings were not 
significantly different before or after dieting (p=0.93) and no significant effect of dieting 
on hunger was seen. The ANOV A on change from baseline data revealed no significant 
main effect of occasion (F=0.31; d.f.=1,3; p=0.59), a significant main effect of time 
(F=7.33; d.f.=3,27; p=0.001) but no significant occasion by time interaction (F=2.33; 
d.f.=3,27; p=0.10). An increase in hunger ratings was also seen in five of the women 
following d-fenfluramine administration before, and four of the women after dieting. Basal 
hunger ratings in the female dieters were not significantly different (p=0.65), and no 
significant effect of dieting on hunger was seen The ANOV A on change from baseline 
data revealed no significant main effect of occasion (F=0.64; d.f.=1,3; p=0.44), no 
significant main effect of time (F=0.33; d.f.=3,30; p=0.80) and no significant occasion by 
time interaction (F=l.66; d.f.=3,30; p=0.20). 
A significant effect of dieting on ratings of happiness was seen in the male dieters 
although basal happiness ratings were not significantly different before and after dieting 
(p=0.79). The ANOVA on change from baseline data revealed no significant main effect 
of occasion (F=l.90; d.f.=3,30; p=0.20), no significant main effect of time (F=l.76; 
d.f.=3,30; p=0.18) but a significant occasion by time interaction (F=3.13; d.f.=3,30; 
p=0.0.04). In the women dieters, baseline happiness ratings were not significantly different 
before and after dieting (p=0.28). The ANOV A on change from baseline data revealed no 
significant main effect of occasion (F=2.34; d.f.=3,30; p=0.16), a significant main effect of 
time (F=4.71; d.f.=3,30; p=0.008), but no significant occasion by time interaction (F=2.24; 
d.f.=3,30; p=0.10). 
3.3.2.5 Correlations 
Following d-fenfluramine administration, no significant correlations were found 
between PRL response and plasma d-fenfluramine or d-norfenfluramine drug levels. In the 
men, correlations between plasma d-fenfluramine (measured as AUC) and plasma PRL 
(measured as AUC-B) before and after dieting were r=0.11; p=0.74 and r=-0.33; p=0.30 
respectively, while correlations between plasma d-norfenfluramine and plasma PRL before 
and after dieting were r=-0.52; p=0.08 and r=-0.19; p=0.56. In the women dieters, 
correlations between d-fenfluramine and plasma PRL responses before and after dieting 
were r=-0.37; p=0.24 and r=-0.23; p=0.48 respectively, while correlations between d-
norfenfluramine and plasma PRL responses before and after dieting also failed to reach 
significance (r=-0.07; p=0.84 and r=0.32; p=0.30). 
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No significant correlation was found between basal plasma PRL concentration and 
PRL response in female dieters either before (r=-0.39; p=0.22), or following (r=-0.34; 
p=0.28) dieting, but a significant negative correlation was found in male dieters before (r=-
0.66; p=0.02), and after (r=-0.83; p=0.0008) dieting such that the lower the PRL level at 
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Figure 3.9. Correlations between basal plasma PRL levels and PRL response 
(mIU!l-1.min-1) in the males before (a), and after (b) dieting. A significant 
negative correlation was found between basal plasma PRL levels (time 0) and 
subsequent PRL response to the d-fenfluramine challenge both before and after 
dieting. 
When PRL response and weight loss were compared, no significant correlation 
between the PRL response after dieting and absolute weight loss (men: r=0.17; p=0.59; 
women: r=0.36; p=0.25) or percentage body weight loss (men: r=0.37; p=0.24; women: 
r=0.17;p=0.60) was found . 
Plasma total and free TRP levels did not correlate significantly with either PRL 
response or weight loss. In the men, no significant correlation was found between plasma 
total TRP and PRL response before (r=0.-0.31; p=0.32), or after (r=0.11; p=0.73; Figure 
3. lOa) dieting. Similarly, no significant correlation was found between plasma free TRP 
levels and the PRL response before (r=-0.27; p=0.40) and after (r=0.17; p=0.60; Figure 
3. lOb) dieting. There was no significant correlation between weight loss and change in 
plasma TRP levels in male dieters in terms of either absolute weight loss (total TRP: 
r=0.14; p= 0.66; free TRP: r=0.35; p= 0.26) or percentage body weight loss (total TRP: 
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Figure 3.10. Correlations in men after dieting between plasma total TRP and 
AUC-B PRL response (rnIU/I-1.min-1) (a), and between plasma free TRP and 
AUC-B PRL response (mlU/1-1.min-1) (b). 
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In the women, neither plasma total or free TRP levels were found to be significantly 
correlated with PRL response before (total TRP: r=0.24; p=0.46; free TRP: r=-0.18; 
p=0.57) or following dieting (total TRP: r=-0.30; p=0.34; free TRP: r=0.05; p=0.87: Figure 
3.11). 
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Figure 3.11. Correlations between plasma total TRP and AUC-B PRL response 
(mIUfl-1.min-1) (a) and plasma free TRP levels and AUC-B PRL response 




No significant correlation was found between weight loss in the women and change in 
plasma total or free TRP levels when assessed either as absolute weight loss versus total 
TRP (r=0.10; p=0.75) or free TRP (r=0.39; p=0.21), or as percentage body weight loss 
(total TRP: r=-0.05; p=0.87; free TRP: r=28; p=0.38). 
A positive and significant correlation between plasma oestradiol concentration and 
PRL response was found in women before dieting (r=0.61; p=0.03; Figure 3.12) but failed 
to reach significance after dieting (r=0.38; p=0.23). 
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Figure 3.12. Correlation between plasma oestradiol levels and AUC-B PRL 
response (mIU/1-1.min-1) in the women dieters before dieting. A significant 
and positive correlation was found before, but not after, dieting. 
In male dieters, no significant correlation was found between plasma d-fenfluramine 
and d-norfenfluramine concentrations before dieting (r=0.49; p=O. l 0), but a significant 
positive correlation between the two drugs was found after dieting (r=0.84; p=0.0006; 
Figure 3.13a). Furthermore, a positive and significant correlation was found between the 
changes in d-fenfluramine and d-norfenfluramine drug concentrations between the two 
challenge tests (r=0.63; p=0.03; Figure 3.13b). In female dieters, no significant 
correlations were found between d-fenfluramine and d-norfenfluramine drug 
concentrations either before dieting (r=0.27; p=0.39), after dieting (r=0.35; p=0.26) or 
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Figure 3.13. (a): A significant, positive correlation was found between AUC 
(ng!InI-1.min-1) plasma d-fenfluramine and d-norfenfluramine drug levels in 
the men after dieting. (b): Similarly, a significant positive correlation existed 
between change in AUC plasma d-fenfluramine and d-norfenfluramine drug 
levels (ng/ml-1.min-l) in the men between challenges. 
3.3.3 EFFECTS OF DIETING ON mCPP-INDUCED PRL RESPONSE 
3.3.3.1 Weight Loss, Oestradiol Levels and Plasma TRP 
All dieters lost weight with a mean ± sem weight loss of 3.31kg ± 0.27 and a 
percentage body weight loss of 4.84% ± 0.41. No dieters were determined, by disparate 
plasma oestradiol levels (> 50pg/ml difference in plasma oestradiol between tests), to have 
been tested at different phases of the menstrual cycle and all were, therefore, included in 
the final analysis. 
Dieting did not significantly alter total or free plasma TRP (Figure 3.14). Mean± sem 
total plasma TRP concentrations before and after dieting were 10.67µg/ml ± 0.57 and 
10.07µg/ml ± 0.42 respectively (p=0.31). There was a trend towards a decrease in plasma 
free TRP concentrations after dieting, but the decrease failed to reach statistical 
significance. Mean± SEM plasma free TRP before and after dieting were l.05µg/ml ± 

























Figure 3.14. Mean ± sem plasma total TRP and free TRP in twelve females 
before and after dieting. No significant differences in plasma total and free TRP 
levels were found after dieting. 
3.3.3.2 Plasma Drug Levels: mCPP 
Following mCPP administration, detectable concentrations of mCPP were present in 
plasma from + 15 minutes. Dieting did not significantly alter plasma concentrations of 

















Figure 3.15. Plasma mCPP drug concentrations (shown as mean AUC ± sem; 
ng/ml-1.rnin-1) in twelve female dieters before and after dieting. Dieting did not 





Peak plasma concentrations of mCPP were detected before (mean ± sem=652ng/ml ± 
211) and after dieting (mean± sem=698 ± 244) at +15 minutes. The ANOVA revealed no 
significant main effect of occasion [i.e. an effect of dieting] (F=0.03; d.f.=1,8; p=0.85), a 
significant main effect of time [i.e. a variation in mCPP drug levels over time] (F=8.84; 
d.f.=8,88; p=0.0001) but no significant occasion by time interaction [i.e. an effect of 
dieting on the variation of mCPP drug levels over time] (F=0.15; d.f.=8,88; p=0.70). 
Similarly, when analysed as area under the curve (AUC), dieting was found to have had no 
significant effect on mCPP drug concentrations (Figure 3.15). Mean± sem mCPP response 
in the female dieters before and after dieting was 13819ng/ml-1.min-1 ± 3539 and 
14201ng/ml-1.min-1 ± 4320 respectively (p= 0.84). 
3.3.3.3 PRL Response to mCPP 
Intravenous administration of mCPP was associated with rapid onset of action of the 
drug. This led to an increase in plasma PRL levels, without the initial fall observed 












~ 20 -0 
I-< 
0... 
crj s 0 er, 
crj -A.. 
-20 
-30 0 30 60 90 120 
Time (min) 
Figure 3.16. Mean± sem plasma PRL concentration (change from baseline) 
following mCPP administration in twelve female volunteers before and after 
dieting. The PRL response was not significantly altered after dieting. 
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Basal PRL concentrations were not significantly different before and after dieting 
(mean ± sem PRL concentration at time 0: pre-dieting=224mlU/l ± 24; post-
diet=234mIU/l ± 22; p=0.54). Similarly, the PRL response to mCPP was not significantly 
altered in the women after dieting when compared to the pre-diet challenge (Figure 3.16). 
The ANOV A on change from baseline data revealed no significant main effect of occasion 
[i.e. an effect of dieting] (F=0.02; d.f.=1,7; p=0.89), a significant main effect of time [i.e. 
the variation in PRL response over time] (F=4.26; d.f.=7,77; p=0.005) but no significant 
occasion by time interaction [i.e. an effect of dieting on the variation in PRL response over 
time] (F=0.24; d.f.=7,77; p=0.98. When analysed as AUC-B, PRL responses were not 
significantly elevated after dieting. Mean ± sem PRL responses before and following 
dieting were 2796mIU/l-1.min-1 ± 1770 and 2938mlU/I-1.min-1 ± 2014 respectively 
(p=0.94). 
3.3.3.4 Subjective Ratings 
All but four of the women reported an increase in VA ratings of nausea following 
mCPP administration before dieting and all but three women reported an increase after 
dieting. Basal nausea ratings, however, were not significantly different before and after 
dieting (p=0.80) and no effect of dieting was found on nausea. The ANOV A on change 
from baseline data revealed no significant main effect of occasion [i.e. effect of dieting] 
(F=0.09; d.f.=1,6; p=0.77), a significant main effect of time [i.e. variation in nausea ratings 
over time] (F=8.10; d.f.=6,66; p=0.0001), but no significant occasion by time interaction 
[i.e. effect of dieting on variation in nausea ratings over time] (F=2.04; d.f.=6,66; p=0.07). 
Following mCPP administration, all women except one reported an increase in light-
headedness before dieting, and all but three women reported an increase after dieting. VA 
ratings of basal light-headedness were not significantly different before and after dieting 
(p=0.97), and no significant effect of dieting on light-headedness was found. The ANOV A 
on change from baseline data revealed no significant main effect of occasion (F=0.02; 
d.f.=1,6; p=0.90), a significant main effect of time (F=12.47; d.f.=6,66; p=0.0001), but no 
significant occasion by time interaction (F=0.87; d.f.=6,66; p=0.53). 
Similar effects were seen on anxiety ratings. Half the women reported an increase in 
anxiety following mCPP administration before dieting, and five after dieting. Basal ratings 
for anxiety, however, were not significantly different before and after dieting (p=0.10), and 
again, no significant effect of dieting on anxiety ratings were seen. The ANOV A on 
change from baseline data revealed no significant main effect of occasion (F=3.08; 
d.f.= 1,6; p=0.11 ), no significant main effect of time (F=2.06; d.f.=6,66; p=0.07) and no 
significant occasion by time interaction (F=2.06; d.f.=6,66; p=0.55) . 
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Increases in VA ratings of unreality were found in all but one of the women following 
mCPP administration before dieting, and in all the women after dieting. Basal ratings of 
unreality were not significantly different before and after dieting (p=0.52), and no 
significant effect of dieting on unreality ratings were found. The ANOV A on change from 
baseline data revealed no significant main effect of occasion (F=2.17; d.f.=1,6; p=0.17), a 
significant main effect of time (F=l0.49; d.f.=6,66; p=0.0001) and no significant occasion 
by time interaction (F=0.68; d.f.=6,66; p=0.67). 
VA ratings of sweatiness were measured and no significant effect of dieting found. 
While all but five women reported an increase in ratings of sweatiness following m CPP 
administration before dieting, only five reported increases after dieting. Baseline VA 
ratings of sweatiness, however, were not significantly different before and after dieting 
(p=0.28), and no significant effect of dieting on sweatiness was found. The ANOV A on 
change from baseline data revealed no significant main effect of occasion (F=0.61; 
d.f.=1,6; p=0.45), no significant main effect of time (F=0.28; d.f.=6,66; p=0.94) and no 
significant occasion by time interaction (F=0.97; d.f.=6,66; p=0.45). 
All but one of the women reported increased ratings of hunger following m CPP 
administration before dieting, and all but three after dieting. Basal hunger ratings were not 
significantly different before and after dieting (p=0.27) and no significant effect of dieting 
on hunger was seen. The ANOV A on change from baseline data revealed no significant 
main effect of occasion (F=l.14; d.f.=1,6; p=0.31), no significant main effect of time 
(F=0.93; d.f.=6,66; p=0.48) and no significant occasion by time interaction (F=l.37; 
d.f.=6,66; p=0.24). 
Increased ratings of happiness were reported following m CPP administration in all but 
two women, both before and after dieting. Basal happiness ratings were not significantly 
different before and after dieting (p=0.73) and no significant effect of dieting was seen on 
happiness. The ANOV A on change from baseline data revealed no significant main effect 
of occasion (F=2.88; d.f.=1,6; p=0.12), a significant main effect of time (F=2.26; 
d.f.=6,66; p=0.05) but no significant occasion by time interaction (F=0.89; d.f.=6,66; 
p=0.51). 
Finally, VA ratings of mellowness also failed to show any significant differences 
before and after dieting. Increased ratings of feeling mellow were reported following 
mCPP administration in all women but three before and in all but two women after dieting 
respectively. Basal ratings were not significantly different before and after dieting (p=0.33) 
and no significant effect of dieting on mellowness was seen. The ANOV A on change from 




significant main effect of time (F=0.90; d.f.=6,66; p=0.50) and no significant occasion by 
time interaction (F=0.99; d.f.=6,66; p=0.44). 
3.3.3.5 Correlations 
Following mCPP administration, no significant correlation was found between PRL 
response and plasma mCPP drug levels. Correlations between plasma mCPP and plasma 
PRL before and after dieting were r=0.40; p=0.20 and r=0.02; p=0.96 respectively. 
No significant difference in basal PRL levels were found before and after dieting (see 
section 3.3.3.3), but a significant negative correlation was found between basal plasma 
PRL concentration and PRL response before dieting (r=-0.70; p=O.Ol; Figure 3.17a), 
although the correlation failed to reach significance following dieting (r=0.19; p=0.56). 
When PRL response and weight loss were compared, no significant correlation between 
the PRL response after dieting and absolute weight loss (r=-0.12; p=0.72) or percentage 
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Figure 3.17. Correlations between basal PRL and PRL response (AUC-B; 
mIUII-1.min-1) before dieting (a), and basal oestradiol and PRL response 
(AUC-B; mIU/1-1.min-1) after dieting (b) in twelve female dieters following 
mCPP administration. 
No significant correlation was found between plasma total TRP and PRL response before 
(r=-0.22; p=0.50), and after (r=0.13; p=0.69) dieting. Similarly, no significant correlation 
was found between plasma free TRP levels and the PRL response before (r=0.39; p=0.21), 
and after (r=-0.15; p=0.64) dieting. There was no significant correlation between weight 
loss and change in plasma TRP levels in terms of either absolute weight loss (total TRP: 
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r=0.32; p=0.31; free TRP: r=-0.29; p=0.36) or percentage body weight loss (total TRP: 
r=0.32; p=0.30; free TRP: r=0.-0.23; p=0.46). A positive and significant correlation 
between plasma oestradiol concentration and PRL response was found in the women, 
however, after dieting (r=0.72; p=0.008; Figure 3.17b) but failed to reach significance 
before dieting (r=-0.02; p=0.94). 
3.3.3.6 Comparisons Between d-Fenfluramine and mCPP dieters 
When the females who participated in the d-fenfluramine and mCPP dieting studies 
were compared, no significant differences in age (p=0.20), body mass index (p=0.20), 
starting weight (p=0.27), plasma oestradiol concentration (p=0.60) or initial plasma total 
(p=0.16) and free (p=0.28) TRP levels were found. Similarly, weight loss between the two 
groups was not significantly different in terms of either absolute weight loss (p=0.82) or 
percentage body weight loss (p=0.37) 
3.4 DISCUSSION 
3.4.1 DIETING AND REPEAT ADMINISTRATION STUDIES WITH 
d-FENFLURAMINE 
Two women dieters and three women in the repeat d-fenfluramine administration study 
were determined by disparate plasma oestradiol levels to have been tested at different 
phases of their menstrual cycle and were, therefore, excluded from further analysis. 
Studies by O'Keane et al (1991) and Hrboticky et al (1989) have demonstrated changes in 
PRL responses to d-fenfluramine and in TRP metabolism respectively, across the 
menstrual cycle. Exclusion of the above females was supported by the finding of a positive 
and significant correlation between plasma oestradiol level and PRL response before 
dieting, and is in keeping with work by O'Keane et al ( 1991) suggesting that variations in 
d-fenfluramine-induced PRL responses across the menstrual cycle are caused by 
fluctuations in oestrogen levels. No significant correlation was found, however, between 
oestradiol levels and PRL response after dieting and in the repeat d-fenfluramine 
administration study. 
A key finding of this study was an enhanced PRL response in women to d-
fenfluramine following a three week period of moderate calorie restriction and subsequent 
weight loss. Although male dieters lost an equivalent amount of weight in both absolute 
and percentage body weight terms, no increase in PRL response was seen in the men after 
dieting. Females who did not diet (i.e. repeat d-fenfluramine administration study) also 
showed no alteration in PRL response to repeat d-fenfluramine challenges one month 
apart. Thus, the enhanced PRL response to d-fenfluramine seen in the female dieters could 
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not be explained by an "order" effect of d-fenfluramine testing. Indeed, PRL responses in 
women undergoing the second challenge in the repeat d-fenfluramine administration study, 
were slightly lower when compared to the first challenge, although neither baseline PRL 
changes nor PRL response to d-fenfluramine reached statistical significance when the 
second challenge was compared to the first. Furthermore, dieting did not alter plasma 
levels of d-fenfluramine or its active metabolite, d-norfenfluramine, suggesting that 
changes in d-fenfluramine disposition could not account for the increase in PRL release 
after dieting. An enhanced PRL response may be seen secondary to a "stress" reaction (see 
section 2.1.5), but this is unlikely to explain the enhanced response seen in the female 
dieters. VA ratings revealed no significant effects of dieting on d-fenfluramine-induced 
subjective changes (eg. nausea, light-headedness and dizziness) that normally accompany 
such a reaction. 
On the basis of earlier studies with TRP, it was hypothesised that moderate weight loss 
through dieting decreases plasma TRP sufficiently in women to reduce brain 5-HT 
synthesis, as synthesis of brain 5-HT has been shown to be dependent upon the availability 
of TRP from plasma (see section 1.2.1 for a full explanation). A subsequent reduction in 5-
HT neurotransmission across the synapse results, which in turn produces a supersensitivity 
of post-synaptic 5-HT receptors, as evidenced by an enhanced PRL response to a TRP 
challenge after dieting. Animal studies in which rats fed a low TRP diet demonstrate 
enhanced PRL responses to 5-HT precursors such as 5-hydroxytryptophan support this 
hypothesis (Clemens et al, 1980). Further support comes from the human study by 
Delgado et al (1989) in which healthy volunteers maintained on a low TRP, non calorie-
reducing diet for ten days also demonstrated enhanced PRL responses to a subsequent TRP 
infusion. The precise synaptic mechanism of the enhanced 5-HT mediated neuroendocrine 
response is, however, unknown although compensatory up-regulation of post-synaptic 5-
HT receptors secondary to decreased 5-HT release appears the most likely explanation. 
Consistent with this hypothesis, dieting in the present study led to a significant 
decrease in both plasma total and free TRP in women but no significant fall in plasma TRP 
was seen in the men. The findings contrast with those of earlier studies in two ways. 
Anderson et al ( 1990a) reported significant decreases in total TRP for both men and 
women dieters (with falls in plasma total TRP greater in the women compared to men), but 
no significant change in plasma free TRP was found for either sex. One possible 
explanation for the finding that dieting lowered plasma total and free TRP in women alone 
is that plasma TRP levels in women are, in general, more vulnerable to dysregulation. 
Support for this possible explanation comes from a study of depressed patients who had 
lost weight, where it was found that significant decreases in plasma TRP were confined to 
female patients (Anderson et al, 1990b ). Another possible explanation for the failure of the 
men studied to lower their plasma TRP would be a smaller weight loss compared to the 
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women dieters. This was not borne out, however, in terms of absolute weight loss or 
percentage body weight loss which were not significantly different between the sexes. 
Moreover, no significant correlation was found between weight loss and plasma total or 
free TRP levels for either male or female dieters. The finding that plasma total and free 
TRP levels did not fall in women who did not diet, further suggests that no systematic 
change over time is likely to explain the significant fall in plasma TRP amongst female 
dieters. 
An alternative explanation to the one outlined above for the enhanced PRL response 
seen in female dieters would be that dieting induces non-specific alterations in the PRL 
response to a 5-HT challenge drug. For example, a dieting-induced increase in the pituitary 
reserve of PRL would lead to an enhanced PRL response. Earlier work carried out by 
Anderson et al (1989), however, demonstrated that the enhanced PRL response in women 
after dieting was not secondary to direct stimulatory effects upon the pituitary lactotrophs 
as dieting had no effect upon TRH-induced PRL release. It was also shown that dieting did 
not alter dopaminergic neurotransmission as no effect of dieting was seen on PRL release 
by the dopamine antagonist metaclopramide, nor was there any effect on the physiological 
release (sleep-induced) of PRL (Anderson et al, 1989). These findings, coupled with the 
results from the present study with the selective 5-HT drug d-fenfluramine, argue against a 
non-specific effect, suggesting instead that dieting selectively alters 5-HT-mediated PRL 
release. 
The selective 5-HT drug d-fenfluramine, is thought to increase PRL through indirect 
enhancement of serotonergic neurotransmission secondary to pre-synaptic release and re-
uptake inhibition (Fuller et al, 1988; Campbell, 1991 ). It could be argued, therefore, that 
partial interruption of pre-synaptic 5-HT function could lead to an enhanced d-
fenfluramine-induced PRL response (similar to that seen after dieting with TRP). Work by 
Meltzer et al (1982), in which rats were pretreated with the tryptophan hydroxylase 
inhibitor para-chloro-phenylalanine supports this theory. Pre-treatment with para-chloro-
phenylalanine, which leads to pre-synaptic depletion of 5-HT, has been shown to result in 
an enhanced PRL response to a subsequent dl-fenfluramine challenge when compared to 
saline pre-treatment. Dieting may produce a partial interruption of pre-synaptic 5-HT 
function secondary to chronic plasma TRP depletion leading to reduced 5-HT synthesis. 
Based on this hypothesis, the failure of the male dieters to lower their plasma TRP could 
explain their subsequent lack of an enhanced PRL response to d-fenfluramine. However, it 
is of interest that in the earlier dieting study by Anderson et al (1990a), significant falls in 
plasma total TRP in male dieters was still not accompanied by enhanced PRL responses to 
TRP. It appears therefore, that even when dieting in men does lead to significant falls in 
plasma TRP they are still less likely to demonstrate enhanced PRL responses, suggesting 
that women may be more vulnerable than men to diet-induced changes in brain 5-HT 
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function. An increased vulnerability in women with respect to alterations in brain 5-HT 
function is further suggested the study by Delgado et al (1989) in which healthy human 
volunteers maintained on a low TRP diet for ten days demonstrated enhanced PRL 
responses to TRP. TRP depletion in the female subjects was found to produce a more 
robust increase in PRL response compared to the men. Interestingly, the fall in plasma 
TRP was also significantly greater in women compared to men. 
It is possible that plasma TRP concentrations do not closely mirror brain 5-HT 
function (see section 1.2.1.1 for full discussion), and that this is reflected in the variable 
results in plasma total TRP seen across all dieting studies to date. If this is the case, it 
could also explain why a significant fall in free TRP occurred in the present study but not 
in earlier work, despite the utilisation of an identical diet and dieting regime and the 
achievement of similar amounts of weight loss. Furthermore, such an explanation is 
consistent with the contrasting correlations found between plasma TRP and PRL across 
studies. In the present study, no correlation was found between absolute or change in 
plasma free and total TRP and subsequent PRL response amongst dieters, while Anderson 
et al (1990a) reported a finding of a trend towards a significant but positive correlation 
between change in plasma total TRP and change in PRL response, such that the greater the 
fall in plasma total TRP the higher the subsequent PRL rise. While this finding was seen 
for the dieting group as a whole, it was not seen when both sexes were considered 
separately. The presence of a complex relationship between plasma TRP and brain 5-HT 
levels in humans is further suggested by a study which utilised CSF TRP as an indirect 
index of brain TRP levels and in which the authors concluded that the relationship between 
plasma free TRP and brain TRP was not clear cut (Perez-Cruet et al, 1974). Moreover, the 
presence of such a complex and variable relationship argues against the earlier proposed 
hypothesis which suggests a direct relationship between plasma TRP depletion, decreased 
brain 5-HT function and subsequent enhanced PRL response. 
The present finding of an enhanced PRL response to d-fenfluramine is also consistent 
with the hypothesis that dieting increases brain 5-HT function as proposed by Curzon 
(1988). In his work on rats, Curzon et al (1972) demonstrated that plasma total TRP levels 
were unaltered in response to fasting yet brain 5-HT levels rose, apparently as a 
consequence of body fat store mobilisation increasing plasma unesterified fatty acids 
which directly compete with TRP for albumin binding. This results in increased 
concentrations of plasma free TRP available for transport into the brain, increasing 5-HT 
synthesis (see section 1.3.3.). Increased brain 5-HT synthesis in turn leads to enhanced 
synaptic 5-HT neurotransmission and to increased PRL responses to d-fenfluramine. What 
is not clear, however, is how the effects of total fasting compare to moderate calorie 
restriction in humans. While the finding of a significant fall in plasma TRP in the female 
dieters is against this latter hypothesis, the possibility remains that plasma TRP changes 
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are transient and/or do not directly relate to brain TRP levels. If this is indeed the case, it 
may explain the finding of variable plasma TRP levels in male dieters despite consistent 
findings of non enhancement of PRL responses to 5-HT challenge drugs after dieting. 
3.4.2 EFFECTS OF DIETING ON mCPP-INDUCED PRL RESPONSE 
A three week period of moderate calorie restriction and subsequent weight loss was 
found to have no significant effect on mCPP-induced PRL responses in women. Thus, in 
contrast to the female dieters in the d-fenfluramine study, the mCPP-induced PRL response 
was not enhanced after dieting. Furthermore, a three week period of moderate calorie 
restriction did not lead to a significant reduction in either plasma total or free TRP levels. 
The finding of normal plasma TRP levels along with unaltered mCPP-induced PRL 
responses in women after dieting raises two possible explanations. Based on the hypothesis 
originally proposed, that dieting-induced changes in PRL response to a 5-HT challenge 
drug is dependent on plasma TRP depletion, failure to achieve such depletion in the 
present study appears the most likely explanation for the subsequent unaltered PRL 
response. What is not clear, however, is why a fall in plasma TRP did not occur. The diet 
utilised along with the dieting regime was identical in both studies, and mCPP female 
dieters lost as much weight as the d-fenfluramine female dieters in both absolute and 
percentage body weight terms. Moreover, starting weights and body mass indexes were 
similar and no significant correlation was found amongst mCPP dieters between change in 
plasma TRP concentration and weight loss, in either absolute or percentage body weight 
loss terms. 
As outlined above, PRL responses to some 5-HT challenge drugs (O'Keane et al, 
1991) are known to vary across the menstrual cycle. While no studies looking at the effects 
of menstrual cycle phase on mCPP-induced PRL responses have been published, the 
present finding of a significant positive correlation between plasma oestradiol levels and 
PRL response after dieting suggests that similar effects occur with mCPP and confirms the 
need to control for menstrual cycle phase. This finding is, however, unlikely to explain the 
disparate PRL results seen between the two groups of female dieters, as all women were 
challenged in the early to mid-follicular phase as confirmed by plasma oestradiol 
concentration. No significant differences in plasma oestradiol levels were found between 
the two groups of females at the pre- and post dieting challenge. 
Dieting-induced alterations in mCPP absorption leading to lower plasma levels are 
unable to explain the failure to find an enhanced PRL response in the women after dieting. 
Plasma mCPP drug levels were not significantly different between challenges. Similarly, 





an unlikely explanation, as the pilot study demonstrated that an intravenous dose of 
0.04mg/kg mCPP produces a significant but submaximal increase in PRL release in 
women when compared to placebo. Moreover, plasma mCPP concentrations measured in 
the study were comparable to those reported in the literature to produce reliable PRL 
responses (Kahn and Wetzler, 1991 ), and no significant correlation was found between 
mCPP drug levels and PRL response, either before or after dieting. 
A significant, negative correlation was found between basal PRL concentration and 
PRL response before, but not after dieting, suggesting that the lower the baseline PRL 
concentration, the greater the subsequent PRL response. Basal PRL levels, however, were 
not significantly different before and after dieting. It is, therefore, unlikely that disparate 
basal PRL levels can account for the unaltered PRL results. 
Based on the findings of the present study, the most likely explanation for unaltered 
plasma TRP levels amongst women mCPP dieters is the possibility that, in humans, plasma 
TRP levels do not closely reflect brain 5-HT function and that previously noted falls in 
plasma TRP are either transient and/or do not directly relate to the diet-induced changes 
seen in brain 5-HT function. Furthermore, the present finding that PRL responses to mCPP 
are unaltered by dieting suggests that post-synaptic 5-HT 2 c receptors are not 
supersensitive. 
While the findings argue against the originally proposed hypothesis that dieting leads 
to decreased brain 5-HT function with the consequent development of post-synaptic 
receptor supersensitivity, they are consistent with the hypothesis that dieting leads to 
increased brain 5-HT neurotransmission. As outlined earlier in the discussion, Curzon 
(1988) suggested that while fasting has no systematic effect on plasma TRP, it does lead to 
increased brain 5-HT function. Thus if we assume that plasma TRP levels are variable and 
do not relate directly to brain 5-HT function, then the failure to find a significant decrease 
in plasma TRP in the mCPP dieters would be in keeping with this hypothesis. Furthermore, 
from this point of view, pre-synaptic enhancement of 5-HT neurotransmission secondary 
to increased 5-HT synthesis, is consistent with both an enhanced PRL response to d-
fenfluramine (a pre-synaptic challenge) and a lack of dieting-induced changes following 
mCPP (a post-synaptic challenge). Enhanced pre-synaptic brain 5-HT neurotransmission is 
thought to lead to an adaptive downregulation of post-synaptic receptors in which the 
receptors become sub-sensitive. Such an adaptive response would result in either a 
reduced, or possibly an unchanged, PRL response to a direct post-synaptic receptor agonist 
such as m CPP. For example, chronic electroconvulsive therapy and antidepressant 
administration have been shown to lead to an attenuation of 5-HT1A receptor-mediated 
responses (8-0H-DPAT-induced hypothermia and serotonin syndrome in the rat), 
secondary to down-regulation of 5-HT IA receptors as an adaptive response to increased 
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availability of pre-synaptic 5-HT (Goodwin et al, 1987a). More recently a similar adaptive 
response has been shown to occur in humans. Lesch et al (l 990) demonstrated attenuation 
of 5-HT IA -mediated hypothermia (ipsapirone-induced) in a group of depressed patients 
following chronic amitriptyline administration. 
One final alternative explanation is suggested by the mCPP results. It is possible that 
dieting-induced changes in brain 5-HT function are not mediated through the post synaptic 
receptors with which mCPP interacts. If this were the case, it would explain the lack of an 
enhanced PRL response to mCPP. It would also suggest that an enhanced response may 
follow administration of agonist drugs more specific for other 5-HT receptor subtypes, for 
example 5-HT IA receptors. 
3.5 CONCLUSIONS 
Findings from the present study provide further evidence in support of the hypothesis 
that dieting-induced alterations in PRL release are 5-HT mediated, and add to the data 
indicating that even moderate dieting can alter brain 5-HT function in women. In addition, 
the findings suggest that the enhanced PRL responses seen in women after dieting 
probably reflect pre-synaptic changes in brain 5-HT function, perhaps as a consequence of 
alterations in the synthesis and release of 5-HT. The present findings do not support the 
proposed hypothesis that dieting-induced enhanced PRL responses occur secondary to the 




EFFECTS OF mCPP ON FOOD INTAKE 
AND PLASMA PROLACTIN IN 
WOMEN 
4.1 INTRODUCTION 
Substantial evidence now exists in support of a central role by serotonergic 
pathways in the control of appetite in both animals and humans. As outlined in the 
literature review in Chapter One, one of the most striking and consistent findings in the 
area of appetite research has been the suppression of food intake by experimental 
conditions that either directly, or indirectly, enhance brain 5-HT neurotransmission 
(Samanin et al, 1980; Gottfries, 1981; Silverstone and Goodall, 1986; Leibowitz, 1990 ). 
The converse also appears to hold true, with an increase in food consumption 
accompanying reduced brain 5-HT function although the finding appears more sensitive to 
experimental design (Lavenstein et al, 1962; Breisch et al, 1976; Silverstone and 
Goodall, 1986). More recent experiments have suggested that 5-HT may also be important 
in the control of circadian feeding patterns, and in determining macronutrient choice 
through satiety mechanisms that involve the termination of feeding behaviour ( Silverstone 
and Goodall, 1986; Leibowitz, 1990). Serotonin appears to be primarily concerned with 
the control of carbohydrate and protein intake, with serotonergic stimulation leading to a 
reduction in the proportion of carbohydrate consumed in the diet. For example, the 
administration of the 5-HT releasing drug d-fenfluramine to healthy male volunteers was 
found to exert an anorectic effect in terms of reduced total calorie consumption and a 
significant reduction in carbohydrate consumption while sparing protein intake (Goodall et 
al, 1991 ). In contrast, acute depletion of plasma TRP by a low TRP drink was found to 
have no effect on total calorie or carbohydrate consumption in a group of healthy male 
subjects, but did lead to a significant reduction in protein intake (Young et al, 1988). 
Interest in the role that different 5-HT receptor subtypes play in mediating human 
feeding behaviour has been stimulated by the recent increased availability of selective 5-
HT drugs suitable for human research. Animal data highlighted the role of 5-HT rni2c 
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receptors in feeding behaviour and appetite control in the rat. 5-HT 18 receptors however 
are absent from the human brain. In a study by Goodall et al (1984), d-fenfluramine-
induced anorexia was blocked in three out of four human subjects by pre-treatment with 
the non-selective 5-HT 112 antagonist metergoline. d-Fenfluramine-induced anorexia in 
another group of twelve healthy male volunteers was attenuated following pre-treatment 
with the 5-HT2A12c antagonist ritanserin (Goodall et al, 1993), suggesting a role of 5-HT2 
receptors in the control of food intake in humans. 
The identification of m CPP as a highly selective probe of serotonergic function 
provided the opportunity to investigate further the role of 5-HT pathways in the control of 
human feeding behaviour. As outlined in section 2.1.4.2, mCPP appears to act primarily as 
a 5-HT agonist and is most potent at 5-HT 2c receptors. A recent paper by Baumann et al, 
(1993), however, has raised the possibility that mCPP may also act pre-synaptically to 
enhance release of 5-HT in a similar way to d-fenfluramine. Animal studies have shown 
that, in keeping with other 5-HT agonist drugs (leading to enhanced serotonergic 
neurotransmission), both peripheral and central administration of mCPP leads to 
hypophagia in rats (Samanin et al, 1979; Kennett and Curzon, 1988b ). Furthermore, 
hypophagia induced by centrally administered mCPP has been blocked by pre-treatment 
with the potent 5-HT 2c antagonist mianserin (Kennett and Curzon, 1988b ). The effect of 
mCPP on appetite in humans has not been explored. Animal work, however, suggests that 
mCPP administration to healthy female subjects should lead to a reduction in food intake, 
along with a selective decrease in carbohydrate consumption, secondary to enhancement of 
5-HT neurotransmission. The finding of a reduction in food intake would provide data in 
support of a role by serotonergic pathways in the control of human feeding behaviour and 
suggest 5-HT 2c receptor involvement in the mediation of these effects. A reduction in 
carbohydrate intake would further suggest a significant role by serotonergic pathways in 
determining human macronutrient choice. 
Administration of oral mCPP, as opposed to intravenous mCPP, to female subjects 
also provided an opportunity to examine its effects on PRL release, as to date, few studies 
utilising oral mCPP as a 5-HT challenge drug in women have been published. 
In the present study a combined neuroendocrine and test meal approach was 
utilised to examine the effects of oral m CPP in healthy women. The aims of the present 
study were four fold. Firstly, a pilot study was carried out to determine a suitable oral dose 
of mCPP for use in neuroendocrine and appetite studies in women. Secondly, the dose 
determined by the pilot study was used to examine the effects of m CPP on food intake in 
healthy female volunteers. More specifically, the effects of oral mCPP on two aspects of 
food consumption were studied i.e. total food consumption (as measured by calorie intake) 






women were determined. The use of mCPP, as an agonist drug with highest affinity for the 
5-HT 2c receptor, also enabled a closer examination of the receptor subtypes involved in 
mediating serotonergic control of food intake in humans . 
4.2METH0DS 
4.2.1 DETERMINATION OF DRUG DOSAGE (ORAL mCPP PILOT 
STUDY) 
4.2.1.1 Introduction 
While the data presented in section 2.1.4.2 demonstrates the reliability of m CPP-
induced PRL release in humans, few published studies have utilised oral mCPP as a 5-HT 
challenge in women. This fact, coupled with the absence of a clear dose-response curve for 
the drug, and the presence of gender differences in absorption of mCPP, make it difficult to 
generalise findings between the sexes (Kahn and Wetzler, 1991). Earlier studies in the 
literature suggested that oral doses of at least 0.25mg/kg were required to produce 
consistent elevations in plasma PRL (Kahn et al, 1990; Kahn and Wetzler, 1991 ). More 
recent work, however, demonstrated a significant decrease in slow wave sleep following 
the administration of oral mCPP at 0.125mg/kg to healthy volunteers, an effect probably 
mediated through activation of 5-HT2c receptors (Katsuda et al, 1993; Sharpley et al, 
1994). Furthermore, personal experience with mCPP in dieters suggested that smaller 
intravenous doses of m CPP than those previously described in the literature are also 
sufficient to produce significant elevations in PRL increases in women (see Chapter 
Three). 
In choosing a dose to examine the effects of m CPP on food intake, the drug's 
propensity to produce side effects such as nausea and light-headedness, which might in 
themselves affect appetite, must be considered. While these effects are largely confined to 
higher doses, especially following intravenous administration, the use of mCPP at a dose 
as low as possible would be important in order to minimise potential side effects that may 
make interpretation of appetite and neuroendocrine effects difficult. Thus, the dose chosen 
would need to be high enough to produce sufficient activation of 5-HT receptors (thereby 
enhancing brain 5-HT neurotransmission), but low enough to ensure a minimum of 
unwanted side effects. 
Based upon data outlined above suggesting that low mCPP doses in women 
produce reliable PRL release, coupled with the need to avoid side effects capable of 




examine the effects of oral mCPP at doses of 7 .5mg and 15mg ( approximately 0.13mg/kg 
and 0.25mg/kg mCPP) on food intake and PRL release in women. 
4.2.1.2 Subjects and Method 
Twelve healthy female volunteers were recruited as described under the Selection 
and Assessment of Subjects section in Chapter Two. Subjects were aged between twenty-
two and thirty-seven years (mean age=29 years± 1.5), and all were of average weight as 
determined by a body mass index of between nineteen and twenty-eight (mean ± sem body 
mass index=22.4 ± 0.56; range 19.5-25.5). All gave written, informed consent before 
participating in the study which had been approved by the local ethics committee. 
The study was a double-blind, placebo controlled, cross-over design with a 
balanced order of drug administration. Subjects were tested on three occasions within the 
early to mid-follicular phase of the menstrual cycle with menstrual cycle phase confirmed 
by plasma oestradiol levels. As challenge days were separated by at least five days, the 
study extended over two consecutive menstrual cycles. Each subject received placebo, 
7.5mg mCPP and 15mg mCPP, given in the form of a single opaque capsule. Subjects 
received either placebo or mCPP at time 0, and blood sampling for PRL and mCPP drug 
levels was carried out at thirty minute intervals from -30 minutes until + 180 minutes. Full 
details of the neuroendocrine procedure will be outlined below in section 4.2.3. 
The test meal (procedure outlined in section 4.2.4) was presented three and a half 
hours after the ingestion of the test drug. Subjects were allowed to take as long as they 
wished over their meal and food intake analysed in the standard manner as outlined in 
section 2.3.3.1. Plasma collection and analysis was carried out using the standard method 
outlined in Chapter Two. 
4.2.1.3 Statistics 
The PRL results were analysed with a two-way repeated measures ANOVA, with 
post hoc t-tests where the interaction term was significant. Data from the test meal were 
analysed with a one way repeated measures ANOV A. The PRL data were also measured 
as area under the curve with subtraction of baseline secretion (AUC-B) extrapolated from 
time O using the trapezoid method. Plasma drug concentrations of mCPP were measured as 
area under the curve (AUC) from time 0. 
4.2.1.4 Results 




Oral administration of 7.5mg and 15mg mCPP led to detectable concentrations of 
mCPP in plasma from +60 and +30 minutes respectively. No detectable concentrations of 
plasma mCPP were seen after placebo administration. Peak plasma concentrations 
following 7.5mg mCPP (mean ± sem=7.07ng/ml ± 3.27) and 15mg mCPP (mean ± 
sem=12.38ng/ml ± 5.21) were seen at+ 120 and+ 180 minutes respectively. (Figure 4. la) 
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Figure 4.1. (a): Mean± sem plasma mCPP levels in twelve female volunteers 
following oral administration of 7.5mg and 15mg mCPP. (b): Effect of oral 
mCPP (7.5mg and 15mg) on plasma PRL (shown as mean± sem change from 
baseline) in twelve female volunteers. Plasma PRL was significantly elevated 
following mCPP, compared to placebo, at the time points indicated. Paired-t 
test: * p < 0.05; ** p < 0.01. 
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Plasma drug concentrations were not significantly different following the two 
doses (Figure 4. la). The ANOVA revealed no significant main effect of occasion [i.e. 
effect of 7.5mg versus 15mg mCPP] (F=0.81; d.f.=1,6; p=0.39), a significant main effect 
of time [i.e. variation in mCPP levels over time] (F=5.60; d.f.=6,66; p<0.0001), but no 
significant occasion by time interaction [i.e. effect of 15mg versus 7 .5mg m CPP on 
variation in mCPP levels over time] (F=l.79; d.f.=6,66; p=0.11) . Similarly, when analysed 
as AUC, plasma mCPP was not significant different following either dose (mean plasma 
mCPP ± sem: 7.5mg=85I.6ng/mI-1.min-l ± 403.5; 15mg=988.2ng/ml-l.min-l ± 273.8; 
p=0.59). 
PRL Response to mCPP 
Following placebo administration, plasma PRL levels fell, in keeping with the 




+ 120 minutes. In contrast when compared to placebo, mCPP administration significantly 
increased plasma PRL concentrations after an initial fall reflecting the circadian decline 
(Figure 4.1 b ). The ANOV A on change from baseline data revealed a significant main 
effect of occasion [i.e. effect of mCPP versus placebo] (F=7.45; d.f.=10,110; p<0.001), a 
significant main effect of time [i.e. variation in PRL over time] (F=2.77; d.f.=5,55; 
p=0.03), and a significant occasion by time interaction [i.e. effect of mCPP on variation in 
PRL over time] (F=7.45; d.f.=10,110; p<0.001). Post-hoc testing revealed that PRL levels 
were significantly higher following 7.5mg and 15mg mCPP, when compared to placebo, at 
+150 and +180 minutes and +90, +120, +150, and +180 minutes respectively. Plasma PRL 
levels were not significantly different between the two mCPP doses. When analysed as 
AUC-B, plasma PRL response was significantly higher following mCPP compared to 
placebo (mean± sem: placebo=-13304mIU/I-1.min-1 ± 1780; 7.5mg=-6631mIU/l-I.min-1 ± 
5176; 15mg=-3060mIU/I-1.min-I ± 3158; p=0.002), but the PRL response was not 
significantly different between the 7.5mg and 15mg mCPP doses (p=0.39). 
Effect of Oral mCP P on Food Intake 
Food intake during the buffet-style lunch was not significantly altered by mCPP 
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Figure 4.2. Food intake in twelve healthy female volunteers following 
placebo, 7.5mg and 15mg mCPP. Food intake following mCPP administration 






No significant effects of oral mCPP was found on neuroendocrine VA ratings 
(nausea, anxiety, light-headedness, happiness and depression), or upon VA ratings 
of appetite (hunger and wish to eat). 
4.2.1.4 Conclusions 
Oral administration of 7.5mg and 15mg doses of mCPP led to detectable levels of 
mCPP in plasma from +60 and +30 minutes respectively. Peak plasma drug levels 
following the 15mg mCPP dose (approximately 0.25mg/kg mCPP) were slightly lower 
than those reported in the literature in male subjects receiving the same oral dose, but are 
in keeping with the gender differences in plasma levels noted for the drug (Kahn et al, 
1990; Kahn et al, 1991). Oral mCPP at doses of 7.5mg and 15mg led to significant 
increases in PRL release compared to placebo. No effect on food intake, in terms of total 
consumption or macronutrient selection was seen. 
The results suggest that while smaller doses of mCPP than those reported in the 
literature do appear sufficient to consistently increase plasma PRL, higher oral doses may 
be required before the anorectic effects widely reported in animal studies are seen in 
human females. An oral dose of 0.4mg/kg was, therefore, chosen for use in the main study 
designed to examine the effect of mCPP on food intake and PRL response in women. It 
was felt that this dose would provide sufficient stimulation of 5-HT receptors, while 
minimising side effects. 
4.2.2 SUBJECTS 
Twelve healthy female volunteers were recruited as described under the Selection 
and Assessment of Subjects section in Chapter Two. All subjects were of average weight 
as determined by a body mass index of between nineteen and twenty-eight (mean ± sem 
body mass index=22.5 ± 0.47; range 19.1-24), and were aged between nineteen and thirty-
four years of age (mean± sem age=26.4years ± 1.18). All gave written, informed consent 
to participating in the study which had been approved by the local ethics committee. 
Subjects underwent neuroendocrine testing with placebo and mCPP on separate 
occasions approximately one week apart. Test meals were carried out at the completion of 
blood sampling. Challenges took place in double-blind, randomised order in the early to 
mid-follicular phase of a single menstrual cycle for all but one of the subjects. One female 
was forced to delay her second challenge test due to illness, so this was carried out at the 
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corresponding time of her following menstrual cycle. Menstrual cycle phase was 
confirmed by plasma oestradiol concentration. 
4.2.2 NEUROEDOCRINE CHALLENGE PROCEDURE 
Neuroendocrine testing was carried out following an overnight fast with subjects 
requested not to eat or drink from midnight. Subjects were brought to the Research Unit at 
approximately 08.30 hours and an indwelling venous cannula inserted into the arm. During 
testing, subjects rested semi-supine on a bed and were not allowed to eat, drink, smoke or 
sleep. 
After insertion of the venous cannula, a blood sample for baseline plasma PRL 
estimation was taken. Subjects were then left to rest quietly on the bed for thirty minutes 
before administration of the test drug between 09.00 and 09.30 hours (time 0). mCPP, 
0.4mg/kg or placebo was administered orally in a single unmarked opaque capsule 
(Littlemore Hospital Pharmacy; Oxford; UK). Blood samples for plasma PRL and mCPP 
drug levels were taken every thirty minutes from time O until + 150 minutes. 
4.2.3 TEST MEAL PROCEDURE 
Fifteen minutes after the completion of neuroendocrine testing, subjects were 
placed at a table in a quiet room on their own. Meal instructions were given by the author 
in the standardised manner outlined in section 2.3.3.1. The food was then presented on 
trays in the standardised format and placed on the table in front of the subject. Subjects 
were left alone to eat and asked to come out of the room when they had finished their 
meal. Following completion of the meal, the trays were removed without comment. Food 
not consumed was weighed and calorie consumption calculated as outlined in section 
2.3.3.1. 
4.2.4 SUBJECTIVE RA TINGS 
mCPP is generally well tolerated by human subjects but side effects have been 
reported, especially at high doses. While our previous experience with the drug suggested 
that an oral dose of 0.4mg/kg would be well tolerated by women, it was also likely that 
transient side effects would occur. VA rating scales for happiness, anxiety, hunger, light-
headedness, nausea, mellowness, sweatiness and a sense of reality were, therefore, 
presented to subjects throughout testing. The VA rating scales were presented in the 
standardised manner outlined in section 2.3.1 at thirty minute intervals between -30 and 
+ 150 minutes. 
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4.2.5 STATISTICAL ANALYSIS 
4.2.5.1 Neuroendocrine Challenge Data Analysis 
PRL data were plotted against time (as change from baseline) and then analysed 
with two way repeated measures ANOV A with Fisher's test of least significance difference 
as a post hoc range test. PRL data were also analysed as area under the curve with 
subtraction of baseline secretion (AUC-B) extrapolated from time O using the trapezoid 
method. Drug concentration data were measured as area under the curve (AUC) from time 
0. VA data were plotted against time and then analysed with ANOV A, with Fisher's test as 
a post hoc range test. 
4.2.5.2 Test Meal Analysis 
All food items were weighed to the nearest O. lgm before and after the meal. 
Calculation of final calorie consumption was carried out as described in section 2.3.3.1. 
Data from the test meals were analysed using paired t testing. 
4.3 RESULTS 
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Figure 4.3. Mean ± sem plasma m CPP concentrations in twelve female 




Following mCPP administration, detectable concentrations of mCPP were present 
in plasma from +30 minutes, while no detectable concentrations of plasma mCPP were 
found following placebo administration (Figure 4.3). Peak plasma concentrations of mCPP 
(mean± sem=13.47ng/ml ± 2.48) were detected at +120 minutes. When analysed as AUC, 
mean± sem plasma mCPP following 0.4mg/kg mCPP administration was 1131.5ng/ml-
1.min-1 ± 211.2. 
4.3.2 PRL RESPONSE TO m CPP 
Following an initial fall, in keeping with the natural circadian fall in PRL release 
seen across the morning, plasma PRL levels increased following mCPP administration. In 
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Figure 4.4 Mean ± sem plasma PRL concentration ( change from baseline) 
following placebo and 0.4mg/kg mCPP challenges in twelve female 
volunteers. PRL responses were significantly increased following mCPP at the 
time points indicated. Fisher's test: * p < 0.05, ** p < 0.01 
Basal PRL concentrations at placebo and mCPP challenges were not significantly 
different (mean± sem PRL at time 0: placebo=236mIU/1 ± 41.7; mCPP=242mIU/1 ± 55.3; 




compared to placebo. The ANOV A on change from baseline data revealed no significant 
main effect of occasion [i.e. effect of m CPP] (F=2.80; d.f.= 1,4; p=0.12), no significant 
main effect of time [i.e. variation in PRL over time] (F=0.86; d.f.=4,44; p=0.50), but a 
significant occasion by time interaction [i.e. effect of mCPP on variation in PRL over time] 
(F=3.50; d.f.=4,44; p=0.01). However, when analysed as AUC-B, PRL responses 
following mCPP administration were not significantly different compared to placebo. 
Mean± sem PRL response following mCPP and placebo were -1687mIU/l-1.min-1 ± 7335 
and-10663mIU/I-1.min-1 ± 3091 respectively (p=0.15). 
4.3.3 EFFECT OF mCPP ON FOOD INTAKE 
mCPP administration was found to have a significant effect on food intake in 
women (Figure 4.5). 
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Figure 4.5. Effect of mCPP on food intake in twelve female volunteers, shown 
as mean± sem kJs consumed. Oral mCPP (0.4mg/kg) had a significant effect 
on food intake in terms of both total energy and macronutrient consumption. 
Paired t test: ** p < 0.01. 
Total calorie consumption in the women was reduced following m CPP 
administration when compared to placebo (mean ± sem: mCPP=2659 .5kJ ± 286.1; 
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placebo=3865.6kJ ± 271.5; p=0.002). Macronutrient intake was similarly reduced 
following mCPP administration when compared to placebo. Reductions in protein intake 
(mean± sem: mCPP=367.2kJ ± 49.7; placebo=572.4kJ ± 47.0; p=0.0007), fat intake (mean 
± sem: mCPP=1051.8kJ ± 159.3; placebo=1578.3kJ ± 160.4; p=0.01) and carbohydrate 
intake (mean± sem: mCPP=1240.3kJ ±119.1; placebo=1715.0kJ ± 128.5; p=0.007) were 
found. 
4.3.4 SUBJECTIVE RA TINGS 
4.3.4.1 Neuroendocrine VA 
An increase in nausea was reported by two women following placebo 
administration, and by all but three women following m CPP administration. Baseline 
nausea ratings in the women were not significantly different between challenges (p=0.15), 
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Figure 4.6. Effect of oral administration of 0.4mg/kg mCPP on VA ratings of 
nausea (a) and anxiety (b), shown as mean± sem. Fisher's test: ** p < 0.01. 
The ANOV A revealed a significant main effect of occasion [i.e. effect of mCPP vs 
placebo] (F=7.63; d.f.=1,5; p=0.02), a significant main effect of time [i.e. variation in 
nausea over time] (F=4.77; d.f.=5,55; p=0.001), and a significant occasion by time 
interaction [i.e. effect of mCPP on variation in nausea over time] (F=3.68; d.f.=5,55; 
p=0.006). At +150 minutes, however, nausea ratings following mCPP administration had 
fallen close to baseline levels and no significant differences between placebo and m CPP 
ratings were seen (mean± sem nausea at+ 150 minutes: placebo=2.42 ± 2.01; mCPP=5.58 
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± 2.04; p=0.20). When measured as AUC-B, differences in nausea ratings for placebo and 
mCPP challenges just failed to reach significance (mean AUC-B ± sem nausea: 
placebo=157.5 ± 134.1; mCPP=1315.4 ± 521.4; p=0.06). 
Four women reported increased anxiety following placebo administration and all 
but three women reported increases after mCPP administration (Figure 4.6b ). Basal anxiety 
ratings were not significantly different between placebo and m CPP challenges (p=0.30). 
The ANOV A revealed no significant main effect of occasion [i.e. effect of m CPP vs 
placebo] (F=2.90; d.f.=1,5; p=0.12), a significant main effect of time [i.e. variation in 
anxiety over time] (F=2.47; d.f.=5,55; p=0.04), but no significant occasion by time 
interaction [i.e. effect of mCPP on variation in anxiety over time] (F=2.12; d.f.=5,55; 
p=0.08). 
Seven women reported increased light-headedness after administration of placebo 
and nine women reported increases after mCPP. Baseline ratings of light-headedness were 
not significantly different between placebo and m CPP challenges (p=0.94), but a 
significant effect of mCPP on light-headedness was seen. The ANOVA revealed a 
significant main effect of occasion [i.e. effect of mCPP vs placebo] (F=8.97; d.f.=1,5; 
p=0.01), a significant main effect of time [i.e. variation in light-headedness over time] 
(F=3.72; d.f.=5,55; p=0.006), and a significant occasion by time interaction [i.e. effect of 
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Figure 4.7. Effect of mCPP on VA ratings of light-headedness (a) and hunger 
(b). Oral administration of 0.4mg/kg mCPP significantly increased ratings of 
light-headedness ( a), and significantly decreased ratings of hunger (b ). Fisher's 




By + 150 minutes, light-headedness ratings were no longer significantly different 
and had fallen to near baseline levels (mean ± sem light-headedness at + 150 minutes: 
placebo=l 1.75 ± 3.67; mCPP=18.25 ± 6.74; p=0.34) 
Following the administration of placebo, all but one woman reported increased 
ratings of hunger and following m CPP administration seven out of the twelve women 
reported an increase. Basal hunger ratings were not significantly different between the two 
challenges (p=0.26), but a significant decrease in hunger followed mCPP administration 
(Figure 4.7b). The ANOVA revealed no significant main effect of occasion [i.e. effect of 
mCPP vs placebo] (F=2.80; d.f.=1,5; p=0.12), a significant main effect of time [i.e. 
variation in hunger over time] (F=3.42; d.f.=5,55; p=0.009), and a significant occasion by 
time interaction [i.e. effect of mCPP on variation in hunger over time] (F=4.35; d.f.=5,55; 
p=0.002). Similarly, when analysed as AUC-B, mCPP administration was followed by a 
significant decrease in hunger ratings (mean± sem hunger: placebo=1531 ± 593; mCPP=-
733 ± 750; p=0.02). Hunger ratings at the end of neuroendocrine testing remained 
significantly different between the two challenges. Mean ± sem hunger at + 150 minutes 
for placebo and mCPP were 60.58 ± 8.52 and 44.08 ± 7.55 respectively (p=0.04). 
In contrast, no significant effects were seen on desire to eat. Seven women 
experienced an increase in desire to eat ratings following placebo administration and three 
women reported a similar increase after mCPP. Baseline desire to eat ratings were not 
significantly different between placebo and mCPP challenges (p=0.10), and no significant 
effect of mCPP on desire to eat was found. The ANOVA revealed no significant main 
effect of occasion [i.e. effect of mCPP vs placebo] (F=0.94; d.f.=1,5; p=0.35), no 
significant main effect of time [i.e. variation in desire to eat over time] (F=2.30; d.f.=5,55; 
p=0.06), and no significant occasion by time interaction [i.e. effect of mCPP on variation 
in desire to eat over time] (F= 1.82; d.f.=5,55; p=0.12). 
Similarly, baseline happiness ratings at placebo and mCPP challenges were not 
significantly different (p=0.16). Happiness following mCPP administration tended to be 
lower than after placebo. The ANOV A revealed a main effect of occasion that just reached 
significance [i.e. effect of mCPP versus placebo] (F=4.63; d.f.=1,5; p=0.05), but no 
significant main effect of time [i.e. variation in happiness over time] (F=l.47; d.f.=5,55; 
p=0.21) and no significant occasion by time interaction [i.e. effect of mCPP on variation in 
happiness over time] (F=l.81; d.f.=5,55; p=0.12). 
Nine out of the twelve women experienced an increase in depression following 
placebo administration while six experienced an increase following mCPP administration. 
Basal depression ratings between the two challenges were not significantly different 
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(p=0.14 ), but m CPP administration was followed by a significant reduction in the rise in 
ratings of depression across the morning when compared to placebo (Figure 4.8). 
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Figure 4.8. Effect of mCPP on VA ratings of depression (shown as mean ± 
sem) in twelve female volunteers. Ratings of depression were significantly 
reduced following mCPP administration when compared to placebo. Fisher's 
test: * p < 0.05; ** p < 0.01 
The ANOVA revealed no significant main effect of occasion [i.e. effect of mCPP 
versus placebo] (F=2.51; d.f.=1,5; p=0.14), a significant main effect of time [i.e. variation 
in depression over time] (F=2.57; d.f.=5,55; p=0.04), and a significant occasion by time 
interaction [i.e. effect of mCPP on variation in depression over time (F=4.59; d.f.=5,55; 
p=0.001). 
4.3.5 CORRELATIONS 
Following mCPP administration, no significant correlation was found between PRL 
response and plasma mCPP drug levels (r=0.39 ; p=0.20). No significant correlation was 
found between nausea ratings (measured as AUC-B) and PRL response for either the 
placebo (r=0.32; p=0.32) or mCPP challenge (r=-0.09; p=0.78). Similarly, no significant 
correlations were found between PRL response and food intake for either placebo or mCPP 
challenges. Correlations between PRL response and food intake following placebo were 
r=0.07; p=0.83 (PRL response versus protein intake); r=0.14; p=0.67 (PRL response 
versus fat intake); r=-0.34; p=0.29 (PRL response versus carbohydrate intake) and r=-0.07; 
p=0.84 (PRL response versus total calorie intake). Following mCPP, correlations between 
PRL response and food intake were not significant at r=0.08; p=0.82 (PRL response versus 
protein intake), r=0.24; p=0.45 (PRL response versus fat intake), r=0.09; p=0.78 (PRL 
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response versus carbohydrate intake) and r=0.18; p=0.57 (PRL response versus total 
calorie intake). 
Nausea ratings were analysed as AUC-B and at + 150 minutes. Correlations 
between nausea ratings and food intake were not significant following placebo 
administration for protein (AUC-B nausea: r=-0.13; p=0.68; + 150 minutes nausea: r=0.11; 
p=0.74), fat (AUC-B nausea: r=-0.29; p=0.35; +150 minutes nausea: r=-0.40; p=0.20), or 
total calorie intake (AUC-B nausea: r=-0.50; p=0.09: +150 minutes nausea: r=-0.50; 
p=0.10). A significant, negative correlation was found between nausea ratings and 
carbohydrate intake following placebo administration (AUC-B nausea: r=-0.65; p=0.02; 
+ 150 minutes nausea: r=-0.60; p=0.04), but examination of the data revealed the 
correlation to be due to a single outlining data point and not therefore a true finding. At 
mCPP challenge, no significant correlations were found between nausea and food intake in 
terms of protein (AUC-B nausea: r=0.06; p=0.85; + 150 minutes nausea: r=0.03; p=0.92), 
fat (AUC-B nausea: r=0.18; p=0.59; +150 minutes nausea: r=-0.19; p=0.56), carbohydrate 
(AUC-B nausea: r=0.01; p=0.97; +150 minutes nausea: r=-0.09; p=0.79) or total calorie 
consumption (AUC-B nausea: r=0.11; p=0.73; +150 minutes nausea: r=-0.13; p=0.68; 
Figure 4.9). 
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Figure 4.9. Correlations between VA ratings of nausea and food intake. No 
significant correlation was seen following the mCPP challenge between nausea 
rating at+ 150 minutes and food intake [total food intake only shown]. 
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Hunger ratings were also analysed as AUC-B and at+ 150 minutes, and correlated 
with food intake. When analysed as AUC-B, no significant correlations were found 
between hunger ratings and food intake following placebo administration in terms of 
protein (r=0.17; p=0.60), fat (r=0.02; p=0.95), carbohydrate (r=0.25; p=0.44) or total 
calorie intake (r=0.16; p=0.62). Similarly, no significant correlations following mCPP 
administration were found between AUC-B hunger ratings and food intake for protein 
(r=0.19; p=0.56), fat (r=0.25; p=0.43), carbohydrate (r=0.17; p=0.59) or total calorie intake 
(r=0.25; p=0.44). When hunger ratings at +150 minutes were correlated with food intake 
however, significant correlations were found. Following placebo administration, a 
significant correlation was found between hunger and protein intake (r=0.62; p=0.03) and 
between hunger and total calorie intake (r=0.63; p=0.03), but not between hunger and fat 
(r=0.43; p=0.16) or carbohydrate intake (r=0.56; p=0.06). Following mCPP administration, 
hunger ratings at + 150 minutes were significantly and positively correlated with both fat 
(r=0.63; p=0.03; Figure 4.10b) and total calorie consumption (r=0.60; p=0.04; Figure 
4.10a), but no significant correlations were seen between hunger at + 150 minutes and 
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Figure 4.10. Correlations between ratings of hunger and food intake following 
mCPP administration. A significant positive correlation was found between 
VA ratings of hunger at + 150 minutes and both fat (b) and total food intake 
(b). 
VA ratings of light-headedness were analysed as AUC-B and at 150 minutes. 
Following placebo challenge, no significant correlation was found between light-
headedness and protein (AUC-B light-headedness: r=0.08; p=0.80; light-headedness +150 
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minutes: r=0.53; p=0.08), fat (AUC-B light-headedness: r=-0.31; p=0.33; light-headedness 
+150 minutes: r=0.14; p=0.66) or total food consumption (AUC-B light-headedness: r=-
0.45; p=0.14; light-headedness+ 150 minutes: r=0.13; p=0.69). A negative correlation, just 
reaching significance, was found after placebo administration between light-headedness 
(measured as AUC-B) and carbohydrate intake (r=-0.60; p=0.04; Figure 4.lla), but failed 
to reach significance when light-headedness was measured at + 150 minutes (r=-0.10; 
p=0.76). Following mCPP administration, a significant positive correlation was found 
between light-headedness at +150 minutes and fat intake (r=0.65; p=0.03; Figure 4.1 lb) 
but not between AUC-B light-headedness and fat intake (r=0.25; p=0.43). No significant 
correlation was seen following mCPP administration between ratings of light-headedness 
and protein (AUC-B light-headedness: r=0.07; p=0.83; light-headedness + 150 minutes: 
r=0.003; p=0.99), carbohydrate (AUC-B light-headedness: r=0.19; p=0.55; light-
headedness at + 150 minutes: r=0.33; p=0.29) or total food intake (AUC-B light-
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Figure 4.11. Significant correlations between VA ratings of light-headedness 
and food intake in twelve female volunteers. A significant, negative 
correlation was found following placebo administration between ratings of 
light-headedness (measured as AUC-B) and carbohydrate intake (a). A 
significant, positive correlation was found between light-headedness and fat 
intake in women following mCPP administration (b ). 
Depression ratings were similarly analysed as AUC-B and at +150 minutes. 
Following placebo administration, no significant correlation was found between ratings of 
AUC-B depression and food intake (protein: r=-0.01; p=0.96; fat: r=0.33; p=0.29; 
carbohydrate: r=0.33; p=0.30; total intake: r=0.35; p=0.27). When depression was 
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measured at+ 150 minutes, a significant positive correlation was found between ratings of 
depression and protein intake after placebo (r=0.62; p=0.03), but not for other measures of 
food intake (fat: r=0.34; p=0.27; carbohydrate: r=0.54; p=0.07), although a trend towards a 
positive correlation was seen between depression at + 150 minutes and total food intake 
(r=0.56; p=0.06). Following mCPP administration, no significant correlation was found 
between AUC-B depression and food intake (protein: r=-0.18; p=0.57; fat: r=0.20; p=0.53; 
carbohydrate: r=0.08; p=0.80; total intake: r=0.12; p=0.72), but when depression ratings 
were analysed at + 150 minutes, a significant positive correlation was seen between ratings 
of depression and fat intake and between depression and total food consumption (fat: 
r=0.63; p=0.03; total intake: r=0.61; p=0.03). No significant correlation was seen between 
depression ratings at +150 minutes and protein (r=0.44; p=0.16) or carbohydrate intake 
(r=0.45; p=0.14). 
mCPP drug levels did not significantly correlate with food intake, in terms of 
protein (r=-0.11; p=0.74), carbohydrate (r=-0.14; p=0.66), and fat intake (r=0.04; p=0.91) 
or in terms of total energy consumption (r=-0.06; p=0.86). No significant correlation was 
found between mCPP drug levels and nausea ratings (nausea (AUC-B): r=0.48; 
p=0.11;.nausea +150 minutes: r=0.17; p=0.61), or between mCPP drug levels and ratings 
of light-headedness (light-headedness (AUC-B): r=58; p=0.05; light-headedness + 150 
minutes: r=0.02; p=0.95). Similarly, no significant correlation was found between mCPP 
plasma levels and ratings of hunger when analysed as AUC-B hunger (r=-0.48; p=0.12) or 
hunger at+ 150 minutes (r=-0.26; p=0.41), or between mCPP plasma levels and ratings of 
depression (depression at +150 minutes: r=-0.34; p=0.29; depression AUC-B: r=-0.34; 
p=0.27). 
4.4 DISCUSSION 
Administration of oral mCPP at a dose of 0.4mg/kg was found to significantly 
increase plasma PRL in women, a finding in keeping with both animal and human data 
demonstrating enhanced PRL responses to mCPP (Aloi et al, 1984; Mueller et al, 1985; 
Bagdy et al, 1989b ). The results add further support to recent data suggesting that smaller 
doses than those originally described in the literature appear capable of stimulating PRL 
release in women. Earlier human studies had suggested that consistent mCPP-induced PRL 
responses followed administration of oral doses between 0.5 and 0.75mg/kg, with only 
marginal effects seen at 0.25mg/kg (Mueller et al, 1985; Murphy et al, 1989; Kahn et al, 
1990). The present results with 0.4mg/kg however, coupled with the findings of the pilot 
study (approximately 0.13 and 0.24mg/kg oral) and the mCPP diet study in women 
(0.04mg/kg intravenous), suggest that consistent and reliable PRL release is seen in 
females after substantially lower oral and intravenous doses than those previously reported. 
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The results are also consistent with data suggesting gender differences in m CPP-
induced PRL release in humans. Two previous studies have found lower mCPP plasma 
concentrations per given dose in women compared to men, although the lower plasma 
levels in women were followed by greater PRL release (Charney et al, 1987; Kahn et al, 
1991). It has been suggested that circulating oestrogens in women may be responsible for 
potentiating mCPP-induced PRL release, as similar PRL potentiation has been reported 
with other 5-HT challenge drugs (Charney et al, 1987; Kahn et al, 1991; O'Keane et al, 
1991). Indeed, reports of oestradiol potentiation of PRL led to the decision to exclude 
results of any women found to have been tested out of phase in terms of menstrual cycle, 
although in this study no exclusions were necessary. 
The significant increase in PRL response following mCPP administration cannot be 
explained by baseline differences in PRL, as basal PRL levels were not significantly 
different at placebo and mCPP challenge. Increased PRL release may accompany a "stress" 
reaction, but this explanation is also unlikely to account for the current findings. 
Significant increases in ratings of nausea and light-headedness were seen following mCPP 
administration compared to placebo, but the increases were transient and in keeping with 
ratings seen following other 5-HT challenge drugs (for further discussion, see below). 
Furthermore, no significant correlations were found between ratings of nausea and light-
headedness (when assessed as either AUC-B and absolute rating at + 150minutes) and 
subsequent PRL response. 
mCPP administration to women led to a significant reduction in food intake. Food 
intake was decreased in terms of total calorie consumption and for all the macronutrients 
measured i.e. protein, fat and carbohydrate. The finding of a decrease in total calorie 
consumption is in keeping with other studies using drugs that enhance brain 5-HT 
neurotransmission. To date, most studies looking at the effects of serotonin on food intake 
in humans have used the 5-HT releasing drug d-fenfluramine. Administration of d-
fenfluramine to both lean and obese subjects has been shown to reduce total food intake by 
11 % to 40%, depending upon experimental design (Blundell and Hill, 1991). Reported 
effects on macronutrient intake, however, have been more variable. While a reduction in 
carbohydrate consumption is the most consistent finding following d-fenfluramine 
administration, decreases in both fat and protein intake have also been reported. A study by 
Wurtman et al (1985), demonstrated a reduction in high fat/carbohydrate foods amongst 
obese subjects after d-fenfluramine administration, while both total calorie intake and fat 
consumption were reduced in healthy males following d-fenfluramine ( Goodall et al, 
1993). In a study by Hill and Blundell (1986), a significant reduction in all three 
macronutrients was found, while again in contrast, no effect on fat consumption followed 
d-fenfluramine administration to male subjects in another study by Goodall et al (1993). 




mCPP at a dose of 0.4mg/kg is consistent with some reports in the literature with d-
fenfluramine. While significant reductions in total calorie, carbohydrate and fat intake are 
more frequently reported, reductions in protein consumption have been found. Indeed a 
recent paper by Baumann et al (1993), suggested a common mechanism of action (through 
pre-synaptic release of 5-HT) for mCPP, the trifluoromethyl analog of mCPP 1-(m-
trifluoromethylphenyl)piperazine, and d-fenfluramine in mediating PRL release in the rat. 
It is possible that the presence of a common mechanism of action on serotonergic 
pathways is also reflected in similar effects on food intake. 
The present finding of a significant effect of 0.4mg/kg mCPP on food intake is in 
contrast to the findings of the pilot study. However, the most likely explanation for the 
failure to find an anorectic effect in the pilot study is the low dose of mCPP employed, as 
both animal and human data utilising 5-HT drugs have suggested dose threshold effects for 
the induction of anorexia. For example, d-fenfluramine shows a dose-response suppression 
of food intake in humans (Silverstone et al, 1975) while in rats, although the dose required 
to produce an anorectic effect is more dependent upon experimental conditions of food 
restriction, a similar threshold effect is seen with both d-fenfluramine(Campbell, 1991) and 
mCPP (Leibowitz and Shor-Posner, 1986). 
Serotonergic drugs, such as mCPP and d-fenfluramine are thought to exert their 
effects on food intake through specific satiety mechanisms. For example, administration of 
d-fenfluramine to obese and lean subjects has been shown to reduce meal size while 
prolonging satiety, as reflected in a decreased number of between meal snacks (Blundell 
and Hill, 1991). A recent study by Kennett and Curzon (1988a), suggested that mCPP's 
ability to reduce food intake in rats occurs by a similar mechanism. Administration of 
mCPP to rats was followed by a significant reduction in food intake and an increase in the 
behavioural satiety sequence, a behaviour normally displayed by free feeding rats on 
reaching satiety. The authors concluded that their results supported the hypothesis that 
mCPP-induced hypophagia does occur specifically through satiety mechanisms, rather 
than through general behavioural effects such as reduced locomotion, which may in turn 
decrease food intake. 
Subjective aspects of eating behaviour including measures of satiety have attracted 
less research. In the present study, VA ratings were utilised to assess some subjective 
aspects of eating behaviour. VA ratings of hunger, but not desire to eat, were significantly 
reduced following mCPP administration when compared to placebo. While the 
interpretation of these subjective experiences in humans is complex, Silverstone and 
Goodall (1986), suggests that hunger is a measure of the psychological sensations that 
accompany food deprivation, while desire to eat is a more accurate measure of "appetite" 




upon the theory that 5-HT drugs act purely on satiety mechanisms involving the 
termination of feeding (see section 1.2.3.1), it could be argued that no effect on hunger but 
some effect on desire to eat should follow m CPP administration, in direct contrast to the 
finding of the present study. Reports in the literature with other 5-HT drugs, however, do 
not clearly follow this pattern. Oral d-fenfluramine administration, like mCPP in the 
present study, has led to significant decreases in hunger ratings, although the changes 
appear somewhat variable. Goodall and Silverstone (1988a), found significant reductions 
in hunger motivation amongst normal weight subjects, during the period between dosing 
with acute d-fenfluramine and being offered a test meal, while Hill and Blundell (1986), 
also reported decreases in hunger ratings following d-fenfluramine administration amongst 
human subjects both before, during and after a test meal. In contrast, 60mg of oral d-
fenfluramine led to significant reductions in the ratings of desire to eat, but not in ratings 
of hunger, amongst healthy volunteers in a study by (Silverstone and Goodall, 1986). Thus 
it would appear that drugs such as d-fenfluramine which exert their anorectic effects via 
satiety mechanisms also produce significant ratings of subjective hunger. The present 
findings with mCPP are in keeping with this. 
The finding of a reduction in food intake provides further data in support of the 
theory that serotonergic pathways are involved in the control of human feeding behaviour. 
More specifically, it suggests a role by 5-HT 2c receptors in mediating these effects. The 
findings are in keeping with animal data which has highlighted the role of 5-HT lB/ZC 
receptors in appetite control in the rat (see section 1.2.3.1). Moreover, they are consistent 
with human work in which the 5-HT ZA/ZC receptor antagonist ritanserin was found to block 
d-fenfluramine-induced anorexia, suggesting a role by 5-HT 2 receptors in the control of 
food intake in humans (Goodall et al, 1993). While similarities between mCPP and d-
fenfluramine on food intake could be explained by a shared mechanism of direct post-
synaptic agonist activity by mCPP and d-norfenfluramine at 5-HT 2c receptors (since d-
norfenfluramine exhibits modest affinity for these receptors), the recent paper by Baumann 
et al (1993), raises a possible alternate shared mechanism of action. Findings suggested 
that mCPP, like d-fenfluramine, is capable of stimulating pre-synaptic release of 5-HT and 
that such a mechanism of action may underlie partial control of mCPP-induced PRL 
release. Pre-synaptic enhancement of 5-HT neurotransmission, possibly acting through 5-
Hf 2 receptors, may also mediate mCPP and d-fenfluramine effects on food intake. 
An alternative explanation for the reduction in food intake must, however, be 
considered. The finding of significant increases in nausea and light-headedness following 
mCPP administration raises the possibility that the decrease in food intake occurred 
secondary to a more general effect on behaviour (i.e. the subjects feeling unwell) and not 
as a consequence of 5-HT-mediated anorexia. Consideration of the nausea ratings just 
before the meal ( + 150 minutes) show that they had returned to near baseline levels and 
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were not significantly different when placebo and m CPP challenges were compared. 
Furthermore, although a significant, negative correlation was found between carbohydrate 
intake and nausea ratings at+ 150 minutes following placebo, indicating that the higher the 
nausea rating the less the amount of carbohydrate eaten, no significant correlation was 
found between nausea ratings (either+ 150 minutes nausea and AUC-B nausea) and food 
intake following mCPP administration. 
VA ratings of light-headedness were also significantly increased following mCPP 
when compared to placebo, but the effects were again transient. By + 150 minutes, ratings 
of light-headedness had fallen close to baseline readings and were no longer significantly 
different from placebo ratings. Moreover, no consistent correlation was found between 
light-headedness and food intake. Following placebo administration, a negative 
correlation, just reaching significance, was seen between AUC-B (but not+ 150 minutes) 
light-headedness and carbohydrate intake indicating that the greater the light-headedness, 
the less the consumption of carbohydrate at test meal. In contrast, mCPP administration 
was followed by a significant positive correlation between ratings of light-headedness at 
+150 minutes (but not AUC-B light-headedness) and fat intake, suggesting that the greater 
the experience of light-headedness, the greater the consumption of fat. 
Other behavioural changes reflected in the VA ratings that might be expected to 
affect food intake were those of anxiety and depression. While a significant increase in 
anxiety over time was seen, no specific effect of m CPP was seen on the ratings. In 
contrast, mCPP administration did lead to a significant decrease in the rate of rise in 
depression ratings seen following both challenges across time. While significant 
correlations were seen between ratings of depression and fat and total food consumption 
following mCPP administration, the correlation was positive such that the greater the 
rating of depression, the greater the consumption of fat and food overall. It could be argued 
that such a correlation would work against the main finding of a decrease in food 
consumption after mCPP administration. 
The findings outlined above suggest that no consistent significant effect on general 
behavioural ratings, apart from positive correlations between food intake and depression 
and hunger ratings were seen following mCPP administration. While hunger ratings 
closely paralleled subsequent food intake and can be seen to reflect specific effects upon 
satiety, the influence of the correlation between depression and food intake would have 
been to minimise the overall decrease in food consumption seen after m CPP 
administration. The findings suggest that the mCPP-induced hypophagic effect observed in 
females was unlikely to have occurred secondary to a more general effect upon behaviour. 
The current finding is in keeping with work by Kitchener and Dourish (1994) who 
demonstrated that mCPP-induced hypophagia in rats is accompanied by specific satiety 
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behavioural patterns, in contrast to administration of the 5-HT 2 agonist DOI and the 5-
Hf 18 agonist RU 24969. Administration of the latter drugs also induces hypophagia but 
does not produce behavioural profiles that resemble satiety, suggesting that these drugs' 
effect on food intake occur through general behavioural changes (such as hypoactivity), in 
contrast to m CPP-induced hypophagia which is mediated primarily through satiety 
mechanisms. Further support for the idea that mCPP acts through specific satiety 
mechanisms comes from another study in rats in which mCPP-induced hypophagia was 
unaffected by pre-treatment with an anti-emetic drug, suggesting that nausea was not the 
underlying mechanism leading to a decrease in food intake ( Silverstone and Feeney, 
1989). 
While overall the data strongly suggests that the decrease in food intake seen in 
women following m CPP administration was mediated through effects on satiety as 
reflected in subjective ratings of hunger, what is not possible to rule out is the situation 
where an earlier experience of feeling ill continues to render a person unwilling to eat, 
even after subjective feelings of nausea and light-headedness have returned to normal. It 
could be argued that the finding of a overall reduction in food consumption supports this 
hypothesis, as a purely serotonergic drug would be expected to reduce total calorie intake 
and to have a more selective effect upon macronutrient intake, although the literature 
outlined above does suggest that 5-HT drug effects on macronutrient intake can be 
somewhat variable. 
4.5 CONCLUSIONS 
An oral mCPP dose of 0.4mg/kg was found to significantly increase plasma PRL in 
women, adding to the data that the 5-HT agonist drug mCPP consistently enhances PRL 
release in humans. The finding of a reliable PRL response to 0.4mg/kg mCPP, supports 
earlier findings that gender differences exist for the drug. Lower doses than those 
originally reported appear sufficient in producing reliable PRL responses in women. 
A decrease in food intake also followed the administration of 0.4mg/kg mCPP in 
women. The reduction in food consumption was characterised by a decrease in total 
calories and a decrease in all macronutrients measured i.e. protein, fat and carbohydrate, a 
finding in keeping with some reports in the literature following administration of the 5-HT 
releasing drug, d-fenfluramine. Decreases in food intake were accompanied by decreases 
in VA ratings of hunger suggesting specific effects on satiety. While no consistent effects 
upon general behaviour were seen that might in itself affect food intake, it is not possible 
to rule out the possibility that an earlier experience of increased nausea and light-
headedness continued to influence food intake, leading to a reduction in food consumption. 
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The finding that mCPP administration induces anorexia, provides further evidence 
in support of the theory that 5-HT pathways are involved in the control of food intake in 
humans. More specifically, it suggests a role by 5-HT zc receptors in mediating these 
effects, either through direct agonist activity at post-synaptic receptor level or possibly 




EFFECT OF ACUTE TRP DEPLETION 
ON MOOD AND FOOD INTAKE IN 
HEALTHY AND RECOVERED 
BULIMIC FEMALE SUBJECTS 
5.1 INTRODUCTION 
The data reviewed in Chapter One provide strong evidence in support of the 
hypothesis that serotonergic dysregulation occurs during clinical episodes of the eating 
disorder bulimia nervosa (see section 1.3.2 for a full review). For example, decreased 
levels of the major 5-HT metabolite, 5-HIAA, have been reported in the CSF of bulimic 
patients compared to controls (Jimerson et al, 1988). Increased platelet 5-HT reuptake 
compared to controls has also been reported, suggesting decreased availability of 5-HT at 
post-synaptic receptors (Goldbloom et al, 1990). Neuroendocrine studies have 
demonstrated blunted PRL responses to the 5-HT agonist mCPP and to the 5-HT releasing 
drugs dl- and d-fenfluramine in both acutely ill and recently recovered bulimic patients, 
again suggesting reduced brain 5-HT function (McBride et al, 1991; Brewerton et al, 
1992). 
It can also be argued that hyposerotonergic activity is consistent with the development 
of many of the behavioural disturbances that accompany bulimia nervosa. Low CSF 5-
HIAA levels have been linked to a greater frequency of bingeing and purging behaviour 
(Jimerson et al, 1988), while a study by Kaye et al (1988), suggested a direct relationship 
between the development of satiety ( defined as the cessation of bingeing and vomiting) 
and the ratio of plasma TRP:LNAA amongst a group of nine actively bingeing bulimic 
patients. The author suggested that when bingeing behaviour led to an increase in the ratio 
of plasma TRP:LNAA, patients experienced satiety and no longer continued to binge. In 
those patients where no increase in TRP:LNAA ratio was demonstrated, satiety was not 
reported and patients continued to binge and purge. The underlying mechanism leading to 
the development of satiety was thought to be an increase in brain 5-HT neurotransmission 
as evidenced by a greater PRL response, secondary to an increased plasma TRP:LNAA 
ratio in patients reporting satiety compared to those patients who did not increase their 
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TRP:LNAA ratio. The observation that many eating disordered patients choose to binge on 
high carbohydrate foods further suggests that bingeing may function as a mechanism 
enabling patients to raise their brain 5-HT levels. Carbohydrate consumption is known to 
cause insulin secretion which in turn promotes the uptake of branch chain amino acids into 
muscle. This process leads to an increase in the ratio of plasma TRP:LNAA, thus 
increasing transportation of TRP across the blood-brain barrier and enhancing brain 5-HT 
synthesis (see section 1.2). 
Further support for a role of hyposerotonergic activity in the development of the eating 
disorders comes from the area of appetite research involving the pharmacological 
manipulation of brain 5-HT function. While one of the most consistent findings in this 
field of research has been a decrease in food consumption following experimental 
proceduresthat either directly or indirectly increase brain 5-HT function, the converse i.e. 
an increase in food consumption following brain 5-HT depletion, also holds true 
(Silverstone and Goodall, 1986; Fuller and Wong, 1989; Leibowitz, 1990). Moreover, 
clinical studies utilising selective 5-HT reuptake inhibitor antidepressant drugs in the 
treatment of bulimia nervosa have demonstrated consistent and significant improvements 
in both low mood and bingeing/purging behaviour, suggesting benefit from the drugs' 
ability to enhance brain 5-HT neurotransmission (Fluoxetine Bulimia Nervosa 
Collaborative Study Group, 1992; Linnoila etal, 1992). 
Blunted neuroendocrine responses to 5-HT challenge drugs, suggesting decreased 5-
HT neurotransmission, have consistently been reported in affective illness, especially 
depression (Deakin, 1991; Deakin and Graeff, 1991; Power and Cowen, 1992), and 
symptoms of low mood along with an increased lifetime risk of major depression are well 
recognised features of bulimia nervosa (Fairburn and Cooper, 1984; Fairburn and Beglin, 
1990). For a subgroup of patients with bulimia nervosa, disorders of impulsivity such as 
shop-lifting, self harm, sexual promiscuity and alcohol abuse are commonplace. Such 
behaviours have been linked to low brain 5-HT function as increasing evidence suggests 
that serotonin exerts a restraining role on behaviour in general (Shaw et al, 1967; Linnoila 
et al, 1992). 
The data reviewed in Chapter One suggests that many cases of clinical eating 
disorders, including bulimia nervosa, develop from "normal" periods of dieting in which 
control has been lost (see section 1.1.4). Furthermore, in Chapter Three it was 
demonstrated that periods of moderate calorie restriction are often associated with falls in 
plasma TRP, and one hypothesis put forward suggests that a reduction in plasma TRP 
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leads to a decrease in brain 5-HT function in female dieters (see section 3.4 for a full 
discussion). Thus dieting-induced falls in plasma TRP and the resultant decrease in brain 
5-HT function may represent a key neurobiological mechanism that contributes to the 
development of eating disorders in vulnerable women ( Cowen et al, 1992). 
Animal studies have demonstrated that dietary manipulations which acutely lower 
plasma TRP produce decreases in brain 5-HT turnover in both rodents and non-human 
primates (Young et al, 1989; Gartside et al, 1992). In a study by Delgado et al (1989), 
acute depletion of plasma TRP in humans by a low TRP diet was shown to produce an 
alteration in the PRL response to a TRP infusion, suggesting a similar decrease in brain 5-
HT function occurs in humans. Acute TRP depletion has also been achieved by the use of 
amino acid mixtures deficient in TRP. The use of such mixtures has been shown to 
produce a fall in plasma TRP and thus a decrease in the plasma TRP:LNAA, which in turn 
leads to a reduced uptake of TRP into the brain (see section 2.2). Studies utilising the 
amino acid mixture have demonstrated a effective and similar magnitude of reduction in 
free and total plasma TRP following 100g and 52g amino acid drinks (Young et al, 1985; 
Delgado et al, 1990; Oldman et al, 1994 ), and have shown that acute TRP depletion is 
associated with a lowering of mood in both healthy (Young et al, 1985) and newly 
recovered depressed patients maintained on antidepressants (Delgado et al, 1990 ), 
although these findings have not been universally consistent (Oldman et al, 1994 ). The 
effect of acute TRP depletion on appetite and food intake in humans, however, has not 
been widely examined. In one study by Young et al (1988), the effects of a 100g amino 
acid drink deficient in TRP on food intake were examined in healthy young males. In 
contrast to what would be expected from the animal data, acute TRP depletion was found 
to have no effect on total food intake or carbohydrate consumption, but did lead to a 
significant reduction in protein selection at a subsequent buffet style meal. No published 
studies to date have examined the effects of acute TRP depletion on mood and appetite in 
healthy women. 
The data from studies utilising amino acid drinks in depressed patients suggest that 
TRP depletion is associated with a rapid return of previous depressive symptomatology. 
Acute TRP depletion in women recovered from bulimia nervosa, therefore, could also be 
expected to lead to a return of the symptoms associated with the disorder. More 
specifically, it could be hypothesised that TRP depletion would lead to a lowering of mood 
and alterations in the subjective experience of satiety, which in turn would be reflected in 
an increased consumption of food at test meal. 
148 
,,, 
The aim of the present study was, therefore, to examine the effects of acute TRP 
depletion on mood and food intake in healthy female subjects and in women who had 
recovered from a previous episode of bulimia nervosa. The study utilised a 52g amino acid 
drink mixture deficient in TRP, as this mixture had previously been shown to produce a 
fall in plasma TRP of similar magnitude to the 100g drink (see section 2.2.2), while being 
far better tolerated by female subjects and causing a much reduced rate of nausea and 
vomiting (Oldman etal, 1994). 
5.2METH0DS 
5.2.1 SUBJECTS AND EXPERIMENTAL DESIGN 
5.2.1.1 Healthy Female Volunteers 
Twelve healthy female volunteers were recruited as described under the Selection and 
Assessment of Subjects section in Chapter Two. In addition, subjects were carefully 
screened to ensure normal dietary habits. Strict vegetarians were also excluded. Volunteers 
were aged between nineteen and twenty-seven years (mean± sem.=22.3years ± 0.8), and 
were all of normal weight for height as determined by a body mass index (mean ± sem. 
body mass index=23.0 ± 0.98; range=17.4-29). All subject gave written, informed consent 
to participating in the study which had been approved by the local ethics committee. 
Using a within-subject [i.e. examining the effects of TRP depletion on individual 
groups of control and recovered bulimic subjects] and between-subject [i.e. comparing the 
effects of TRP depletion on recovered bulimic subjects with the effects of TRP depletion 
on control subjects] comparison design, the study involved examining the effects of a TRP 
depletion condition (T-), a balanced amino acid condition (B) and a placebo control 
condition (P) on mood changes across the morning and on appetite and food intake, as 
measured by a test meal procedure. The experimental conditions were achieved by the use 
of amino acid drinks (see below), with subjects undergoing testing on three separate 
occasions approximately one week apart. In order to avoid the late luteal phase of the 
menstrual cycle, all test sessions were carried out between day three and day twenty-one. 
As for most subjects this meant running the study over two consecutive menstrual cycles, 
randomisation of the different drinks in terms of menstrual cycle phase was also carried 
out to ensure no systematic bias occurred. 
The highly distinctive consistency and taste of the two amino acid drink mixtures 
meant it was always possible for subjects to distinguish them from the (P) condition (but 




condition always given first in a single-blind fashion. The final two test sessions were 
carried out in double-blind cross-over design (Table 5.1). 
Table 5.1. Design of TRP depletion study in healthy volunteers 
Group Size Session 1 Session 2 Session 3 
6 Placebo (B) Mixture (T-) Mixture 
6 Placebo (T-) Mixture (B) Mixture 
5.2.1.2 Subjects Recovered From Bulimia Nervosa 
Eight female subjects were recruited as described under the Selection and Assessment 
of Subjects section in Chapter Two. All subjects had previously met criteria for DSM-IIIR 
Bulimia Nervosa but had now recovered. Subjects had met recovery criteria (as defined in 
section 2.4.2.2 in Chapter Two) for a mean period of six years (range=6months-27years), 
and none had received psychotropic medication within the previous twelve months. Six of 
the women had previously met criteria for DSM-IIIR affective disorder, while three had a 
family history of affective illness. Subjects were aged between twenty-four and fifty-two 
years (mean ± sem age=32.4years ± 3.4), and were all of normal weight for height as 
determined by body mass index (mean ± sem body mass index=24.8 ± 1.13; range=2 l. l -
29 .1 ). Six of the eight recovered bulimic patients had normal menstrual cycles, one had 
previously undergone hysterectomy but was still able to recognise a regular monthly 
pattern of mood and physical changes suggestive of a menstrual cycle. The remaining 
female subject was post-menopausal and on hormone replacement treatment. All subjects 
gave written, informed consent to participating in the study which had been approved by 
the local ethics committee. 
The experimental design of the study was identical to that outlined above for the 
healthy volunteers and is summarised below in Table 5.2. 
Table 5.2. Design of TRP depletion study in recovered bulimic patients 
Group Size Session 1 Session 2 Session 3 
4 Placebo (B) Mixture (T-) Mixture 
4 Placebo (T-) Mixture (B) Mixture 
5.2.2 ACUTE TRP DEPLETION PROCEDURE 
5.2.2.1 Composition of Amino Acid Drink 
The procedure for TRP depletion was based on the method described by Young et al 




experimental drink consisted of fifteen amino acids in the same ratio as those found in 
human milk, but with aspartic acid and glutamic acid omitted because of concerns about 
their toxicity. The control drink, designed to be nutritionally balanced, consisted of the 
same composition of amino acids to which had been added 1.15g of TRP. The final weight 
of the mixture was 51.25g for the experimental drink and 52.40g for the control drink. 
Thus, apart from being only half the dose, the composition of the amino acid drinks were 
similar to the 1 OOg drink described by Young et al ( 1985). 
The amino acid powder was prepared for consumption immediately prior to drinking. 
300ml of cold water, to which had been added 12.5mg of saccharin and blackcurrant 
flavouring, was mixed into the powder and the ensuring suspension served in a standard 
drinking glass with a straw. Subjects were asked to consume the entire drink and then 
allowed to rinse their mouths with water and if they desired, chew sugar free gum for thirty 
minutes to remove the taste. 
Table 5.3. Amino acid composition of drink. 








L-Lysine monohydrochloride 5.5g 
L-methionine 1.5g 







5.2.2.2 General Procedure 
Volunteers were requested to eat normally during the day preceding the test but to fast 
from midnight, although a small amount of water was allowed prior to the test session. 
Subjects were brought to the laboratory at 08.30 am and placed in a quiet room on their 
own. After a settling in period of ten minutes, baseline VA ratings for mood were obtained 
and a venous blood sample taken for estimation of plasma total and free TRP. Subjects 
were then given one of the three drinks and returned to their room where they rested 
quietly for the next 4.5 hours. During this time, VA ratings of mood were presented to all 
subjects at hourly intervals in the standardised manner outlined in Chapter Two. At +4.5 
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hours pre-meal VA ratings of appetite were filled out by the subjects and a further blood 
sample taken for plasma total and free TRP level estimation. 
5.2.3 TEST MEAL PROCEDURE 
After the second blood sample had been taken, subjects were placed back in the room 
at a table. The test meal consisted of a buffet lunch which contained a range of foods of 
different macronutrient content, with each food portion being presented to excess (see 
section 2.3.3.1 for full details). Meal instructions were given by the author in the 
standardised manner outlined in section 2.3.3.1. The food was then presented on trays in 
the standardised format and placed on the table in front of the subject. Subjects were left 
alone to eat and asked to come out of the room when they had finished their meal. The 
trays were then removed without comment and post-meal VA ratings of mood and appetite 
given to the subject for completion. Food not consumed was weighed and calorie 
consumption calculated as outlined in section 2.3.3.1. The test procedure is summarised 
below in Table 5.4. 
Table 5 .4. Summary of test procedure 
Time Measure/procedure 
08.30 Arrival of subject and settled into test room 
08.40 Baseline VA ratings of mood completed (VAs and 
POMS) 
08.50 Fasting blood sample for plasma total and free TRP 
estimation 
09.00 Administration of drink 
09.30-13.30 VA ratings of mood completed at hourly intervals (V As 
andPOMS) 
13.30 Pre-meal VA ratings of appetite completed 
13.35 Blood sample for +4.5hour plasma total and free TRP 
estimation 
13.40 Test meal followed by post-meal VA ratings of appetite 
14.15 End of session. Subject returned home by taxi 
5.2.4 SUBJECTIVE MEASURES 
5.2.4.1 Measures of Mood 
Mood was measured using a combination of VA ratings (Appendix 5.1) and the Profile 
of Mood State Questionnaire (POMS) which had been amended to examine current mood 
(Appendix 5.2). The VA rating forms of mood (despondent/sad; anxious; irritable and 
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tense), were presented in the standard manner as outlined in section 2.3.4, at baseline 
(08.40 hours) and then at hourly intervals across the morning until 13.30 hours. The POMS 
was presented at baseline (08.30 hours) and again at 13.30 hours. 
5.2.4.2 Measures of Appetite 
VA ratings of hunger were presented hourly across the morning from baseline to 
13.30. Pre- and post-meal VA rating scales (wish to eat, hunger, feel full and find/found 
meal satisfying) were used to measure satiety before and after completion of the test meal 
respectively (Appendix 5.3). VA rating scales of appetite were presented to subjects in the 
standardised manner outlined in section 2.3.3. 
5.2.5 BIOCHEMICAL MEASURES 
10ml venous blood samples were collected into heparin tubes and immediately 
separated by centrifugation. Plasma samples were stored at -30° C until assay. Plasma total 
and free TRP levels were determined by fluorometric detection according to the method of 
8Bloxam and Warren (1974) and Bloxam et al (1977) as outlined in section 2.3.2.6. 
5.2.6 STATISTICAL ANALYSIS 
The data were analysed with a two or three way repeated measures analysis of 
variance using both within and between subject comparisons, with Greenhouse-Geisser 
(Greenhouse and Geisser, 1959) correction for repeated measures. The factors analysed 
were group (bulimic patients versus controls), condition [(P), (B) and (T-) drinks] and 
time. Significant F values were followed up with post-hoc t-tests. 
5.3RESULTS 
5.3.1 AMINO ACID DRINK ADMINISTRATION IN HEALTHY 
FEMALE SUBJECTS 
5.3.1.1 Effect of Placebo and Amino Acid Drinks on Plasma TRP Levels 
Plasma concentrations of total and free TRP were analysed by three way repeated 
measures analysis of variance. Baseline plasma total TRP levels were not significantly 
different for the three conditions (mean± sem baseline total TRP: (T-)=13.26µg/ml ± 0.75; 
(B)=13.08µg/ml ± 0.72; (P)=12.98µg/ml ± 0.63; p>0.05). The ANOVA on total TRP 
following (P) and amino acid drink administration revealed a significant main effect of 
condition [i.e. effect of (T-) versus (B) versus (P) drinks] (F=33.77; d.f.=2,22; p<0.001), a 
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significant main effect of time [i.e. variation of plasma total TRP over time] (F=45.13; 
d.f.=2,22; p<0.001) and a significant condition by time interaction [i.e. effect of (T-), (B) 
and (P) drinks on variation in plasma total TRP over time] (F=45.13; d.f.=2,22; p<0.001). 
Post-hoc testing revealed that while no significant difference between baseline and +4.5 
hour plasma total TRP was found following the (B) drink condition (mean ± sem total 
TRP: baseline=l3.08µg/ml ± 0.72; +4.5 hours=15.42µg/ml ± 1.48; p>0.05; Figure 5. la), a 
significant decrease in plasma total TRP concentration between baseline and +4.5 hours 
followed administration of the (T-) drink (mean± sem total TRP: baseline=13.26µg/ml ± 
0.75; +4.5 hours=2.89µg/ml ± 0.72; p<0.0005; Figure 5.la) and the (P) drink condition 
(mean ± sem total TRP: baseline=l2.98µg/ml ± 0.63; +4.5 hours=9.93µg/ml ± 0.63; 
p<0.0005; Figure 5.la). Following the (T-) condition, a 78% decrease in plasma total TRP 
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Figure 5.1. Effect of (P) and amino acid drinks on plasma total (a) and free (b) 
TRP shown as mean ± sem at time O and time +4.5 hours. A significant fall in 
plasma total and free TRP followed administration of the (T-) drink condition. 
Paired t test: ** p < 0.0005; * p < 0.001. 
Basal plasma free TRP concentrations were not significantly different between the 
three conditions (mean ± sem baseline plasma free TRP: (T-)=0.91µg/ml ± 0.09; 
(B)=0.88µg/ml ± 0.09; (P)=0.84µg/ml ± 0.08; p>0.05), but the ANOV A following (P) and 
amino acid administration revealed a significant main effect of condition [i.e. effect of (T-) 
versus (B) versus (P) drinks] (F=l 1.14; d.f.=2,22; p<0.001), a significant main effect of 
time [i.e. variation in plasma free TRP over time] (F=30.32; d.f.=1,11; p<0.001) and a 
significant condition by time interaction [i.e. effect of (T-), (B) and (P) drinks on variation 




significant decreases in plasma free TRP levels at +4.5 hours compared to baseline 
following the (T-) condition (mean± sem free TRP: baseline=0.91µg/ml ± 0.09; +4.5 
hours=0.3lµg/ml ± 0.03; p<0.0005; Figure 5.lb) and following the (P) condition (mean± 
sem free TRP: baseline=0.84µg/ml ± 0.08; +4.5 hours=0.64 µg/ml ± 0.05; p<0.001; Figure 
5.lb), but plasma free TRP levels were not significantly different at baseline and +4.5 
hours after administration of the (B) drink (mean± sem free TRP: baseline=0.88µg/ml ± 
0.09; +4.5 hours=0.97µg/ml ± 0.08; p>0.05; Figure 5.lb). Following the (T-) drink 
condition, a 67% decrease in plasma free TRP was seen across the 4.5 hours, while a 24% 
decrease followed administration of the (P) drink condition. 
5.3.1.2 Subjective Measures 
Measures of Mood 
VA ratings of mood were examined to see whether or not the (T-) condition had 
any additional effect on changes in subjective ratings of mood over the (B) and (P) 
conditions. While significant decreases in the ratings of sad/despondency were seen across 
the morning following administration of all three drink conditions (Figure 5.2a), the effect 
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Figure 5.2. Changes in VA ratings of (a) sad/despondency and (b) irritability 
following administration of (P) and amino acid drinks in twelve healthy female 
volunteers. Data are shown as mean ± sem ratings at time O and time +4.5 
hours. Significant falls in ratings of sad/despondency were seen following 
administration of all three drink conditions [ANOV A] (a). Ratings of 
irritability were significantly higher in the initial (P) condition session 
compared to the (B) and (T-) conditions [ANOVA] (b). 
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The ANOV A following (P) and amino acid drink administration revealed no 
significant main effect of condition [i.e. effect of (P) vs (B) vs (T-) on ratings of 
sad/despondency] (F=0.38; d.f.=2,20; p>0.05), a significant main effect of time [i.e. 
variation on ratings of sad/despondency over time] (F=4.58; d.f.=6,66; p<0.05; Figure 
5 .2a) but no significant condition by time interaction [i.e. effect of (T-) condition on 
variation in sad/despondency ratings over time] (F=0.87; d.f.=12,120; p>0.05). 
Mean VA ratings of irritability decreased between baseline and +4.5 hours 
following administration of all three conditions but the decrease did not reach statistical 
significance. The ANOV A following administration of (P) and amino acid drinks revealed 
a significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) on ratings of 
irritability] (F=4.95; d.f.=2,20; p<0.05), no significant main effect of time [i.e. variation in 
irritability over time] (F=2.54; d.f.=6,60; p>0.05) and no significant condition by time 
interaction [i.e. effect of (P) vs (B) vs (T-) drink on variation in irritability over time] 
(F=0.92; d.f.=12,120; p>0.05) was found. Examination of the data revealed that the 
significant main effect of condition reflected increased scores in the initial (P) condition 
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Figure 5.3. Changes in VA ratings of tension (a) and anxiety (b) following 
administration of (P) and amino acid drink conditions in twelve healthy female 
volunteers. Data are shown as mean ± sem ratings at time O and +4.5 hours. 
Significant falls in ratings of tension (a) and anxiety (b) followed 
administration of all three drink conditions [ANOV A], but no additional 
effects of (T-) administration on ratings of tension and anxiety were seen. 
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The ANOV A on VA ratings of tension and anxiety (Figure 5.3) following 
administration of (P) and amino acid drinks revealed no significant main effects of 
condition [i.e. effect of (P) vs (T-) vs (B) drink on ratings of tension and anxiety] (Tension: 
F=4.31; d.f.=2,20; p=0.06; Anxiety: F=4.03; d.f.=2,20; p=0.07), significant main effects of 
time [i.e. variation in ratings of tension and anxiety over time (Tension: F=5.13; d.f.=6,60; 
p<0.01; Anxiety: F=4.15; d.f.=6,60; p<0.05) and significant condition by time interactions 
[i.e. effect of (P) vs (T-) vs (B) drinks on variation in ratings of tension and anxiety over 
time] (Tension: F=3.43; d.f.=12,120; p<0.05; Anxiety: F=3.44; d.f.=12,120; p<0.05). 
Closer examination of the data, however, revealed that all of these effects were a reflection 
of the high scores seen in the first session i.e. (P) condition, suggesting that the amino acid 
loading conditions had no real impact on the VA scales. 
POMS ratings of depression demonstrated a significant fall across the morning 
following administration of the (T-) drink, but no significant effect of TRP depletion was 
seen on the ratings of depression (Figure 5.4a). The ANOVA revealed no significant main 
effect of condition [i.e. effect of (T-) drink] (F=2.21; d.f.=2,20; p>0.05), a highly 
significant main effect of time [i.e. variation in ratings of depression over time] (F=41.25; 
d.f.=2,20; p<0.00001) but no significant condition by time interaction [i.e. effect of (T-) 
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Figure 5.4. Changes in POMS VA ratings of depression (a) and 
tension/anxiety (b) in twelve healthy female volunteers following (P) and 
amino acid drink administration. Data shown as mean ratings at time O and 
+4.5 hours. Significant falls in ratings of depression and tension/anxiety were 





Similar findings were seen with the POMS rating of anxiety/tension (Figure 5.4b). 
Again, a significant fall in the VA ratings was seen across the morning following 
administration of all three drink conditions, but no additional effect of (T-) drink 
administration over (P) and (B) drink administration on changes in ratings of 
anxiety/tension were seen. The ANOV A following administration of (P) and amino acid 
drinks revealed no significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) 
drink] (F=0.19; d.f.=2,20; p>0.05), a highly significant main effect of time [i.e. variation in 
ratings of anxiety/tension over time] (F=17.91; d.f.=2,20; p<0.0005), but no significant 
condition by time interaction [i.e. effect of (P) vs (T-) vs (B) drink on variation in ratings 
of anxiety/tension over time] (F=l.07; d.f.=4,40; p>0.05). 
Measures of Appetite 
VA ratings of appetite were examined to see whether or not the (T-) condition had 
any additional effects on subjective ratings of appetite over and above those seen with the 
(P) and (B) conditions. A significant increase in hunger occurred across the morning 
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Figure 5.5. Change in VA ratings of hunger (a) and satiety VA measures of 
wish to eat (b) following administration of (P) and amino acid drinks in twelve 
healthy female volunteers. Data are shown as mean ± sem ratings at time O and 
+4.5 hours, and pre-and post-meal respectively. A significant increase in rating 
of hunger followed administration of all three conditions [ANOVA] (a), and a 
significant decrease in rating of wish to eat was seen post-meal following 




The ANOV A following administration of (P) and amino acid drinks revealed a 
significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) drink] (F=8.52; 
d.f.=2,20; p<0.005), a highly significant main effect of time [i.e. variation in ratings of 
hunger across time] (F=37.7; d.f.=6,60; p<0.00001) but no significant condition by time 
interaction [i.e. effect of (P) vs (T-) vs (B) drink on variation in ratings of hunger across 
time] (F=2.16; d.f.=12,120; p=0.09). While the ANOVA suggested a significant condition 
effect, examination of the means demonstrated that baseline hunger ratings for the (B) 
drink condition was considerably lower than the other two conditions, and that the 
condition effect suggested was merely a contamination effect of this difference throughout 
the test session (Figure 5.5a). 
Pre- and post-meal V As of satiety i.e. wish to eat, feel full and find/found the meal 
satisfying were also examined to see if the (T-) drink condition had any additional effect 
on subjective ratings of satiety compared to administration of (P) and (B) conditions 
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Figure 5.6. Changes in VA ratings of feel full (a) and find meal satisfying (b) 
following administration of (P) and amino acid drinks in twelve healthy female 
volunteers. Data are shown as mean ± sem VA ratings before and after test 
meal. Significant increases in ratings of feel full and meal satisfaction were 
found over time following administration of all three drinks (ANOV A). 
The ANOVAs following administration of (P) and amino acid drinks revealed 
significant main effects of time [i.e. variations in ratings over time i.e. variations after 
compared to before the meal] (wish to eat: F=132.3; d.f.=1,10; p<0.00001; feel full: 
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F=220.4; d.f.=1,10; p<0.00001; find meal satisfying: F=8.69; d.f.=1,10; p<0.01), but no 
significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) drink] (wish to eat: 
F=0.82; d.f.=2,20; p>0.05; feel full: F=l.68; d.f.=2,20; p>0.05; find meal satisfying: 
F=0.66; d.f.=2,20; p>0.05) and no significant condition by time interaction [i.e. effect of 
(P) vs (T-) vs (B) drink on variation in ratings seen before and after the meal] ( wish to eat: 
F=3.26; d.f.=2,20; p=0.06; feel full: F=l.55; d.f.=2,20; p>0.05; find meal satisfying: 
F=l.83; d.f.=2,20; p>0.05). 
5.3.1.3 Effect of Amino Acid Drinks on Food Intake 
No significant effect on food intake either in terms of total calorie consumption, or 
in terms of macronutrient selection was seen following administration of all three drink 
conditions. The ANOV A following administration of (P) and amino acid drinks revealed 
no significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) drink] for 
carbohydrate intake (F=0.35; d.f.=2,20; p>0.05), protein intake (F=0.6; d.f.=2,20; p>0.05), 
fat intake (F=2.37; d.f.=2,20; p>0.05) or total food consumption (F=l.67; d.f.=2,20; 
p>0.05). Food intake at test meal for all three conditions is summarised below in Table 5.5. 
Table 5.5. Food intake at test meal 
Placebo (T-) Drink (B) Drink 
(mean±sem) (mean±sem) (mean±sem) 
Carbohydrate (kJ) 1839 (± 167) 1907 (± 187) 1848 (± 178) 
Protein (kJ) 648 (± 64) 688 (± 48) 649 (± 56) 
Fat (kJ) 1824 (± 177) 2075 (± 170) 1899 (± 185) 
Total Food Intake (kJ) 4445 (± 307) 4663 (± 377) 4395 (± 388) 
5.3.1.4 Correlations 
No significant correlations were found between changes in free or total plasma 
TRP, mood and appetite ratings or food intake. 
5.3.2 EFFECT OF AMINO ACID DRINK ADMINISTRATION IN 
RECOVERED BULIMIC PATIENTS 
5.3.2.1 Effect of Amino Acid Drink Administration on Plasma TRP Levels 
Plasma total and free TRP levels were compared for both within (i.e. effects within 
the recovered bulimic group) and between (i.e. comparison of control versus recovered 
bulimic subjects) group effects across the three drink conditions. 
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The ANOV A on plasma total TRP data following administration of (P) and amino 
acid drink conditions revealed a significant main effect of group [i.e. recovered bulimic 
subjects versus control subjects] (F=l 1.32; d.f.=1,16; p<0.005). Post hoc testing 
demonstrated that basal plasma total TRP levels (time 0) were significantly lower in the 
recovered bulimic subjects compared to controls for all three test conditions (Figure 5.7; 
(T-) and (B) conditions only shown). In addition, recovered bulimic subjects' total plasma 
TRP levels were significantly lower compared to controls at +4.5 hours, following both (T -
) and (B) drinks but not following (P). A highly significant main effect of condition [i.e. 
effect of (P) vs (T-) vs (B) drink] (F=60.28; d.f.=2,32; p<0.00001), and a significant 
condition by time interaction [i.e. effect of (T-) drink on variation in total TRP over time] 
(F=64.33; d.f.=2,32; p<0.00001) was found. Examination of the data demonstrated that 
these significant effects reflected the ability of the (T-) drink to lower plasma total TRP at 
+4.5 hours. No significant interaction of group [i.e. recovered bulimic subjects versus 
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Figure 5.7. Change in plasma total TRP levels following administration of (a) 
(T-) and (b) (B) drinks conditions in twelve healthy controls and eight 
recovered bulimic subjects. Data shown as mean ± sem at times O and +4.5 
hours. Baseline and +4.5 hour plasma total TRP levels were significantly 
lower in the recovered bulimic group compared to controls. In addition, (T-) 
administration led to a significant fall in plasma total TRP in both control and 
bulimic subjects at +4.5 hours. Paired t test: ** p < 0.01. 
For plasma free TRP, no significant group effect [i.e. effect of recovered bulimic 





was seen. Administration of the (T-) drink did, however, lead to a significant lowering of 
plasma free TRP by +4.5 hours (Figure 5.8; (T-) and (B) conditions only shown). The 
ANOVA revealed a significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) 
drinks] (F=19.97; d.f.=2,32; p<0.00001), and a significant condition by time interaction 
[i.e. effect of (P) vs (T-) vs (B) drink on variation in plasma free TRP levels over time] 
(F=69.15; d.f.=2,32; p<0.00001). Again, no significant group by time or group by time by 
condition interactions were seen (all p values >0.1). 
,,_ 













1.2 1.1 .. , .. ,fl,,,... Rec bulimics ,,_ 
-0-- Controls ! 1 ...... [J ...... Rec bulimics 
::::t 1 
'-" 













Baseline +4.5 Hours Baseline +4.5 Hours 
(a) (b) 
Figure 5.8. Change in plasma free TRP levels in twelve healthy and eight 
recovered bulimic subjects following administration of [a] (T-) and [b] (B) 
drink conditions. Data shown as mean ± sem at times O and +4.5 hours. 
Baseline and +4.5 hour concentrations were not significantly different between 
control and bulimic groups, but administration of (T-) led to a significant fall in 
plasma free TRP at +4.5 hours [a]. Paired t test: ** p < 0.01. 
Measures of Mood 
VA ratings of mood were examined to see whether or not the (T-) condition had 
any additional effect on subjective ratings of mood compared to those seen following 
administration of (P) and (B) drinks, and to determine any between group differences (i.e. 
recovered bulimic versus controls) in effects of (T-) drink administration. Following 
administration of (P) and amino acid drinks, a significant main effect of group was seen on 
all VA ratings of mood [i.e. effect of recovered bulimic versus control subjects] 
(sad/despondency: F=5.85; d.f.=1,16; p<0.05; tense: F=4.53; d.f.=1,16; p<0.05; anxiety: 
F=7.26; d.f.=1,16; p<0.05; irritable: F=7.37; d.f.=1,16; p<0.05), and examination of the 
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data demonstrated that these effects came from an overall higher rating of negative mood 
in the recovered bulimic subjects compared to controls. No significant main effect of 
condition was seen following administration of the drinks [i.e. effect of (T-) drink versus 
(B) and (P) drinks] (sad/despondency: F=0.20; d.f.=2,32; p>0.05; tense: F=2.32; d.f.=2,32; 
p>0.05; anxiety; F=l.71; d.f.=2,32; p>0.05; irritable: F=0.16; d.f.=2,32; p>0.05), and no 
significant group by condition interaction [i.e. effect of bulimic versus control subjects on 
(T-) drink] (sad/despondency: F=l.01; d.f.=2,32; p>0.05; tense: F=2.32; d.f.=2.32; p>0.05; 
anxiety: F=l.71; d.f.=2,32; p>0.05; irritable: F=2.42; d.f.=2,32; p>0.05) was seen. 
Furthermore, no significant effect of time was seen on ratings of mood and no significant 
interactions between time, group and condition were seen (all p values > 0.1), indicating 
that the (T-) drink did not increase negative ratings of mood in either the recovered bulimic 
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Figure 5.9. Changes in POMS ratings of depression following (P) and amino 
acid drink administration. (a): Mean± sem POMS dysphoria ratings following 
(P) and amino acid drink administration at +4.5 hours in eight recovered 
bulimic women and twelve healthy female controls. POMS ratings for all 
measures except depression were significantly higher in bulimics compared to 
controls [ANOVA]. (b): Mean ± sem POMS ratings of depression at +4.5 
hours following administration of (P) and (T-) drinks. Ratings were 
significantly higher for both control and bulimic subjects during the (P) 
condition compared to the (T-) and (B) conditions CANOVA). 
Following administration of (P) and ammo acid drinks, POMS ratings of 
depression demonstrated a significant main effect of group [i.e. effect of recovered bulimic 
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versus control subjects] (F=8.62; d.f.=1,13; p=0.01; Figure 5.9a), again reflecting the 
higher ratings of negative mood in the recovered bulimic subjects, and a significant main 
effect of condition [i.e. effect of (P) vs (T-) vs (B) drink] (F=4.34; d.f.=2,26; p<0.05; 
Figure 5.9b) with ratings of depression for both subject groups higher during the initial (P) 
drink day. No significant group by condition interaction [i.e. effect of recovered bulimic 
versus control subjects on (P) vs (T-) (B) drinks] (F=2.35; d.f.=2,24; p>0.05) and no 
significant effect of time was seen on POMS ratings of depression. Furthermore, no 
significant interactions between time, group and condition was seen, indicating that the (T -
) drink did not increase negative ratings of mood in either group of subjects. 
For POMS rating of anxiety/tension, no significant main effect of group [i.e. effect 
of recovered bulimic versus control subjects] (F=5.78; d.f.=1,13; p>0.05), no significant 
main effect of condition [i.e. effect of (P) vs (T-) vs drinks] (F=2.33; d.f.=2,26; p>0.05) 
and no significant group by condition interaction [i.e. effect of bulimic versus control 
subjects on (P) vs (T-) vs (B) drinks effects] (F=0.19; d.f.=2,26; p>0.05) was seen. 
Similarly, no significant effect of time was seen on ratings of anxiety/tension and no 
interactions between time, group and condition were found (all p values > 0.1), again 
indicating that the (T-) drink did not increase negative ratings of mood in either the 
recovered bulimic or control subjects. 
Measures of Appetite 
Appetite ratings were examined to determine the effects of the (T-) drink within the 
groups of recovered bulimic subjects, and to determine if differences between the groups 
resulting from (T-) drink administration existed. 
Following administration of (P) and amino acid drinks, VA ratings of hunger 
increased in both subject groups across the morning, as reflected in a highly significant 
main effect of time [i.e. variation in ratings of hunger across time] being demonstrated on 
AN OVA (F=43.59; d.f.=6,96; p<0.00001; Figure 5.10a: (T-) condition only shown). A 
significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) drinks] (F=9.74; 
d.f.=2,32; p=0.0005) but no significant condition by time interaction [i.e. effect of (P) vs 
(T-) vs (B) drink on variation in ratings of hunger over time] (F=2.92; d.f.=12,192; 
p>0.050) was seen. Examination of the data revealed that the effect of condition appeared 
to result from a significant suppression of hunger following administration of both (T-) and 
(B) drinks, and that no additional effect following the (T-) drink was present. No 
significant main effect of group [i.e. effect of recovered bulimic versus control group] 
(F= 1.1 O; d.f.= 1, 16; p>0.05), and no significant group by condition interaction [i.e. effect of 
recovered bulimic versus control subjects on (P) vs (T-) vs (B) drinks] (F=2.57; d.f.=2,32; 
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Figure 5.10. Change in VA ratings of hunger following administration of (P) 
and amino acid drinks in eight recovered bulimic women and twelve healthy 
controls. Data are shown as mean± sem. (a): A significant increase in ratings 
of hunger was seen in both control and bulimic groups over time [(T-) drink 
condition only shown] CANOVA). (b): A significantly lower rise in ratings of 
hunger was seen in both subject groups following administration of (T-) and 
(B) amino acid drinks compared to placebo (ANOV A; bulimic data only 
shown). 
VA ratings of satiety (i.e. wish to eat; feel full; satisfaction of meal and could eat a 
large amount) were measured pre- and post-meal. Ratings of wish to eat were decreased 
following the test meal, and a significant main effect of condition [i.e. effect of (P) vs (T-) 
vs (B) drink] (F=5.61; d.f.=2,32; p=0.01) was found such that both amino acid drinks 
significantly suppressed the desire to eat (Figure 5 .11 a), although the effect was weaker 
when the control subjects were analysed separately (perhaps because of the smaller group 
size). Similarly, a significant group by time interaction was found [i.e. effect of recovered 
bulimic versus control subjects on variation in wish to eat over time] (F=5.26; d.f.=1,16; 
p<0.05; Figure 5.1 lb), in which the recovered bulimic subjects expressed less desire to eat 
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Figure 5.11. Changes in VA ratings of wish to eat in twelve healthy control 
and eight recovered bulimic subjects following administration of (P) and 
amino acid drinks. (a): A significant decrease in wish to eat was seen in both 
control and recovered bulimic subjects following administration of (T-) and 
(B) amino acid drinks compared to (P) [ANOVA]. (b): Recovered bulimic 
subjects rated significantly less wish to eat before, and 8igRifioaHtly greater 
wish to eat after the test meal compared to controls (ANOV A; (T-) condition 
only shown). 
As expected, ratings of fullness were increased significantly after the meal 
following administration of all three drinks as demonstrated by a significant main effect of 
time [i.e. variation in fullness from before to after the meal] (F=182.3; d.f.=1,16; 
p<0.0001), although all other time interactions failed to reach significance (all p values 
>0.1). Similarly, no significant main effect of condition [i.e. effect of (P) vs (T-) vs (B) 
drink] (F=0.46; d.f.=2,32; p>0.05) and no significant condition by group interaction [i.e. 
effect of (P) vs (T-) vs (B) drink on effect of recovered bulimic versus control groups] 
(F=0.76; d.f.=2,32; p>0.05) was seen. 
Following administration of (P) and amino acid drinks, a significant main effect of 
group [i.e. effect of recovered bulimic versus control subjects] (F=22.43; d.f.= 1, 16; 
p<0.0005) was seen for VA ratings of meal satisfaction with control subjects rating meal 
satisfaction significantly higher than recovered bulimic subjects. No significant main effect 





significant group by condition interaction [i.e. effect of recovered bulimic versus control 
group on (P) vs (T-) vs (B) drink effects] (F=0.59; d.f.=2,32; p>0.05) was found. 
Following administration of (P) and amino acid conditions, VA ratings of "could 
eat a large amount of food" were significantly decreased after the test meal as revealed by 
a highly significant main effect of time on ANOVA (F=74.9; d.f.=1,16; p<0.0001). A 
significant group by time interaction [i.e. effect of recovered bulimic versus control 
subjects on variation in ratings over time] (11.35; d.f.=1,16; p<0.005; Figure 5.12a) and a 
significant group by time by condition interaction [i.e. effect of recovered bulimic versus 
control subjects on variation in ratings following (P) vs (T-) vs (B) drink over time] 
(F=5.23; d.f.=2,32; p<0.05). Post-hoc t-tests revealed that recovered bulimic subjects 
scored less on the rating of "could eat a large amount of food" prior to the meal following 
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Figure 5.12. Changes in VA ratings of "could eat a large amount of food" 
following administration of (P) and amino acid drinks in eight recovered 
bulimic women and twelve healthy female controls. Data shown as mean 
ratings ± sem pre-and post-meal (a); pre-meal (b). Bulimic women scored 
significantly less desire to eat a large amount of food prior to test meal 
following (P) and (T-) drinks compared to controls. Unpaired t test:* p < 0.05. 
Overall, the data do not indicate any specific effect of the (T-) condition on VA 
ratings of appetite in either control or recovered bulimic subjects. Administration of both 
(T-) and (B) drinks, however, did appear to decrease the desire to eat. 
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5.3.2.3 Effect of Amino Acid Drink Administration on Food Intake 
Food intake at test meal was compared within the subject groups, as well as 
examining differences between the groups. Following administration of (P) and amino acid 
drinks, total calorie intake at test meal was significantly less in the recovered bulimic 
group compared to the control subjects (post-hoc t-testing: p<0.05; Figure 5.13). The 
ANOV A on total food intake revealed a significant main effect of group [i.e. effect of 
recovered bulimic versus control subjects] (F=4.75; d.f.=1,16; p<0.05), a significant main 
effect of condition [i.e. effect of (P) vs (T-) vs (B) vs (P) drinks], in that both subject 
groups ate less at the initial (P) test (F=4.15; d.f.=2,32; p<0.05), but no significant group 
by condition interaction [i.e. effect of recovered bulimic versus control subjects on effects 
of (P) vs (T-) vs (B) drinks] (F=3.0; d.f.=2,32; p=0.08) was found, indicating no specific 
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Figure 5.13. Mean± sem food intake at test meal in twelve healthy and eight 
recovered bulimic females following administration of (P) and amino acid 
drinks. Total calorie consumption in the recovered bulimic subjects was 
significantly less than in controls. Unpaired t test: * p < 0.05. 
Analysis of macronutrient data following administration of (P) and amino acid 




subjects compared to controls. The ANOV A revealed a significant main effect of group 
[i.e. effect of recovered bulimic versus control subjects] on fat intake (F=4.60; d.f.=1,16; 
p<0.05), a significant main effect of condition (F=4.99; d.f.=2,32; p<0.05) but no 
significant group by condition interaction (F=2.69; d.f.=2,32; p=0.09). The significant 
effect of condition was seen following administration of the (P) drink and appeared to 
result from the decrease in total calories seen during the initial session. 
In terms of carbohydrate and protein intake, the ANOV A following administration 
of (P) and amino acid drinks revealed no significant main effect of group [i.e. effect of 
recovered bulimic versus controls] (carbohydrate: F=3.91; d.f.=1,16; p=0.07; protein: 
F=3.06; d.f.=1,16; p>0.05), no significant main effect of condition [i.e. effect of (P) vs (T-) 
vs (B) drinks] (carbohydrate: F=0.21; d.f.=2,32; p>0.05; protein: F=l.63; d.f.=2,32; 
p>0.05) and no significant group by condition interaction [i.e. effect of recovered bulimics 
versus controls on effects of (P) vs (T-) vs (B)] (carbohydrate: F=l.35; d.f.=2,32; p>0.05; 
protein: F=l.46; d.f.=2,32; p>0.05). 
In summary, no additional effect of the (T-) drink over either (P) or (B) drinks on 
food intake was seen, in terms of total calorie or macronutrient choice in recovered bulimic 
or control subjects. 
5.3.2.4 Correlations 
No significant correlations were seen between changes in plasmll total or free TRP, 
mood and appetite ratings or food intake. 
5.4 DISCUSSION 
5.4.1 EFFECT OF PLASMA TRP LOWERING ON MOOD AND FOOD 
INTAKE IN HEALTHY FEMALE SUBJECTS 
The administration of a 52g amino acid drink deficient in TRP led to a significant 
reduction in both plasma total and free TRP over 4.5 hours, confirming the efficacy of this 
smaller dose to lower plasma TRP and in keeping with the findings of Oldman et al 
(1994 ). In addition to being well tolerated by the female subjects, the results in terms of 
TRP depletion were comparable to those obtained by Young et al (1985), using the 100g 
dose. In the present study, a reduction in total TRP of 78% and in free TRP of 67% was 
obtained, while Young et al (1985), reported decreases of 76% and 60% respectively. The 
two studies did, however, contrast in respect to changes in plasma TRP following 
administration of the (B) drink. Young et al (1985) reported significant increases in plasma 
free and total TRP following the 100g (B) drink (in the order of 72% and 84% 
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respectively), while in contrast, no significant change in plasma total and free TRP were 
seen following administration of the 52g (B) drink. Furthermore, the present study design 
incorporated a placebo condition following which significant falls in total (23%) and free 
(24%) plasma TRP across the 4.5 hours were seen. While the fall in plasma TRP seen in 
the placebo condition was of a much smaller magnitude than that seen following TRP 
depletion, it is of interest to note such changes which presumably reflect the effects of 
overnight fasting. 
In contrast to the hypothesis proposed in the introduction, TRP depletion was not 
associated with a lowering of mood in healthy women. This finding differs from those of 
Young et al (1985) and Smith et al (1987) who both reported small but significant 
increases in depression subscale scores in healthy male volunteers following TRP 
depletion with a 100g amino acid drinks. One possible explanation for the failure to find a 
lowering of mood in the present study is the variation in drinks utilised between the two 
studies. As outlined in Chapter Two, amino acid loading reduces brain TRP by two 
mechanisms. In addition to directly lowering plasma TRP levels ( due to incorporation of 
TRP into protein), the (T-) drink also increases the ratio of LNAA:TRP, which in turn, 
increases competition for the transportation of TRP into the brain across the blood brain 
barrier (see section 2.2.2). While the 52g dose led to a comparable fall in levels of both 
total and free plasma TRP to that seen with the 100g drink, it is possible that the smaller 
amino acid load inherent in the 52g drink would result in less LNAA to TRP competition 
at the blood brain barrier, such that a greater percentage of TRP would reach the brain. In 
this situation, brain 5-HT synthesis may not be reduced sufficiently to produce a detectable 
lowering of mood. It is of interest that in a study by Abbott et al (1992), which also 
utilised the 50g amino acid dose, TRP depletion was found to block the analgesic effect of 
morphine on tolerance to cold pressor pain in healthy male subjects but had no effect on 
mood. 
All published studies to date examining the effects of TRP depletion on mood have 
used male subjects, and it is possible that sex differences in responses to TRP depletion 
account for the current findings i.e. that women are more resilient to the effects of TRP 
depletion in terms of mood. This possibility seems unlikely, however, in view of the fact 
that rates of affective disorder are twice as high in women compared to men, and results 
from previous dieting research suggests that they are more vulnerable in terms of 
alterations in brain 5-HT function. As discussed in Chapter Three, considerable evidence 
exists to suggest that moderate dieting in women, but not men, is associated in alterations 
in brain 5-HT function and that one possible mechanism underlying these dieting-induced 
changes is plasma TRP depletion (Anderson et al, 1990a; Cowen et al, 1992). 
Furthermore, while a diet that restricted TRP intake to 200mg/day was found to lead to 
alterations in brain 5-HT function in both men and women, a more moderate restriction of 
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TRP (700mg/day) was found to only affect brain 5-HT function in women (Delgado et al, 
1989). Taken together, these data suggest that women should be more vulnerable to the 
effects of TRP depletion, in contrast to the present finding. 
Mood and appetite changes are well documented across the menstrual cycle, 
especially during the pre-menstrual phase ( Goodall et al, 1991; Goodall and Silverstone, 
1993). In the current study, all tests were completed outside the pre-menstrual phase and 
no evidence suggestive of systematic bias in terms of allocation of particular drinks to a 
specific phase of the cycle was found. It would seem unlikely, therefore, that menstrual 
cycle effects confounding the effects of TRP depletion could account for the failure to see 
a mood lowering effect in women. 
In keeping with the effects on mood, TRP depletion induced by the (T-) drink was 
found to have no significant effect on subjective ratings of appetite or on food intake in 
healthy women. Although few studies have examined the effects of TRP depletion on food 
intake, the present findings are in contrast to those of Young et al (1988) who found a 
small but significant reduction in protein intake amongst twenty-two male volunteers 
following a 50g amino acid load. Sex differences in appetite responses to TRP depletion is 
a possible explanation for the contrasting findings. In support of this hypothesis, 2g and 3g 
TRP loading has been found to produce significant reductions in calorie consumption in 
men but not women (Leiter et al, 1987). 
5.4.2 EFFECT OF TRP DEPLETION ON MOOD AND FOOD INTAKE 
IN SUBJECTS RECOVERED FROM BULIMIA NERVOSA 
Examination of the data revealed differences between the group of women who had 
recovered from bulimia nervosa and the group of healthy controls. The differences were 
characterised by abnormalities of mood, subjective measures of appetite and food intake. 
In addition, although no specific effects of TRP depletion were seen, significant 
differences in basal TRP levels were found. 
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In keeping with the findings outlined above in healthy female subjects, a 52g 
amino acid drink deficient in TRP significantly lowered plasma total and free TRP over 
4.5 hours in recovered bulimic women . In addition, basal plasma total TRP levels were 
significantly lower in recovered bulimic women compared to controls. The difference in 
basal total TRP levels was found for all three drink conditions, and following the (T-) and 
(B) drinks, persisted at +4.5 hours. In view of the hypothesis suggesting impaired 5-HT 
function in bulimia nervosa and, more specifically, that hyposerotonergic activity is 
consistent with bulimic behaviour, this finding is of considerable interest. To date few 
studies in the literature have addressed this issue, but one study by Lydiard et al (1988) 
found no baseline plasma TRP/LNAA ratio differences in normal weight bulimic patients 
compared to healthy controls. As this study was carried out on acutely ill patients, 
however, and the literature reviewed in section 1.3.2 clearly demonstrates alterations in 
measures of brain 5-HT function between phases of acute illness and recovery, the findings 
are difficult to compare. As far as the author is aware no published studies have looked at 
TRP levels in long-term recovered subjects but our findings are consistent with the 
hypothesis of persistent hyposerotonergic activity amongst women recovered from bulimia 
nervosa. 
An alternative explanation for the reduced basal plasma total TRP levels found in 
recovered bulimic women must be considered. Ongoing dietary restrictions in terms of 
reduced intake of food could explain the present findings. Data outlined in Chapter Three, 
coupled with the studies by Anderson et al (1990a) and Anderson et al (1990c) have 
suggested that moderate calorie restriction leads to reductions in plasma TRP levels, 
especially amongst women. Furthermore, diets sufficient in calories but moderately 
deficient in TRP have also been shown to lead to reduced plasma total TRP (Delgado et al, 
1989). The women in the present study were carefully screened for persistent abnormal 
eating habits, including unusual dietary restrictions, and demonstrated normal measures of 
dietary restraint on the EDE-Q3 when compared to controls. Nevertheless, it is possible 
that the screening procedures utilised were unable to detect more subtle abnormalities of 
diet and eating behaviour that persist in clinically recovered bulimic women. Indeed, a 
high level of dietary restraint would be consistent with the finding of reduced food intake 
amongst recovered bulimic women seen in the present study at test meal (see below). 
Subjective measures of appetite were found to differ in several aspects between 
control and recovered bulimic subjects. While no significant differences in ratings of 
hunger were seen between the two groups across the morning, significant difference in pre-
meal ratings of satiety were found. The recovered bulimic women rated themselves as 
having less "wish to eat" and scored significantly lower on ratings of "could eat a large 
amount of food" prior to the meal. These lower ratings were reflected in actual food intake 
at test meal, with the recovered bulimic women consuming significantly less calories than 
controls. Interestingly, post-meal satiety measures also differed between the two groups in 
that the recovered bulimic women scored significantly lower on ratings of meal 
satisfaction and significantly higher on ratings of wish to eat. The present findings in 
subjective appetite ratings combined with the reduced food intake amongst recovered 
bulimic women can be interpreted in two ways. Firstly, the findings may indicate that 
recovered bulimic subjects continue to exercise dietary restraint (as reflected in reduced 
food consumption) in addition to cognitive restraint (as reflected in the lower scores of 
"wish to eat" and "could eat a large amount of food" prior to the meal). Voluntary dietary 
restraint would be in keeping with post-meal ratings of significant less meal satisfaction 
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and higher scores of "wish to eat", suggesting the subject did not allow herself to eat to 
complete satiety. Alternatively, the findings may represent an persisting state of satiety 
dysregulation, perhaps secondary to decreased brain 5-HT function, as indicated by the 
low plasma TRP levels, although as discussed above, the plasma TRP findings are also 
consistent with dietary restriction. 
Although no effect of TRP depletion was seen on ratings of mood, recovered 
bulimic subjects scored consistently higher on all ratings of dysphoric mood i.e. 
depression, tension, anxiety and irritability when compared to controls. To date, there are 
few long-term studies which have examined residual symptoms amongst patients 
recovered from bulimia nervosa, and they have tended to focus on aspects of eating 
behaviour and menstrual functioning as these symptoms have been used as measures of 
recovery (Swift et al, 1987; Hsu and Sobkiewicz, 1989; Herzog et al, 1991). The women 
in the present study all met strict criteria for recovery (see section 2.4.2) and many 
considered themselves to have been well for a number of years, yet despite this, 
abnormalities of mood appear to persist. 
While the ratings of depression found in the recovered bulimic women could not be 
considered clinical in extent, the results are nevertheless of considerable interest in view of 
the high incidences of personal and family history of depression amongst patients with 
bulimia nervosa. Furthermore, the findings raise the issue of the exact nature of the 
relationship between the eating and affective disorders. Considerable debate exists within 
the literature as to whether or not the co-existance of eating disorders and depression 
simply represents co-morbidity in women with a high vulnerability for developing 
psychiatric illness in general; whether depressed mood occurs as a complication of the 
eating difficulties, perhaps secondary to the effects of food restriction and weight 
fluctuations; or whether or not the eating disorders represent a variation in the presentation 
of an affective illness (Russell, 1979; Hatsukami et al, 1984; Wilson and Lindholm, 
1987; Walters et al, 1992). It could be argued that the present finding of persistent 
depressive symptomatology despite recovery from bulimia nervosa, suggest the presence 
of a primary, underlying affective disturbance (although it is not possible to rule out a 
persisting mood disturbance that has developed secondary to the eating disorder), a 
hypothesis supported by the clinical observation that antidepressant treatment is very 
effective at improving both mood and disturbed eating behaviours (Pope et al, 1983; 
Mitchell and Groat, 1984; Fluoxetine Bulimia Nervosa Collaborative Study Group, 1992). 
Obviously, this is an area that requires further research, perhaps utilising longitudinal 
studies that would enable the relationship to be untangled. 
In contrast to the proposed hypothesis, TRP depletion had no effect on subjective 
ratings of appetite, objective measures of food intake or ratings of mood. While some 
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methodological issues and gender differences that may account for these findings have 
been discussed in general in the section on control subjects, the results are surprising in 
view of the vulnerability of the patients studied. To date, the amino acid mixture paradigm 
has been used in several patient groups. For example, TRP depletion in remitted depressed 
patients on antidepressant drugs is associated with an acute relapse in depressive 
symptomatology (Delgado et al, 1990 ), while patients in remission from obsessive-
compulsive disorder on selective serotonin reuptake inhibitors also report an exacerbation 
of depressive but not obsessive compulsive symptoms following acute TRP depletion 
(Barr et al, 1992). 
More recently a study by Weltzin et al (1994) demonstrated significant increases in 
ratings of anxiety, indecisiveness, over-reactivity and fear of fatness, along with a trend 
towards increased ratings in depression and fatigue amongst a group of thirteen bulimic 
women after TRP depletion. This study contrasted to the present one in that it was carried 
out on acutely ill patients and utilised a 100g amino acid mixture with or without 2.3g TRP 
as the (T-) and (B) drink respectively. The authors demonstrated significant reductions in 
plasma TRP and TRP:LNAA following the (T-) drink, and emphasised the need to obtain 
this fall in amino acid ratio before adequate brain 5-HT depletion would occur. Although 
care must be taken in generalising findings from a study on acutely ill bulimic women to 
women who are in remission, it is possible that the smaller 52g dose of amino acids did not 
produce sufficient fall in TRP:LNAA (and hence insufficient competition at the blood 
brain barrier), to decrease brain 5-HT synthesis to a degree enabling changes in mood and 
appetite to be seen. 
Finally, in terms of the failure to find an effect of TRP depletion on appetite ratings 
and food intake, it is possible that the overnight fast resulted in a ceiling effect in terms of 
hunger which obscured any effect of TRP depletion on food intake the next day, although 
Goodall and Silverstone (1988b) were able to demonstrate increased food intake in normal 
subjects following administration of metergoline utilising a similar experimental design. 
Bulimic patients may, however, be more sensitive to such effects. Furthermore, the 
unfamiliarity and unnatural atmosphere of the laboratory setting may also have influenced 
the test meal results. 
5.5 CONCLUSIONS 
In conclusion, a 52g amino acid drink deficient in TRP produced a significant 
reduction in plasma total and free TRP in both healthy and recovered bulimic women over 
4.5 hours. In contrast to the proposed hypothesis, however, no effect of TRP depletion, 
was seen in either control subjects or recovered bulimic patients in terms of subjective 
ratings of appetite and mood or upon objective measures of food consumption. 
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Basal plasma total TRP levels were significantly lower in recovered bulimic 
subjects compared to controls, and recovered bulimic subjects exhibited abnormalities in 
subjective ratings of appetite and satiety. The findings suggest that either recovered 
bulimic women continue to exercise dietary restraint, or alternatively, that a persistent state 
of hyposerotonergic activity exists in women recovered from bulimia nervosa. 
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Chapter 6 
GENERAL DISCUSSION AND 
CONCLUSIONS 
6.1 OVERVIEW 
In the introduction to this thesis it was suggested that while clear evidence now 
exists in support of serotonergic dysregulation occurring during clinical episodes of 
anorexia and bulimia nervosa, the precise nature of the dysregulation remains unclear. 
Furthermore, it was discussed that interpretation of research into the eating disorders is 
confounded by complications of the illnesses themselves, i.e. the effects of low body 
weight, starvation or chronic food restriction, along with the consequences of behaviours 
such as bingeing and purging. In addition, understanding of the neurobiological processes 
involved in the pathogenesis of these illnesses is hampered by our limited knowledge of 
the serotonergic mechanisms involved in the normal control of feeding behaviour in 
humans. It was suggested, therefore, that a better understanding of the effects that the 
confounding factors have on brain 5-HT function, coupled with greater knowledge of the 
normal mechanisms involved in serotonergic control of feeding behaviour, would lead to 
increased understanding of the disorders themselves. In particular, such knowledge would 
enable those factors arising as complications of the illnesses to be disentangled from those 
neurobiological abnormalities central to the underlying pathogenesis of the disorders. 
The present studies utilised a neuroendocrine challenge paradigm to investigate the 
effects of weight loss on brain 5-HT function in humans. A combined neuroendocrine 
challenge and test meal approach was then used to examine the effects of the 5-HT agonist 
mCPP on PRL, food intake and mood in women. In addition, acute TRP depletion in 
conjunction with a test meal paradigm was utilised to examine the effects of TRP depletion 
on food intake and mood in healthy females subjects and female patients recovered from 
bulimia nervosa. 
Throughout the thesis, particular attention has been paid to the possibility of gender 
differences and to the search for female neurobiological vulnerabilities that may lead to the 
development of the eating disorders. The reason for this emphasis is three-fold. Firstly, 
anorexia and bulimia nervosa are primarily disorders of young women, with only 10% of 
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cases occurring in men (Fairburn, 1983). Secondly, earlier work carried out by Goodwin et 
al (1987b) and Anderson et al (1990a) demonstrated that moderate food restriction and 
weight loss leads to alterations in brain 5-HT function in women but not men, suggesting 
that females may have a differing biological response to altered food intake compared to 
men. Thirdly, recent epidemiological evidence strongly suggests that normal dieting 
behaviour is in itself a risk factor in the development of eating disorders amongst 
vulnerable individuals, and in our society, dieting behaviour is more commonly carried out 
by young women (Jakobovits et al, 1977; Johnson-Sabine et al, 1988; Patton et al, 1990). 
The investigations described in this thesis provide further evidence in support of 
the hypothesis that females are more vulnerable to the effects of food restriction and 
weight loss than men, by confirming earlier work that suggested moderate weight loss 
leads to alterations in brain 5-HT function in women alone. In addition, the findings 
provide evidence to suggest that the mechanism underlying the 5-HT-mediated changes in 
brain function probably occur pre-synaptically, perhaps as a consequence of alterations in 
the synthesis or release of 5-HT. No evidence was found to support the hypothesis that 
dieting leads to the development of post-synaptic 5-HT receptor supersensitivity as 
proposed by Goodwin et al (1987b) and Anderson et al (1990a). In this light, findings 
from this thesis are in keeping with the hypothesis that food restriction and weight loss 
may lead to increased brain 5-HT function secondary to an increase in pre-synaptic 
synthesis of 5-HT as proposed by Curzon (1988). 
Evidence for a central role of serotonergic pathways in the control of food intake in 
humans was provided by the findings of the mCPP studies in Chapter Four. In keeping 
with animal data, oral mCPP at a dose of 0.4mg/kg significantly decreased food intake in 
healthy women in terms of total calorie consumption, a reduction reflected in a general 
decrease in all three macronutrients measured i.e. protein, fat and carbohydrate. The 
decrease in food intake was accompanied by a decrease in VA ratings of hunger, 
suggesting specific effects on satiety, in keeping with serotonergic pathway stimulation. In 
addition, the finding that mCPP decreased food intake suggested a role of the 5-HT2c 
receptor subtype in the control of human feeding behaviour. 
In view of the data outlined in the introduction suggesting that serotonergic 
dysregulation occurs during clinical eating disorders, the finding that TRP depletion did 
not alter mood or food intake in such a vulnerable population as recovered bulimic women 
was unexpected. It is possible that the neurobiological abnormalities present in bulimia 
nervosa are not affected by TRP depletion or that methodological issues account for the 
negative findings and these will be briefly discussed below. Nevertheless, the study did 
provide interesting and new data to suggest that women who have recovered from bulimia 
nervosa have low basal plasma total TRP levels and continue to exhibit abnormalities in 
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ratings of appetite and satiety, along with abnormalities of food intake compared to 
controls. While the most probable explanation for the present findings is that they reflect 
dietary restraint on the part of the recovered bulimic women, one alternate and intriguing 
explanation also in keeping with the data, is that the findings represent evidence of 
persistent hyposerotonergic activity. For example, it could be argued that if reduced brain 
5-HT function is an abnormality intrinsic to the disorder, then women suffering from 
bulimia nervosa may use dieting as a means of "self medication" to increase their levels of 
brain 5-HT function. While this intriguing theory would be in keeping with the present 
dieting results in normal women, it makes interpretation of low plasma TRP levels in 
apparently asymptomatic and "recovered" bulimic women more difficult to explain. 
One possibility is that "recovery" in our bulimia nervosa patients was relative, and 
that while some women manage to curb the more distressing and problematic behaviours 
that arise from the disorder, such as bingeing, purging and severe dieting, their persistent 
vulnerability remains (as reflected in a chronic underlying state of hyposerotonergic 
activity), but in a modified form through the practice of dietary restraint. Thus low plasma 
TRP may represent a trait marker for the disorder. This interpretation is in keeping with the 
findings of Jimmerson et al (1988;1990), who found that bulimia nervosa patients with a 
binge frequency of two or more per day had lower concentrations of CSF 5-HIAA than 
less symptomatic patients. As no correlation was found between 5-HIAA levels and either 
changes in body weight or a history of depression, the authors suggested that the low CSF 
5-HIAA levels may reflect persistently reduced central serotonin turnover which in turn 
may have been reversed by a higher binge frequency. Alternatively, it is also possible that 
bulimic women practice dietary restraint in order to achieve low plasma TRP levels. Such 
a practice would suggest an underlying state of hyperserotonergic activity in bulimia 
nervosa and is in direct contrast to the dieting findings in normal women presented in this 
thesis. 
The association between reduced central serotonin function and the presence or 
absence of depressive symptomatology has important implications for the current study. A 
substantive body of research data exists to suggest that abnormalities of serotonergic 
neurotransmission occur during clinical episodes of depression (Meltzer and Nash, 1988; 
Deakin and Graeff, 1991; Power and Cowen, 1992). Metabolite studies, although 
somewhat conflicting, have demonstrated low CSF 5-HIAA levels amongst depressed 
patients compared to controls, a finding most consistent in a subgroup of depressives prone 
to impulsive violent suicide (Linnoila et al, 1992). Furthermore, neuroendocrine studies 
have shown that PRL and GH responses to the 5-HT precursor, TRP, and the 5-HT 
releasing drug d-fenfluramine are blunted during episodes in depression, again suggesting 
decreased serotonergic neurotransmission (Power and Cowen, 1992). 
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The majority of our recovered bulimic patients had previously met criteria for 
major depression at some stage in their lives, and although none were currently clinically 
depressed, our subjects scored consistently higher on all ratings of dysphoric mood i.e. 
depression, tension, anxiety and irritability when compared to controls. It is possible, 
therefore, that the finding of low plasma TRP amongst our group of recovered bulimic 
subjects was a reflection of their depressive symptomatology, rather than a trait marker 
relating specifically to bulimia nervosa. Against this hypothesis is the consistent research 
finding that changes in serotonergic function amongst depressed patients are state 
dependent, with abnormalities reverting to normal upon clinical recovery. Furthermore, 
although both plasma TRP and CSF 5-HIAA concentrations are thought to reflect central 
5-HT function, the exact manner in which the two measures relate firstly to each other, and 
secondly to central 5-HT neurotransmission, is still open to debate. 
One of the important themes running through-out this thesis has been that of 
possible gender differences in vulnerability to altered food intake. In keeping with earlier 
work (Anderson et al, 1990a), our dieting findings suggested that moderate weight loss 
leads to alterations in brain 5-HT function in women but not men. Furthermore, amongst 
recovered bulimic women, the finding of low plasma TRP levels raises the possibility of 
persistent central hyposerotonergic function. While this latter finding may represent a trait 
marker, it may equally reflect a persistent hyposerotonergic state consequent upon the 
disorder itself i.e. as a result of persistent food restriction, bingeing and purging 
behaviours. 
Persistent dysregulation of central serotonergic function as a result of food 
restriction has been suggested by the work of Keys et al (1950), in which normal men 
dieted to lose 26% of their total body weight. Restoration of full body weight along with 
unrestricted access to adequate food did not immediately reverse typical eating disordered 
behaviours, including a tendency to binge. Such behaviours persisted for up to six months 
after full body weight recovery. Furthermore, dieting and weight loss amongst obese 
subjects who had never previously engaged in bingeing behaviours led to the development 
of binge eating in the three months following completion of their diet (Telch and Agras, 
1993). 
In view of the findings from this thesis and earlier dieting research, it is probable 
that women are particularly vulnerable to such persistent dysregulation. The reasons for 
such gender differences are unclear, although in terms of brain serotonergic function, data 
exists to suggest that females have a higher basal rate of turnover of 5-HT compared to 
males (Young et al, 1980). In evolutionary terms, one might speculate that the 
consequences of food restriction and subsequent weight loss would be greater for the 
female sex who carry responsibility for perpetuation of the human species. As normal 
179 
menstrual functioning ceases once fat composition of the female body drops below 
approximately 10%, it is possible that females have greater in-built protective mechanisms 
against food restriction. For example, it is possible that the threshold for food restriction 
and weight loss triggering central neurotransmitter dysregulation, and hence compensatory 
behaviours such as binge eating, is lower in women. Such a suggestion would be in 
keeping with findings from the dieting work presented in this thesis in which alterations in 
brain 5-HT function were seen only in women, even though male dieters sustained a 
greater weight loss, in both absolute and percentage body weight loss terms. Alternatively, 
the degree of compensatory behavioural change may be greater in women than in men and 
in view of the research data to date, it is also likely that any central neurotransmitter 
dysregulation that may result as a consequence of food restriction would also persist longer 
in women. 
Longitudinal studies on bulimic patients and studies using vulnerable populations 
(e.g. relatives of eating disordered patients, families with affective illness) to examine 
plasma TRP levels while carefully controlling for dietary habits would help clarify these 
issues. 
In direct contrast to previously reported findings amongst normal males (Young et 
al, 1985; Young et al, 1988), acute TRP depletion did not lead to a lowering of mood or 
produce alterations in food intake amongst healthy women. This finding was unexpected in 
view of the widespread literature published suggesting women are more vulnerable to the 
mood lowering effects of TRP depletion (Delgado et al, 1989; Anderson et al, 1990a; 
Cowen et al, 1992). While it is possible that gender differences may account for the 
findings, in that females are in fact more resilient than men to the effects of TRP depletion 
(a finding not previously reported), methodological issues make firm conclusions difficult 
to draw. 
6.2 FUTURE RESEARCH 
The dieting studies outlined in this thesis suggest that pre-synaptic changes in brain 
5-HT function may underlie the dieting-induced changes in PRL responses and provide 
some evidence against the development of dieting-induced post-synaptic 5-HT receptor 
supersensitivity. Such conclusions must, however, be considered tentative in that they are 
based upon a single study and on the assumption that dieting-induced changes are 
mediated through receptors with which mCPP interacts. Furthermore, in contrast to earlier 
studies, plasma TRP levels did not fall (Anderson et al, 1990a). Future work should be 
directed towards further determination of the exact mechanism underlying dieting-induced 
alterations in brain 5-HT function. This would involve carrying out neuroendocrine 
challenge tests utilising selective 5-HT agonist and antagonist drugs (as they become 
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available) that interact with other 5-HT receptor subtypes to test the presence of post-
synaptic supersensitivity and to determine the receptor subtypes involved in mediating the 
effects of dieting. For example, animal studies have indicated the importance of 5-HT 1B 
receptors in the control of feeding behaviour (Leibowitz and Shor-Posner, 1986). In the 
absence of 5-HT 1B receptors in the human brain, it has been suggested that the 5-HTrn 
receptor may play an important role in determining food intake in humans. Recently 
sumatriptan, a 5-HT ID receptor agonist suitable for human work, has become available 
providing an opportunity to investigate this hypothesis. 
In view of the methodological issues raised in Chapter Five and the paucity of 
published data examining the effects of TRP depletion in women, further TRP depletion 
studies in both healthy and recovered bulimic patients need to be carried out. Utilisation of 
a 1 OOg amino acid dose would help ensure depletion of plasma TRP levels and an adequate 
fall in plasma TRP:LNAA thus maximising depletion of brain 5-HT, although such 
benefits would have to be weighed against an increased incidence of confounding side 
effects. In addition, the introduction of a standard diet for all subjects on the day prior to 
the study would help eliminate any effects of dietary variations on basal TRP levels. 
Alternatively, a low TRP diet utilised for several days prior to administration of the amino 
acid drink would ensure a standard diet while maximising brain 5-HT depletion. Such 
methodological refinements will in turn improve the chances of detecting any effects on 
mood and appetite changes in women that may follow acute TRP depletion. 
Investigation into the role of serotonergic pathways in the control of human feeding 
behaviour is also in the early stages, but its development is hampered by a lack of suitable 
selective 5-HT agonists and antagonists challenge drugs available for use in humans. As 
new drugs do become available, however, a combined neuroendocrine and test meal 
approach similar to that outlined in Chapter Four, would enable further delineation of the 
5-HT receptor subtypes involved in the control of human feeding behaviour. One 
immediate possibility would be to investigate the effects of the 5-HT ID receptor agonist 
sumatriptan on food intake in humans. In addition, interpretation of the study carried out 
with 0.4mg/kg mCPP was complicated by the possibility of side effects having a direct 
effect on food intake. In future work using mCPP, a slightly reduced dose (eg. 0.35mg/kg) 
may be enough to eliminate this problem while still maintaining the anorectic effects of the 
drug. 
In conclusion, investigations outlined in this thesis provide important data 
contributing to our understanding of the mechanisms underlying dieting-induced changes 
in brain 5-HT function and support earlier work indicating the increased vulnerability of 
women to these effects. In addition, abnormalities in ratings of appetite and satiety, along 
with abnormalities of food intake can be seen amongst women apparently recovered from 
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bulimia nervosa. Interpretation of these findings in terms of possible neurobiological 
processes underlying the disorder bulimia nervosa, is however, made difficult by the 
paucity of neurobiological research carried out on the disorder. It is the author's intention 
to investigate more closely the state of brain 5-HT function in recovered bulimic women 
(using a neuroendocrine approach) in order to determine whether or not abnormalities of. 
brain 5-HT function persist beyond recovery from the clinical illness. Such research into 
the neurobiological basis of the eating disorders is required before a more accurate 
interpretation of the dieting and TRP depletion studies can be made and applied directly to 
the eating disorders. 
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APPENDIX 1: Fenfluramine Challenge VA 
Please place a mark in the line to indicate how you feel right now 
O 10 20 30 40 50 60 70 80 90 100 
Not at all drowsy Exremely drowsy 
O 10 20 30 40 50 60 70 80 90 100 
No nausea at all Extreme nausea 
O 10 20 30 40 50 60 70 80 90 100 
Not at all dizzy Extremely dizzy 
0 10 20 30 40 50 60 70 80 90 100 
I 
Not at all hungry Extremely hungry 
0 10 20 30 40 50 60 70 80 90 100 
I I I 
Not at all light-headed Extremely light-headed 
0 10 20 30 40 50 60 70 80 90 100 
I 
Not at all depressed Extremely depressed 
:> 
,, 
0 10 20 30 40 50 60 70 80 90 100 
I I I 
Not at all happy Extremely happy 
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APPENDIX 2: mCPP Dieting Study VA 
'y 
Please place a mark on the line to indicate how you feel right now 
O 10 20 30 40 50 60 70 80 90 100 
I I 
Not at all light-headed Extremely light-headed 
O 10 20 30 40 50 60 70 80 90 100 
No nausea at all Extreme nausea 
0 10 20 30 40 50 60 70 80 90 100 
Not at all anxious Extremely anxious 
~ 
0 10 20 30 40 50 60 70 80 90 100 
/. 
No feelings of unreality at all Extreme feelings of unreality 
0 10 20 30 40 50 60 70 80 90 100 
I 
Not at all sweaty Extremely sweaty 
0 10 20 30 40 50 60 70 80 90 100 
I 
Not at all hungry Extremely hungry 
0 10 20 30 40 50 60 70 80 90 100 
I I I 
Not at all happy Extremely happy 
0 10 20 30 40 50 60 70 80 90 100 
I 
Not at all mellow Extremely mellow 
-
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APPENDIX 3: mCPP Appetite Study VA 
Please place a mark on the line to indicate how you feel right now 
O 10 20 30 40 50 60 70 80 90 100 
No nausea at all Extreme nausea 
O 10 20 30 40 50 60 70 80 90 100 
Not at all anxious Extremely anxious 
0 10 20 30 40 50 60 70 80 90 100 
I I I 
"' 
Not at all light-headed Extremely light-headed 
'I 
0 10 20 30 40 50 60 70 80 90 100 
I 
Not at all hungry Extremely hungry 
0 10 20 30 40 50 60 70 80 90 100 
No desire at all to eat Extreme desire to eat 
:;-
0 10 20 30 40 50 60 70 80 90 100 
I I I 
Not at all happy Extremely happy 
O 10 20 30 40 50 60 70 80 90 100 
Not at all depressed Extremely depressed 
APPENDIX 4: Food Item Checklist 
FOOD PREFERENCE 
NAME ................................................ . 
CODE ......................... . 
Please rate the following foods according to your preferences, using the scale below: 
Bread 
White 
__ Soft Grain (Mighty White) 
Wholemeal 
Sandwich Fillings and Cold Meats 
Cheddar Cheese 






__ Strawberry Jam 
Chocolate 
Milk Chocolate 
__ Plain Chocolate (Bourn ville) 
__ White Chocolate (Milky Bar) 
Biscuits 
Rich Tea 
__ Morning Coffee 
__ Digestive 
Desserts 
__ Strawberry Yoghurt 
__ Raspberry Yoghurt 
__ Black Cherry Yoghurt 
__ Fruit Salad (tinned) 
__ Rice Pudding 
Crisps 
__ Ready Salted 
__ Smoky Bacon 






APPENDIX 5: Test Meal Food Items 
Choice Range Quantity Approx. Weight 
Bread Wholemeal; white; 8 slices of one type 270g 
softgrain 
Margarine Small tub 250g 
Sandwich Fillings Ham; tuna; chicken 4 choices (minimum eg. 230g Tuna; 250g 
roll; cheddar cheese; of 2 to be protein) cottage cheese; 1 OOg 
cottage cheese; jam ham; 340g peanut 
peanut butter; butter 
marmite 
Crisps 3 flavours 2 packets of one 60g 
type 
Pudding Yoghurt: rice 1 type eg. 270g yoghurt 
pudding: fruit salad 
Fruit Apple; banana; 1 item each of 2 eg. 120g apple; 100g 
orange types banana 
Biscuits Digestive; rich tea; 1 type 120g 
morning coffee 
Chocolate Milk; plain; white 12 squares of 1 type 75g 
Tomatoes 2 tomatoes 140g 




APPENDIX 6: Food Record Sheet 
RECORD SHEET 
Subject Name: ................................................................... . 
Date: .......................... .. 
Code· . ···································· Time Taken· ........ 















!TOTALS I I I I 
APPENDIX 7: TRP Depletion Study Appetite VA 
Please place a mark on the line to indicate how you feel right now 
0 10 20 30 40 50 60 70 80 90 100 
No wish at all to eat Extreme wish to eat 
O 10 20 30 40 50 60 70 80 90 100 
Not at all hungry Extremely hungry 
0 10 20 30 40 50 60 70 80 90 100 
Do not feel at all full Feel extremely full 
0 10 20 30 40 50 60 70 80 90 100 
Do not expect to find the 
meal at all satisfactory 
Expect to find the meal 
extremely satisfactory 
0 10 20 30 40 50 60 70 80 90 100 
I 
Did not find the 
meal satisfactory at all 




APPENDIX 8: TRP Depletion Study Mood VA 
Please place a mark on the line to indicate how you feel right now 
O 10 20 30 40 50 60 70 80 90 100 
Not at all sad/despondent Extremely sad/despondent 
O 10 20 30 40 50 60 70 80 90 100 
Not at all anxious Extremely anxious 
O 10 20 30 40 50 60 70 80 90 100 
Not at all tense Extremely tense 
O 10 20 30 40 50 60 70 80 90 100 
Not at all irritable Extremely irritable 
APPENDIX 9: Profile of Mood State (POMS) Questionnaire 
Volunteer No: ..................... . Visit: ......................... . Date: .............. . 
Initials: ............................... . Time: ....................... . Time: ............... . 
Below is a list of words that describe feelings people have. Please read each carefully. 
Then fill in the circle under ONE of the numbers (0 to 4) to the right corresponding to 
the phase which best describes HOW YOU ARE FEELING RIGHT NOW. 
The numbers refer to the phrases: 0 = Not at all 
1 = A little 
01234 
1. Friendly 00000 
01234 
2. Tense 00000 
01234 
3. Angry 00000 
01234 
4. Worn out 00000 
01234 
5. Unhappy 00000 
01234 
6. Clear headed 00000 
01234 
7. Lively 00000 
01234 
8. Confused 00000 
2 = Moderately 
3 = Quite a bit 
4 = Extremely 
01234 
9. Sorry for things O O O O 0 17. Grouchy 
done 
01234 
10. Shaky 00000 18.Blue 
01234 
11. Listless 00000 19. Energetic 
01234 
12.Peaved 00000 20. Panicky 
01234 
13. Considerate 00000 21. Hopeless 
01234 I 
14. Sad 00000 22. Relaxed 
01234 
15. Active 00000 23. Unworthy 
01234 



















01234 01234 01234 
25. Sympathetic 00000 39. Bitter 00000 53. Furious 00000 
01234 01234 01234 
26. Uneasy 00000 40. Exhausted 00000 54. Efficient 00000 
01234 01234 01234 
27. Restless 00000 41. Anxious 00000 55. Trusting 00000 
28. Unable to 
concentrate 01234 01234 01234 
00000 42. Ready to fight O O O O 0 56. Full of pep 00000 
01234 01234 01234 
29. Fatigued 00000 43. Good Natured O O O O 0 57. Bad tempered O O O O 0 
01234 01234 01234 
30. Helpful 00000 44. Gloomy 00000 58. Worthless 00000 
01234 01234 01234 
31. Annoyed 00000 45. Desperate 00000 59. Forgetful 00000 
01234 01234 01234 
32. Discouraged 00000 46. Sluggish 00000 60. Carefree 00000 
01234 01234 01234 
33. Resentful 00000 47. Rebellious 00000 61. Terrified 00000 
01234 01234 01234 
34. Nervous 00000 48. Helpless 00000 62. Guilty 00000 
01234 01234 01234 
35. Lonely 00000 49. Weary 00000 63. Vigorous 00000 
64. Uncertain about 
01234 01234 things 01234 
36. Miserable 00000 50. Bewildered 00000 00000 
01234 01234 01234 
37. Muddled 00000 51. Alert 00000 65. Bushed 00000 
01234 01234 MAKE SURE YOU HA VE 
38. Cheerful 00000 52. Deceived 00000 ANSWERED ALL ITEMS 
APPENDIX 10: Beck Depression Inventory 
NAME: ..................................................... . DATE: ....................... . 
On this questionnaire are groups of statements. Please read each group of statements 
carefully. Then pick out the one statement which best describes the way you have 
been feeling in the past week including today. Circle the number beside the statement 
you picked. If several statements apply equally well, circle each one. Be sure to read 
all the statements in each group before making your choice. 
1 0 I do not feel sad 
1 I feel sad 
2 I am sad all the time and can't snap out of it 
3 I am so sad or unhappy I can't stand it 
2 0 I am not particularly discouraged about the future 
1 I feel discouraged about the future 
2 I feel I have nothing to look forward to 
3 I feel the future is hopeless and that things cannot improve 
3 0 I do not feel like a failure 
1 I feel I have failed more than the average person 
2 As I look back on my life, all I can see is a lot of failures 
3 I feel I am a complete failure as a person 
4 0 I get as much satisfaction out of things as I used to 
1 I don't enjoy things the way I used to 
2 I don't get real satisfaction out of anything anymore 
3 I am dissatisfied or bored with everything 
5 0 I don't feel particularly guilty 
1 I feel guilty a good part of the time 
2 I feel guilty most of the time 
3 I feel guilty all the time 
6 0 I don't feel I am being punished 
1 I feel I may be punished 
2 I expect to be punished 
3 I feel I am being punished 
7 0 I don't feel disappointed in myself 
1 I am disappointed in myself 
2 I am disgusted with myself 
3 I hate myself 
194 
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8 0 I don't feel any worse than anybody else 
1 I am critical of myself for my weaknesses or mistakes 
2 I blame myself all the time for my faults 
3 I blame myself for everything bad that happens 
9 0 I don't have any thoughts of killing myself 
1 I have thoughts of killing myself, but I would not carry them out 
2 I would like to kill myself 
3 I would kill myself if I had the chance 
10 0 I don't cry any more than usual 
1 I cry more than I used to 
2 I cry all the time now 
3 I used to be able to cry, but now I can't cry even though I want to 
11 0 I am no more irritated now than I ever am 
1 I get annoyed or irritated more easily than I used to 
2 I feel irritated all the time now 
3 I don't get irritated at all by things that used to irritate me 
12 0 I have not lost interest in other people 
1 I am less interested in other people than I used to be 
2 I have lost most of my interest in other people 
3 I have lost all of my interest in other people 
13 0 I make decisions about as well as I ever could 
1 I put off making decisions more than I used to 
2 I have greater difficulty in making decisions than before 
3 I can't make decisions anymore 
14 0 I don't feel I look any worse than I used to 
1 I am worried that I am looking old or unattractive 
2 I feel there are permanent changes in my appearance that make me 
look old or unattractive 
3 I believe that I look ugly 
15 0 I can work as well as before 
1 It takes an extra effort to get started at doing something 
2 I have to push myself hard to do anything 
3 I can't do any work at all 
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16 0 I can sleep as well as usual 
1 I don't sleep as well as I used to 
2 I wake up 1-2 hours earlier than usual and find it hard to get back to 
sleep 
3 I wake up several hours earlier than usual and cannot get back to 
sleep 
17 0 I don't get any more tired than usual 
1 I get tired more easily than I used to 
2 I get tired from doing almost anything 
3 I am too tired to do anything 
18 0 My appetite is no worse than usual 
1 My appetite is not as good as it used to be 
2 My appetite is much worse now 
3 I have no appetite at all anymore 
19 0 I haven't lost much weight if any lately 
1 I have lost more than 5 pounds 
2 I have lost more than 10 pounds 
3 I have lost more than 15 pounds 
20 0 i am no more worried about my health than usual 
1 I am worried about aches and pains, upset stomach, constipation 
2 I am very worried about physical problems and it is hard to think of 
much else 
3 I am so worried about my physical problems, that I can't think about 
anything else 
21 0 I have not noticed any recent change in my interest in sex 
1 I am less interested in sex than I used to be 
2 I am less interested in sex now 
3 I have lost interest in sex completely 
.. 
APPENDIX 11: Eating Attitudes Test 
For each of the numbered statements, place an 'X' in the column which applies best to 
how you have been over the PAST FOUR WEEKS. Most of the questions relate to 
food or eating, although other types of questions have been included. Please answer 
each question carefully. 
Always Very Often Some- Rarely 
Often times 
1. Like eating with other people 
2. Prepare food for others but do not 
eat what I cook 
3. Become anxious prior to eating 
4. Am terrified about being overweight 
5. Avoid eating when I am hungry 
6. Find myself preoccupied with food 
7. Have gone on eating binges where I 
feel I may not be able to stop 
8. Cut my food into small pieces 
9. Aware of the calorie content of the 
food I eat 
10. Particularly avoid foods with a high 
carbohydrate content ( eg. Bread, rice ) 
11. Feel bloated after meals 
12. Feel that others would prefer if I 
ate more 
13. Vomit after I have eaten 




APPENDIX 11 contd· 
Always Very Often Some- Rarely Never 
Often times 
15. Am preoccupied with a desire to be 
thinner 
16. Exercise strenuously to burn off 
calories 
17. Weigh myself several times a day 
18. Like my clothes to fit tightly 
19. Enjoy eating meat 
20. Wake up early in the morning 
21. Eat the same food day after day 
22. Think about burning up calories 
when I exercise 
23. Have regular menstrual periods 
24. Other people think that I am too 
thin 
25. Am preoccupied with the thought 
of having fat on my body 
26. Take longer than others to eat my 
meals 
27. Enjoy eating at restaurants 
28. Take laxatives 
29. A void foods with sugar in them 
30.Eat diet foods 
31. Feel that food controls my life 
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Always Very Often Some- Rarely Never 
Often times 
32. Display self control around food 
33. Feel that others pressure me to eat 
34. Give too much time and thought to 
food 
35. Suffer from constipation 
36. Feel uncomfortable after eating 
sweets 
37. Engage in dieting behaviour 
38. Like my stomach to be empty 
39. Enjoy trying rich new foods 
40. Have the impulse to vomit after 
meals 
APPENDIX 12: Daily Eating Plan And 1 OOOkcal Diet For Diet Study 
1 pint skimmed milk 
112oz (2 level teaspoons) of low fat spread 
3 meat exchanges 
4 bread exchanges 
2 portions of fruit 
Plenty of freely allowed foods 
* * * * * * * * * * * * * * * * * * * * * * * * * * * 






Milk allowance: 1 pint skimmed milk 
Fat allowance: 112oz low fat spread 
Breakfast cereal ( or 1 bread exchange) 
1 slice wholemeal bread ( or 1 bread exchange) 
Tea or coffee 
Milk and fat allowance 
Low calorie drink or tea or coffee with milk from allowance 
2oz lean meat ( or 1 meat exchange) 
Large serving salad or freely allowed vegetables 
1 slice wholemeal bread ( or 1 bread exchange) 
Fruit - fresh or stewed without sugar 
Tea or coffee 
Low calorie drink or tea or coffee with milk from allowance 
4oz lean meat ( or 2 meat exchanges) 
Large serving salad or freely allowed vegetables 
1 small potato ( or 1 bread exchange) 
Fruit - fresh or stewed without sugar 
Tea or coffee 
Tea or coffee with rest of milk allowance 
200 
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2oz lean meat or chicken 
20z oily fish (drain off excess oil) 
4oz white fish 
1oz (matchbox size) hard cheese 
30z cottage cheese 
5oz carton yoghurt 
1 small slice wholemeal bread 
2 wholemeal crispbreads (eg Ryvita) 
1 serving breakfast cereal (one weetbix; 1oz puffed wheat; 
shredded weat; 1 oz bran flakes; 4oz porridge) 
1 small potato 
1 112oz (3 tablespoons) cooked brown rice 
2 112oz (3 tablespoons) baked beans 
Freely Available Foods: 
Fruit: eg. grapefruit, melon, rhubarb, gooseberries, 
blackberries 
Vegetables: eg. asparagus, aubergine, french beans, celery, 
cabbage 
Condiments: eg. pepper, mustard, tomato juice, vinegar, 
herbs, oxo 
Drinks: eg. sugar free drinks, soda water, vichy, perrier water 
Cooking Methods: 
Grilling, poaching, casserole, bake, boiled 
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